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r-1 1027 142 Systolic Versus Diastolic Heart Failure in Communitv Practice: Clinical Features and 
Outcomes-in 1,694 Patients 
Edward F. Philbin, Thomas A. Rocco, Jr., Norman W. Lindenmuth, Paul 
L. Jenkins. Henry Ford Hospital, Detroit, Mi; Unity Health System, 
Rochestes NY USA 
Background: Patients with heart failure (HF) and abnormal versus normal 
left ventricular (LV) systolic function often differ in other fundamental charac- 
teristics and their clinical outcomes. This study examined such differences 
among patients with HF treated in community practice. 
Methods: From a registry of 2,906 unselected consecutive patients with 
confirmed HF admitted to 10 acute care community hospitals, we identi- 
fied 1,694 who had measurement of LV systolic function. Charts were re- 
viewed after hospital discharge and patients were followed prospectively for 
6 months. 
Results: Median age was 76 years; 56% were women. Mean ejection 
fraction (EF) was 36 f 15%. A LV EF 5 39% or abnormal global contractility 
was present in 946 (56%) patients (Sys-HF), while an EF 2 40% or normal 
contractility was present in 748 (44%) (Dias-HF). Using regression analy- 
ses, older age, female sex, higher body weight, hypertensive etiology and 
lower hematocrit were significant predictors of Dias-HF. Prior history of HF, 
diabetes, ischemic etiology, idiopathic HF and radiographic cardiomegaly 
predicted Sys-HF (all P < 0.05). Mean hospital length of stay (7.4 vs 7.7 
days), mean hospital charges ($8165 vs $8157) and mean NYHA functional 
class 1 month after discharge (2.2 vs 2.2) were similar between Sys-HF and 
Dias-HF (all P > 0.05). Crude rates of death and hospital readmission with 
odds ratios (OR) and confidence intervals (Cl) for the groups are shown in 
the Table. As shown. death rates were lower among Dias-HF patients while 
hospital readmission rates were not different. 
Clinical Outcome 
In-hospital death 
Post-discharge death 
Total B-month mortality 
HF rehospitalization 
Any rehospitalization 
Dias-HF Sys-HF OR 95% Cl P 
3.6% 5.1% 0.72 0.44-1.16 0.17 
13.0% 18.1% 0.70 0.54-0.91 0.008 
16.6% 23.2% 0.69 0.54-0.88 0.002 
22.5% 25.2% 0.86 0.69-1.08 0.20 
43.6% 42.5% 1.04 0.86-1.27 0.65 
Conclusions: Among patients with HF hospitalized in the community 
setting, the sizeable subset with preserved LV systolic function has clinical 
characteristics and a natural history pattern different than that with abnor- 
mal LV systolic function. Thus, the assessment of LV systolic function has 
important diagnostic and prognostic implications in managing HF. 
1027-I 43 From Systolic to Diastolic Chronic Heart Failure 
Pierre V. Ennezat, Caroline A. Ennezat, Slawomir Malendowicz, 
Pugazhendhi Vijayaraman, Edmund H. Sonnenblick, Thierry H. LeJemtel. 
Albert Einstein College of Medicine, Bronx, New York, USA 
Background and Methods: In order to evaluate changes in left ventricular 
ejection fraction (EF% by 2D echo) and functional class (FC, NYHA) in 
patients (pts) treated for chronic heart failure (CHF) due to systolic or diastolic 
dysfunction, data of 319 pts followed in our CHF clinic’for an average of 32 
months (range 12-73) and who at least had 2 echocardiograms over the 
duration of the study were analyzed. 
Results: Of the 319 pts, 72 pts had an initial EF > 45%. Their EF and FC 
averaged 60% and 2.3 respectively, and remained unchanged during follow 
up. The remaining 247 pts had an initial EF < 45%. 109 pts were treated 
witin standard therapy (SD Rx), 87 with beta blockade (BB) + SD Rx and 
51 underwent coronary bypass surgery (CABG). Response to SD Rx, BB 
and CABG was variable: EF normalized in 90 pts while average FC did not 
change. In this group, FC improved by at least 1 class in 25 pts, decreased 
in 15 pts and remained unchanged in 50 pts. 
EF > 45% SD Rx(22) BB (41) CABG (27) 
(n = 90) EF (%) FC EF (%) FC EF (%) FC 
Initial 29 2.3 30 2.3 31 2.5 
F/U 58 2.3 54 2.1 54 2.3 
Neither EF nor FC improved in 157 pts. 
EF < 45% SD RX(87) BB(46) CABG (24) 
(rl=157) EF (%) FC EF(%) FC EF (%) FC 
lnitlal 27 2.7 32 2.6 29 2.6 
F/U 29 2.7 31 2.5 32 2.6 
Conclusions: Over two thirds of our pts treated for CHF for rl year 
who have preserved EF, formerly had systolic dysfunction. Their therapeutic 
responses included recovery of systolic function, but variable symptomatic 
improvement presumably due to unmasked diastolic dysfunction. In contrast, 
transition from diastolic to systolic dysfunction is not observed. The ventricular 
response to current therapy for CHF is heterogeneous. 
1027-144 Is Flash Pulmonary Edema Due to Diastolic 
Dysfunction or Transient Systolic Dysfunction? 
John Powers, Karen Fowle, Kevin Rankin, Abdel-Mohsen Nomeir, 
Sanjay Gandhi, Dalane Kitzman, William C. Little. Wake forest University 
School of Medicine, Winston-Salem, NC, USA 
Background: Patients with flash pulmonary edema are frequently markedly 
hypertensive and subsequently, after control of the blood pressure (BP), 
found to have preserved left ventricular (LV) ejection fraction (EF). However, 
the pulmonary edema may not result from isolated diastolic dysfunction but 
instead be due to transient LV systolic dysfunction produced by hypertension 
and/or ischemia. 
Methods: In 21 patients with flash pulmonary edema and systolic BP > 
160 mmHg we evaluated LV function by 2-D echocardiography both during 
the acute episode and one to four days later, after treatment. There were 5 
men and 16 women, age = 70 f 11 (mean f SD). 
Results: Systolic BP during the initial echo was 200 i 24 and was 
reduced to 138 f 19 mmHg (p < 0.05) during the follow-up echo. Despite the 
marked difference in BP, LV EF was similar during the acute episode (0.50 
XIZ 0.15) and after treatment (0.52 It 0.15). EF after treatment predicted the 
EF during the acute episode (r = 0.88, y = 0.94x + 0.01; p < 0.05). Fourteen 
patients had preserved EF (>0.40) after treatment. In all these, the EF was 
also >0.40 during the acute episode. Similarly, the 10 patients with EF > 
0.50 after treatment all had EF > 0.50 during the acute episode. 
Conclusion: LV ejection fraction is similar both during an acute episode 
of hypertensive pulmonary edema and subsequently after treatment. Thus, 
a preserved EF after treatment indicates that the pulmonary congestion 
was due to hypertensive exacerbation of diastolic dysfunction not transient 
systolic dysfunction. 
1027-I 45 Evaluation of Left Ventricular Diastolic Function 
bv the Ratio of Maximal Flow Velocity of the 
Ekly Filling Wave to its PropogationwVelocity 
Ehud Schawammenthal, Bogdan A. Pupescu, Andreea C. Pupescu, Elio Di 
Segni, Elieser Kaplinsky, Babeth Rabinowitz, Victor Guetta, Shmuel Rath, 
Micha S. Feinberg. Heart Institute, Chaim Sheba Medical Center, Tel 
Hashomer; Sackler School of Medicine, Tel Aviv UniversiQ lsrael 
Active left ventricular relaxation creates a small intraventricular gradient 
which determines the propagation velocity of the early filling wave from the 
base of the left ventricle to the apex (VP), which can be assessed by color 
M-Mode echocardiography. Impaired relaxation will reduce Vp and cause 
vortex formation as blood flow entering the ventricle interacts with stagnant 
blood within the cavity, In this case maximal particle velocity during early 
filling (VE), assessed by pulsed wave Doppler, will significantly exceed VP. 
We therefore hypothesized that the ratio of VE to Vp will be directly correlated 
to the severity of left ventricular pathology and examined 96 consecutive 
subjects: 25 normals, 26 patients with LVH, and 45 patients with reduced EF. 
While the E/A ratio showed an expected U-shaped relation to the severity 
of LV pathology, VENP showed a direct linear correlation. Out of 24 patients 
with a V&p > 1.85 19 patients (79%) had either a history of pulmonary 
congestion or developed it within 6 months. 
+iGL L””  EF < 60% EF ‘ 10% 
A-- 
Nonn~lr L””  EF G 611% EF c 10% 
Conclusion: VENP is a parameter of diastolic function which increases 
directly with the severity of left ventricular pathology and potentially predicts 
outcome. 
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I 1027-146 1 A Rapid Bedside Test for Brain Natriuretic Peptide Accurately Delineates Both Systolic and 
Diastolic Dysfunction in Patients Referred for 
Echocardiography 
Jen Koon, Judy Hope, Alex Garcia, Radmila Kasanegra, Nancy Gardetto, 
Anthony DeMaria, Alan S. Maisel. VAMC and UCSD, La Jolla, CA, USA 
Background: As brain natriuretic peptide (BNP) accurately reflects left ven- 
tricular stretch, we hypothesized that a BNP level might be a useful diagnostic 
marker in screening patients for either systolic or diastolic dysfunction. 
Methods: Ninety seven subjects referred for echocardiography had BNP 
levels measured by a point of care immunoassay (Biosite Diagnostics, La 
Jolla, CA). BNP results were blinded from cardiologists making the assess- 
ment of left ventricular function. Patients with normal systolic function plus 
E/A reversal, shortened mitral valve deceleration time and ‘a’ wave reversal 
in the pulmonary vein, were classified as diastolic dysfunction. 
Results: BNP levels were significantly lower (38 f 4 pglml.) in normal 
patients than in those with either diastolic dysfunction (416 * 31 pg/ml) or 
systolic dysfunction (480 f 48 pglml, P < 0.001). ROC curve analysis re- 
vealed that a BNP level of 100 pg/ml was 91% sensitive and 100% specific 
for detecting the presence or absence of left ventricular dysfunction deter- 
mined by echocardiography. BNP levels were able to differentiate patients 
with completely normal ventricular function (38 f 4 pg/ml) from patients with 
normal ejection fraction but with wall motion abnormalities (177 f 20 pg/ml), 
as well as those patients with impaired ejection fraction (523 f 50 pg/ml, p < 
0.001). In patients with normal systolic function, a BNP level of greater than 
130 pg/ml was 100% sensitive and 100% specific for diastolic dysfunction. 
Conclusions: An easy, rapid test for BNP can reliably predict the pres- 
ence or absence of even mild degrees of left ventricular systolic function 
as well as to delineate diastolic dysfunction in those patients with a’normal 
ejection fraction. We believe that BNP may be an excellent screening tool for 
left ventricular dysfunction, and may, in fact, represent an important adjunct 
for the diagnosis of diastolic dysfunction. 
!IIl 1027 147 Is Increased Heart Rate Predictive of Poor 
Survival in Patients With Preserved LV Svstolic 
Function? 
Prakash C. Deedwania, Enrique V. Carbajal, Ronna Mallios. VACCHCS, 
Fresno, CA; UCSF School of Medicine, San Francisco, CA, USA 
Heart failure (HF) with preserved LV systolic function (DHF) is becoming an 
increasing clinical problem. Because of the preserved LV function and lack 
of significant neurohormonal activation, it is believed that patients with DHF 
have better prognosis. However, little information is available regarding the 
prognostic markers in unselected patients with DHF. We recently evaluated 
the prognostic value of 71 variables including clinical features, LV function 
data, exercise capacity, and Holter monitoring data in 575 patients followed 
at our institution from 1992 to 1997. Mean age was 69 f IO years, mean 
LVEF was 38 f 16, 64% had ischemic etiology, 79% were on ACE inhibitor, 
92% on diuretics, 62% on digoxin, and 65% on other vasodilators. During the 
five years follow-up, 174 (30%) patients had died, and of all the variables as- 
sessed increased heart rate (HR), elevated BUN, and worsening symptoms 
were the best predictors of cardiac death. LV function data were available for 
510 (88%) patients and, of these, 238 (46%) had DHF (LVEF > 40%). We 
evaluated if increased HR was as predictive of poor survival in DHF patients 
as it was in patients with poor LV systolic function (SHF). The mean HR was 
higher in SHF patients compared to DHF patients (82% * 13 vs. 78 f 11, 
p < 0.001). Thirty-nine percent of SHF patients and 33% of DHF patients 
died during the five-year follow-up. Increased HR was highly predictive (p 
< 0.0001) of higher mortality in both HF groups. Among the DHF, patients, 
mean HR was significantly higher in 79 patients who had died compared 
to the 159 survivors (82 f 11 vs. 76 jl 10, p < 0.0001). In the multivariate 
analyses, increased HR remained a powerful and independent predictor of 
cardiac death in both HF groups. 
Conclusion: Increased HR is equally predictive of poor survival in heart 
failure patients with preserved LV systolic function. 
LLL 1027 148 Relation of Left Ventricular Contractile 
Dysfunction to Left Ventricular Mass in Aortic 
Valve Disease 
Kazuhiro Taniguchi, Satoru Kuki, Takahumi Masai, Shuji Endo, K. Yoshida. 
Osaka Rosai Hospita/, Sakai, Japan 
Background: Identifying the transitional stage from physiologic hypertrophy 
to pathologic hypertrophy has important implications in determining the timing 
of therapeutic as well as operative interventions for aortic valve disease. To 
elucidate this transitional stage, we studied the relations of left ventricular 
contractile performance to lefl ventricular chamber volume, hemodynamic 
load and mass. 
Methods: Data were obtained from quantitative cineangiography. and 
pressure measurements in 73 patients with aortic regurgitation (AR) and 
39 patients with aortic stenosis (AS). Thirty patients without heart disease 
served as normal controls. Forty-one patients with AR and 20 patients with 
AS were reevaluated (average, approximately 23 months) after aortic valve 
replacement. By using the relation of ejection fraction to end-systolic stress 
(afterload-corrected EF), a slightly impaired contractility was defined as < 
predicted EF - 1 x SD, and a severely impaired contractility as < predicted 
EF-2SD. 
Results: Fourteen of 73 patients with AR and 8 of 39 patients with AS 
had a slightly impaired contractility, and 38 with AR and 19 with AS had a 
severely impaired contractility. In multivariate analysis, the most important 
discriminator of normal, slightly impaired, or severely impaired contractility 
for all 112 patients was left ventricular mass, rather than left ventricular 
chamber volume or hemodynamic load (p < 0.05). Let? ventricular mass 
index associated with a slightly impaired contractility was similar in the two 
patient groups (187 * 40 g/m* in AR and 194 f 31 g/m2 in AS, respectively, 
p = NS). Patients with a severely impaired contractility had mostly a left 
ventricular mass index > 192 g/m*, double its normal value (96 i 13 g/m’ 
for controls). Contractile dysfunction tended to improve, but did not return to 
normal completely after surgery in both groups, especially in patients with a 
preoperative mass index > 192 g/m’, and moderate to severe LVH persisted. 
Conclusion: These findings suggest that LVH becomes pathologic hy- 
pertrophy at the similar degree in left ventricular mass index (about double 
its normal value) for the volume and pressure overload. 
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/ 1028-l 51 1 The Expression of Bcl-2 Associated Protein X 
and Bcl-2 in Cardiomyocytes is Related to Left 
Ventricular Remodeling in Patients With Dilated 
Cardiomyopathy 
Akio Hirata, Masatake Fukunami, Tsuyoshi Shimonagata, Kazuaki Kumagai, 
Takahisa Yamada, Hisakazu Ogita, Yoshihiro Asano, Mitsutoshi Asai, 
Noritake Hoki. Osaka Prefectural Genera/ ffospital, Osaka, Japan 
Background: It is reported that the myocardial cell death in dilated cardiomy- 
opathy (DCM) would be partly related to apoptosis. To clarify the relationship 
between the apoptosis and the progression in DCM, we examined left ven- 
tricular endomyocardial biopsy specimen in 13 patients with DCM diagnosed 
clinically and pathologically. 
Methods: The expression of Bcl-2 associated protein X (Bax) and Bcl-2 
was estimated using immunoenzyme-assayed biopsy specimen. We counted 
each number of positively stained cell by anti- Bax or Bcl-2 in the mirror 
section per IO different high power fields (x400) randomly selected. The pro- 
gression of left ventricular hear-l failure was assessed echocardiographically, 
by comparing left ventricular end-diastolic dimension (LVDd) and ejection 
fraction (EF) measured at the time of biopsy with those 1 year after. There 
were no significant correlations between the number of positive cells and 
age, sex, NYHA classification, LVDd and EF at the beginning, or drugs which 
the patients received. 
Results: The ratio of the number of Bax positive cell and Bcl-2 positive 
cell (Bax/Bcl-2) showed a significant correlation with a % increase of LVDd 
(r = 0.735, p < 0.005), while it tended to show an inverse correlation with a 
% increase of EF. 
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Conclusion: Bax/Bcl-2 would be a predictor of left ventricular remodeling 
in patients with DCM. 
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/ 1028 152 Peripartum Cardiomyopathy: Analysis of Clinical Outcome, Left Ventricular Function, Plasma 
Levels of Cytokines and Fas/APO-1 
Karen Sliwa, Daniel Skudicky, Anette Bergemann, Geoffrey Candy, 
Pinhas Sareli. Heart Failure Research Unit, Department of Cardiology: 
Baragwanath Hospital, Johannesburg. South Africa 
Background: previous studies in patients with peripartum cardiomyopathy 
(PPC) were done when ACE inhibitors and fi blockers were not routinely 
used in heart failure. inflammatory cytokines play an important role in the 
pathogenesis and progression of heart failure of other etiologies. However, 
there is a paucity of data regarding cytokine expression in patients with PPC. 
Plasma concentrations of FasiAPO-l receptors (an apoptosis-signalling re- 
ceptor) have not been reported in this population. 
Objectives: 1) to evaluate the outcome of patients with PPC on current 
treatment for heart failure, 2) to assess the circulating plasma levels of 
cytokines and Fas receptors, and 3) to identify predictors of prognosis, 
Methods: We followed prospectively 29 consecutive black women with 
PPC. All patients were treated with diuretics, digoxin, enalapril and carvedilol. 
Echocardiograms were performed at baseline and after 6 months of treat- 
ment. Cytokine and sFas/Apo-I plasma levels were measured at baseline. 
Results: Tumor necrosis factor-a, Interleukin-6 and Fas/APO-I levels 
were significantly elevated in the study patients compared to 20 healthy 
volunteers. Eight patients died. sFas/Apo-I levels were significantly higher 
in patients who died compared to survivors (8.98 ZIZ 4.5 vs 5.33 * 3 U/ml 
respectively, p = 0.02). At 6 months, ejection fraction improved from 26.7 i 
IO to 42.7 i- 16%, p = 0.00003, with an increment of more IO units in IO 
patients (28.1 -+ 4 to 51.9 i 8%, p = 0.000008). 
Conclusions: Cytokine and sFas levels are elevated in patients with PPC. 
Despite treatment with ACE-inhibitors and fi blockers, mortality remains high. 
However, in 34% of the patients, left ventricular function almost completely 
normalized. 
1028-l 53 Pentoxifylline Improves Left Ventricular 
Performance in Patients With Idiopathic Dilated 
Cardiomyopathy Treated With Digbxjn,, 
Angiotensin Converting Enzyme lnhrbrtors and 
Carvedilol 
Daniel Skudicky, Anette Bergemann, Karen Sliwa, Geoffrey Candy, 
Pinhas Sareii. Heart failure Research Unit, Department of Cardiology: 
Baragwanath Hospita!. Johannesburg, South Africa 
Background: Carvedilol has been shown to improve left ventricular perfor- 
mance in patients with systolic dysfunction already treated with digoxin and 
ACE inhibitors. Whether the addition of pentoxifylline (an inhibitor of TNF-0 
production) to carvedilol can further improve left ventricular function in these 
patients is unknown. 
Methods: In a prospective, randomized, double blind, placebo control 
study we enroled 29 consecutive patients (mean age 49 i 11 years) with 
idiopathic dilated cardiomyopathy and an ejection fraction < 40% following 
at least 3 months of therapy with diuretics, digoxin, ACE inhibitors and 
carvedilol. Patients were randomized to pentoxifylline 400 mg TDS (n = 
15) or placebo (n = 14). Echocardiograms and radionuclide studies were 
performed at baseline and after 6 months. 
Results: 5 patients died during the study period (3 in the placebo group). 
Left ventricular dimensions at end-diastole (EDD), end-systole (ESD) and 
radionuclide ejection fraction (EF) for patients that completed the 6 months 
are shown in the table. 
EDD, mm 
ESD, mm 
EF, % 
Pentoxhfylline (n = 13) Placebo (n = 11) 
Baseline 6 months P Baseline 6 months p 
66k7 65 i- 8 0.6 68z!rlO 68f 10 0.8 
58 * 7 55 + 8 0.14 56~t8 581-12 0.4 
21 &IO 29+ 12 0.03 2319 23zk-13 0.9 
Conclusion: The addition of pentoxifylline to background therapy with 
digoxin, ACE inhibitors and carvedilol further improves left ventricular function 
in patients with idiopathic dilated cardiomyopathy. 
1 1028-l 54 ] lmmunohistological Changes During 
lmmunoadsorption Therapy With Subsequent 
lmmunoglobulin Substitution in Dilated 
Cardiomyopathy 
Alexander Staudt, Frank Schlper, Peter Bramlage, Wolf V. Dorffel, 
Verena Stangl, Karl Stangl, Gert Baumann, Stephan 8. Felix. Department of 
internal Medicine; ’ lnstitut of Pathology, Char&$ Humboldf llniversity, 
Berlin, Germany 
Background: lmmunoadsorption (IA) was performed in 11 patients suffering 
from dilated cardiomyopathy (DCM) and induced an increase of cardiac index 
from 2.2 & 0.2 to 2.9 !I 0.3 I/minim* (p < 0.01). The underlying mechanisms 
of beneficial effects mediated by IA remain to be elucidated. 
Methods: 11 patients with DCM (NYHA Ill-IV, EF < 30%, stable medica- 
tion) received IA therapy and subsequent immunoglobulin substitution (0.5 
g/kg) at one-month intervals until month 3. Before and after (~7 d) IA therapy 
5 to 8 right ventricular biopsies were obtained from all patients. DCM patients 
(controls, n = 7, EF < 30%, NYHA Ill-IV) were treated with conventional 
therapy only. From these patients biopsies were also obtained in an interval 
of 3 months. Biopsies were fixed in 4% formalin and embedded in paraf- 
fin. The sections were 2 brn thick. The staining procedure with the labeled 
streptavidin-biotin (LSAB) method was used. The following antibodies were 
used: anti CD3; -CD4; -CD8, -CD45 RO, HLA-DP. The number of positive 
cells (cells/mm2) was counted under high power magnification (400x) by two 
independent observers. 
Results: 
CD3 CD4 CD8 CD 45R0 
Baseline 4.5 1.86 2.2 11.6 
After IA therapy 2.3 0.6 1.5 7.2 
P < vs. baseline 0.01 0.01 0.05 0.05 
In controls the number of immunopositive cells and the expression of 
HLA-DP remained stable during follow up. 
Conclusion: IA reduces the inflammatory process in myocardium of DCM 
patients. 
1 1028-l 55 1 Circulating Matrixmetalloproteinase in Patients 
With Dilated Cardiomyopathy 
Taketoshi Yamazaki, Jong-Dae Lee, Hiromasa Shimizu, Takanori Ueda. 
First Department of internal Medicine, Fukui Medical University, Fukui, 
Japan 
Background: It has been reported that MMP protein content and activity 
were upregulated in the failing human heart, suggesting that these proteins 
may contribute to myocardial remodeling. However, there are few reports to 
describe the level of circulating MMPs in chronic heart failure (CHF). 
Purposes and Methods: To examine whether the circulating MMPs are 
also involved in the pathogenesis of CHF, we measured circulating lev- 
els of MMP-2, MMP-9 and its inhibitor, tissue inhibitor of metalloproteinase 
(TIMP-I) using enzyme-linked immunosorbent assay methods in 29 patients 
with CHF (left ventricular ejection fraction (L VEF) < 50%, 19 men 66 f 12 
years old), 14 patients with idiopathic dilated cardiomyopathy (DCM) and 15 
with old myocardial infarction (OMI). Eleven age-matched subjects having 
normal coronary arteries and normal ejection fraction were used as controls 
(CTL). None had inflammatory, signs. No differences were found in the in- 
cidence of hypertension and diabetes mellitus, and in lipid profiles among 3 
groups. 
Results: As a whole, LVEF had significant correlations with both MMP-2 
(r = -0.79, p < 0.03) and MMP-9 (r = -0.50, p < 0.03). The level of MMP-9 
was significantly greater in DCM (111 f 114 rig/ml) compared to OMI (31 =t 
29 rig/ml, p < 0.05) and CTL (24 i 13 rig/ml, p < 0.05), while the levels of 
MMP-2 (DCM: 918 & 616 rig/ml, OMI: 649 f 206 rig/ml, CTL: 483 i 172 
nglml) did not show significant differences among 3 groups. TIMP-1 (DCM: 
152 rt 62 rig/ml, OMI: 169 f 53 rig/ml, CTL: 147 + 29 rig/ml) was identical 
in each group. Thus, the ratio of MMP-SfTIMP-I was significantly greater in 
DCM (0.71 i 0.62) than in OMI (0.19 i 0.15, p < 0.05) and CTL (0.17 i 
0.10, p < 0.05). 
Conclusion: Our data indicated that MMP-9 production was increased in 
DCM patients, suggesting a close relation between this enzyme activity and 
the degrdation of cardiac interstitial tissue. 
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1 1028-l 56 ( Association Between Aldosterone Synthase 
Gene Polymorphism and Left Ventricular Size in 
Patients With Congestive Heart Failure 
Eiji Takai, Hozuka Akita, Kenji Kanazawa, Nobuyuki Shiga, 
Masahiro Terashima, Yasuaki Matsuda, Chikao Iwai, Hiroya Kawai, 
Akira Takarada’ , Hiroyuki Kurogane’ , Mitsuhiro Yokoyama. The First 
Department of Internal Medicine, School of Medicine, Kobe University; 
’ Himeji Cardiovascular Center, Japan 
Background: Cardiac steroidgenic system is postulated to play an essen- 
tial role in cardiac interstitial remodeling. Recently, aldosterone synthase 
(CYPlIB2) gene T (-344) C promoter polymorphism, which modulates its 
transcription, was reported to be associated with left ventricular (LV) char- 
acteristics in normal subjects. However, it has not been explored whether 
the relationship between this polymorphism and LV characteristics exists in 
patients with heart failure. 
Methods: To investigate the relation between this polymorphism and 
LV characteristics in failed heart, we assessed the T (-344) C genotype, 
the hemodynamic parameters, and LV end diastolic and systolic volume 
index (EDVI, ESVI) in 183 dilated cardiomyopathy (DCM) patients. We also 
analyzed serum aldosterone, plasma renin level and the semi-quantitative 
assessmenis of fibrosis from biopsy specimens. We further conducted a 
case-control study to elucidate whether this polymorphism can be a genetic 
risk factor for DCM. 
Results: TC + CC genotype had significant larger LV size and smaller 
cardiac index (Cl) than TT genotype. 
Number 
EDVI (ml/m*) 
ES/l (ml/m”) 
Cl (I/min/m? 
EF (%) 
TT 
80 
132.5 i 4.0 
87.0 5 3.7 
2.96 zt 0.07 
35.1 * 10.7 
TC+CC 
103 
148.9 * 4.8 
102.9 * 4.7 
2.67 i 0.07 
32.8 + 12.1 
p < 0.02 
p < 0.05 
p < 0.01 
p=o.17 
Whereas, biochemical and histological data were not different between 
TT and TC + CC. There was no statistical difference of allele distribution 
between DCM and control, suggesting that this polymorphism is not a genetic 
risk factor for DCM. 
Conclusion: The T (-344) C CYPIIBP promoter polymorphism could 
modulate the dilative cardiac remodeling in patients with congestive heart 
failure due to DCM. 
11028-1571 Coxsackie B Virus RNA Replication in the 
Myocarclium of Patients With End-Stage 
ldiopaphic Dilated Cardiomyopathy 
Shigekazu Fujioka, Yasushi Kitaura, Fumio Terasaki, Akira Ukimura, 
Hirofumi Deguchi, Keishiro Kawamura, Akira Shimizu, Tadashi Isomura, 
Hisayoshi Suma. Osaka Medical College, Takatsuki; Shonan Kamakura 
Genera/ Hospital, Kamakura, Japan 
Background: Molecular biological techniques have demonstrated the impor- 
tance of enterovirues (Eves) in the pathogenesis of dilated cardiomyopathy 
(DCM). Recently, associations of hepatitis C virus or adenovirus with DCM 
have been reported. We evaluated viral infection of the myocardium from 
patients with idiopathic DCM. 
Methods: Myocardial specimen from 24 patients with idiopathic DCM, 
which obtained at partial left ventriculectomy (PLV) were examined. Strand- 
specific detection of EV RNA was performed to differentiate active viral 
replication and latent persistence. Sequence analysis of PCR products was 
carried out to clarify the genotypes of detected EV genomes. PCR were used 
to detect hepatitis C virus, adenovirus, cytomegalovirus, influenza A, or B, 
mumps, herpes simplex virus genomes. 
Results: Plus-strand EV RNA was detected in 9 (38%) of the 24 patients. 
Minus-strand EV RNA was demonstated in 7 (78%) of these 9 plus-strand 
positive patients. Five (71%) of 7 minus-strand EV RNA positive patients died 
within a year after PLV. Sequence analysis of PCR products revealed that 
detected Eves were coxsackie B viruses such as coxsackievirus 83 and 84. 
These viruses are known to be cardiovirulent and were reported to induce 
myocarditis in murine model. However, genetic materials with other viruses 
were not detected. No viruses were isolated by conventional methods in any 
of the cases. 
Conclusion: Coxsackie B viruses were demonstrated in end-stage idio- 
pathic DCM hearts. Active viral RNA replication appeared to be present in 
a significant proportion of these cases. Minus-strand coxsackieviral RNA in 
the myocardium may be a marker for poor clinical outcomes after PLV. There 
was no evidence of other virus infection in DCM hearts. 
) 1028-l 58 1 Frequency of Viral Persistence in End-Stage 
Dilated Cardiomyopathy \ 
Niall G. Mahon, Paul Risley, Behnam Zal, Christina Baboonian, Michael 
J. Davies, William J. McKenna. St George’s Hospital Medical School, 
London, UK 
Background: Conflicting data on the importance of viral infection in idiopathic 
dilated cardiomyopathy (DCM) may partially be explained by variations in ill- 
ness duration prior to virus testing. Recent work has demonstrated a high 
frequency of detectable myocardial viral sequences shortly after presenta- 
tion. The aim of this study was to determine the frequency of persistence 
of enteroviral, adenoviral and cytomegaloviral (CMV) genetic material in the 
myocardium in end-stage DCM. 
Methods: 2-3 mm samples from the left ventricle (LV) and septum of 
explanted hearts of 24 DCM patients, 23 patients with ischaemic heart dis- 
ease (IHD), 1 hypertrophic cardiomyopathy patient (HCM) and 2 patients 
with valvular hear disease (VHD) were snap frozen at explantation. RNA for 
enterviral polymerase chain reaction (PCR) was extracted using Triazole, re- 
verse transcribed using random hexamer and superscript II and cDNA used 
in nested PCR, with myoglobin mRNA as the housekeeping gene. Amplifica- 
tion of human CMV and adenovirus sequences was performed using nested 
PCR following DNAzole extraction. 
Results: Mean age of DCM patients undergoing transplantation was 41.2 
(f8.1) years v5 (15.7) years in IHD, HCM and VHD (controls), p < 0.001. 
There was no significant difference between LV end-diastolic dimension (7.1 
mm v 7.3 mm), fractional shortening (12.2 v 12.4), or NYHA class (3.7 v 
3.6) between DCM patients and controls. Five DCM patients had a clinically 
suspected viral aetiology. Mean time from diagnosis to transplantation in DCM 
patients was 1.8 (&I .6) years. Among DCM patients histology demonstrated 
typical fibrosis and myocyte changes in 75% and was atypical in 25%. 
There were no cases of acute or chronic myocarditis. Double-blind spiking of 
random wells demonstrated an in-house sensitivity for detection of vires of 1 
gene fragmenuassay. Despite this, enteroviral, adenoviral or CMV sequences 
were detectable neither in DCM patients nor controls. 
Conclusion: Viral persistence is not detectable in end stage DCM. 
L--l-L 1028 159 Hypercholesterolemia is Associated With Impaired Aerobic Capacity in Patients With 
Dilated Cardiomyopathy: Normalizing Effects of 
Chronic Exercise Training 
Josef Niebauer’,*, Katharine Webb-Peploe’, Andrew J.S. Coats’, ‘iVHL/, 
London, UK; “University of Leipzig - Heart Center, Germany 
Background: We have previously shown in mice that hypercholesterolemia 
is associated with an impaired oxidative capacity and that this can be normal- 
ized by exercise training. In the present study we set out to assess whether 
these effects can also be found in patients with mild hypercholesterolemia 
and dilated cardiomyopathy. 
Methods: 21 patients and 9 healthy volunteers were randomly assigned 
to 8 weeks of exercise (>5 diwk, ergometer training, 30 min/d; calisthenics 9 
min/d) followed by 8 weeks of rest, and vice versa (crossover study). Plasma 
nitrite and nitrate (NOx) concentrations were measured by Griess reaction. 
Results: After rest, there was an inverse correlation between cholesterol 
and mv02 in patients who were not prescribed oral nitrates as part of their 
regular medical treatment (r = -0.524, p < 0.05) and healthy volunteers 
(r = -0.727, p < 0.04). This was lost after exercise training due to an 
improved mVOn (p < 0.05) (r = -0.245, p = 0.4060 and r = -0.209, p =. 
0.6710, respectively), and it was not seen in patients on oral nitrates (r = 
0.467, p < 0.6126). Patients on oral nitrates showed NOx levels not different 
from healthy volunteers, but significantly higher than in patients without oral 
nitrates (p < 0.05). In patients without oral nitrates, there was a strong inverse 
relation between plasma NOx levels and mVOp after rest (r = -0.680, p < 
0.006), and this correlation was lost after 8 weeks of exercise training (r = 
-0.330, p < 0.2781) and it was neither seen in patients who were taking 
oral nitrates (r = 0.413, p < 0.6605). In keeping with these observations, an 
inverse correlation was noted for plasma NOx levels and anaerobic threshold 
in patients after rest (r = -0.780, p < 0.0005) and this was again lost after 
exercise training (r = -0.108, p < 0.7316) and not found in patients on oral 
nitrates (r = -0.082, p < 0.9343) or healthy volunteers. 
Conclusion: This study provides evidence in humans that already mild 
hypercholesterolaemia may be associated with an impaired aerobic capacity, 
possibly via an NO-antagonizing effect. 
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TXP). Event-free survival @I year was 68 i 14% for the combined medium 
and high risk strata vs. 96 f 2% for the low risk stratum (p = 0.0005). In 
conclusion, the HFSS is a valid and generalizable method to predict one year 
event-free survival in patients with end stage heart failure referred for TXP. 
Event-free survival for patients in the high and medium risk strata is poor, and 
these patients should be listed for TXP. TXP listing can be safely deferred for 
low risk strata patients. 
I 1029 120 Effect of Race in Outcomes After Heart Transplantation 
Jon A. Kobashigawa, Danielle Devereaux, Jaime 0. Moriguchi, 
Nobuyuki Kawata, Michele A. Hamilton, Antoine Hage, Hillel Laks. 
University of California at Los Angeles, Los Angeles, California, USA 
1029-l 22 Effects of Cardiac Transplantation on 
Flow-Mediated Arterial Vasodilatation of the 
Peripheral Vasculature 
Sherry J. Saxonhouse, Dave Edwards, Richard S. Schofield, Wilmer 
W. Nichols. University of Florida, GainesviNe, Norida, USA 
Background: Multicenter studies in both heart and kidney transplant re- 
cipients have suggested that recipient race has an impact on survival. 
Specifically$ the black race appear to have lower survival, however this is 
controversial. Therefore, we performed this large single center study with 
standardized post-operative care to assess the impact on race on outcomes 
after heart transplant. 
Background: Patients with congestive heart failure demonstrate peripheral 
vasculature endothelial dysfunction as indicated by attenuated flow-mediated 
vasodilatation (FMV). The aim of this study was to determine if FMV is 
attenuated in patients before and after cardiac transplantation. 
Methods: Between December 1986 and January 1999, 702 adult heart 
transplant patients underwent heart transplant at a single institution. Patients 
were divided by race into various groups where outcomes of survival and 
freedom from rejection were determined. 5 year actuarial survival data is 
expressed. 
Methods: With high-resolution ultrasound, we measured the diameter 
of the brachial artery at rest and at peak reactive hyperemia following five 
minutes of total occlusion in 30 individuals. Ten patients with class IV con- 
gestive heart failure listed for cardiac transplantation, 10 stable patients after 
cardiac transplantation (ranging 1 -month to 7-years), and IO age-matched 
non-smoking healthy volunteers (without systemic hypertension, diabetes or 
heart failure) were studied. 
Results: 702 adult heart transplant patients on triple drug immunosup- 
pression (no cytolytic induction) were divided into the following racial groups: 
White (n = 556): Black (n = 69), Asian (n = 40), and Hispanic (n = 37). 5 year 
actuarial survival was not significantly different among the four ethnic groups 
(White 71%, Black 70%, Asian 73%, Hispanic 73%). However, freedom from 
rejection was significantly different between the white vs. black group (59% 
vs. 51%, p = 0.003). The Asian group had significantly more patients free 
of rejection compared to the White group (68% vs. 59%, p = 0.018). Other 
group combinations did not show statistical difference mostly due to relative 
small numbers of the groups 
Results: Peak reactive hyperemic response or flow-mediated vasodilata- 
tion was unchanged in patients with class IV congestive heart failure and 
patients alter cardiac transplantation (3.34 f 1.23 versus 4.40 f 1.49% p = 
NS). However, in comparison to healthy volunteers there was a significant 
difference in flow-mediated vasodilatation between class IV congestive heart 
failure patients and normal subjects (3.34 i 1.23 versus 9.75 ZIZ 3.01%, P 
< 0.001). In addition, there was also a significant difference between the 
patients after cardiac transplantation and normal subjects (4.40 i 1.49 ver- 
sus 9.75 rt 3.01%, p c 0.001) indicating impaired peripheral vasculature 
endothelial function despite transplantation. 
Conclusions: Attenuated brachial artery flow-mediated vasodilation and 
endothelial function in patients with severe congestive heart failure appears 
to persist after cardiac transplantation. 
1029-l 23 Modulatory Impact of Diabetes Mellitus on 
Doppler Derived Indices of Mitral Inflow in Heart 
Transplantation 
Conclusion: Ethnic race appears to have an effect on rejection after 
heart transplantation, however this factor does not appear to affect overall 
survival. This suggests that ethnic heterogeneity may be enough to tend 
toward rejection, however rejections appear to be well tolerated, not leading 
to mortality. Psychosocial factors such as socioeconomic status, medical 
compliance in addition to immune mechanisms no doubt play some role in 
outcome but are not evident in mortality outcome in this study. 
Arshad Alit, Frank Smart’, Hector Ventura’ , Mandeep Mehra’. St John 
Hospital, Detroit, Michigan; 7 Tulane University Medical Center; ‘Qch,mer 
Clinic, New Orleans Louisiana, USA 
Background: Abnormalities in diastolic function are frequently noted in haart 
transplant recipients. We studied the independent impact of diabetes mellitus 
(DM) on the indices of diastolic function in cardiac allograft recipients. 
1029-I 21 Independent Prospective Validation of a Clinical 
Index to Predict Survival in Ambulatory Patients 
Referred for Cardiac Transplant Evaluation 
Marco Bobbio, Sarah Dogliani, Giuseppe Giacomarra, Keith D. Aaronson. 
University of Turin, Turin, Italy; University of Michigan, Ann Arbor, Michigan, 
USA 
Methods: 42 cardiac allograft recipients, 24 diabetics (57%) with normal 
systolic function and without angiographic evidence of epicardial coronary 
arterial disease, were evaluated. 2D echo/Doppler was performed within 
8 hr of right heart catheterization/endomyocardial biopsy. Ejection fraction 
(EF), wall thickness, and ventricular diameter were measured. PW Doppler 
across mitral inflow was used to calculate lsovolumic relaxation time (IVRT). 
E/A ratio and deceleration time (DT). Left ventricular mass index (LVMI) 
was obtained. Biopsy (Bx) scores were calculated according to previously 
defined formula. All studies were performed after 1 month (early) and 12 
months (late) following transplantation. 
The Heart Failure Survival Score (HFSS) is derived from 7 commonly ob- 
tained clinical measures, and may be grouped into 3 HFSS Strata, which 
have been shown to predict death or urgent transplant (TXP) in ambulatory 
patients referred for TXP evaluation. This clinical index was derived and then 
validated on data from two separate TXP centers. However, investigators at 
both centers were the same, and both are located in the urban northeastern 
US; this homogeneity may have falsely enhanced HFSS validity. Therefore, 
we studied 107 ambulatory patients (age 51 f 8 [mean f SD], 86 male) 
presenting for TXP evaluation between March 96 and Feb 97 to our center in 
Turin to independently examine HFSSvalidity and generalizability. Event-free 
survival (no TXP in inotrope-dependent patients or pre-TXP death) for HFSS 
Strata was determined by the Kaplan-Meier method and compared by the 
log rank test, Baseline model characteristics: HR 80 i 14, mean BP 99 f 13, 
LVEF 26 i 9, serum sodium 140 i 3, peak VOs 16.0 i 4.7, CAD (36%) and 
QRS 2 120 (33%). HFS Score was 9.03 i 0.97 (range 6.42-11.43) which 
classified patients into these HFS Strata: high risk 2 (1.9%); medium risk 
18 (16.8%) and low risk 87 (81.3%). There were 7 events (6.5%) during the 
first year after evaluation (3 (2.8%) deaths and 4 (3.7%) inotrope-dependent 
Results: Both groups were matched for heart rate, pre-load and after-load 
at the time of RHC. There was no difference between the diabetics and 
non-diabetics in EF, diastolic function, or LVMI, at the early time point. The 
late results are shown: 
LATE EF E/A IVRT -_ll~- DT LVMI aim* 
Diabetics n = 24 6Oi4 1.3io.5 74 + 22 194i40 91+34 
Non diabetics n = 18 60 + 5 1.9iO.8 81 i 22 169h36 83zt 13 
P Vah NS NS NS co.05 NS 
The Bx score for diabetics was 0.6 + 0.3 and for non-diabetics was 0.8 
i 0.6 (NS) There was a negative correlation between Bx Score and DT (r = 
-0.4, p < 0.009). 
Conclusion: Our data alludes to a possible modulatory impact of DM on 
indices of left ventricular diastolic function, with development of relaxation 
abnormality over time. The concerted impact of episodes of allograff rejaction 
and DM contributes to the development of restrictive diastolic dysfunction. 
Implantation of a non-diabetic heart in a diabetic recipient may serve as a 
human model to study the impact of DM over time on myocardial function. 
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1029-l 24 impact of New UNOS Listing Categories on Cost 
and Outcome Pre-Transplant lrrl 
1029 126 Clinical Patterns of Recurrence of Tobacco 
Smoking in Prior Smokers Underooing Heart 
Transplantation 
- - 
Helen Hauff, Simon Maybaum, Niloo Edwards, Donna Mancini. Columbia 
University: New York, New York, USA 
Background: On January 20th 1999 UNOS listing regulations changed al- 
lowing stable patients on inotropic support (status 16) to be discharged home 
until cardiac transplant. From l/20/99 through 9/i/99, 49 patients have been 
prioritized as status 16 at our institution. Of these candidates, 30 patients 
were discharged home. Criteria for discharge were hemodynamic stability on 
low dose parenteral inotrope defined as dobutamine at ~7.5 mg/kg/min or 
milrinone < 0.5 mg/kg/min. 
Methods: Cost saving, readmissions and events at home were collected 
prospectively. Cost saving per patient was calculated as the hospital charge 
per day minus daily home care costs. 
Results: There were 22 males, 8 females with mean age 54 i 10 yrs. 20 
patients had dilated cardiomyopathy, 8 ischemic heart disease and 2 patients 
transplant coronary artery disease. 12 patients received milrinone at a dose 
of 0.45 i 0.16 p/kg/min and 18 patients received dobutamine at a dose 
of 3.5 f 1 p/kg/min. Patients were at home for 47 f 49 days. Mean cost 
saving/patient was $70,000. There were 27 readmissions with a mean stay 
of 8 f.6 days. 8 patients required more than 1 admission. 52% of admissions 
were for worsening CHF, 33% for infection or occlusion of the indwelling 
intravenous line. 11 patients wore a LIFECOR external defibrillator vest for 
253 f 228 hours. 2 patients died suddenly at home, one patient received 
milrinone 0.5 w/kg/min and the other dobutamine 3 &kg/min. 
Conclusions: Significant cost saving is achieved with home inotropic 
therapy while awaiting cardiac transplant. Mortality remains low but read- 
mission rate is high. Improved continuous intravenous delivery systems may 
significantly reduce the number of readmissions and further reduce costs. 
1029-l 25 Chagas’ Heart Disease: An Etiology Associated 
With Better Survival After Heart Transplantation 
in Comparison With lschemic and Idiopathic 
Etiologies 
Edimar A. Bocchi, Alfred0 Fiorelli. Transplantation and Heart Failure Clinics, 
Heart Institute, SYto Paul0 University Medical School, Sio Paulo, Brazil 
Results of heart transplantation may be influenced by many factors including 
etiology. We investigated the influence of age, sex, etiology, period of heart 
transplantation, on the results of heart transplantation and causes of death 
in a multicenter study. 
Methods: 835 patients who underwent heart transplantation, from June 
1984 to April 1999 in 16 centers were included in this study, 632 male, age 
less than 7 years 30 pts, from 7 to 30 years 125 pts, from 30 to 60 years 568 
pts, >60 years 56 pts, and the etiology was idiopathic dilated cardiomyopathy 
in 407 pts, ischemic in 196 pts, chagas heart disease in 117 pts, valvular 
in 29 pts, congenital in 14 pts, peripartum in 12 pts, hypertrofic in 7 pts, 
retransplantation in 6 pts, restrictive in 5 pts, alcoholic in 4 pts, and drug in 
1 pt. 
Results: The survival rate at I,‘4 and 8 years was 66%, 54% and 
40%, respectively. Survival improved from 1990 to 1999 (p < O.OOOl), and 
it was better in chagasic etiology compared with idiopathic and ischemic 
(p < 0.02) (Fig 1). Sex and age didn’t influence survival. Regarding the 
causes of death: rejection and neoplasia were more commom in chagasic 
etiology, postoperative bleeding in ischemic, graft coronary artery disease 
and graft disfunction in idiopathic and ischemic. Reactivation of Chagas’ 
disease occurred in 15% of the pts. during follow-up. 
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In conclusion: The etiology can influence the survival and causes of 
death. Chagasic cardiomyopathy is a defined indication for heart transplan- 
tation with better results in comparison with other etiologies. 
Ananth Prasad, Mandeep R. Mehra, Patricia A. Uber, Robert L. Scott, 
Myung H. Park. Ochsner Medical Institutions, New Orleans, LA, USA 
Background: While most transplant programs emphasize smoking cessa- 
tion, little information exists on risk factors for return to tobacco abuse. 
We sought to identify rates of return to smoking and clinical predictors for 
recurrence of tobacco smoking in heart transplant recipients who had demon- 
strated compliance with smoking cessation prior to transplantation. 
Methods: We prospectively examined 50 heart transplant recipients with 
admitted pre-transplant smoking history, and established compliance with 
pre-transplant smoking cessation (age 54 f 11 years, 83% men; 77% Cau- 
casian; 64% urgent status I candidates). Patterns of tobacco exposure were 
evaluated by means of a direct questionnaire, and all patients underwent 
urine testing for estimation of nicotine and cotinine levels by Gas Chro- 
matography/Nitrogen Phosphorus Detection (Non Habitual Smoker Limits: 
Nicotine 10 rig/ml; Cotinine 40 rig/ml, and Habitual Smoker Limits: Nicotine 
> 100 rig/ml; Cotinine > 200 rig/ml). 
Results: 
Type of Exposure 
Admitted habitual smokers 
Admitted exposure to passive or active smoking 
Any positive urine test 
Positive test in habitual smoking range 
Number 
8150 (16%) 
9150 (18%) 
1950 (30%) 
12/50 (24%) 
Thus, 40% of those with detectable tobacco exposure did not admit to 
active or passive smoking, while 33% of habitual smokers denied tobacco use 
by history. On stepwise multi-variable regression analysis of clinical variables, 
predictive of recurrence of habitual smoking, only smoking cessation within 
6 months of transplantation remained in the model (r = 0.6, p < O.OOOl), 
while age, race, gender, educational status, smoking in family members or 
friends, amount of cigarettes smoked prior to transplant and status at time of 
transplantation were not found to be predictive. 
Conclusions: 1. A large proportion of heart transplant recipients return 
to tobacco abuse after heart transplantation, yet only few openly admit to 
it. 2. Smoking cessation within 6 months of transplantation identifies those 
at greatest risk for recurrent tobacco use. 3. Efforts directed towards closer 
surveillance for recurrent smoking and continued participation in compliance 
programs for tobacco avoidance, especially in the high-risk subset, are war- 
ranted after heart transolantation. 
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1048-l 42 Reduction of Oxidative Stress by Trolox and 
Superoxide Dismutase Abolishes 
Norepinephrine-Induced Myocyte Apoptosis and 
P-Adrenergic Receptor Downregulation in 
Ferrets 
Fuzhong Qin, Junya Shite, Chang-seng Liang. University of Rochesfer 
Medical Center, Rochester, NK USA 
Background: Recent studies have demonstrated that norepinephrine (NE) 
produced myocyte apoptosis and myocardial @-adrenergic receptor (BAR) 
downregulation. To determine if these changes are mediated via oxidative 
stress produced by NE, we assessed the effects of antioxidant vitamin E 
analogue trolox and free radical scavenger superoxide dismutase (SOD) on 
myocyte apoptosis and ,6AR density in ferrets receiving chronic NE infusion, 
Methods: Ferrets were administrated either NE (40 mg) or vehicle and 
simultaneously assigned to receive trolox (100 mg), SOD (60000 U) or saline 
for 4 weeks. We measured: 1) total cardiac oxidative stress by examining 
the ratio of myocardial reduced to oxidized glutathione (GSH/GSSG); 2) 
nuclear DNA fragmentation, a marker of apoptosis, by TUNEL staining and 
the number of TUNEL positive nuclei per 5000 myocytes; 3) PAR density 
(fmol/mg) by [“sI]iodocyanopindolol radioligand assay. 
Results: Chronic NE infusion decreased myocardial GSH/GSSG, in- 
creased the number of TUNEL positive nuclei, and downregulated BAR 
density. Trolox or SOD had no effects in the vehicle-treated ferrets, but atten- 
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uated the increase of the number of TUNEL positive nuclei and the reductions 
of myocardial GSH/GSSG and BAR density in NE infusion ferrets (Table). 
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esis of previously reported cardiac pathologies including ventricular remod- 
eling, cardiomyopathy, and sudden cardiac death. 
GSHIGSSG TUNEL positive nuclei BAR 
Saline 143.6 * 16.9 3.5 + 0.8 107.4 * 4.3 
Saline + trolox 181.5 + 20.6 3.2 5 0.4 100.7 zt 4.9 
NE 95.6 * 10.8’ 13.5 + 1.1’ 72.7 Y!T 3.1* 
NE + trolox 142.1 + 15.4t 4.2 + 0.d 104.1 i 23.4t 
NE + SOD 166.8 i 22.4t 4.4 * 0 7t 104.8 i 2.6t 
n = C-8, value are means + SE. *p .Z 0.05 vs saline, tp < 0.05 vs NE 
Conclusion: The results suggest that NE-induced myocyte apoptosis 
and myocardial BAR downregulation may be mediated via oxidative stress 
produced by NE, and that antioxidant therapy may be beneficial in the 
treatment of heart failure. 
1048-l 43 Inhibition of p38 a/@ MAPK Attenuates 
Hypoxia-Mediated and Angiotensin-II-Mediated 
Apoptosis of Carcliomyocytes Isolated From 
Dogs With Chronic jiHeart Failure 
Victor G. Sharov, Anastassia Todor, Sudhish Mishra, Takayuki Mishima, 
George Suzuki, Sidney Goldstein, Hani N. Sabbah. Henry Ford Heart and 
Vascular Institute, Detroif, Michigan, USA 
Background: We previously showed that exposure of failed cardiomyocytes 
to angiotensin-Ii (A-II) or to hypoxia (HX) leads to overexpression of p38 
MAPK. In the present study we tested the hypothesis that inhibition of p38 
MAPK will rescue failed cardiomyocytes from HX or A-II mediated apoptosis. 
Methods: Studies were performed in cardiomyocytes isolated from 5 dogs 
with chronic heart failure (HF) produced by multiple intracoronary microem- 
bolizations (LV ejection fraction ~30%). Cardiomyocytes were exposed to 
HX (95% Na and 5% COs) or to A-II (0.5 FM) for 3 hours in the pres- 
ence (5 PM) and absence of the p38 a/,!l MAPK inhibitor SB 203580 (Inh). 
Overexpression and inhibition of ~38 MAPK was confirmed by Western blots. 
Cardiomyocytes exposed to normoxia (NX) (95% air and 5% COa) for 3 hours 
served as controls. The percent of apoptotic cardiomyocytes was assessed 
immunohistochemically using TUNEL. 
Results: The data are shown in the table. 
% of Apoptotic Cardiomyocytes 
HYPOXIA ANGIOTENSIN-II 
NX 4.8 i 0.7 NX 4.8 & 0.7 
HX alone 16.9 i 2.0* NX i A-II 9.3 + 1.4* 
HX + Inh 9.1 zk 0.4*-’ NX + A-II + Inh 2.6 f 0.6*’ 
[* = p c 0.05 vs. NX: *- = p < 0.05 vs. HX alone or NX + A-II] 
Exposure of failed cardiomyocytes to HX or A-II enhanced apoptosis 
which, in turn, was significantly attenuated after inhibition of p38 MAPK. 
Conclusion: The results indicate that inhibition of ~38 culfl MAPK can 
effectively rescue failed cardiomyocytes from HX-mediated or A-II-mediated 
programmed cell death. 
L-l-L 1048 144 Anabolic Steroids Induce Dose-Dependent Apoptotic Cell Death in Adult Ventricular 
Myocytes in Vitro 
Michael Zaugg, Nasir Z. Jamali, Mahmood Alam, Weimin Xu, Saiyid 
A. Shafiq, M.A.Q. Siddiqui. State Universify of New York, Health Science 
Center, Brooklyn, N): USA 
Background: Anabolic-androgenic steroids (AASS) abuse has been associ- 
ated with ventricular remodeling, cardiomyopathy, myocardial infarction, and 
sudden cardiac death. AASs exert direct toxic effects on cardiomyocytes. 
The purpose of this study was to determine whether exposure to AASs 
would induce apoptosis in adult cardiomyocytes in vitro. 
Methods and Results: Adult ventricular myocytes from male Sprague- 
Dawley rats were exposed to increasing concentrations of the representative 
AAS, stanozolol, (STZ) (1 pmol/L, IO pmol/L, 100 fimol/L). After 20 hours, 
the percentage of myocytes undergoing apoptosis was determined by ter- 
minal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) and 
compared to control myocytes (CTL): 1 KmoliL (STZ) 2 + 1% vs CTL 2.5 
f I%, (p = 0.95); 10 @mol/L (STZ) 12 + 1% vs CTL (p < 0.0001); and 
100 fimol/L 42 -+ vs CTL (p < 0.0001). STZ induced concentration-depen- 
dent apoptotic cell death was corroborated by a significantly increased DNA 
laddering in myocytes when exposed to greater than IO hmol/L as com- 
pared to control myocytes. Furthermore, STZ exposure markedly increased 
the expression of the pro-apoptotic oncogene, Bax, as assessed by reverse 
transcriptase-polymerase chain reaction. 
Conclusions: STZ induces concentration-dependent apoptotic cell death 
in rat myocytes. AASs induced apoptosis may be implicated in the pathogen- 
L--d 1048 145 Qxidative Stress in Ethanol-Induced Cardiomyocyte Apoptosis 
Zhanjun Guan, Charles Y. Lui, Eugene Morkin, Cleamond D. Eskelson. 
University Heart Center, University of Arizona, Tucson, AZ 85724, USA 
Background: Previous studies have shown that alcohol induces myocardial 
damage via a reactive oxygen intermediate (ROI) pathway. 
Methods: To determine whether ethanol induces apoptosis in neonatal 
cardiomyocytes, cardiomyocytes from 1 to 2 day-old Sprague-Dawley rats 
were treated with ethanol at 0 mM, 25 mM, 50 mM, 100 mM and 200 mM for 0 
h, 4 h, 8 h, 16 h and 24 h. u-Tocopherol phosphate (1 mM) and ascorbic acid 
(0.2 mM) were added to medium 1 hr before addition of ethanol. Apoptosis 
was measured by transmission electron microscopy, fluorescent microscopy 
and flow cytometry. Intracellular glutathione was detected by fluorescent 
microscopy. Production of ROI was detected by fluorescent microscopy and 
flow cytometry. Mitochondrial membrane potential (MMP) was measured by 
laser confocal microscopy and flow cytometry, Cytochrome c was assayed by 
immunocytochemistry and caspase-3 activity was measured by calorimetry. 
Results: Histologically, typical apoptosis was found with chromatin con- 
densation, membrane blebing, shrinkage and cytoplasm condensation. Apop- 
tosis wasconcentration-dependent within 0 - 100 mM ethanol (0.68%, 2.03% 
and 9.66% at 0 mM, 50 mM and 100 mM). Necrotic cells were increased 
in 200 mM ethanol. Intracellular production of ROI was increased and glu- 
tathione and MMP decreased after ethanol treatment. Cytochrome c was 
increased in cytosol of cells in ethanol groups compared to nonethanol 
groups. Caspase-3 activity was higher in ethanol-treated groups (P < 0.05). 
Both a-tocopherol and ascorbic acid inhibited oxidative stress and myocyte 
apoptosis in ethanol treated groups (P < 0.05). 
Conclusion: Our data indicated that ethanol induced cardiomyocyte 
apoptosis at 1200 mM and necrosis at >200 mM. The mechanism of action 
appeared to involve mitochondrial damage via an increase in oxidative stress 
and release of cytochrome c, which activates caspases that initiate chromatin 
fragmentation and apoptosis. Antioxidants markedly inhibited oxidative stress 
and apoptosis induced by ethanol. 
1048-146 Anti-ErbB-2-Antibody and Doxorubicin Induce 
Cardiomvocvte Apoptosis Accompanied bv a 
Decreased Phosphdrylation of Al6 and ERK l/2 
Wolfgang Backer, Luanda Grazette, Syed Haq, Anthony Rosenzweig, 
Thomas Force, Roger J. Hajjar. Massachusetts General Hospital. Harvard 
Medical School, Boston, Massachusetts, USA 
ErbB-2 gene (neu or HER2) encodes a transmembrane tyrosine kinase 
receptor. Inhibitory anti-erbB-2 antibodies have been shown to inhibit the 
growth of breast cancer cells and have been introduced as anti-tumor ther- 
apy in addition to anthracyclines. Recent clinical trials have revealed dele- 
terious effects of anti-erbB-2 on cardiac function and additive toxic effects 
in the presence of anthracylines with 28% of women with combined therapy 
for breast cancer experiencing severe cardiac dysfunction. The mechanism 
by which anti-erbB-2 antibodies and anthracyclines synergistically leads to 
cardiac toxicity is not known. In this study we examined the effects of erbB-2 
antibody on cardiac myocyte apoptosis in vitro alone and in combination with 
doxorubicin. To further evaluate the mechanism by which these substances 
lead to apoptosis, we investigated the Akt and ERK l/2 signal transduction 
pathways, which are known to be activated by tyrosine kinase receptors. 
Cultured neonatal myocytes were exposed either to-5 &ml of anti-erbB-2 
antibody or to 1.0 wmol/L doxorubicin (therapeutic dose) alone or in com- 
bination. After 24 hours of treatment cell death was investigated by DNA 
laddering, flow cytometry, TUNEL and ELISA detecting histone associated 
DNA fragments. Both, anti-erbB-2 and doxorubicin revealed significant in- 
creases of apoptosis detected by DNA laddering and an additive effect was 
present in cardiomyocytes exposed to the combination of anti-erbB2 and 
doxorubicin. Similarly flow cytometry, TUNEL and ELISA showed an additive 
effect of anti-erbB2 and doxorubicin on apoptosis. We found in our study, that 
both anti-erbB2 antibody and doxorubicin treatment decrease Akt and ERK 
l/2 phosphorylation in rat neonatal myocytes. This effect occurred within 30 
min. and persisted for 24 hours. These results indicate that the anti-erbB-2 
antibody and doxorubicin induce apoptosis in cardiac myocytes by dephos- 
phorylation of Akt and ERK 112, and that both substances have additive toxic 
effects on cardiomyocyte viability. 
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1 1048-l 471 Endothelin-1 E&presses Nitric Oxide Induced 
Caspase-3 Activation and Antagonizes 
Apoptosis in Cardiomyocytes 
Michiaki Hiroe, Masayoshi Shichiri, Shigeru Ishiyama, Takashi Shimojo, 
Shinji Abe, Susumu Adachi, Mimi Tamamori, Hiroshi ho, Yukio Hirata, 
Fumiaki Marumo. Tokyo Medical and Dental University Women’s Medical 
University, Tokyo, Japan 
Background: Endothelin-I (ET-l), an endothelin-derived vasoactive pep- 
tide, functions as a potent growth factor of cardiomyocye, leading to hyper- 
trophy. In contrast, Nitric oxide (NO) has shown to cause apoptotic death 
of cardiomyocyte. In the present study, we studied the mechanisms of inhi- 
bition by ET-I of NO-induced apoptosis in cultured neonatal rat cardiomy- 
ocytes. 
Methods and Results: Addition of S-nitroso-N-acetylpenicillamine 
(SNAP), a NO donor, induced a fraction of ceils undergoing apoptosis de- 
termined by DNA fragmentation on terminal deoxy-nucleotidyl transferase- 
mediated dUTP-biotin nick end labeling method, agarose-gel electrophore- 
sis. and electron microscopy. Both ET-l and ETa receptor agonist (BQ3020) 
markedly suppressed SNAP-induced apoptosis, and the effect was blocked 
by coincubation with ETs receptor antagonist (BQ123) but bot with ETA re- 
ceptor antagonist (BQ788). Western blot analysis revealed caspase-3 and 
proapoptotic Sax protein expression fo!lowing SNAP administration which 
was inhibited by conincubation with ET-I, whereas Bcl-2 was unaffected by 
either SNAP or ET-I. The regulation of caspase-3 by NO and ET-1 was fur- 
ther confirmed by measurement of caspase-3 enzyme activity. The inhibitory 
effect of ET-1 on NO-induced caspase-3 activation was not abrogated by 
pretreatment with a MAP kinase-kinase-I inhibitor, PO98059. 
Conclusion: These data demonstrate the inhibitory effect of ET-I on 
NO-induced caspase 3 activation and subsequent apoptosis via the ETs 
receptor in cardiomyocytes, suggesting a cell-protective role for ET-I in the 
event of NO production in cardiomyocytes. 
1048-l 48 Exposure of Isolated Canine Failed 
Cardiomvocvtes to Anniotensin-II is Associated 
With Overexpression Gf FasL That is Reversed 
by Inhibition of p38 CyIp MAPK 
Anastassia Todor, Victor G. Sharov, Sudhish Mishra, Takayuki Mishima, 
Pervaiz Chaudhry, Omar Nass, Sidney Goldstein, Hani N. Sabbah. Henry 
Ford Heart and Vascular Institute, Detroit, Michigan, USA 
Background: Long-term therapy with ACE inhibition has been shown to 
attenuate cardiomyocyte apoptosis in animals with heart failure (HF). The 
mechanism by which ACE inhibition rescues cardiomyocytes from apoptosis 
remains unclear. In this study, we tested the hypothesis that exposure of 
cardiomyocytes to angiotensin-II (A-II) leads to overexpression of FasL. 
FasL acting on Fas, present on cardiomyocytes, promotes apoptosis. 
Methods: Studies were performed in cardiomyocytes isolated from 5 
dogs with chronic heart failure produced by multiple sequential intracoronary 
microembolizations (LV ejection fraction ~30%). Cardiomyocytes were ex- 
posed to A-II (0.5 kM) for 3 hours in the presence (5 PM) and absence of 
the p38 o/p MAPK inhibitor SB 203580 (Inh). Overexpression and inhibition 
of FasL and p38 MAPK was confirmed by Western blots. Cardiomyocytes 
exposed to normoxia (NX) (95% air and 5% COs) for 3 hours in the ab- 
sence of A-II or Inh sewed as controls. Western blots were quantified using 
a densitometer and expressed in densitometric units, 
Results: The data are shown in the table in densitometric units. 
FasL 
~38 MAPK 
NX (control) 
3.3 * 0.4 
3.9 + 0.2 
NX + A-II 
6.7 i 0.3* 
6.7 A 0.2* 
NX + A-II + Inh 
3.8 * o.z** ___--I 
1.4 i 0.4** _- 
[* = p < 0.05 vs. NX; ** = p < 0.05 A-II alone vs. A-II + Inh] 
Exposure of failed cardiomyocytes to A-II caused significant upregulation 
of FasL that was reversed by inhibition of p38 MAPK. 
Conclusion: The results indicate that A-II may promote apoptosis by 
upregulation of FasL and p38 MAPK. The findings also suggest a cross talk 
between FasL and the ~38 MAPK in A-II-mediated cardiomyocyte apoptosis. 
p-l . 1048 149 Apoptosis in Skeletal Muscle of Patients With Chronic Heart Failure: Role of Inducible Nitric 
Oxide Synthase and IL-lp Expression 
Volker Adams, Rainer Hambrecht, Hong Jiang, Sven-Mobius-Winkler, 
Gerhard Schuler. University Leipzig - Heart Center, Department of 
Cardiology: Leipzig, Germany 
Background: Recently apoptosis (Ap) of skeletal muscle (SM) myocytes was 
detected in animal models of chronic heart failure (CHF) and in patients (pts) 
with CHF. Several in vitro studies demonstrated that inflammatory cytokines 
and high concentrations of nitric oxide (NO) are potent agents to induce 
Ap. It is still unknown which factors induce apoptosis in SM of patients 
with CHF. Therefore, we analyzed the expression of inflammatory cytokines 
and inducible nitric oxide synthase (INOS) in SM of patients with CHF and 
correlated these factors with the occurrence of Ap. 
Methods: SM biopsies (m.vastus lateralis) of 39 CHF pts (NYHA 11-111) 
and 8 age-matched healthy controls were analyzed by TUNEL for the pres- 
ence of Ap and by quantitative immunohistochemistry for INOS, TNF-a, IL-l,f! 
and IFN-I/. Four sections of each biopsy were screened for apoptotic nuclei. 
A sample with at least 2 positive nuclei per section was classified as positive 
Maximal oxygen consumption (VOamax) was determined by ergospirome- 
try. 
Results: Ap was detected in 15/39 (38%) CHF-pts and in none of the 
controls. Pts with Ap positive SM exhibited a significant lower V02max (15.5 
f 0.9 vs 19.8 f 0.9 ml/kg min; p = 0.004) a higher iNOS expression (5.6 & 0.8 
vs 2.3 j, 0.3% positive tissue area; p < 0.001) and a higher IL-la expression 
(1.4 i 0.1 vs 1.0 & 0.08% positive tissue area; p < 0.02) compared with 
pts exhibiting Ap negative SM biopsies. No difference was detected between 
Ap positive and negative SM with respect to local expression of TNF-(Y and 
-IFN-)/. 
Conclusion: For the first time a correlation between IL-l/? expression 
and Ap could be detected in SM of pts with CHF. This suggests that IL-ij! 
and iNOS are possibly involved in the regulation of Ap, finally contributing to 
a reduced exercise capacity. 
1048-l 50 Reactive Oxygen Species Activate p38 
Mitogen-Activated and C-Jun N-Terminal Kinase 
(JNK) Signaling Cascades in Myocytes, and 
Synergizes With Cytokines ta Induce Myocyte 
Apoptosis 
Hiroshi Nakamura, Min Irwin, Tom Parker, Jim Woodgett, Josef Penninger, 
Peter Liu. The Toronto and Princess Margaret Hospitals, Toronto, Ontario, 
Canada 
Background: Reactive oxygen species (ROS) are potent intracellular sig- 
naling molecules, and are associated with reperfusion and inflammation, and 
localized cytokine production, such as tumour necrosis factor (TNF). We 
determined the potential interaction of ROS with cytokines in the induction of 
apoptosis through stress activated kinases. 
Methods: Neonatal rat myocytes were exposed to low doses of Ha02 (0.1 
to 10 wM), and the cells were harvested serially from 5 to 90 minutes. The 
activation of p38 MAP kinase phosphorylated form can be detected within 5 
minutes of exposure, and persists beyond 30 minutes. Kinase activity can be 
detected by IO min, and continued to increase after 60 min of exposure, as 
measured by phosphorylation of substrate GST-c-Jun. Western blot analysis 
demonstrated that both JNK isoforms (46 kd JNKI and 57 kd JNK2) and ERK 
pathways were activated within 5 minutes of exposure and persists beyond 
90 minutes. 
Results: Myocyte viability showed: 
W’z 0i~M 0.1 KM 1 PM lO/*M -_ 
TNF 300 mg 10016% 75 zk7% 65*5% 63 i 2% 
TNF 1000 mg 85f7% 65 zk 8% 49 * 2% 46 zk 4% 
- 
The presence of apoptosis was confirmed by DNA ladder formation and 
characteristic nuclear morphology. 
Conclusion: ROS are potent activators of the signaling cascade of JNKs 
and ~38 MAPK in myocytes, and collaborates with cytokine such as TNF in 
the induction of myocyte apoptosis. 
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c__- 1049 151/ A Rapid Bedside Test for Brain Natriuretic Peptide Accuratelv Predicts Theraoeutic 
Response and Clinical Outcomes in Patients 
Admitted With Decompensated Heart Failure 
Van L. Cheng, Radmila Kasanegra, Nancy Gardetto, Alan S. Maisel. VAMC 
and UCSD, La Jolla, CA; USA 
Background: While therapy for patients with decompensated congestive 
heart failure (CHF) often leaves patients feeling better, there are no objective 
measures of improvement that correlate with the short-term outcomes of 
mortality and readmission. Because brain natriuretic peptide (BNP) reflects 
boih left ventricular stretch as well as neurohormonal modulation, we hypoth- 
esized that this peptide would be useful in assessing therapeutic responses 
and outcomes in patients admitted with decompensated CHF. 
Methods: BNP was measured daily (Biosite Diagnostics, La Jolla, CA) 
during parenteral treatment (inotropes, vasodilators, diuretics) of 43 patients 
admitted with decompensated NYHAclass IV CHF. Discharge BNP levels as 
well the change in BNP levels were related to subsequent end-points, which 
included mortality (during hospitalization) and readmission within 30 days. 
Results: Of the 43 patients admitted with decompensated CHF, fifteen 
endpoints occurred (death: n = 8, readmission: n = 7). The delta BNP change 
during treatment was (-)337 pgiml in patients without an endpoint and 
(+)I56 pg/ml in patients with end-points (P < 0.001). No end-points occurred 
in those patients whose discharge BNP level was less than 900 pg/ml. Of 
the 21 patients whose discharge BNP was greater than 900 pg/ml, 15 (71%) 
developed an end-point. Patients whose discharge BNP was greater than 900 
pg/ml were hospitalized longer (17.5 vs. 7.9 days) and had less of a decrease 
in NYHA with therapy (-0.64 vs. -1.23) than patients with discharge BNPs 
less than 900 pg/ml. Of the eight patients who died in the hospital, only one 
had a decrease in BNP levels during treatment. 
Conclusions: In patients admitted with decompensated CHF, changes in 
BNP levels both during treatment and at discharge are strong predictors for 
mortality and early readmission. The results of this study further suggest that 
therapy for decompensated heart failure should be tailored to decreasing the 
BNP levei during hospitalization. 
1049-I 52 / Usefulness of a Rapid, Bedside Test for Brain 
Natriuretic Peptide in the Evaluation of Patients 
Presenting to the Emergency Room With 
Possible Congestive Heart Failure 
Quyen Dao, Padma Krishnaswamy, Radmila Kasanegra, 
Rambod Amirnovin, Alan S. Maisel. VAMC and UCSD, La Jo//a, CA, USA 
Background: Congestive heart failure (CHF) is commonly misdiagnosed in 
the emergency room (ER) setting, in part because of the poor specificity 
and/or sensitivity of signs and symptoms. Because brain natriuretic peptide 
(BNP) is released only in setting of left ventricular (Iv) stretch, we hypothe- 
sized that it might be useful as a diagnostic marker in the emergency room 
setting. 
Methods: We evaluated 100 patients who presented to the ER with signs 
or symptoms possibly compatible with CHF (dyspnea, edema, weight gain, 
etc). BNP was measured (Biosite Diagnostics, La Jolla, CA) and the results 
were blinded from both ER personnel, who made diagnoses at the time of 
disposition. and 2 cardiologists who made the final diagnosis, taking into 
account the results of subsequent tests (ethos, lung function tests, etc). 
Results: Specificity and sensitivity of usual signs of CHF were: jugular 
venous pressure: 92% and 34%; third heart sound: 90% and 26%; rales: 
81% and 57%. BNP was, however, the single best predictor for diagnosing 
CHF. In patients with a final diagnosis of CHF, BNP level was 630 i 77 
pg/ml vs. 37 i 4 pg/ml in patients without CHF (P < O.OOl), At a BNP cutoff 
value of 100 pgiml, specificity was 98% and sensitivity was 100%. Patients 
with a final diagnosis of pulmonary disease (bronchitis, pneumonia, asthma) 
had BNP levels of only 30 f pg/ml vs. 645 i 77 for patients with CHF (P < 
0.001). In patients presenting with edema, BNP was 37 * 8 pgiml in patients 
with no CHF vs. 670 + 104 pg/ml when CHF was present. All ten patients 
misdiagnosed by ER personnel would have been correctly identified by BNP 
levels. 
Conclusion: We found BNP to be both highly sensitive and specific in 
differentiating congestive heart failure from other medical problems encoun- 
tered in the emergency room setting. This rapid, point of care test should 
greatly enhance a physicians diagnostic ability in patients presenting with 
symptoms possibly consistent with congestive heart failure. 
/ i 049-l 53 1 Plasma Brain Natriuretic Peptide Response to 
Exercme is Augmented in Patients With Left 
Ventricular Dysfunction and Heart Failure 
Toru Kinugawa, Masahiko Kato, Akihiro Endo, Shuichi Osaki, 
Kazuhide Ogino, Osamu Igawa, lchiro Hisatome, Chiaki Shigemasa. 1st 
Dept. ht. Med. Toftori Universit): Yonago, Japan 
Background: We have previously demonstrated that patients with symp- 
tomatic heart failure (HF), but not with asymptomatic left ventricular dysfunc- 
tion (LVD) have augmented plasma atrial natriuretic peptide (ANP: pg/ml) 
response to exercise. The aim of this study was to determined if responses 
of plasma brain natriuretic peptide (BNP: pg/ml) are augmented in patients 
with LVD and HF. 
Methods: Ventilatory and plasma ANP & BNP responses were assessed 
in 24 patients with LVD, 25 patients with HF (NYHA classes 11-111) and 
18 normal subjects during symptom-limited cardiopulmonary exercise test- 
ing. The increment in plasma BNP was divided by the increment in VOs 
(mliminlkg) and this BNP-Ex Ratio (ABNP/AVO~) was compared among 
the three groups. We used this ratio as an index of exercise BNP response 
normalized by the exercise tolerance. 
Results: see Table (mean & SEM, *p < 0.05 vs Normal, #p < 0.05 
vs LVD). Exercise tolerance was progressively decreased and plasma BNP 
levels were increased as HF worsened. ANP-Ex Ratio was higher only in 
patients with symptomatic HF, while BNP-Ex Ratio was augmented both in 
patients with LVD and HF. 
NOrlTlal LVD HF 
Peak VOs 
LVEF (%) 
rest BNP 
peak BNP 
BNP-Ex Ratio 
ANP-Ex Ratlo 
27zk2 21+1 16&l 
69i2 42+3= 35%3*# 
is*4 132+32* 285i47*# 
2517 181 *43* 345&56‘# 
0.3 h 0.1 2.6 +0.8* 4.5 i 1.0* 
0.8 4 0.2 2.7 + 0.6 7.3 * 2.o*# 
Conclusion: These data showed that the augmented BNP-Ex Ratio be- 
came apparent in patients with LVD and progressively higher in HF, sug- 
gesting that augmented exercise BNP ratio exists early in the course of 
developing HF. 
/ 1049 154 The Cardiac Hormone BNP is a Marker for Left Ventricular Hypertrophy in Dialysis Patients 
Alessandro Cataliotti, Michihisa Jougasaki, Hanna Leskinen, Denise 
M. Heublein, Lorenzo Malatino’ , lgnazio Bellanuova’ , Giuseppe Giacone’, 
Saverio Parlongoa, Giovanni Tripepi’, Carmine Zoccalis, John C. Burnett 
Jr.. ‘/stifufo di Clinica Medica Luigi Condoreli, Cafania; “Divisione di 
Nefrologia, Reggio Calabria, Italy; Mayo Clinic and Foundation, Rochester, 
Minnesota, USA 
Background: The cardiac hormones atrial natriuretic peptide (ANP) and 
brain natriuretic peptide (BNP) and the endothelial derived natriuretic pep- 
tide CNP are elevated in plasma of patients with end-stage renal disease 
(ESRD). Studies suggest that in hypertension and heart failure ANP and 
BNP are markers for left ventricular hypertrophy (LVH). In addition to ANP, 
BNP and CNP, a potential fourth member of the natriuretic peptide (NP) 
family, Dendroaspis natriuretic peptide (DNP), has been reported. How- 
ever, it is not known whether the plasma concentration of DNP is increased 
in patients with ESRD. The aim of the current study was to determine if 
plasma concentrations of ANP, BNP, CNP and DNP are all elevated in 
plasma of dialysis dependent patients and if they serve as serum markers of 
LVH. 
Methods: We compared plasma NP concentrations in 59 dialysis subjects 
without LVH with that in 51 dialysis patients with LVH (LVMI > 125 g/m*). To 
evaluate the contribution of renal disease on plasma NP concentrations, we 
selected 20 patients without LVH or other diseases. 
Results: In dialysis patients with LVH, there were marked increases in 
ANP and BNP as compared to those in patients without LVH (ANP 89 f 6 vs 
55 * 5, BNP 107 f 11 vs 31 i 3 pgiml; p < 0.05 for both), while CNP and DNP 
were not different. Importantly, in the subset of dialysis patients without LVH 
or other disease, plasma BNP concentrations were not increased compared 
to controls (18 t 1 vs 12 i 4 pg/ml) while ANP, CNP and DNP were higher 
(ANP 40 + 2 vs 15 f 3, CNP 18 & 0.4 vs 15 i 1 and DNP 21 * 2 vs IO I! 2 
pg/ml; p < 0.05 for all). 
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Conclusions: These studies demonstrate that in dialysis patients the 
elevation of plasma BNP is associated with altered cardiac structure whereas 
a normal BNP suggests the absence of LVH. Thus, BNP as compared to the 
other known NP serves as a serum marker for LVH that is a major risk factor 
for increased morbidity and mortality in dialysis patients. 
L-A-I 1049 155 Nesiritide Therapy for Decompensated CHF is Not Proarrhythmic 
Andrew J. Burger’, George Dennish III, Jay Dinerman, Darlene P. Horton, 
Michael J. Koren, Guillermo Torre2. ‘Beth lsfael Deaconess Hospital, 
Boston, MA; ‘Baylor College of Medicine, Houston, TX, USA 
Background: Increased ventricular ectopy during dobutamine therapy for 
decompensated CHF (dCHF) is,common but not well studied. Applying 
proarrhythmia criteria to baseline and on-treatment Holter recordings, the 
PRECEDENT study (Prospective Randomized Evaluation of Cardiac Ectopy 
with DobutaminE or Nesiritide Therapy) compared the proarrhythmic effects 
of 2 doses of IV nesiritide (b-type natriuretic peptide, 0.015 or 0.03 &kg/min) 
to dobutamine (minimum dose of 5 bg/kg/min). 
Methods: Subjects (n = 246) had NYHA Class Ill or IV CHF, were hospital- 
ized for treatment of symptomatic dCHF, and underwent Holter monitoring (n 
= 225) both 24-hours before and during the first 24-hours of therapy. Therapy 
was open-label. Core Holter analysis was blinded to treatment. Comparing 
baseline to on-treatment Hotter recordings, to declare treatment as proar- 
rhythmic in a given subject, the Velebit criteria required a 4-fold increase in 
total hourly premature ventricular beats (PVBs) or a 1 O-fold increase in repet- 
itive forms. Using criteria from the Cardiac Arrhythmia Pilot Study (CAPS), 
proarrhythmia was declared with a 3- to 1 O-fold increase in total hourly PVBs, 
determined by a formula adjusted for baseline frequency of PVBs. 
Results: The number (percent) of subjects for whom treatment was 
proarrhythmic is summarized in the table below: 
Proarrhythmia Dobutamine 
rating (n = 73) 
_I---__. ” -. 
Nesiritide (~gikglmin) P-ValUe 
0.015 (n = 80) 0.030 (n = 72) (Fisher) -I__-. ______.___ 
Velebit-Yes 17 (23%) 3 (4%) 0 (0%) <O.OOl 
NO 56 (77%) 77 (96%) 72 (100%) 
GAPS -Yes 7 (10%) 0 (0%) 0 (0%) 0.001 
NO 66 (90%) 80 (100%) 72 (100%) __--_ _,.-----. --- 
At 24 hours, mean systolic blood pressure was decreased by 12 and 13 
mm Hg in the 2 nesiritide dose groups, respectively, and was decreased by 
1 mm Hg in the dobutamine group. (p-value is <O.OOl) 
Conclusions: Nesiritide, a new intravenous therapy for dCHF, was not 
proarrhythmic in this study, whereas dobutamine was associated with signif- 
icant proarrhythmia. 
Efficacy of Combination Therapy With Atrial 
Natriuretic Peotide and Nitroalvcerin in Patients 
With Congestive Heart Failure w 
Hideki Watanabe, Masaaki Kakihana. K/NU Medical Association Hospital, 
Mitsukaido; lbaraki Prefectural University, Ami, Japan 
Background: Nitrate tolerance is a major limitation in nitroglycerin (NTG) 
therapy in patients with congestive heart failure (CHF). Recently, atrial na- 
triuretic peptide (ANP) has been used therapeutically in CHF patients, but 
continuous administration of ANP has been reported to induce downregu- 
lation of ANP receptor. Recently, it has been reported that small dose of 
ANP may attenuate the activation of neurohormonal factors. Therefore, we 
invesiigated the effects of the combination therapy with ANP and NTG in 
patients with CHF. 
Methods: Twenty-four patients with CHF (NYHA class Ill or IV) were ran- 
domized to receive intravenous infusion of ANP alone (A group, n = 8), NTG 
alone (N group, n = 8) or both (A + N group, n = 8). Dose titration was started 
by the infusion of ANP at 0.05 &kg/min (A group), NTG at 0.3 Fgikglmin 
(N group), or ANP at 0.025 and NTG at 0.15 &kg/min (A + N group), and 
these doses were doubled every 15 minutes to achieve a 30% reduction in 
mean pulmonary arterial pressure (mPA, mmHg). After achievement of the 
desired response, there were no differences in hemodynamics among the 
three groups. The infusion rates were maintained for 24 hours following the 
titration (Final dose: A group, ANP 0.18 f 0.11 Fg/kg/min; N group, NTG 1 .O 
& 0.21 pg/kg/min; A + N group, ANP 0.08 f 0.02 bg/kg/min + NTG 0.48 
* 0.06 mgikgimin), and measurements and blood sampling were repeated 
every 4 hours. Blood samples were drawn from the right atrium for deteimi- 
nation of plasma cGMP (second messenger of ANP, pmol/ml), platelet cGMP 
(second messenger of NTG, pmolil Og PLT) levels and plasma aldosterone 
levels (pg/ml). 
Results: In the A group, mPA was elevated (23 i 5 to 35 & 5, p < 0.05) 
and plasma cGMP was decreased (39 f 8 to 21 f 9, p < 0.05) at 16 hours 
after the titration. In the N group, mPA was elevated (22 f 6 to 34 i 6, p < 
0.05) and platelet cGMP was decreased (2.1 + 0.9 to 0.6 * 0.5, p < 0.05) at 
12 hours after the titration. However, in the A + N group, mPA (24 * 4 to 25 
* 5), plasma cGMP (26 & 6 to 25 f 5) and platelet cGMP (1.4 & 0.7 to 1.5 
& 0.8) remained for 24 hours after the titration. Plasma aldosterone level at 
24 hours after the titration was significantly decreased in the A group and A 
+ N group (A group: 131 f 25 to 98 f 17, p < 0.05; N group: 133 f 21 to 
130rt19,NS;A+Ngroup:126+23to104f16,p~0.05). 
Conclusion: The combination therapy with ANP and NTG may maintain 
hemodynamic effects without tolerance or downregulation, and may attenu- 
ate neurohormonal factors in patients with CHF. 
I 1049 157 Salutary Effect of Exogenous Atrial Natriuretic Peptide on Left Ventricular Relaxation in 
Patients With Left Ventricular Hypertrophy 
Yoichi Kijima, Katsuya Hata, Hideyuki Takaoka, Hiroya Kawai, 
Toshiro Shinke, Masakazu Nanahoshi, Hideaki Okubo, Takeomi Murata, 
Soichiro Qta, Mitsuhiro Yokoyama. Kobe University Hospital, Kobe, Japan 
Background: Effects of atrial natriuretic peptide (ANP) on vascular system 
have been well investigated. However, direct effects of ANP on myocardial 
contractile and diastolic function, especially in pathological condition, has not 
been well elucidated. The aim of this study was to assess the direct effect of 
intracoronary infusion of exogenous ANP on left ventricular (LV) systolic and 
diastolic function in patients with LV hypertrophy (LVH). 
Methods: Six patients with LVH (5 hypettrophic cardiomyopathy, 1 hy- 
pertension, mean LV ejection fraction 53%) were enrolled in this study. We 
measured LV end-systolic and end-diastolic pressure (ESP and EDP), stroke 
volume (SV), relaxation (tau), contractility (Emax, LV elastance measured 
by the slope of the end-systolic pressure-volume relation), and arterial af- 
terload (Ea, effective arterial elastance caluculated by ESP/SV) before and 
after intracoronary infusion of low and high dose (0.02 and 0.1 &g/kg/min) 
of ANP, using manometer tipped conductance catheter with atrial pacing to 
keep heart rate constant. 
Results: ANP sigmificantly improved LV relaxation with no influence on 
LV contr&tility regardless of infused dose. On the other hand, high dose of 
ANP decreased ESP, EDP and Ea, and increased SV, reflecting systemic 
effects in this dose. 
ESP EDP _~ 
(mmHal 
tau 
(msec) 
EmaX Ea 
~mmHa/ml~m’) 
Control 110.9 14.6 61.6 44.9 3.56 2.90 
0.02 ~g/kg/min 116.5 13.4 59.3 41.9* 3.31 3.24 
0.1 onikolmin 102.0x 11 9* 66.5* 37.9* 3.38 2.60” 
*p < 0.05 VS CONTROL 
Conclusion: Low dose of exogenous ANP improved LV relaxation with 
no influence on LV contractility and systemic hemodynamics in patients with 
LVH, indicating that it will be a novel strategy for treating patients with LVH 
showing diastolic dysfunction without contractile dysfunction. 
L--L--- 1049 158 Results of an Open Label Dose Response Study of Thalidomide in Patients With Advanced Heart 
Failure and Elevated Levels of TNF 
Biykem Bozkurt, Adrienne Chee, Dorellyn Lee-Jackson, Anita Deswal, 
Jerome 8. Zeldis, Douglas L. Mann. Baylor College of Medicine, Houston, 
TX; Celgene Corporation, Warren, NJ, USA 
Background: Recent studies suggest that inhibition of TNF (Tumor Necrosis 
Factor) in chronic heart failure (HF) can result in suppression of the inflamma- 
tory response and improvement in clinical parameters. In \litro, thalidomide 
causes inhibition of TNF production by human monocytes. This study exam- 
ines the safety and efficacy of increasing doses of thalidomide in patients 
with class Ill-IV HF. 
Methods: 7 patients with NYAclass Ill-IV HF, LVEF < 40% and circulating 
TNF levels greater than 1.5 times upper limit of normal were treated with 
thalidomide in an open label dose response design involving five escalating 
doses ranging from 50 mg to 800 mg per day, with each dose titration 
occurring every two weeks for IO weeks if tolerated, followed by a 12-week, 
maintenance phase. LV EF and TNF levels were measured at baseline and 
upon completion of the maintenance phase. 
Results: 5 patients completed the study. 2 patients were withdrawn at 
the beginning of the titration phase, one due to worsening renal function 
with overdiuresis, the second due to psychiatric problems. Patients on lower 
dose thalidomide did not have reduction in the TNF levels and did not have 
changes in the EF. Two patients who were able to tolerate the highest dose 
of thalidomide (800 mg/day), had reduction in their TNF levels (-23% and 
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-29%), accompanied by marked improvement in the EF (+ll and +I9 units) 
compared to baseline. 
Conclusion: Higher doses of thalidomide suppressed TNF levels in pa- 
iients with advanced heart failure. Moreover, this was accompanied by im- 
provement in LVEF. These results suggest a larger randomized placebo 
controlled study with thalidomide or its analogue with a lesser toxicity profile 
may be warranted. 
1 1049-l 59 Roles of Apoptosis and Cytokine Families on 
the Reperfusion lniurv in the Patient With Acute 
fvlyocardial Infarction* 
Eiichi Geshi, Akihiko Nomizo, Hideo Hara, Takashi Katagiri. Third 
Department of lnfemal Medicine, Show Universify School of Medicine 
Tokyo, Japan 
Background: The roles of apoptosis and cytokines on the mechanism 
of reperfusion injury after PTCA have been still controversial. Recently, 
Fas/Fas-L system has been established as one of the regulating pathways of 
the apoptotic cell death. The aim of this study is to clarify roles of Fas/Fas-L 
system and cytokines in the process of reperfusion injury after PTCA in 
patients with acute myocardial infarction (MI). 
Methods: In the 34 patients with acute anteroseptal Ml with successful 
recanalyzation by PTCA, blood samples were obtained from coronay sinus 
(Cs) and peripheral vein (PC) at just before and after (0, 12, 24, 48 and 
72 hr) recanalyzation. Plasma concentrations of sFas-L (soluble Fas-ligand; 
apoptosis introducing factor), sFas (soluble Fas; apoptosis inhibiting factor), 
gp130 (cytokine relating factor), and NMP (nucler matrix protein; incidence 
of cell death) were measured by the ELISA and compared with BNP and 
CKMB activity. 
Results: Plasma sFas-L concentration of Cs indicated 0.080 rig/ml before 
PTCA. It was transiently increased to 0.16 at 12 hr after PTCAthen decreased 
to 0.092. Those of Pe were lower than Cs in all periods and did not indicate 
significant changes. The sFas concentration of Cs indicated 1.02 rig/ml before 
PTCA. There was no significant change at 12 hr but increased significantly to 
1.70 at 24 hr, then gradually decreased. The sFas-L of 12 hr indicated highly 
correlation with the sFas of 24 hr. Plasma NMP concentration of Cs before 
PTCA was 5.44 U/ml and it was transiently increased to 8.78 at 12 hr, then 
gradually decreased. Those of Fe were significantly lower than those of Cs 
in all periods. NMP and sFas-L concentrations in Cs indicated similar pattern 
and there was significantly high correlation between them. The gp130 of Cs 
was significantly increased at 12 hr and was higher than that of Pe in all 
periods. Furthermore peak sFas-L and gp130 indicated highly correlations 
with both peak CKMB and BNP of 7th day. 
Conclusion: We concluded that in Ml patients with PTCA apoptosis and 
cytokine families induced by the reperfusion in the acute stage were strongly 
related with the infarcted size and cardiac function in the chronic stage. 
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1 1050-I 20 / Distribution of Angiotensin Converting Enzyme 
Polymorphism is Related With the Level of 
Physical Performance 
Aris Anastasakis, Antigone Miliou, Dimitris Markou, Angeles Rigopoulos, 
Artemis Theopistou, Evangelia Karvouni, Elias Sevdalis, 
Dimos Panagiotakos, Christodoulos Stefanadis, Pavlos Toutouzas. 
Department of Cardiology University of Athens, Greece 
Background: Angiotensin converting enzyme (ACE) genotype has been as- 
sociated with increased physical performance. However, recent data remain 
controversial, implicating either the II or the DD genotype. In this study we as- 
sessed the ACE genotype distribution among elite athletes, college athletes 
and control subjects. 
Methods: ACE genotype distribution was compared among 48 elite ath- 
letes (Group A; 16 male, mean age 22.2 & 10.5 years), 255 college athletes 
(Group B; 243 male, mean age 20 i 5 years) and 100 healthy volunteers 
from the general population (Group C; 53 male, mean age 36.6 f 20 years). 
Group A consisted of 28 weight lifters, 5 medium- and long-distance runners, 
and 5 rowers. DNA was extracted from peripheral blood samples and ACE 
genotype (DD, ID, II) was determined using a three-primer polymerase chain 
reaction amplification. 
Results: 
ACE genotype 
DD 
ID 
II 
Total 
Group A 
22 (45.8%) 
15 (31.2%) 
11 (23.0%) 
48 (100%) 
Group 6 
200 (78.4%) 
32 (12.5%) 
23 (9.1%) 
255 (100%) 
Group C 
94 (94.0%) 
4 (4.0%) 
2 (2.0%) 
100(100%) 
II genotype was significantly more common in elite athletes than in the 
other 2 groups (p < 0.001). Moreover, college athletes had a higher percent- 
age of II genotype comparing to the control group (P < 0.001). 
Conclusions: Our results support the association of II genotype with 
increased physical performance. Furthermore, the prevalence of &I genotype 
is related to the level of performance. 
1 1050-l 21 / Epineprine Induces Free Radical Release and 
Upregulates Endogenous Superoxide Dismutase 
Gene and Protein Expression in Human 
Coronary Artery Endothelial Cells 
Jawahar L. Mehta, Francesco Romeo, Dayuan Li, Min Shi. University of 
Norida and VA Medical Center, Gainesville, FL, USA; University of Rome 
“Tor Vergafa”, Rome, /fa/y 
Background: Several studies have shown that exercise is an oxidant stress, 
and yet it protects humans from cardiovascular disease. A previous study 
from our group has shown that moderate exercise immediately increases lipid 
peroxidation, but soon thereafter causes a sustained increase in antioxidant 
activity is serum (Am J Cardiol80: 1640-l 642, 1997). Since there is a positive 
correlation between antioxidant production and cardiac events, we designed 
this study to examine the effect of catecholamines on free radical release and 
endogenous superoxide dismutase gene and protein expression in human 
coronary artery endothelial cells (HCAECs). 
Methods: HCAECs were exposed to epinephrine (0.1 to IO PmoliL) 
for 24 hours. Parellel groups of cells were incubated with an intracellular 
free-radical scavenger Trolox, or the beta-blockers carvedilol and atenolol 
(each IO Fmol/L). 
Results: At 1 hr of incubation with epinephrine, superoxide anion gener- 
ation increased by 50 f 5% in the HCAECs. At 24 hrs of incubation, there 
was approximately 100% increase in MnSOD and Cu/ZnSOD gene (RT- 
PCR) and proteins (Western analysis). SOD activity, measured as inhibition 
of pyrrogallol oxidation, was also increased (109 * 9%). Trolox and the beta- 
blockers carvedilol and atenolol superoxide anion generation decreased (P 
< 0.01 vs. epinephrine alone). The upregulation of SOD was also blocked by. 
pre-treatment of HCAECs with Trolox. Treatment of cells with two different 
beta-blockers catvedilol and atenolol also blocked the upregulation of SOD 
(P < 0.01 vs. epinephrine). 
Conclusions: These observations show that epinephrine via beta-adreno- 
ceptor activation causes free radical generation, but at 24 hrs it causes a 
marked increase in endogenous anti-oxidant species. These observations 
may be the basis of long-term benefits of exercise. 
L---CL 1050 122 Intravenous Testosterone has no Effect on Cardiovascular and Ventilatory Responses to 
Exercise in Elderly Men With Coronary Artery 
Disease 
Niall M. Moyna, Alan W. Ahlberg, C. Michaeal White, M. Ferraro-Borgida, 
Carol C. McGill, Gay V. Heller, Rehan Qayyum, Paul D. Thompson. 
Hartford Hospital, Hartford, CT; USA 
Background: Data suggest that the acute IV administration of physiologic 
doses of testosterone alters the ischemic threshold in men with coronary 
artery disease (CAD). However, the effects of acute administration of phys- 
iologic and supraphysiologic doses of testosterone on cardiovascular and 
ventilatoy responses to exercise are unknown. 
Methods: Seventeen men (67 & 5 yr) with stable CAD, and evidence of 
exercise induced ischemia by radionucleotide imaging received intravenous 
testosterone or placebo in double-blind randomized order prior to undertak- 
ing a treadmill exercise test (Bruce protocol). The testosterone dose was 
individualized to double (physiologic) or increase to 6 times (supraphysio- 
logic) baseline serum testosterone levels, based upon our previous pharma- 
cokinetic study (J Clin Pharmacol, (3) 792-97, 1998). Cardiovascular and 
ventilatoy measures were compared at the anaerobic threshold (AT) and 
peak exercise. 
Results: Acute administration of physiologic orsupraphysiologic IV testos- 
terone had no effect on HR (heart rate), V02 (oxygen uptake), Ve (minute 
ventilation) or RER (respiratory exchange ratio) at the AT (Table 1) or total 
exercise time, HR, V02, Ve, RER, RPP (rate pressure product) and RPE 
(rating of perceived exertion) at peak exercise. (Table 2) 
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Table 1: Cardvxascularand ventilatotymeasures atthe anaerobic threshold 
-_-_ ..- 
Placebo Physiologic Supraphysiologic P value ___- 
VO2 (mllkglmin) 10.09 * 3.03 12.41 f2.01 12.46f1.92 NS 
%VOPmax 59.89 k 8.87 61.56zt 9.55 62.00 zt 10.61 NS 
Ve (I/min) 22.16 zk 5.42 22.81 i4.41 22.90 + 4.56 NS 
RER 0.77f0.05 0.78 + 0.06 0.76 f 0.05 NS _--- 
Table 2: Garaiovascular and ventilatory measures at peak exercise 
Placebo Physiologic Supraphysiologic P value 
Time (see) 524.4i 163.6 525.Pzt 165.5 529.8f161.4 NS 
Heart rate (bimin) 143.8 & 21.5 144.2 & 19.1 145.3 f 17.8 NS 
V02 (mlikglmin) 22.8 zt 6.4 22.5 zt 6.4 22.7 zt 6.7 NS 
RER 1.16 + 0.09 1.17% 0.08 1.16 i 0.08 NS 
RPP 23809.4% 5351.5 24632.5 l 5579.0 24685.6* 5298.6 NS 
RPE 16.1 * 2.2 15.6 f 2.3 15.9 + 2.2 NS 
Values in table 1 and table 2 are mean i SD 
Conclusion: Acute administration of physiologic and supraphysiologic 
doses of testosterone has no effect on the cardiovascular and ventilatoty 
responses to exercise in men with CAD. 
c__T? 1050 123 The Skeletal Muscle Intrinsic Mitochondrial Oxidative Capacity Contributes to Determine the 
Exercise Capacity-in Normal Subjects 
Bertrand Mettauer, Herve Sanchez, Joffrey Zoll, Eliane Lampett, 
Florence Ribera, Vladimir Veksler’, Xavier Bigard, Eric Epailly, 
Jean Lonsdorfer, RenQe Ventura-Clap&. CHRU Sfrasbourg; ‘INSERT U 
446, and CRSSA Grenoble, France 
Background: Although skeletal muscle (SM),morphologic and biochemical 
features are known to be determinants of the max oxygen uptake (mV0,) 
and VOe at the ventilatory threshold (VT), their intrinsic mitochondriae (Ml) 
respiration features have never been directly assessed in humans, nor related 
to mVOp or VO2 at the VT. 
Methods: SM Vastus Lateralis biopsies have been obtained from 7 seden- 
tary normals (SED, mVOp < 100% of predicted), 7 physically active normals 
(PA, 100% < mVOn < 130% of predicted) and 7 trained subjects (TR, mVOp 
> 130% of predicted). After saponin permeabilization the in-situ Ml 02 uptake 
(V, pmol02/min/g dry weight) has been measured in the absence of ADP 
(VO) and presence of increasing levels of ADP, without (Cr-) and with (Cr+) 
creatine. This permitted to determine a Vmax of the MI, representing their 
oxldative capacity, a Km, representing their affinity for ADP and an accep- 
tor control ratio (ACR = Vmax/VO), representing the phosphorylation-VOZ 
coupling efficiency. 
Results: Values are expressed in table as means i SEM, p < 0.05 
‘SEDvsfR $SEDvsPA #PAvsTR, The Vmax is correlated with mV02 and 
VQ at the VT (figure). 
vo vmax Cr- ACRCr- KmCr- VmaxCr+ KrhCr+ 
SED 1.39 zt 0.26 3.62 zt 0.70* 3.05 zt 0.45* 128f56* 3.77* 0.21* 125 * 59 
PA 1.81 -i- 0.24 7.12il.O6§ 3.74i 0.43 22Ort58 7.30*1.15§ 134i74 
TR 1.42i0.26 8.78i0.49 7.44f1.02' 571f115' 7.88hO.84 208i46 
Conclusion: The SM Ml oxidative capacity contributes to determine the 
max exercise capacity and the VT in normals, in the TR (but not in SED 
and less so in PA), as the Km for ADP varies between the CR- and Cr+ 
conditions, the Ml creatine kinase participates in the control of the high 
energy phosphates channeling front the Ml matrix to the contractile protein 
compartment. 
L-..i-k 1050 124 Relationship Between Exercise Capacity and Peripheral Vessel Sympathetic Function 
Determined With ‘* I-meta-iodobenzylguanidine 
(MIBG) 
exercise may depend on an attenuated muscle blood flow response. Whether 
it is related to the sympathetic nervous system of the peripheral vessels, 
however, is unknown. 
Methods: We quantitatively assessed the function of the sympathetic 
nerves to the peripheral vessels using whole-body MIBG imaging m 21 men 
(58 f 7~0) without heart failure or myocardial ischemia, and then investigated 
whether peripheral MIBG uptake was correlated with rapid leg fatigue in the 
symptom-limited treadmill exercise test (Bruce protocol). Early (20 min) and 
late (4 h) MIBG uptake, the leg (L) to brain (B) uptake ratio (UB), and the 
washout rate (WR) from early to delayed images were determined. 
Results: 1) There was a tendency for the late UB to be lower and WR 
to be greater in patients with diabetes mellitus than in normal individuals. 2) 
The exercise capacity (METS) of the normal UB ratio group was higher than 
of the low L/B ratio group (8.5 f 1.3 vs. 7.5 f 1.3 METS, p < 0.1). On the 
other hand, WR was not correlated with exercise capacity. 3) In the higher 
UB ratio and higher WR group, the exercise capacity was greater than in 
other groups (9.0 i 1.0 vs. 6.8 + 1.9 METS, p c 0.05). 
Conclusion: Peripheral MIBG uptake, which reflects the reuptake of 
noradrenaline by the peripheral sympathetic synapses, is correlated with ex- 
ercise capacity, suggesting that catecholamine dynamics in skeletal muscle 
influences the leg blood flow response to physical exercise. 
1 1050-I 25 ( Estimate of Metabolic Equivalent by 
Accelerometer or Minute Ventilation Sensors in 
Implanted Detiices: Initial Observations 
Weimin Sun, Donald L. Hopper, Wyatt K. Stahl, Bruce R. Jones, 
John Hummel, Roger A. Freedman. Guidant Corporation/CRM, St. Paul, 
Minnesota, USA; University of Utah, Salt Lake Oil: Utah, USA 
Background: The ability to estimate levels of metabolic activity in ambula- 
tory patients would have applications for exercise training and pacing therapy 
research. The present study examines the accuracy of implanted accelerom- 
eters (XL) and implanted minute ventilation (MV) sensors to estimate levels 
of metabolic activity during treadmill testing. 
Methods: A prospective study was performed on 28 patients who had 
a dual-sensor pacemaker implanted and underwent treadmill test with the 
Chronotropic Assessment Exercise Protocol (CAEP). At each stage of the 
CAEP, XL and MV sensor signals were analyzed from trended data stored 
in the pacemaker. Trending was set to store data every 4 seconds during 
the CAEP. Linear regression analysis was used to estimate the metabolic 
equivalent (MET) from the measured XL and MV sensor signals. 
Results: Across all stages and all patients in the study, the measured XL 
sensor outputs show a correlation of 0.860 with the MET reading at each 
stage, and the MV sensor yields a correlation of 0.779. For each individual 
patient, the XL and MV sensor outputs correlated with the MET level yielding 
average R-square of 0.915 * 0.070, and 0.890 jr 0.129 respectively. 
c ~~,~~~ 
0 50 ml 154 Zoo 250 0 100 ml xw m 5w 
XL 0w) Mv mmhi”) 
Conclusions: The XL and MV adaptive-rate sensors in an implantable 
device may be able to monitor and estimate the patient MET levels during 
free-living daily activities. Further study using a greater variety of activities is 
planned. 
1 1050-I 26 ( Angiotensin Converting Enzyme Polymorphism 
in Endurance and Non-Endurance Elite Athletes 
Aris Anastasakis, Antigone Miliou, Artemis Theopistou, 
Angelos Rigopoulos, Dimitris Markou, Elias Sevdalis, Dimos Panagiotakos, 
Christina Kotsiopoulou, Christodoulos Stefanadis, Pavlos Toutouzas. 
Department of Cardiology: University of Athens, Greece 
Background: II genotype of the angiotensin converting enzyme (ACE) gene 
has been reported to appear in excess in elite endurance athletes when 
compared to controls and has been associated with increased response to 
physical training. In this study we investigated the possible difference in ACE 
genotype distribution between endurance arid non-endurance elite athletes. 
Methods: DNA was extracted from peripheral blood samples of 28 non- 
endurance (weight-lifters; 11 male, mean age 23.1 f 10.5 years), 20 en- 
durance (4 medium- and 5 long-distance runners, 11 rowers) elite athletes 
(5 male, mean age 21 .I f 7.5 years) and 100 healthy volunteers (53 male, 
Keiko Oikawa, Nagaharu Fukuma, Noriko Aisu, Takaya Tsuchida, 
Kohsuke Mabuchi, Hiroyuki Matsuda, Yoshiki Kusama, Kazuo Munakata, 
Hiroshi Kisida, Teruo Takano, Shinichiroh Kumita, Tatsuo Kumazaki. Nippon 
Medical School, Tokyo, Japan 
Background: Previous repotts have indicated that rapid leg fatigue during 
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mean age 36.6 i- 20 years). ACE genotype (DD, ID, II) was determined 
using a three-primer polymerase chain reaction amplification and compared 
among the 3 groups. 
Results: 
ACE genotype Endurance 
athletes 
Non-endurance 
athletes 
DD 10 (50%) 12 (42.9%) 94 (94.0%) 
ID 5 (25%) 10 (35.7%) 4 (4.0%) 
I! 5 (25%)' 6 (21.4%)' 2 (2.0%)' 
Total 20 (100%) 28 (100%) 100 (100%) 
‘p < 0.1, ‘p < 0.001 
Conclusions: Genotype distribution of ACE gene polymorphism differed 
significantly between elite athletes (endurance and non-endurance) and 
controls, with a relative excess of the II genotype and deficiency of DD 
genotype in the athletes. No significant difference between endurance and 
non-endurance athletes was detected. 
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1071-l 421 Effect of ACE Inhibitor and AT 1 Blocker on 
Mvocardial Expression of TNF-or in Post MI 
Ventricular Remodeling 
Sudhir Gupta, Arun J.C. Prahash, lnder S. Anand. Division ofCardio/ogl: VA 
Medical Center and University of Minnesota, Minneapolis, MN-554 17, USA 
Background: Increased levels of TNF-ol seen in chronic heart failure (CHF) 
have been shown to depress myocardial function. ACE inhibitors (ACE-I) 
and AT1 blockers (AT1 -B) are beneficial in CHE 
Methods: We studied the effects of ACE-I (Enalapril) and ATI-B (Can- 
desartan) on TNF-(U production in the remote non infarcted myocardium 
(RNM) of 6 week post Ml rats and corresponding areas of sham operated 
rats. We also investigated whether this TNF-a production affects myocyte 
contractile function in this region, Infarcted rats were treated with either wa- 
ter, ACE-l (1 mg/kg), ATI-B (IO mg/kg) or combination in drinking water. 
Treatment was started within 24 h aider Ml and continued for 6 weeks, when 
rats were sacrificed. 
Results: Ml hearts were significantly remodeled and dysfunctional. Both 
ACE-I and ATI-B inhibitors improved LV function (table). TNF 01 levels were 
undetected in sham myocardium but increased in water treated Ml hearts 
(0.84 i 0.08 pg/ml). ATl-B alone-reduced TNF (Y production in Ml hearts 
(0.63 & 0.03 pg/ml) where as ACE-I alone did not (0.81 i 0.03 pg/ml). In 
contrast, ACE-1 in combination with ATI -B had a marked effect on TNF-(U pro- 
duction (0.41 i 0.01 pg/ml). However the contractile function of LV myocytes 
in response to serial doses of [Cae+], was not different in all the groups. 
Serial Echocardiographyand isolated Perfused Heart Function 
LV DP, mm Ha 
LV dpldt max: 
mmHg/sec 
LVlDd 
LVlDs 
Sham MI ACE-I AT-1 B ACE-I + AT-I B 
112zk7 5619 91*5 75f5 94*4 
2653zk207 1423i223 1983zt106 1755ilO 2188xb102 
5.7 + 0.3 8.5 zk 0.3 6.5 it.9 7.4 ck 0.3 7.1 i 0.8 
2.6 zk 2.2 6.9 f 0.4 5*i 5.4 h 0.7 4.9fl.l 
Fractional Shortening 55.3 i 2.2 19.1 f 2.5 27 h 6.6 33.7i 7.4 36.1+ 7.8 
Conclusion: These data suggest that elevated levels of TNF-ol seen in 
6 week post MI, globally dysfunctional hearts, do not affect isolated myocyte 
contractile function. The role of TNF-or in global LV dysfunction is unclear. The 
mechanism and implication of these findings need to be clarified. 
1 1071-l 43 1 Effect of Adrenergic Blockade on Myocardial 
Collagen Type Will Ratio and Cytokine 
Expression Post Myocardial Infarction 
Shan Wei, Ka B. Lai, Louis T.C. Chow, John E. Sanderson. Division of 
Cardiology The Chinese University of Hong Kong, China 
Background: /I-adrenergic blockade reduces mortality post myocardial in- 
farction (Ml) and in heart failure but there is little information on its effect on 
myocardial collagen and fibrogenic cytokine expression which is important for 
compliance and the process of remodeling. In an experimental post Ml/heart 
failure rat model we have studied the effect of carvedilol (C)on myocardial col- 
lagen type I and Ill, transforming growth factor (TGF-,@ and tumour necrosis 
factor (TNF) gene expression. 
Methods: Using the rat model of Ml induced by coronary ligation, myocar- 
dialmRNAlevelsforcollagen I, Ill, TGF-fi,andTNFwereevaluated inthe non- 
infarcted myocardium (NIM) and infarcted area by quantitative competitive re- 
verse transcriptase PCR (MIMIC fragment technique) after 11 weeks oral ther- 
apy with C and compared to untreated ligated animals and sham operated. 
Results: In the NIM, C therapy was associated with a significant reduction 
(18-fold)ofcoll I mRNAlevels4(p=0.004), but unchangedcoll III mRNAlevels 
and therefore a reduced toll 1/1ll ratio compared to untreated NIM. There were 
no significant changes in TGF-B or TNF levels in the NIM compared to sham. 
In the infarcted area there were highly significant increases in toll I, Ill, TGF-B 
and TNF mRNA levels (all p < 0.001) but these were unaffected by C therapy. 
Conclusions: C therapy is associated with a significant reduction of type 
I collagen in the non-infarcted myocardium which may have an important 
impact on compliance. This action of C appears to be independent of both 
TGF-B and TNF. 
Ll O’i’l-I 44 1 Neurohumoral Response During Exercise in 
Healthy Controls and Patients With Chronic 
Heart Failure 
Mohammed Yousufuddin, Waqar Shamim, Michael Henein, Fouad R. Amin, 
Stefan D. Anker, Michael Kemp, J. Hooper, Andrew J.S. Coats. National 
Heart and Lung lnsfitute and Royal Brompton Hospital, London, UK 
Background: Interaction between the autonomic nervous system and the 
heart and peripheral vessels may plays an important role in determining exer- 
cise capacity. The response of various neurohumoral factors during exercise 
in patients with CHF may be different from normals. 
Methods: We measured plasma concentrations of norepinephrine (NE, 
as a measure of sympathetic nervous system activity), atria1 natriuretic pep- 
tide (ANP), brain natriuretic peptide (BNP), both of which indirectly reflect 
central haemodynamics in CHF, and endothelium-derived endothelin-I (one 
of the measures of endothelial dysfunction) in IO healthy controls (37 & 14 
yr) and 29 patients (51 * 15 yr) with stable CHF (LVEF 31 f 15%) after 30 
min supine rest and immediately after maximal treadmill exercise in 12 hour 
post-absorptive state. 
Norepinephrine 
(nmol/L) 
PW Pnt 
ANP 
(pmol/L) 
PTP Post 
Controls 1.48 -t 1 3.5 f 2.7 5.6 h 3.4 11.3i7.2 
Patients 1.53zLOo.6 2.4 + 1.0 24.4 + 22.7 40.2 -i- 33.7 
p = value 0.8 0.11 0.02 0.01 
BNP Endothelin-1 
Controls 
(pmol/L) (pmol/L) 
Pre Post Pre Post 
2.1 i 1.8 2.9 * 2.7 1.7 + 0.17 2.1 + 0.1 
Patients 44.4% 49.6 50.6 + 53 2.9 zt 0.8 4.2 i 1. 
D = value 0.01 0.01 co.ooo1 <0.0001 
Results: Peak oxygen consumption was higher in controls compared to 
patients (33.7 If: 7 vs 20.8 f 8 ml/kg/mm; p < 0.0001). Resting values for NE, 
ANP, BNP, and ET-I were all positively correlated with those of the postexer- 
cise values in both controls and patients with correlation coefficients between 
0.72 to 0.98 and p values between 0.02 to <O.OOOl. Exercise induced in- 
crease in NE level was higher in controls compared to patients (128 f 95 vs 
59 f 45%; p = 0.008). Increase in plasma ET-I level was greater in patients 
than controls (47 i 28 vs 20 & 18%; p = 0.01). There was no difference be- 
tween two groups with regard to exercise induced percent change in plasma 
concentrations of ANP and BNP. Preexercise resting plasma ET-I was posi- 
tively correlated with both preexercise and post exercise plasma levels of ANP 
[pre (p = 0.01) post (p = O.OOl)] and BNP [pre (p = 0.0005) post (p = 0.0005)] 
in patients but not in controls. 
Conclusion: Of all the neurohumoral factors studied, NE in controls and 
ET-I in patients showed a greater percent increase with exercise indicating 
potentially greater importance of ET-1 to the exercise pathophysiology in CHF. 
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1 1071-i 45 1 Clinical Assessment of Myocarcliai Dysfunction 
in Targeted Expression of MCP-1 in the Murine 
Heart 
Michael F. Deucher, Pappachan E. Kolattukudy, Doug M. Brown, Patricia 
Sanitate Hatton, Philip F. Binkley. Ohio State Medical Center, Columbus, OH, 
USA 
Targeted expression of MCP-I in the murine myocardium chemotactically re- 
cruits monocytes causing a severe cardiomyopathy highlighted by mononu- 
clear infiltrates, myocyte hypertrophy, interstitial edema, and fibrosis. The 
purpose of this study is to characterize the functional cardiac changes in this 
model over time. 
Methods: Studies were performed in mice with targeted expression of 
MCP-I and age-matched, litter-mate controls. Two-dimensional and M-mode 
echocardiography were performed on anesthesized mice and continuous 
ECG monitoring units were implanted intraperitoneally. ECG signals were 
continuously recorded on FM tape and digitized using Windaq. A BP 2000 
Analyzer recorded BP measurements. 
Results: By ECHO, heterozygous transgenic mice had substantial left 
ventricular hypertrophy and dilatation. LV mass was 29% greater with both 
systolic and diastolic left ventricular internal diameters increased. Fractional 
shortening (FS) showed dramatic reduction with first-generation transgenics 
having a value of 37% and controls 54%. Subsequent generations of these 
heterozygous mice and homozygous mice were both found to have more 
severe reduction in ventricular function. At two months, homozygotes had 
a FS of 30% and by six months the second-generation heterozygotes were 
found to have a FS of 15%. ECG monitoring in the heterozygotes showed 
the QRS complex progressively lengthened from 6-9 months, the JT interval 
abruptly increased at 6 months, and the QT interval gradually prolonged from 
6-9 months. In heterozygotes, the average systolic BP was 12% greater 
than the cpntrpls, and a nonsignificant trend towards higher readings were 
observed in the younger transgenics. 
Conclusions: Targeted expression of MCP-I in murine myocardium initi- 
ates a progressive cardiomyopathic process resulting in left ventricular hyper- 
trophy and dilatation, lengthening of the QRS complex, JT and QT intervals, 
and mild elevation in systolic BP. 
L---L 1071 146 U-74 inhibits the Cytokine induced iNOS Expression Via Elevation of i&B and Depression 
of NFIEB in Cultured Endotheiiai Ceils 
Ronald J.P. Bronsaer, Marjolein M.I. Hofland, Pieter A. Doevendans, 
Rien van der Zee. Dept, of Cardiology; Cardiovascular Research Institute 
Maastricht; RdG Hospital, Delft, The Netherlands 
Introduction: Myocardial NO production is increased in patients with heart 
failure, due to increased inducible NOS (INOS) expression. High NO levels 
lead to myocyte injury and reduced contractility. Cytokines like interleukin-Ia 
(IL-1p) are able to activate the iNOS gene. Potentially, selective inhibition 
of iNOS activity could preserve cardiac function. U-74, a 21-aminosteroid- 
lazaroid inhibits the transcription of cytokine induced iNOS but not ecNOS in 
cultured endothelial cells. In the present study, we tested the hypothesis that 
U-74 increases the expression of IKB and depresses the expression of NFKB 
which potentially can inhibit the iNOS transcription. 
Methods: Cells were cultured in phenol-red free medium and treated with 
5 pg/ml IL-lb in the absence or presence of U-74 (lOmg M), 60 minutes after 
cytokine stimulation total protein was isolated. NO release was measured 
via the Griess assay. The expression of iNOS at the RNA and protein level 
was studied by RT-PCR and Western analysis. In identical experiments, the 
expression of IKB and NFKB was assessed via Western analysis. 
Results: A rise in NO release up to 80 FM/m” was detected 40 minutes 
after addition of IL-1,6. This rise could be blocked completely by adding U-74 
simultaneously. U-74 alone did not influence baseline NO production. Western 
analysis revealed that U-74 did not influence ecNOS protein levels, but a 
marked reduction of cytokine induced iNOS expression was found. RT-PCR 
showed that U-74 inhibited the transcription of the iNOS gene completely. 
Detection of either IKE or NFKB showed a marked U-74 dependent increase 
in 1x6 (2.5x) and adepression of NFKB (2x). 
Conclusion: U-74, a 21-aminosteroid-lazaroid inhibits the transcription 
of cytokine induced iNOS but not ecNOS in cultured endothelial cells. The 
mechanism involves elevation of IKB protein and a marked down-regulation 
of NFKB mediated via U-74. 
I 1071 147 Myocardial Dysreguiation of Chemokines and Their Receptors in Human End-Stage Heart 
Failure 
Jan K. Dam&, Hans G. Eiken, Erik Plie, Vigdis Bjerkeli, Arne Yndestad, 
Thor Ueland, Geir Christensen, Theis Tennessen, HBvard Attramadal, Odd 
R. Geiran, Halfdan Aass, Svein Simonsen, Stig S. FrBland, Lars Gullestad, 
P&l Aukrust. The Nafional Hospital, University of OS/O, Oslo, Norway 
Background: Persistent immune activation has recently been implicated in 
the pathogenesis of congestive heart failure (CHF). Chemokines are essen- 
tial for the recruitment and activation of leukocytes from the circulation into 
inflamed tissue, and recent studies suggest that chemokines also may be 
important mediators of several other biological processes such as collagen 
turnover, angiogenesis and apoptosis. We have hypothesized a pathogenic 
role for chemokines in the development of CHF, and in the present study 
we examined the myocardial gene expression and cellular localization of 
chemokines and their corresponding receptors in human end-stage heart 
failure. 
Methods: We examined mRNA levels of 23 different chemokine and che- 
mokine receptor genes in explanted hearts from 10 patients with end-stage 
heart failure (all chambers) and in IO organ donors (left ventricle [n = 41 
and atrium [n = 61) using RNase protection assays. By immunohistochemical 
techniques we examined the localization of the chemokines and chemokine 
receptors with the highest mRNA expression. 
Results: Several findings were revealed: (i) 8 chemokine and 9 chemokine 
receptor genes were expressed in both chronic failing and norifailing myocar- 
dium. (ii) Particular high mRNA levels were found for monocyte chemoattrac- 
tant protein (MCP)-1, interleukin (IL)-8 and the chemokine receptor, CXCR4 
in both chronic failing and nonfailing myocardium. (iii) In the chronic failing 
myocardium left atria expressed elevated chemokine mRNA levels compared 
to left ventricles (p < 0.001). (iv) Chronic failing left ventricles and left atria 
expressed decreased chemokine (e.g., MCP-1, p < 0.01) and increased che- 
mokine receptor (e.g., CXCR4, p < 0.01) mRNA levels compared to corre- 
sponding chambers in the nonfailing hearts. (v) The chemokines MCP-1 and 
IL-8 and the chemokine receptor CXCR4 were immunolocalized to the car- 
diomyocytes. 
Conclusion: This first demonstration of myocardial chemokine and che- 
mokine receptor expression may point to family of previously unrecognized 
mediators present in the human myocardium, possibly involved in the patho- 
genesis of CHF. 
1 1071-I 48 1 The Positive inotropic Effects of Hydrostatic 
Pressure are Buffered by the Endocardiai 
Endotheiium Via Prostagiandins 
Christopher J. Zeitz, Stanislas U. Sys, Dirk L. Brutsaerl. Departmenf of 
Physiology and Medicine, University of Anfwerp, Belgium 
Background: Despite evidence of mechano-sensitive pathways in endocar- 
dial endothelium (EE), an effect of increased hydrostatic pressure (P) on my- 
ocardial contractile function has not been demonstrated. We have subjected 
isolated cardiac muscle to200 mmHg sustained P, followed by its removal and 
examined the impact on contractile indices. 
Methods: Rabbit right ventricular papillary muscles (n = 84; ox KR; 0.6 
Hz) were either immediately stabilized under P for at least 2 hrs or stabilized 
at atmospheric pressure for >2 hrs with subsequent addition of P. When 
required, the EE was removed with 0.5% Triton. Following stabilization, P 
was either added (+P) or removed (-P), depending on the stabilization state, 
with subsequent monitoring for 40 minutes, using pairedconfrolmuscles. The 
impact of IO WM L-NMMA (n = 6), IO PM lndomethacin (Indo) (n = 6) or 1 
PM 86-123 (n = 6) on the response to -P and +P was also examined versus 
control muscles (n = 6) subjected to the same P protocol. 
Results: 
Effect (%) at 30 mins (Mean * SEM) 
Active Tension Time i/2 Relaxation 
-P, +EE (n = 7) 2.5 It 3.7 -2.2 * 1.3* 
+P, +EE (n = 8) 6.6 * 2.6 2.5 zt 0.6 
-P> -EE (n = 7) 3.2 f 4.7 -1.4 * 0.3* 
+P, -EE (n = 8) 13.2 f 5.2 3.2 * 1.0% 
-P, +EE, +L-NMMA -0.2 * 5.4 -1.511.0 
+P, +EE, +L-NMMA 2.1 * 3.8 3.3 f 1.2 
-e +EE, +lndo 76.PLk 9.P -4.1 * 1.F 
+F: +EE, +Indo 12.4 + 3.4* 2.4 i 1.31 
-P, +EE, +BQ-123 1.7&3.0 -4.451.1* 
+P, +EE, +BQ-123 5.8 * 7.3 8.7 + 3.8 
*p < 0.05 on repeated measures ANOVA vs control muscle groups 
Peak Shortening 
1.5* 1.9 
4.3* 1.7 
1.7 zk 2.3 
8.7 h 2.7” 
-2.7 i 3.2 
2.5i 1.1 
-15.9% 10.5= 
8.4 * 3.7 
-0.9 * 1.2 
4.4 5 2.4 
Addition of P resulted in a positive inotropic effect that was virtually abol- 
ished in the presence of EE. Effects of +P and -P were maximal when 
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prostaglandin synthesis was blocked by Indo. P effects on time to half re- 
laxation (tHR) appear largely independent of EE and pharmacology. 
Conclusions: This is the first demonstration that contractile function of 
cardiac muscle is directly modulated by P. The P ‘buffering’ effect of the EE is 
almost totally mediated via prostaglandins. 
j 1071-149 / Endothelium-Dependent and Independent 
Vascular Responses and Blood Flow in the 
Brachial Artery of Healthy Controls and Patients 
With Chronic Heart Failure (CHF): Relationship 
to Peak Oxygen Consumption and Left 
Ventricular Ejection Fraction 
Mohammed Yousufuddin, Waqar Shamim, Jonathan S. Chamber, Fouad 
R. Amin, Stefan D. Anker, Andrew J.S. Coats. National Heart andLung 
Institute and Royal Brompton Hospital, London, UK 
Background: Endothelial function may be of relevance in the pathophysiol- 
ogy of exercise tolerance in healthy controls and patients with CHF. 
Methods: Endothelium-dependent (flow) and independent (GTN) vascu- 
lar responses in the brachial artery were assessed by high-resolution ultra- 
sound imaging in 9 volunteers (age 41.2 f 12 yr.) and 21 patients (age 55.6 
f 12 yrs) with CHF. Peak oxygen consumption (MV02) was determined on 
a modified Brace treadmill protocol. LVEF was measured by radionucleide 
ventriculography in patients. 
Results:Theflow-mediated (10.93+3.94%vs2.17* 1.12%; p < O.OOOl), 
GTN-induced (16.10 + 5.9% vs. 7.65 i 3.8%; p = 001) percentage dilatations 
and MV02 (33 f 6 vs 22 * 7 ml/kg/min; p = 0.001) were higher in controls than 
in patients. There was no difference between patients and controls in resting 
(7.2 i 3 vs 7 & 5 ml/min/lOO ml; p = 0.95), peak hyperaemic flow (45.5 f 15 vs 
52 i 27 ml/minllOO ml; p = 0.5) or total flow over 5 min of reactive hyperaemia 
(66-+ 2.1 ml vs. 69 *2.7; p = 0.88). MV02 wasclosely related toflow-mediated 
dilatation (r = 0.72; p < 0.0001) but not to GTN-mediated dilatation (r = 0.37; p 
= 00.18) nor to blood flows (r = 0.22; p = 0.23). There was no relation between 
f!ow-dependent or GTN mediated dilatation and LVEF in patients. 
Conclusion: The strong relation between flow-dependent endothelium- 
mediated vascular response and MV02, suggests that the vascular endothe- 
lial function may be an important predictor of maximal exercise capacity in 
normal individuals and patients with heart failure. 
/ 1071 150 ’ Non-Invasive Assessment of Exercise Induced Alterations of the Conduit Artery Tone in Healthy 
Controls and Patients With Chronic Heart Failure 
(CHF): Relationship to Endothelin-1 and 
Nor-Epinephrine 
Mohammed Yousufuddin, Waqar Shamim, Jonathan S. Chamber, Michael 
Y. Henein, Fouad R. Amin, Stefan D. Anker, Michael Kemp, J. Hooper, 
Andrew J.S. Coats. NationalHeartand Lung lnsfitute and RoyalBrompton 
Hospital, London, UK 
Background: This study is aimed at determining alterations in brachial artery 
tone induced by exercise and their relationship with endothelin-I or nore- 
pinephrine in patients with CHF and healthy controls. 
Methods: Brachial artery diameter and blood flow was measured before 
and after exercise in 8 healthy volunteers (age 39.7 i 14 yrs) and 18 pa- 
tients (age 51.0 f 15 yrs) with stable chronic heart failure by high-resolution 
ultrasound. 
Results: Maximal exercise resulted in brachial artery dilatation in controls 
(4.42 f 0.39 vs 4.77 i 0.39 mm; p < 0.0001) in contrast to constriction seen 
in the patients (5.27 i 0.67 vs 5.12 i 0.66 mm; p = 0.07). Both groups demon- 
strated a significant increase in blood flow after exercise. The pre-exercise 
(2.83 + 0.76 vs 1.69 + 0.15 pmol/l; 0.0004) post-exercise (4.15 f 1.5 vs 2.02 
+ 0.34 pmol/l; p = 0.0004) and the percent increase (47.15 i 32.5 vs 19.0 It 
10.5%; p = 0.02) in endothelin-I levels were significantly greater in patients 
than controls. In contrast to endothelin-I, the exercise induced increase in 
norepinephrine was greater in controls than patients (100.7 + 51.8 vs 49.8 f 
43.4%; p = 0.01). The percent change in the diameter of the brachial artery in 
response to maximal exercise was significantly correlated to pre- (r = 0.64; p 
= 0.003) and post-exercise (r = 0.47; p = 0.05) endothelin-I levels in patients 
but not in controls pre-exercise (r = 0.07; p = 0.86) post-exercise (r = 0.310; 
p = 0.47). 
Conclusion: The change in the diameter of the brachial artery did not cor- 
relate with pre or post exercise plasma norepinephrine levels. These findings 
suggest that endothelin-I contributes to the exercise induced brachial artery 
constriction in CHF. 
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L-l-- 1072 152 Survival Rates are Similar Between African-Americans and Other Races With Heart 
Failure 
Stephanie H. Dunlap, Carla A. Sueta, Todd A. Schwartz, Tasneem Islam, 
Korana Webster, Kirkwood F. Adams Jr.. University ofNorth Carolina, Chapel 
Hi//, NC, USA 
Background: Baseline clinical characteristics are known to differ between 
African-Americans (AA) and other races with heart failure, suggesting mortal- 
ity rates may differ as well. We investigated the association between race and 
survival in patients (pts) with heart failure. 
Methods: Data from the UNC Heart Failure Database was analyzed in 680 
patients (pts) who were 44% African-American (AA) and 31% female who had 
symptomatic heart failure (NYHA Class 2.8 i 0.8, mean f SD) with reduced 
left ventricular ejection fraction (LVEF) of 25 & 13 and a body mass (Bmass) 
of 27 * 7.3. Data on vital status was available in 97% of these patients with 
mean length of follow-up 1.9 f 2.1 years. 
Results: AA were more likely to have hypertension (67 vs. 38%), be fe- 
male (37 vs 26%), and have causes other than ischemic heat-l disease as 
their primary etiology of heart failure (14 vs 45%) than other races (all p < 
0.01). LVEF (26 -f7 14 versus 26 rt 12&) and NYHA class (2.8 f 0.7 vs 2.9 f 
0.7) were similar between AA and other races (all p > 0.1). Body mass was 
greater in AA than in other races (28.2 f 8.6 vs 26.4 f 6.1) and baseline 
systolic blood pressure was higher (124 i 23 vs 116 i 19 mmHg), both p < 
0.01. (Unadjusted analysis suggested better survival in AA versus other races 
(relative risk 0.76, 95% Cl 0.590-0.977, p = 0.032). Adjusted analysis taking 
into account characteristics previously shown to be of prognostic importance 
in our database (LVEF, age, gender, etiology, NYHA Class) and other differ- 
ences in baseline characteristics found no difference in survival between AA 
and other races (relative risk (1.097 95% Cl 0.830-I ,451, p = 0.514). 
Conclusion: Although baseline clinical characteristics differed between 
AA and other races, adjusted analysis taking these differences and other 
prognostic factors into account found similar survival rates between AA and 
other races. 
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LzIrl 1072 153 Depression in Heart Failure: Clinical Characteristics and Impact on Outcomes 
Christopher M. O’Connor, Wei Jiang, Jude Alexanda, Eric Christopher, 
Maggie Kuchibhatla, Chad Davenport, Christopher Simons, Ranga 
R. Krishnan. Duke University Medical Center, Durham, North Carolina, USA 
Background: Previous studies have indicated that patients with ischemic 
heart disease, suffer a high rate of depression which is associated with in- 
creased morbidity and mortality. However, such a relationship has not been 
studied thoroughly in patients with heart failure (HF). The purpose of this study 
was to examine the prevalence and clinical characteristics of depression in 
patients with HF and its impact on mortality. 
Methods: 374 consecutive patients hospitalized with a clinical diagnosis 
of HF with a left ventricular ejection fraction below 35% were approached for 
the study from April 1997 to June 1998. 357 patients consented for participa- 
tion. The patients were first given the Beck Depression Inventory (BDI), then 
underwent Diagnostic Interview Schedule (DIS) if the BDI score was 310. The 
median age of the cohort was 63 years, 37% were female, 30% were minority, 
and 55% had ischemic etiology. 
Results: Overall, 34% of patients had a BDI score 3 10 indicative of minor 
depression and 14% were DIS positive @ suggesiive of major depression. 
The short and long term mortality rates are shown below. 
SC& 3 month mortality P 12 month mortality P 
f%) value (%) value 
EDI? 14.6 0.008 22.0 0.02 
BDI < 10 5.9 11.7 
DIS CB 15.9 0.038 27.2 0.006 
DISH 6.7 11.7 
Conclusion: HF patients have a high prevalence of minor and major de- 
pression which is associated with a greaterthan 2 times higher rate of mortality 
at 3 months and 12 months than HF patients who are not depressed. 
1072-I 54 Prognostic Significance of Left Bundle Branch 
Block in a Cohort of 8931 Patients With Different 
Levels of LV Systolic Function 
Sriram Padmanabhan, Jatin Amin, Helme Silvet, Ramdas G. Pai. Loma 
Linda VA Medical Center, Loma Linda, CA, USA 
Left bundle branch block (LBBB) is uncommon as a benign abnormality. How- 
ever, whether it has any impact on mortality in those with normal LV perfor- 
mance and in those with various degrees of LV dysfunction is not known. We 
investigated the prognostic significance of LBBB in 8,931 patients undergoing 
echocardiography, 5,130 of whom had normal LV systolic function (age 66 f 
13 years, EF 51 f 15%). LBBB was present in 385 patients and there were 
1,911 deaths over a mean follow up of 913 days. 
Results: The prevalence of LBBB increased with diminishing LV function: 
being 1.2% in patients with normal LV function (EF > 55%) 4.5% in those with 
mild LV dysfunction (EF41-54%), 9.0% in thosewith moderate LVdysfunction 
(EF26-40%) and 14.5% in those with severe LVdysfunction (EF < 25%) (p < 
0.0001). Other correlates of LBBB includes greater age (p < O.OOOl), larger 
LV size (p < O.OOOl), presence of atrial fibrillation (p < O.OOl), presence of 
greater degrees of mitral regurgitation (p < 0.0001) and greater dimensions 
of all cardiac chambers (p c 0.0001). The 7 year survival was twice as much 
in those without LBBB in the whole cohort (62 vs. 32%, p < 0.0001). Among 
the various su,bgroups, the effect of LBBB on survival was most pronounced 
in those with severe LV dysfunction (50 vs. 15%, p = 0.0027). The survival 
curves were not statistically different in other subgroups. 
Conclusions: 
(1) The prevalence of LBBB increases with diminishing LV systolic function, 
increasing age and chamber enlargement. 
(2) There is an increase in mortality with the presence of LBBB. 
(3) The effect of LBBB on mortality is most pronounced in those with severe 
LV dysfunction. 
1072-l 55 Prognostic Significance of Right Bundle Branch 
Block is a Function of the Level of LV Svstolic 
Function: Results From a Cohort of 8931 
Patients 
Helme Silvet, Jatin Amin, Sriram Padmanabhan, Ramdas G. Pai. Loma 
Linda VA Medical Center, Loma Linda, CA, USA 
Right bundle branch block (RBBB) is present in 1% of normal individuals 
and is thought to be a benign abnormality. We investigated the prognostic 
significance of RBBB as function of the level of LV systolic function in 8931 
patients undergoing echocardiography (age 66 f 13 years, EF 51 & 15%), 
5130 with normal LV systolic function. RBBB was present in 693 patients and 
there were 1911 deaths over a mean follow up of 913 days. 
Results: The prevalence of RBBB increased only minimally with diminish- 
ing LV function: being 7% in patients with normal LV function (EF > 55%) 8% 
in those with mild LV dysfunction (EF 41-54%), 10% in those with moderate 
LV dysfunction (EF 2640%) and 10% in those with severe LV dysfunction 
(EF x 25%) (p < 0.0001). Other correlates of RBBB includes greater age (p c 
O.OOOl), larger LV size (p < O.OOOl), presence of Atrial fibrillation (p < O.OOl), 
presence of inferior but not anterior myocardial infarction on the electrocar- 
diogram (p < O.OOOl), presence of greater degrees of mitral and tricuspid 
regurgitation (p < 0.0001) and greater dimensions of all cardiac chambers (p 
< 0.0001). The 7 year mortality was 52% in those with RBBB compared to 
37% in those without (p < 0.0001). Among the various subgroups, the effect 
of RBBB on mortality was most pronounced in those with mild (7year mortality 
48 vs. 34%, p = 0.005) and moderate LV dysfunction (7 year mortality 72 vs. 
47%, p = 0.002) compared to those with normal LV function (7 year mortality 
45 vs. 30%, p = 0.03) and those with severe LV dysfunction (7 year mortality 
68 vs. 53%, p = ns). 
Conclusions: 
(1) The prevalence of RBBB increases minimally with diminishing LV systolic 
function, but is strongly associated with age, cardiac chamber size and 
valvular disease. 
(2) There is an increase in mortality with the presence of RBBB in those with 
normal LV function and patients with mild or moderate LV dysfunction. 
(3) The effect of RBBB on mortality is least pronounced in those with severe 
LV dysfunction. 
1072-I 56 Severity of Left Ventricular Dysfunction After 
Acute Myocardial Infarction: Longterm Mortality 
With Optimized Medical Treatment in Clinical 
Practice 
Andreas Kilkowski, Caroline Bergm,eier, Rudolf Schiele, Anselm K. Gitt, 
Ulf Gieseler’ , Helmut Thomas’, Jochen Senges. For the 
MITRA-Investigators; ‘Department of Cardiology, Herzentrum 
Ludwigshafen, Speyer; ‘Bad Diirkheim, Germany 
Purpose: The extent of left ventricular dysfunction (LVD) and longterm mor- 
tality in nonselected patients (P) with acute myocardial infarction (AMI) after 
implementation of high rates of acute recanalisation, aspirine, fi-blockers and 
ACE-inhibitors was assessed. 
Methods: The Southwest German “Maximal Individual Therapy in Acute 
Myocardial Infarction” (MITRA) - trial is a prospective multicenter observa- 
tional study of the current treatment of AMI. 4495 consecutive P with AMI 
were discharged from hospital alive from 5/94 to l/97. Left ventricular ejec- 
tion fraction (EF) was evaluated echocardiographically. Acute treatment: 58% 
recanalisation, 94% aspirine, 53% ,&blockers, 51% ACE-inhibitors. Mean fol- 
low-up time was 18 months. 
Results: 
(1) At discharge 1889 P (42%) had normal EF, 1303 (29%) showed slight, 
924 (21%) moderate and 379 (8%) severe reduction of EF. 
(2) Medication at discharge in P with normal, slightly, moderately and severely 
reduced EF: B-blockers in 68.7%, 65.1%, 51.7% and 35.8% respectively; 
ACE-inhibitors in 63%, 73.8%, 80.8% and 80.2% respectively. 
(3) Longterm mortality (“* pi 0.001): 
Longterm mortality 
Odds ratio multivariate 
Reduction of EF 
normal EF slight moderate ?A?“C?le 
4.8% 9.3%“* 18.6%** 32.8%** 
- 1.74 3.19 5.7 
95% confidence interval 1.22-2.47 2.22-4.53 3.59-9.03 
Conclusion: 1. In the era of recanalisation at about 30% of unselected P 
after AMI are discharged with a slight, another 30% with a moderate or severe 
reduction of EF. 2. Present data reveal no threshold: Increase in longterm 
mortality is associated with LVD in a stepwise manner. 3. With optimized 
medical treatment severity of LVD after AMI is a strong independent predictor 
of longterm mortality. 
I 1072 157 Usefulness of Iodine 123 Metaiodobenzylguanidine Scintigraphy in 
Assessing Sympathetic Activation in Patients 
With Mild Heart Failure 
Reisuke Yuyama, Fumio Yuasa, Makoto Hikosaka, Masayuki Motohiro, 
Tetsuro Sugiura’ , Toshiji Iwasaka. Kansai Medical University, Osaka; ‘Kochi 
Medical School, Kochi, Japan 
Background: Increased sympathetic nervous activity is associated with poor 
prognosis in chronic heart failure (HF). Because plasma noradrenaline (NA) 
levels are often within normal range in patients with mild HF, less is known 
about sympathetic nerve activity in these patients. To assess sympathetic 
JACC February 2000 ABSTRACTS - Cardiac Function and Heart Failure 179A 
nerve activity in patients with mild HF, we examined myocardial iodine 123 
metaiodobenzylguanidine (MIBG) and muscle sympathetic nerve activity 
(MSNA). 
Methods: Twenty patients with mild HF (LVEF 48 rt 10%) underwent my- 
ocardial MIBG, MSNA and plasma NA measurement within 3 days. The heart 
to mediastinum ratio (HMR) was obtained 4 hours after 111 MBq 1231-MIBG 
injection from chest anterior vi’ew image. MIBG washout was calculated with 
the decay-corrected count density in a region drawn around the heart. MSNA 
was recorded by microneurography. 
Results: Plasma NA in patients with HF was within normal range (290 i 
130 pg/ml). HMR was 1.9 & 0.3 and MIBG washout was 33.8 i 7%. Plasma 
NA had no significant relation with HMR, MIBG washout and MSNA. How- 
ever, HMR had negative correlations with MSNA burstsimin (r = -0.77, p < 
0.01) and MSNA bursts/100 beats (r = -0.75, p < 0.05). MIBG washout was 
positively correlated with MSNA burstsimin (r = 0.61, p < 0.05) and MSNA 
bursts/l00 beats (r = 0.80, p < 0.05). 
Conclusions: Despite normal NA level, sympathetic nerve activity was 
increased in patients with mild HF. Myocardial MIBG scintigraphy is an useful 
noninvasive method to detect early alterations of sympathetic nerve activity. 
i 1072-l 58 / Cytokines Only Slightly increased Under 
Optimized Medical Treatment in Unselected 
Patients With Advanced Heart Failure Due to 
Coronary Artery Disease 
Thomas Kleemann, Caroline Bergmeier, Andreas Kilkowski, 
Matthias Banger?, Boris Fraiture, Gunnar Taubert, Tanja Kottmann, 
Dieter Nagel, Dietmar Seiler, Jochen Senges. Herzzenbum Ludwigshafen, 
Germany 
Background: Recent studies suggest that cytokines apart from neurohor- 
mones increase with progression of chronic heart failure in patients (P) with 
left ventricular dysfunction (LVD). 
Aim of the Study: was to compare neurohormone and cytokine levels 
according to NYHA functional classes I to IV in unselected P with LVD due to 
coronary artery disease (CAD). 
Patients and Methods: 327 consecutive P with CAD and LVD (EF 5 
45%) admitted to a non-universitary hospital were registered (Mean age: 
63.0 years, 82.1% male, mean EF 29.3%). Blood samples were obtained 
before discharge when P received optimized medical treatment for heart fail- 
ure (ACE inhibitor 93%, beta blocker 57%, diuretics 69%). Plasma activities of 
norepinephrine (NE), atrial natriuretic peptide (ANP), interleukin-6 (IL-6) and 
tumor necrosis factor alpha (TNF) were measured by radio immuno assay. 
Results: Coronary P with advanced heart failure (NYHA Ill/IV) showed a 
significant increase of the neorohormones NE and ANP compared to those 
with NYHA I or II. TNF showed only a slight increase in P with advanced 
heart failure whereas IL-6 did not change significantly compared to those with 
NYHA I or II. 
NE [ngil] 
ANP [ngil] 
IL-6 [ngil] 
TNF [ng/ll 
NYHA l/II NYHA Ill/IV p-VallE 
(n = 641166) (n = 8819) 
340 z!T 292 520 5 402 <O.OOl 
361 + 235 468 + 300 <O.OOl 
22 i 51 32f99 ns 
4 + 2.7 5.1 i 3.8 co.05 
Conclusion: 1. Under optimized heart failure therapy P with CAD and 
advanced heart failure had elevated plasma levels of the neurohormones NE 
and ANP compared to asymptomatic and oligosymptomatic LVD-P. 2. TNF 
increased only slightly with severity of heart failure and IL-6 did not even 
change. 3. These data suggest that under optimized heart failure treatment 
P with advanced heart failure show if at all only a slight increase of cytokine 
plasma levels. 
1072-l 59 Insulin Resistance in Chronic Heart Failure - 
TNF-Alpha, Norepinephrine, or Leptin-Related? 
Wolfram Doehner, Mathias Rauchhaus, Ian F. Godsland, Constantinos 
H. Davos, Andrew J.S. Coats, Stefan D. Anker. Cardiac Medicine, National 
Heart and Lung Institute, London, UK 
Background: Chronic heart failure (CHF) is an insulin resistant state, regard- 
less of aetiology. The cause of impaired insulin sensitivity remains unclear. 
Elevated levels of tumor necrosis factor (TNF)-u and norepinephrine (NE) 
have been implicated to cause impaired insulin sensitivity (Si) in CHF. The 
controverse of how leptin (L) affects Si is ongoing. We aimed to study the 
relative importance of these parameters in a large group of CHF patients. 
Methods: In 62 CHF patients (age 60 + 11 y, NYHA-class 2.6 ?C 0.8, 
peak VOs 17.7 I+ 6.3 mlikgimin, LVEF 28 + 15%; mean i SD) we used 
an intravenous glucose tolerance testing (IVGTT) and the minimal model 
approach to assess Si and measured TNFol, soluble TNF receptors (sTNFR) 
1 and 2, NE, and L. Analyses were compared to a control group of similar age 
(n = 17). 
Results: L was elevated in CHF patients compared to controls (7.7 ZIZ 5.2 
rig/ml vs 4.8 * 3.1 rig/ml, p CI 0.05) as was NE (3.7 & 2.5 nmol/l vs 1.7 i 0.7 
nmol/l, p = 0.01). No elevated levels were found for TNFa, but sTNFR 1 and 
sTNFR 2 were significantly increased in CHF patients (1296 i 834 pg/ml vs 
636 f 233 pg/ml and 2495 f 1109 pg/ml vs 1879 f 921 pg/ml, respectively). 
In CHF patients Si was 2.36 min’/$J.ml-‘1104, which was 34% lower than 
in controls (p < 0.05). 
In CHF there was no correlation of the Si with TNFa! nor with sTNFR1 and 
sTNFR2. Also NE did not correlate with Si (all r < 0.2, p > 0.1). In contrast, 
we found a strong inverse correlation between Si and L (r = -0.48, p < 
0.001). In stepwise regression L emerged as the only significant predictor of 
Si (SC = -0.43; p < O.OOl), independently of NE, TNFol and sTNFR 1 and 2, 
NYHA-class and total body fat (assessed by DEXA scanning). 
Conclusion: In CHF, insulin resistance js strongly and independently cor- 
related with Leptin. However, in contrast to common thinking TNFol and NE do 
not predict impaired insulin sensitivity. 
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I 1073 120 Beneficial Effects of Comprehensive Cardiac 
Rehabilitation and Exercise Training Programs 
on Restenosis in Patients With Coronary Artery 
Disease After Coronary Stenting 
Tatsuhiko Hata, Seiichirou Motohara, Hidenori Komori, Kunihiko Kosuga, 
Akiyoshi Kawashima, Shigeo Matsui, Yung-Sheng Hsu, Hideo Tamai, 
Hiromu Uehata. Shiga Medical Center for Adult Diseases, Moriyama, Japan 
Background: Comprehensive cardiac rehabilitation (CCR) is known to result 
in improvements in multiple risk factors and increases in peak aerobic capac- 
ity (pkVO2 (mliminlkg)) and prevents the decline in physical activity due to 
depressive state or the overactivity due to poor insight into disease in patients 
with coronary artery disease (CAD) after coronary stenting. Adjustmentation 
of daily physical activity due to CCR and augmentation of pkV02 as a result 
of CCR may prevent restenosis after coronary stenting. 
Methods: Ninety eight male patients (mean age 61 i 11) with CAD who 
underwent a successful coronary stenting were randomly allocated to the 
training group (T) or the control group (C) at 2 weeks after angioplasty. Seven- 
month supervised AT level exercise training and mental supportive therapy 
were performed with the patients of T while ambulatory once a month was 
given to the patients of C. They performed cardiopulmonary exercise tests at 
2 weeks, 4 months (M) and 7 M after coronary stenting. PkV02 and peakV02 
were measured. Restenosis was defined as a residual stenosis at the time of 
follow-up angiography of more than 50% of luminal diameter. Analysis of % 
stenosis was done by blinded core lab QCA method. 
Results: PkV02 and PeakV02 significantly (p < 0.01) increased in T while 
that in C did not change. The reference vessel size and the percent stenosis 
just after coronary stenting were comparable between the two groups. The 
restenosis rate in T was significantly (p < 0.05) lower than that in C (at 4 M; T: 
18.2%, C: 30.1%, at 7 M; T: 20.3%, C: 36.0%). 
Conclusion: CCR and exercise training programs prevent restenosis after 
coronary stenting in addition to contributing to reduction in total and cardio- 
vascular mortality. 
( 1073-l 21 ] Short-Term Endurance Exercise Training 
Enhances Endothelium-Dependent Vasodilation 
in Healthy Premenopausal Women 
Morton R. Rinder, Jeffrey Greiwe, Ali A. Ehsani. Dept. of Medicine, 
Washington University School of Medicine, St Louis, Missouri, USA 
Background: To test the hypothesis that short term endurance exercise train- 
ing (EET) improves endothelium-dependent vasodilation (EDD), we exam- 
ined the effect of training on flow mediated dilation (FMD) in response to 
L-arginine (a precursor of nitric oxide synthesis), since FMD is normal at 
baseline in healthy premenopausal women. 
Methods: Eight women (age = 26 f 1.3 years old, mean f SE.) were 
studied during the late luteal phase of their menstrual cycle. Training con- 
sisted of running or cycling for 40 minutes per day, 6 days per week increasing 
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to 60 minutes per day in the fourth week in order to achieve 75% of their 
maximal head rate during maximal exercise testing. FMD was determined 
by measuring the brachial arterial diameter with high resolution ultrasound 
before and after a 5 minute blood pressure cuff occlusion. FMD was also mea- 
sured during the infusion of 1,3, and 7grams of L-arginine intravenously in the 
contralateral arm in an attempt to stimulate nitric oxide synthesis. Endothe- 
lium-independent vasodilation (EID) was determined by measuring brachial 
arterial diameter before and after the sublingual administration of 0.4 mg of 
nitroglycerin. 
Results: Maximal oxygen consumption was higher after training (35.2 f 
0.9 vs. 38.9 f 0.8 ml/kg/min, p 4 0.001). EID was similar before and after 
endurance training (121.5 vs. 122.8% of baseline diameter p = 0.58). FMD 
was marginally greater after 4 weeks of exercise training. 
Maximal FMD per dose of L-arginine (% of baseline f SE.) 
0 1 gm. 39m 7w 
Before EET 107.6 + 1.8 106.6 + 2.5 108.4zk 1.7 113h1.6 
After EET 112.1 f 1.7 112.1 It 2.3 114h2.5 111 * 1.4 
p = 0.056, two way repeated measures ANOVA 
Furthermore, EET improved the response to L-arginine (dose x condition 
interaction, p = 0.02). 
Conclusion: Our data suggests that EDD is enhanced by short term train- 
ing in healthy, non-smoking women with normal baseline endothelial function. 
This enhancement is measurable even in conduit arteries supplying untrained 
muscle groups suggestive of a systemic arterial adaptation to exercise. 
1073-122 Long-Term Exercise Training Leads to Sustained 
Improvement of Coronary Endothelial Function 
and Flow Reserve in Patients With Coronary 
Artery Disease 
Anamaria Wolf, Rainer Hambrecht, Axel Linke, Nina Schoene, 
Stephan Gielen, Sandra Erbs, Jiirgen Hofer, Gerhard Schuler. Heart Center 
- University of Leipzig, Leipzig, Germany 
Background: Short-term supervised intensive exercise training (ET) has the 
potential to improve coronary endothelial dysfunction in patients (pts) with 
stable coronary artery disease (CAD). Aim of this prospective randomized 
invasive study was to assess whether the short-term effects can be sustained 
over 6 months by home-based moderate ET. 
Methods: 19 pts with stable CAD were randomized to a training (T, bicy- 
cle ergometer training Gx/day for 4 weeks in hospital, Px/day at home for 5 
months) or to an inactive control group (C). Coronary endothelial function in 
response to 7.2 bg/min acetylcholine and flow reserve (CFR) after 2.4 mg 
adenosine/min were invasively measured at 0, 1, and 6 months (mo). Quan- 
titative coronary angiography and Doppler flow wire were used to determine 
vessel diameter (ID) and average peak velocity (APV). 
Results: 
TOmo T 1 mo T6mo COmo c 1 mo C6mo 
%A ID -15.1&2.2 -6.8f2.5*1 -8.9f2.8* -10.9rt2.1 -10.0*2.1 -9.2zt2.5 
%A APV 78.1 * 15.3 141.6+27*n 85.7+ 19.3 65.2* 13.6 56.9* 16.9 60.3* 10.9 
CFR 2.8 zk 0.2 3.6 zk 0.2* 3.3 * 0.3* 3.4*0.3 3.3 i 0.2 3.2 zt 0.2 
flp < 0.05 vs. control, *p < 0.05 vs. 0 mo 
Conclusion: In pts with CAD high-intensity supervised ET significantly 
improves coronary endothelial dysfunction and CFR. However, these positive 
effects were not completely sustained by a moderate intensity home-based 
ET. 
1073-I 23 Effect of Exercise on Haemostatic Markers in 
Patients With Atrial Fibrillation 
Foo LCSaw-Hee, Andrew D. Blann, Gregory Y.H. Lip. Haemostasis, 
Thrombosis and VascularBiology Unit, University Dept. of Medicine, City 
Hospital, Birmingham B 18 7QH, UK 
Background: Although chronic atrial fibrillation (AF) is known to confer a hy- 
percoagulable state, it is uncertain whether this is further altered by exercise. 
Methods: We measured levels of von Willebrand factor (vWf IU/dL, a 
marker of endothelial dysfunction), plasminogen activator inhibitor-l (PAI 
rig/ml, fibrinolysis), soluble P-selectin (sP-sel, rig/ml, platelet activation) (all 
by ELISA) and fibrinogen (fib, g/L Clauss method) in 20 AF patients not on any 
antithrombotic therapy (13 men; mean age 65 * 11 years). All had treadmill 
exercise test (ET) (standard Bruce protocol) achieving a mean workload of 4.9 
* 1.7 metabolic equivalents and a mean exercise time of 4.9 f 2.0 minutes. 
Bloods were taken at baseline, immediately and 20 minutes post-ET. Baseline 
levels were compared to matched healthy controls in sinus rhythm. (vWf, Fib 
mean * SD; PAI, sP-sel median and interquartile range) 
Results: 
vWF 
Fib 
PAI 
SP-Se1 
Controls 
105f30 
2.6 zt 0.8 
4.9 
(3-14.8) 
(465-865) 
Pre-ET Imm after After 20 mins P value” 
132&37* 135rt42 136&43 0.308 
3.1 h 0.8* 3.4 + 1 3.4 * 1 0.047 
4.8 4.8 4.2 0.001 
(0.7-24.1) (i-32.2) (0.3-20.3) 
* 
(657-8104) (S::,) (66?06) 
0.071 
‘P < 0.001 (t-test/Mann-Whitney, controls vs pre-ET). “Repeated measures ANOVA. 
Conclusions: AF patients have higher vWf, fibrinogen and sP-sel lev- 
els consistent with increased thrombogenesis, endothelial dysfunction and 
platelet activation. Levels of fibrinogen increased and PAI decreased signifi- 
cantly after ET. Exercise in AF patients enhances prothrombotic state which 
is partially counteracted by reduction of inhibition of fibrinolysis. 
1073-l 24 A Comparison of Outcomes in Patients With and 
Without Left Ventricular Dysfunction 
Undergoing Cardiac Rehabilitation 
Jose A. Tallaj, Bonnie Sanderson, Jenny Breland, Vera Bittner. University of 
Alabama at Birmingham, Birmingham, Alabama, USA 
Background: Multiple studies have shown the benefits of enrolling patients 
with left ventricular (LV) dysfunction of various etiologies in a supervised exer- 
cise program (Cardiac Rehabilitation [CR]). However, this intervention is not 
covered by most insurances. 
Purpose: To compare clinical outcomes of patients with and without LV 
dysfunction enrolled in our CR. 
Methods: Retrospective analysis of the data prospectively collected at en- 
try and completion of the CR program at our institution. Patients were grouped 
according to their left ventricular ejection fraction (LVEF) into two groups: 
LVEF 1 40% and LVEF < 40%. Demographics, history of coronary risk fac- 
tors, usual physical activities, diet score, Body Mass Index (BMI), 6-min walk, 
lipid levels and quality of life (QOL) scores (SF36) were assessed at entry and 
completion of the CR program. 
Results: A total of 101 patients completed the program: 72 in the LVEF ? 
40% and 29 in the LVEF < 40% group. Baseline characteristics and primary 
diagnosis were similar in both groups. Both groups had similar change in blood 
pressure, lipid levels, BMI, diet score and QOL measures. Patients with LVEF 
< 40% showed a significantly greater increase in the 6-min walk (279 f 238 
vs 128 f 197 ft, p 0.002) when compared to their high LVEF counterparts. 
Conclusions: CR is at least as effective in patients with LV dysfunction 
as compared with patients with normal LV function. However, patients with LV 
dysfunction show agreater improvement in functional capacity manifested as 
a significant improvement in the 6-min walk distance. Randomized studies are 
needed to evaluate the role of CR in mortality and risk of hospitalization in pts 
with severe LV dysfunction. 
1073-l 25 Effects of Atrial Flutter vs Sinus Rhythm on 
Exercise Tolerance in Grown-Up Congenital 
Heart (GUCH) Patients 
Wei Li, Jane Somerville. Royal Brompton Hospital and imperial Co//ege 
School of Medicine, London University: UK 
Background: Atrial flutter (AFL) is common in GUCH patients and leads to 
deterioration of patients’ effort tolerance and functional Ability Indices. 
Methods: Exercise tests using modified Bruce protocol were performed 
in 20 consecutive GUCH patients who presented with symptomatic atrial flut- 
ter (AFL) during and again 24-48 hours after DC conversion to sinus rhythm 
(SR). Diagnoses were one ventricle 9 (5 with Fontan type surgery), transpo- 
sition of great arteries 4 (3 had Mustard and 1 arterial switch), hypertrophic 
cardiomyopathy (HCM) 3, closed atrial septal defect 2 and other lesions 2. 
Age at study was 21-62 years, 11 female. The first AFL attack was in 4 and 
recurrent in 16 patients. 
Results: 1 
Exercise test 
Duration (min) 
Heart rate at rest (bpm) 
Heart rate at peak (bpm) 
Delta Systolic BP (mmHg) 
Oxygen Saturation at rest (%) 
Oxygen Saturation at peak (%) 
AFL 
6.4 zk 4.1 
106k21 
157*31 
5524 
91 *lo 
79+22 
SR 
10.9 f 3.7 
77*14 
129*24 
23+16 
9117 
81 f14 
P value 
<O.OOl 
<O.OOl 
<O.Ol 
<O.Oi 
NS 
NS 
During AFL, the 5 patients with Fontan dropped SBP by 16 i 5.5 mmHg 
lower than the other 15 patients, P < 0.001, but the mean exercise duration 
was not different. Exercise test was limited by near-syncope in 415 Fontan 
and 1 arterial switch patients. Heart rate was over 200 bpm within 0.5 to 
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12 minutes in 4 patients who were not taking antiarrhythmic medicine. With 
sinus rhythm exercise was terminated mainly because of fatigue or breath- 
lessness. 
Conclusion: Atrial flutter causes dramatic reduction in exercise tolerance 
in GUCH patients and results in syncope and hypotension. Marked improve- 
ment in effort tolerance occurred after regaining sinus rhythm. Thus, it is 
important to return and maintain sinus rhythm in GUCH patients. 
arterial desaturation at max E with an increase difference between alveolar 
and arterial PO*, despite alterated diffusing capacity were observed. 
Conclusion: This results support a relationship between reduced diffus- 
ing capacity during exercise and excessive ventilatoty response through an 
adaptative response: excessive hyperventilation exercise, inducing higher 
difference between alveolar and arterial POs, preserves stable normal blood 
gases, despite altered diffusing capacity at exercise observed in most severe 
CHF ots. 
1 1073-l 26 1 Warm-Up Phenomenon is Lost in Elderly 
’ Patients With Coronary Artery Disease 
Nicola Ferrara, Giancarlo Longobardi, Pasquale Abet& Dario Leosco, 
Antimo Papa, Giuseppe Furgi, Nunzio Guerra, Claudio Calabrese, 
Franc0 Rengo. Chair of Geriatrics, University of Nap/es “Federico II” and 
Fondazione “Salvafore Maugen”, Telese Terme, BN, Ha/y 
Background: In patients with coronary artery disease, brief periods of ex- 
ercise following by resting lead to reduce the severity of exercise-induced 
ischemia (warm-up phenomenon). This phenomenon, which may represent a 
clinical counterpart of ischemic preconditioning has not been investigated in 
elderly patients. 
Methods: Two consecutive ergometric exercise stress tests (Tests 1 and 
2) were performed in 18 adult (mean age: 55 f 6 years) and 15 elderly (mean 
age: 73 f 5 years) patients with chrome stable angina and comparable coro- 
nary angiographic findings. Time to 1 mm ST segment depression (STD) in 
set, maximum ST segment depression (maxSTD) in mm, and recovery time 
of ST depression to >l mm of baseline (RecT) in set were considered. 
Results: The results are shown in the following table. 
MaxSTD 1.9 i 0.5 1210.6' 1.8ztO.6 1.7 * 0.5 
Rt?CT 166zk75 76i59" 27Oi93 300% 11 
p < 0.001 "s Test1 
Conclusion: A previous exercise following by resting is able to reduce 
the ischemia induced by a successive exercise stress test in aldult but not in 
elderly patients with coronary artery disease. Moreover, our results confirm 
experimental data on the age-related reduction of ischemic preconditioning, 
ORAL 
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827-I Relationship Between Reduced Pulmonary Diffu’sing 
Capacity and Excessive Ventilatory Response to 
Exercise in Patients With Chronic Heart Failure 
Richard Gervasoni, Jerome Brunet, Laurent Poirette, Christian Prefaut, 
Jean-Marc Davy, Robert Grolleau, Patrick Messner-Pellenc. Departments of 
Cardiology Department of Physiology: Universify Hospifal of 
Monfpeliier-Nimes, France 
Background: Chronic heart failure (CHF) is characterized by exercise intol- 
erance. Excessive ventilator-y response contributes to exercise limitation. The 
determinants of exercise hyperventilation remain unclear. In CHF, pulmonary 
diffusing capacity for carbon monoxide (DLCO) is reduced at rest and mostly 
impaired during exercise. The aim of this study was to determinate the rela- 
tionship between impaired diffusing capacity during exercise and excessive 
ventilator-y response. 
Methods: Maximal peak oxygen consomption (pVOs) was assessed dur- 
ingcardiopulmonaryexercisetesting in lrlcontrol subjects, in 15 CHF patients 
(pts) with pVOn z 16 ml/kg/min (Group 1) and in 8 CHF pts with pVOs < 16 
ml/kg/min (Group 2). DLCO (mmHg/ml/min i SD) and DLCO/alveolar vol- 
ume (VA) were simultaneously mesured at rest and during exercise, both by 
intra-breath method. Blood gases were mesured at rest and at maximal exer- 
cise (max E). Ventilatory response was calculated during exercise (VENCOs 
slope). 
Results: At rest DLCO (19.7 i 8 vs 30.1 i 10.4, p < 0.001) and maximal 
DLCO (22.3 i 12 vs 47.6 i 18.5, p < 0.0001) are lower in all CHF pts vs 
control. Rest-DLCO, max-DLCO, max-DLCONA were both inversely corre- 
lated with the VENCOs slope. Regarding to the severity of CHF, DLCONA 
was reduced at rest and did not increase during exercise only in group 2, 
suggesting an impairment in alveolar-capillary capacities. Nevertheless, no 
9:30 a.m. 
i-i 827 2 Decreased Submaximal Exercise Tolerance and 
Increased Sympathetic Activation in Response to 
Cold Exposure in Patients With Congestive Heart 
Failure 
Michel White, Martin Juneau, Jean L. Rouleau, Johanne Marquis, 
Nicole Poitras, Anique Ducharme, Jean-Claude Tardif, Lizanne Bussieres. 
Montreal Heart Institute, Montreal, Quebec, Canada 
Background: Cold exposure decreases ischemic threshold and exercise du- 
ration in patients with coronary artery disease. The purpose of this study was 
to investigate the effects of cold exposure on exercise tolerance assessed by 
submaximal endurance protocols, and on systemic adrenergic activation in 
patients with congestive heart failure (CHF) caused by coronary artery dis- 
ease or dilated cardiomyopathy. 
Methods: Twelve patients with CHF NYHA class 11-111, aged 61 f 9 years 
(mean f SD), mean EF = 24 5 5% (18-34%) all treated with an ACE-inhibitor 
but not treated with a p-blocker, and IO age-matched healthy volunteers (HV) 
perfomed a VOs max on a Ramp protocol and two endurance exercise tests c6 
f 4.3% above the anaerobic threshold at 20°C and at -8°C. Norepinephrine 
levels were measured at baseline and at the time of exhaustion. 
Results: Patients with CHF had lower VOn max (19 f 4.5 (CHF) vs 32.9 
i 4.2 mllkgimin (HV), P < 0.05). Exercise duration was similar at 20°C and 
at -8°C in HV (1386 f 498 (20°C) vs 1505 f 422 set (-8’C), P= 0.26). In 
contrast, exercise-time decreased by 20 i 22% at -8°C in patients with CHF 
(1000 f 394 (2O’C) vs 821 i 431 set (-8”C), P= 0.005). NE increased to the 
same extent in HV and CHF patients at 2O’C [+1559 i 1500 (CHF) vs cl558 
f 828 pg/ml (HV)] but tend to increase more in CHF patients at -8°C (+2501 
f 2048 (CHF) vs +1543 f 1081 pg/ml (HV) P= 0.07). Exercise was limited by 
dyspnea in all patients. 
Conclusion: As opposed to healthy volunteers, patients with symptomatic 
CHF with or without CAD exhibit decreased exercise capacity and likely 
increased systemic adrenergic activation in the cold as measured by sub- 
maximal endurance protocols. This provides an additional rationale for using 
p-adrenergic blockade in patients with CHF frequently exposed to cold. 
9:45 a.m. 
L--L 827 3 Prognostic Value of the “Circulatory” Power During Exercise in Patients With Heart Failure 
Jean-Yves Tabet, Damien Logeart, Pierre Bourgoin, Chabnam Guiti, 
Christine Alonso, Alain Cohen Solal. Hopita/ Beaujon, Clicb~ France 
Background: Cardiac power (cardiac output x arterial pressure) measured 
by catheterism during exercise was shown to have a greater prognostic value 
than the classical exercise variables in patients with chronic heart failure 
(CHF). We wondered whether this measurement non invasively approached 
had similar value. 
Methods: 175 CHF patients (ejection fraction < 40%) underwent car- 
diopulmonary exercise testing; the product of VOa by arterial pressure equals 
cardiac power x arteriovenous 02 difference (“circulatory” power) was cal- 
culated at peak exercise; its prognostic value was assessed after a mean 
follow-up of 26 months. 
Results: Age was 53 I! 10 years and ejection fraction 25 * 10%. The 
mean value of the maximal circulatory power was 243 & 107 mm Hg.1 or 
3199 i 1269 mm Hg.1 .kg-I. Patients who died or underwent transplantation 
has lower circulatory power than those surviving (2477 f 905 vs 3573 f 1273 
mm Hg.1 .kg-‘, p < 0.0001). By univariate analysis, both variables had high 
20 1,. _,.,.,...,._.,...,...,..., t Months 
0 20 40 60 
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prognostic value (x2 = 18 and 26 respectively, both p < 0.0001). Peak VOn 
had the highest x2 value (x’ = 32). However, by multivariate analysis, the 
circulatory power indexed by weight or predicted values (x2 = 4.4 and 5.1, p < 
0.05) was the only predictor of outcome whereas peak VOn was not any more. 
Conclusion: The “circulatory” power, product of systolic arterial pressure 
by V02, that integrates cardiac, vascular and peripheral factors, appears as a 
surrogate of cardiac power that does not necessitate invasive measurements. 
Its peak exercise value appears as a very powerful prognostic factor. 
10:00 a.m. 
III . 827 4 Comparison of the Prognostic Value of Left Ventricular Filling and Peak Oxygen Uptake in 
Patients With Heart Failure 
Jean-Yves Tabet, Damien Logeart, Chabnam Guiti, Pierre Ennezat, 
Christine Alonso, Alain Cohen Solal. HopitalBeaujon, Clicbx France 
Background: Whether a lee ventricular (LV) restrictive doppler mitral inflow 
pattern has better prognostic value than peak oxygen uptake (VOp) in chronic 
heart failure (CHF) is unknown. 
Methods: 100 consecutive CHF patients (ejection fraction < 45%) under- 
went exercise testing after Doppler evaluation; prognosis (death, transplanta- 
tion) was assessed after a mean follow-up of 17 months. 
Results: Forty-five patients (age 55 f IO years) were in NYHA class II, 
47 in class III and 8 in class IV. Ejection fraction was greater Group 1 (non 
restrictive pattern: E/A mitral wave ratio ~1 or >I and 12 with E deceleration 
time (DT) 2 140 msec) than in Group 2 patients (restrictive pattern: E/A > 2 
or >l and ~2 with E deceleration time < 140 msec) (29 f 9 vs 22 f IO%, p 
< 0.05). Peak VOn was lower in Group 2 (17 i 4 vs 22 * 5 mllminikg; 57 i 
11 vs 75 & 15% of predicted values; p < 0.05). Only end-diastolic diameter 
(Chi2 = 5.0, p = O.OZ), E/A (Chi2 = 4.2, p = 0.04) and indexed peak VOp (ChiP 
= 5.6, p = 0.01) were predictors of death by univariate analysis (continuous 
variables). By multivariate analysis, only indexed peak VOS (risk ratio = 0.91 
(95% Cl:O.84-0.99) and DT (risk ratio:1.02, 95% Cl: 1 .OO-1.05) (both p = 
0.03) predicted death. 
When deaths and transplantations were considered, age, end-diastolic 
diameter, A wave velocity, E/A, peak VOn and indexed peak VO:! were pre- 
dictors of outcome. By multivariate analysis, only indexed peak VOn (risk ratio 
= 0.91 (95% Cl: 0.85-0.96, p = 0.002) and DT (risk ratio = 1.01, 95% Cl: 
1.00-l .02, p = 0.02) were predictive of outcome. The risk ratio of events of 
Group 2 vs Group 1 was 3.1 (95% Cl: 1.3-7.1, p = 0.009). Finally, when the 
restrictive/non restrictive pattern was used instead of the other doppler vari- 
ables in the model, only indexed peak VOp (risk ratio 0.95,95% Cl: 0.92-0.98, 
p = 0.02) predicted outcome. 
Conclusion: Although the LV pattern is a strong predictor of outcome in 
CHF patients, independently of the ejection fraction, peak VO2 remains a 
more powerful prognostic variable. 
IO:15 a.m. 
1 827-5 1 Percutaneous Septal Ablation in Patients With 
Hypertrophic Obstructive Cardiomyopathy Results 
in Improvement of Exercise Capacity 
Peer Ziemssen, Lothar Faber, Juergen Schlichting, Werner Meyners, 
Dieter Horstkotte, Hubert Seggewiss. Dept. ofCardio/ogl: Heart Center 
NRK Ruhr-University Bochum, Bad Oeynhausen, Germany 
Background: Pts. with HOCM show an improvement of symptoms after per- 
cutaneous septal ablation (PTSMA). We analyzed exercise capacity by cardio 
pulmonary ecercise testing (CPX) in symptomatic patients with HOCM before 
and 3 as well as 12 months after PTSMA. 
Patients and Methods: 15 consecutive pts. (46 f 13 years, 9 men, NYHA 
2.7 f 0.6) underwent CPX using a bicycle ergometer ramp protocol (A 10 
watts/min). The following variables were measured before and 3 as well as 12 
months after PTSMA: peak oxygen consumption, % of maximal predicted oxy- 
gen consumption (%V02), pVOn at anaerobic threshold (AT), oxygen pulse 
(02 pulse), maximal work load (WL), and determined by echocardiography left 
Pts. (n = 15) Baseline 3 Months 
Peak-V02 (ml/kg/min) 22.1 * 7.1' 22.8 i 7.42 
%VO2 (%) 72.4 + 18.8’ 72.4 zk 20.3' 
AT (mllkgimcn) 15.0 * 4.4' 16.1 zt 4.1' 
02.Pulse (ml) 12.7zk 3.2 13.5 f 3.6 
Workload (Watts) 93*33' 106&40' 
LVOTGR (mmHg) 61 i 22’ 15 i 19’ 
LVOTGV (mmHg) 129&46’ 3Ob32' 
NYHA 2.7 zk 0.6'~' 1.2 * 0.4’ 
1 Year 
25.4 c!z 8.7'a2 
88.9f21.2',2 
18.8& 5.1',2 
15.5 It 6.6 
115*45',2 
7+11' 
21 * 14’ 
1.2 * 0.3' 
p-Value 
‘,2<0.05 
',0.05; 
*<0.01 
‘~210.01 
“S. 
’ <0.01; 
Go.05 
‘p < 0.0001 
‘p < 0.0001 
‘,2p c 0.0001 
ventricular outflow tract obstruction at rest (LVOTGR) as well as at Valsalva 
(LVOTGV). 
Results: The table shows the CPX data and LVOTG of all pts.. 
Conclusions: After PTSMA symptomatic pts. with HOCM show an im- 
provement of subjective as well as objective measurements of exercise ca- 
pacity. These changes are predominantly seen during the longer-term fol- 
low-up due to the previously documented remodeling after circumscribed 
therapeutic infarction. 
ORAL 
Novel and Established Surgical Approaches 
to Heart Failure 
Monday, March 13,2000, 1l:OO a.m.-l 2:15 p.m. 
Anaheim Convention Center, Room 304A 
1l:OO a.m. 
838-i Influence of the Passive ACORN@ Cardiac Support 
Device on Systolic and Diastolic Left Ventricular 
Function 
Franz X. Kleber, Steffen Sonntag, Heike Krebs, Katrin Stantke, 
Birgit Rombeck, Wolfgang Konertz. Dept of Cardiology UKB; Dept. of 
Cardiovascular Surgery Charif&, Humboldt University Berlin, Germany 
Background: Heart failure is characterized by progressive increase in ventric- 
ular volumes, dilation and reshaping of ventricles and deterioration of hemo- 
dynamics. According to La Place’s law ventricular chamber size importantly 
contributes to afterload, thus limiting the heart’s ability to translate tension 
development into volume work. The surgical placement of a passive con- 
straining device over the ventricles could halt ventricular dilation or decrease 
ventricular volumes. However it might unfavourably influence diastolic func- 
tion by directly limiting filling or by an excessive fibrotic response leading to 
constrictive pericarditis. 
Methods: In 7 male patients (age46 f 11 yrs; baseline LVEF23%; median 
NYHA Ill) we studied left ventricular function 3 months after implantation of 
an ACORNm cardiac support device, 5 of whom had preimplantation studies 
for comparison (see below). Simultaneous right and left ventricular pressures 
were analyzed, pressure volume curves were constructed by micromanome- 
ter tip LV pressure recordings and biplane contrast ventriculography applying 
Simpsons rule. The time constant of isovolumic relaxation (r), the chamber 
stiffness constant and the slope of the end-systolic PV relationship (ESPV 
slope) were calculated. 
Results: No patient showed clinical signs of constriction, though 1 pa- 
tient was still conge’sted when investigated. LV-RV pressure differences were 
preserved and relaxation as well as late diastolic function were unimpaired 
at operating LV volumes, while systolic function improved and volumes de- 
creased. 
LVEDVI ml/m” 
LVESVI ml/m’ 
LVEF % 
tau; msec 
chamber stiffness constant: 
ESPV slope mmHglml/m*: 
Pre-Implant 
170f22 
143&27 
22.8 i 14.0 
65.0 h 5.8 
0.097f 0.043 
1.28 * 0.91 
Post-Implant 
145152 
111 i- 39 
29.7* 12.2 
51.8i 13.3 
0.079 f 0.030 
2.09 * 1 .oo 
Conclusions: The ACORNa cardiac support device does not have un- 
favourable constricting effects on the heart 3 months after implantation. Sys- 
tolic and early diastolic left ventricular function is improved, late diastolic stiff- 
ness is not increased. Further safety and efficacy studies are needed to con- 
firm these initial results. 
11:15 a.m. 
838-2 Short-Term Safety of the Acorn Cardiac Support 
Device in Patients With Advanced Heart Failure 
Wolfgang Konertz, Birgit Rombeck, Holger Hotz, Michael Zytowski, 
Steffen Sonntag, Franz X. Kleber’, Hani N. Sabbah”. Dept Cardiovascular 
Surgery Charite, Berlin; ‘Dept. Cardiology Unfallkrankenhaus, Berlin, 
Germany; 2Henry Ford Heart and Vascular Institute, Detroit, Michigan, USA 
Background: The Acorn Cardiac Support Device (CSD), a preformed-knitted 
polyesterdevice surgicallyplacedoverthecardiacventricles, has been shown 
to prevent progressive LV remodeling and improve LV ejection fraction in dogs 
with heart failure (HF). As an initial safety study, the CSD was implanted in 16 
patients (14 males, 2 females; age = 56 f 3 yrs) with advanced HF (NYHA 
class 2.8 i 0.1). 
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Methods: Of the 16 patients, 11 had concomitant mitral valve repair or 
replacement, 1 had concomitant LVAD placement and 4 received only the 
CSD. The CSD was placed while on bypass but with the heart beating, was 
anchored at the AV groove and tailored anteriorly to fit around the ventricles. 
Results: All patients tolerated the surgery with no complications, Two pa- 
tients died from non-CSD related causes 23 and 40 days post-operatively; 1 
from heparin-induced thrombocytopenia and 1 from complications of a sud- 
den death having had history of VT. None of the remaining 14 patients had 
any CSD related adverse events during an average 2.9 * 0.3 months fol- 
low-up. Ten of 14 patients have completed a 1 month follow-up and none had 
clinical signs or echo/Doppler findings suggestive of constrictive or restrictive 
physiology. Their pre- and 1 month post-implant findings are in the table. 
NYHA Class 
Pm-Implant 
2.8 * 0.2 
1 Month 
2.1 + 0.3 
LV End-Diastolic Dimension (mm) 74 * 2 70*3 
LV End-Systolic Dimension (mm) 6712 60+4 
LV Ejection Fraction (%) 1913 25zk4 
Mitral Regurgitation Grade (0 to 4+) 2.1 * 0.3 0.9 f 0.3 
Conclusion: The results to date indicate that the Acorn CSD is safe and 
well tolerated by patients with advanced HF. Longer follow-ups are needed to 
confirm safety before efficacy trials are undertaken in patients with HF. 
11:30 a.m. 
838-3 Device Based Left Ventricular Shape Change 
Immediately Reduces Left Ventricular Volume and 
increases Ejection Fraction in a Pacing Induced 
Cardiomyopathy Model in Dogs: A Pilot Study 
Patrick M. McCarthy, Kiyotaka Fukamachi, Masami Takagaki, 
Guy Armstrong, James B. Young, Cyril J. Schweich, Jr., Todd J. Mortier, Marc 
R. Raffe. C/eve/and Clinic Foundation, Cleveland, OH; Nlyocorlnc., 
Plymouth, MN, USA 
Background: Left ventricular (LV) remodeling in heart failure leads to dil- 
itation, ventricular shape alteration, and physiologic changes that result in 
depressed LV contractile function. We tested the hypothesis that a LV shape 
change from globular to bilobular reduces ventricular wall radius of curvature, 
reduces wall stress and improves contractile function in an experimental hear-l 
failure model. 
Methods: Heart failure was induced in six healthy mongrel dogs implanted 
with transvenous pacemakers by pacing at 230 bpm for an average of 23 
days. induction progress was monitored weekly and considered complete 
when transthoracic 2D echocardiography (2DE) ejection fraction (EF) was 
reduced to 50% of prepacing value. A novel device, the Myocor Myosplint’“, 
was surgically implanted in the LV to produce an estimated 20% or 30% 
reduction in wall stress by changing LV shape. Shape change was achieved 
by placing 3 Myosplint’” devices perpendicular to the LV long axis and drawing 
the opposing LV walls inward, creating a symmetric, bilobular LV. Cardiac 
output (CO), strokevolume (SV), heart rate (HR), and systemic blood pressure 
(SBP) were measured prior to, and immediately following, 20% and 30% 
stress reduction level. 2DE measurements for end diastolic volume (EDV), 
end systolic volume (ESV) and EF were collected. Comparisons were made 
using paired t-tests corrected for multiple comparisons. 
Results: Mean decreases in EDV (-16.5 ml, -27.6 ml) and ESV (-22.2 
ml, -29.7 ml) were significant (p x 0.05) at 20% and 30% stress reduction 
levels yielding increases in mean EF from 0.27 to 0.36 at 20% and from 0.28 
to 0.38 at 30% stress reduction levels, respectively. HR, SV, CO, and SBP 
were unchanged from baseline. 
Conclusions: Shape change produced by the Myocor Myosplint’” imme- 
diately improved EF and reduced ventricular volumes. Hemodynamic function 
remained stable following LV shape change. 
Methods: We studied 57 patients (age = 59 f 8 years, 46 men) with EF 5 
40% referred for CABG with dobutamine (up to 40 pg/kg/min) stress-reinjec- 
tion 201 thallium SPECT and radionuclide ventriculography (RNV) at rest and 
at low dose dobutamine (5-10 pg/kg/min) before and 3 months after CABG. 
Results: An increase of resting EF 2 5% occurred in 12 patients (group A) 
after CABG (EF = 34% before and 46% after CABG), whereas the remaining 
45 patients (group B) failed to demonstrate such increase (EF = 34% before 
and 32% after CABG). A significant increase of EF from rest to low dose dobu- 
tamine RNV occurred before and after CABG. However, the magnitude of 
increase was more significant after than before CABG in group A (12% vs 7%) 
as well as in group B (13% vs 7%, both p < 0.001). Patients of both groups 
demonstrated a significant reduction of stress, rest and ischemic perfusion 
defect scores after CABG. However, the percentage of reduction of rest per- 
fusion defect score was more significant in group A than in group B (60% vs 
30% respectively, p < 0.01). 
Conclusion: In patients with reduced EF, CABG induces a significant 
improvement of resting myocardial perfusion and EF response to inotropic 
stimulation even in absence of improvement of resting EF. 
Noon 
/ 838-5 ( Does Improvement in Left Ventricular Ejection 
Fraction Predict Long Term Survival After Coronary 
Artery Bypass Surgery in Patients With lschemic 
Cardiomyopathy? 
Mohammad Bashir, Michael S. Lauer, Nicholas G. Smedira, 
Eugene Blackstone, lmran Afridi. Cleveland Clinic Foundation, Cleveland, 
OH, USA 
Background: Left ventricular ejection fraction (LVEF) is a major determinant 
of survival in patients with coronary artery disease. Coronary artery bypass 
surgery (CABG) has been shown to improve LVEF in selected patients with 
ischemic cardiomyopathy. 
Objective: The purpose of this study was to determine whether improve- 
ment in LVEF after CABG predicts long term survival of patients with ischemic 
cardiomyopathy. 
Methods: We reviewed CABG database at our institution from 1990-97 
to identify patients with LVEF 5 35%, who survived isolated first CABG and 
underwent echocardiography within 3 months prior to and after CABG. An 
improvement in LVEF of 2.5% was considered significant. 
Results: Study criteria were met by 131 pts (90 male, age 64 -+ 11 years). 
After CABG there was significant improvement in LVEF (31 i 10% vs. 27 f 
7%, P < 0.0001). In 63 patients (48%) LVEF improved ~5%. During a mean 
follow up of 3.5 years 48 patients died (37%). Although, a trend toward im- 
proved early survival was noted in the group with post-operative improvement 
in LVEF, there was no difference in late survival (figure). 
0 1 2 3 4 
Yrs 
Conclusions: Contrary to popular belief, improvement in LVEF after CABG 
did not predict long term survival of patients with ischemic cardiomyopathy. 
POSTER 
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838-4 Improvement of Resting Myocardial Perfusion and 
Ejection Fraction Response to lnotropic Stimulation 
After Coronary Artery Bypass Grafting in Absence 
of Improvement of Resting Ejection Fraction 
Abdou Elhendy, Jan H. Cornei, Ron T. van Domburg, Roelf Valkema, Jeroen 
J. Bax, Peter R. Nierop, Jos R.T.C. Roelandt. Thoraxcenterandfhe 
Department of NuciearMedicine, Rofterdam, The Nefherlands 
Objectives: The aim of this study is to assess the effect of coronary artery 
bypass grafting (CABG) on rest and stress-induced myocardial perfusion ab- 
normalities and left ventricular (LV) contractile reserve in patients with reduced 
ejection fraction (EF). 
Background: Improvement of resting LV function is the end point for eval- 
uaiion of the LV myocardium after CABG. However, little is known about the 
effect of CABG on contractile reserve and resting perfusion. 
[ 1094 1 New Methods to Assess Myocardial Function 
Monday, March 13,2000, Noon-2:00 p.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: 1:OO p.m.-2:00 p.m. 
I 1094 120 Correlation Between Endocardial Voltage Mapping and Myocardial Perfusion: Implications 
in the Assessment of Myocardial lschemia 
Shmuel Fuchs, Matie Shou, Anthony Pierre, Martin B. Leon, Ran Kornowski. 
The Cardiovascular Research Foundation, Washington Hospital Center, 
Washington, DC, USA 
Background: Recent experimental and clinical experiences using anon-flu- 
oroscopic 3 dimensional (D) left ventricular (LV) mapping system showed 
considerable alterations in voltage amplitudes detected in endocardial zones 
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sustaining myocardial ischemia and/or infarction. However, the relationship 
between measured voltage potentials and myocardial perfusion has not been 
defined. 
Methods: In a pig model of chronic myocardial ischemia (n =20), LVendo- 
cardial unipolar voltage (UpV) mapping was performed using the Biosense’” 
3D navigation system 4 weeks following ameroid constrictor placement around 
the left circumflex artery (LCx). Echocardiography was used to assess re- 
gional %myocardial thickening (MT), and fluorescent microspheres (4 x 1 Os/in- 
jection) were used to quantify rest regional myocardial blood flow (MBF) in 
ischemic (LCx) and non-ischemic (LAD) regions. 
Results: 
lschnmic Non-lschemic P 
MBF (mllgmlmin) 
Endocardial 0.50 zt 0.16 0.74 * 0.15 0.001 
Epicardial 0.55 f 0.13 0.62 & 0.16 0.13 
MT (%) 26.1 f 12.0 37.4 5 0.1 0.003 
uov ImVI 9.9 * 3.3 13.3 f 3.3 0.003 
A positive correlation was found between UpV and rest endocafdial (but 
not epicardial) blood flow using the regression formula: UpV (mV) = 7.8 + 5.9 
x MBFendmardial (R = 0.32, P = 0.05). 
Conclusions: Chronic myocardial ischemia, resulting in reduced perfu- 
sion and function at rest (i.e. hibernating myocardium), is characterized by 
a significant reduction (-25%) in endocardial voltage potentials which cor- 
relates well with reduced endocardial blood flow at rest. Thus, LV guided 
endocardial voltage mapping can identify and localize the severity of regional 
endomyocardial hypoperfusion at rest. 
1 1094-l 21 1 Different Effect of Enalapril on Hypertrophy and 
Metabolic Abnormalities in Two Models of 
Pressure Overload Induced Left Ventricular 
Hypertrophy 
Simon N. Allo, Susan M. Polizzi, Charles J. Storey, Theodore Abraham, 
Craig R. Malloy. UTSouthwestern Medical CenterDallas, Texas, USA 
Background: Left ventricular hypertrophy (LVH) is associated with increased 
cardiovascular morbidity and mortajity, which are reduced by normalization of 
LV mass with therapy. Hearts with LVH, even when mild, have increased glu- 
cose oxidation and decreased long chain fatty acid oxidation. It is not known 
if the profile of energy sources also returns to normal after therapy with angio- 
tensin converting enzyme inhibitors. We examined the effects of enalapril on 
regression of LVH and metabolic abnormalities induced by pressure overload. 
Methods: Two animal models of pressure overload induced LVH (aortic 
banded (AB) and spontaneously hypertensive (SH) rats) were compared to 
sham operated and wistar controls respectively. Prior to treatment, LVH was 
documented by echocardiography and/or magnetic resonance imaging at 28 
days after banding for AB rats and 14-18 weeks of age for SH rats. Sham 
and AB or SH and wistar animals were treated with low (LE) or high (HE) dose 
enalapril or no therapy for 28 days. Blood pressure (BP) was determined by tail 
cuff method for SH and carotid cannulation for AB rats. Substrate metabolism 
was studied after enalapril therapy in isolated perfused working hearts using 
13C nuclear magnetic resonance spectroscopy. 
Results: Untreated animals from both models had increased mean ar- 
terial pressure and LV mass/body weight. Isolated perfused working hearts 
from untreated animals showed decreased cardiac output, coronary flow, rate 
pressure product and long chain fatty acid oxidation, Treatment with HE nor- 
malized BP in both models and resulted in complete regression of LVH in SH 
but only partial regression in AB rats. LE resulted in partial reduction of BP 
and LVH in both models. Despite complete regression of LVH in SH rats by 
HE, fatty acid oxidation remained decreased. In AB animals, control of BP and 
normalization of LV mass was associated with recovery of normal fatty acid 
oxidation. 
Conclusion: In AB animals, metabolic abnormalities correlate with LV 
mass and return towards normal with enalapril therapy. In SH rats LV mass 
returns to normal with high dose enalapril therapy, but abnormal fatty acid 
oxidation persist. The metabolic response of the hypertrophied myocardium 
to angiotensin converting enzyme inhibitors may depend on the etiology of the 
LVH. 
) 1094-I 22 ) Transmission of Atrial Systolic Velocity in the 
Left Ventricle: Umea General Population Survey 
Study 
Michael Y. Henein, Andesh Waldenstrom, Kjell Karp, Per Lindqvist, 
Elsadig Kazzam, Derek G. Gibson. Umea UniversityHospital, Sweden; 
Royal Brompton Hospital, London, UK 
Background: The left atrium functions in systole as a reservoir and in late 
diastole it contributes to the stroke volume by active mechanical contraction. 
Methods: The aim of this study was to achieve detailed analysis of nor- 
mal atrioventricular coupling using tissue Doppler technique. We studied 60 
normal subjects; Group I-40 with dominant early diastolic LV filling, age 43 
i 10 years and Group II-20 with dominant late diastolic filling, age 60 + IO 
years using pulsed wave tissue Doppler technique. None of the subjects had 
systemic or cardiac disease. Systolic and diastolic myocardial velocities were 
taken from the lateral, septal, anterior and posterior LVsegments at the basal, 
mid-cavity and apical thirds. Mean values of the 4 segments were calculated 
at the 3 LV levels. 
Results: Systolic myocardial shortening velocity fell by 50%, equally in the 
2 groups, between the LV base and apex. Early and late diastolic velocities 
are shown in the table (all values in m/s). 
E wave (I) E wave (II) 
BaS.d 0.15 f 0.03 0.09 It 0.03’ 
Mid-cavity 0.13 * 0.03 0.08 i 0.03* 
Apical 0.08 * 0.02 0.05 i 0.02” 
*: p < 0.001 E &A velocities in the 2 groups. 
A wave (I) A wave (II) 
0.12 * 0.03 0.15f0.03* 
0.09 * 0.02 0.14 * 0.04’ 
0.05 * 0.02 0.1 * 0.03* 
Conclusion: Although systolic velocity propagation did not differ in the two 
groups early diastolic ones were much lower and late diastolic higher in late 
filling ventricles. The higher apical velocity of atrial contraction in the same 
group suggests an accentuated mechanical atrial activity balancing the fall in 
early diastolic velocities with age. 
Ll-. 1094 123 Multiple Frequency Volume-Conductance Catheter Provides True Volume in the Mouse Left 
Ventricle 
Marc D. Feldman, Yi Mao, Gregory L. Freeman, Jonathan W. Valvano, John 
A. Pearce. University of Texas Health Science Center, San Antonio, Texas; 
University of Texas, Austin, Texas, USA 
Background: Transgenic mice provide a valuable way to relate specific gene 
products to phenotype. Assessment of cardiac performance in the pressure- 
volume plane would be useful to help assess how specific genes impact on 
cardiac physiology. Volume-conductance technology can generate an instan- 
taneous left ventricular (LV) volume signal, but is limited by current leakage 
into the myocardium. We hypothesized that assessing conductance across a 
range of frequencies could solve this problem. 
Methods: Myocardial and blood resistivity, LV end-systolic volume (ESV), 
end-diastolic volume (EDV), and stroke volume (SV) were determined in 8 
mice. We combined these data with an analytical approach to extract LV 
blood volume from the raw conductance signal, and compared it to the current 
standard conductance technique (hypertonic saline technique). 
Results: The figure shows that mouse myocardial resistivity varies with 
frequency while blood resistivity does not. Thus, EDV and ESV vary with 
frequency while SV does not. The table shows the multiple frequency method 
gave similar results to the standard method. 
EDV (uL) ESV (uL) sv (UL) 
Multiple frequency 21 *9 12zk7 6*2 
Standard method 27f12 13flO 10*4 
Individual values increased similarly (EDV r = 0.9, ESV r = 0.7, SV r = 0.8). 
Conclusion: The multiple frequency volume-conductance system can 
empirically solve for left ventricular blood volume in the mouse. It is a new 
tool to relate specific gene products to phenotype in transgenic mice. 
1094-I 24 Effect of Increased Afterload on Left Ventricular 
Function in Mice 
Marc D. Feldman, Yi Mao, Gregory L. Freeman. Universityof Texas Health 
Science Center, San Antonio, Texas, USA 
Background: The availability of the transgenic mouse as a tool to relate car- 
diac phenotype to specific gene alterations has increased interest in routine 
physiology, of which little is known. Specifically, it is unknown how the mouse 
left ventricle (LV) responds to a sustained increase in afterload. Accordingly, 
we determined the effects of steady-state increases in afterload on the LV 
pressure-volume relationship. 
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Methods: Mice (n = 6) underwent thoracotomy for placement of a transapi- 
cal dual-field conductance system to provide high fidelity pressure and vol- 
ume signals, and an aortic flow probe, 01 was determined as the ratio of 
flow probe to conductance stroke volume. End-systolic pressure (Pes), end- 
systolic elastance (Ees), effective arterial elastance (E,), ventricular-arterial 
coupling (EesiEa), end-diastolic volume (EDV), the time constant for isovol- 
umetric relaxation (Tau), and end-diastolic pressure (Ped) were determined 
at steady state and following caval occlusion; before and after partial aortic 
clamping. 
Results: Heat rate did not change (446 + 73 to 439 f 43 bpm, p = NS). 
P% ES Ea EeslEa EDV Tau ped 
Baseline 52 + 8 14+12 452 3+2 15zt8 1615 3+1 
Afterload SO+ 11” 13* 10 7 f 2* 2f 1” 1716 20 + 7* 4 * 2* 
“p < 0.05 
Results show that P,, and E, both increased with afterload, and E,, did 
not change. Therefore, E,,/E, decreased. End-diastolic pressure increased. 
An example is shown. 
Conclusion: Preload reserve participates in response to afterload in the 
murine heart. While afterload leads to altered ventricular - arterial coupling 
and slowed relaxation, it has no significant effect on myocardial contractility. 
1094-125 Ventricular Diastolic Impedance: A New Index of 
Global Diastolic Function 
Jonathan M. Milde, Mark S. Sessoms, Jennifer B. Lisauskas, Andrew 
W. Bowman, Michael R. Courtois, Sandor J. Kovacs. Cardiovascular 
Siophysics Laboratory, Washington University in St. Louis, MO, USA 
Background: The best invasive index of diastolic function (DF) is the LV 
end-diastolic pressure, defined at a single point in diastole. Noninvasive DF 
indexes have relied on selected attributes of the Doppler E- and/or A-wave, 
apical color M-mode, Doppler tissue imaging of mitral valve annular velocity, 
or pulmonaryvenousflow patterns. Systolicventriculo-arterial impedance (Z,) 
a function of frequency (w). is defined as the ratio of pressure (Ps) to flow (Q,) 
during ejection. In analogy, we propose and define diastolic impedance (Z,) 
to be the ratio of diastolic LV pressure (Pd) to transmitral flow (Qd) during 
early-rapid filling (E-wave). 
Methods: Simultaneous Doppler E-wave images and micromanometric 
(Millar) Pd were recorded during diagnostic catheterization in 19 subjects 
(IO normal, 9 abnormal). Fourier analysis of model-based image processed 
E-wave flow and digitized Pd was performed. The ratio of the amplitudes of 
each harmonic Z,(w) = P,(o)/Q,(w) vs. harmonic number n was plotted. 
Results: The indexZ, (0) easily differentiated between “impedance-matched” 
(0 = normal DF) and “impedance-mismatched” (X = abnormal DF) subjects 
as illustrated in the example below. Abnormal DF exhibits larger impedance, 
or larger resistance to blood flow at a given pressure, at any given harmonic. 
Comparison of slopes of linear regression for normal (0) vs abnormal (X) 
DF groups by Student’s unpaired t-test differentiated among groups with p < 
0.001 significance. 
impedance&fatching 
yj120 
and Mismatohing 
~1cu! 
z: 80 
= 60 
g40 
f ““, 
012345678310 
Hanonic Number, n 
Conclusions: Ventricular diastolic impedance Z,, constitutes a new in- 
dex of global DF. It quantitates diastolic dysfunction in dynamic terms (w), 
uses the entire E-wave and Pd as input and differentiates between normal 
and abnormal DF states. Application to selected pathologic subsets is war- 
ranted Development and validation of a method to generate Z,(w) using only 
noninvasive data and correlation with conventional Doppler DF indexes is in 
progress. 
/ Sufficient Ventricular End-Systolic Potential 
Energy is Stored to Power Diastolic Untwist and 
Mechanical Suction-Initiated Doaoler E-Wave 
Generation 
. . 
Andrew W. Bowman, Jennifer 8, Lisauskas, Sandor J. Kovacs. 
Cardiovascular Biophysics Laborator) Washington University St. Louis, MO, 
USA 
Background: Pressure-volume loops and the end-systolic pressure-volume 
relation (ESPVR) have been used to characterize LV function. Suga and 
Sagawa have proposed that the triangular area bounded by the linear ESPVR 
and the isovolumic relaxation portion of the pressure-volume loop represent 
stored end-systolic potential energy (ESPE). No prior attempts have been 
made to account for utilization of ESPE as heat (Q) and external work dur- 
ing diastole. We hypothesized that ESPE is used for untwisting (E,,r,) during 
isovolumic relaxation and as the source of potential energy (Es-wave) at mitral 
valve opening for mechanical, suction-initiated E-wave generation. According 
to the first law of thermodynamics, ESPE = E,,,, + Esswave + Q. 
Methods: Simultaneous Doppler E-waves and micromanometric (Millar) 
LV pressures, and ventriculographic LV volumes were recorded in 5 normal 
subjects during catheterization. E-wave images were subjected to analysis 
via model-based image processing to provide Es.wave. To compute ESPE, 
the linear ESPVR was determined via the single-beat estimation method of 
Senzaki eta/. The figure schematically shows the ESPVRas well as the ESPE 
(blue) to Q + Eunt, (orange) and Eswave (green) relation. 
Results: For n = 5, E,,,, = 38.4 f 2.9% of the ESPE, Eswave = 27.4 + 
10.5%, and Q = 34.2 * 11.6%. Note that the sum of E,,,, and Es.wave is 
<iOO% of ESPE. 
Conclusion: Sufficient potential energy (elastic strain) is stored at end- 
systole to account for untwisting during isovolumic relaxation and to act as a 
source of LV recoil to power suction-initiated, E-wave generation. Conversion 
of stored potential energy to external work in diastole elucidates one method 
of mechanically coupling systole to diastole. It reinforces the heart’s role as a 
mechanical suction-pump. Application to pathologic states is in progress, 
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l-.-l-l 1095 142 Electroanatomical Left Ventricular Mapping 
(NOGA’“) for Prediction of Functional Recovery 
Karl-Christian Koch, Alexander Sasse, Monika Wenderdel, 
Elisabeth Ostwald, Christoph Stellbrink, Udalrich Buell, Peter Hanrath, 
Juergen vom Dahl. University Hospital, Aachen, Germany 
Background: Electroanatomical mapping with a nonfluoroscopic, catheter- 
based system (NOGA’“, Biosense) may be a method to assess myocardial 
viability In this study the predictive value of the regional electrogram ampli- 
tude measured by NOGA for wall motion recovery was assessed. 
Methods: Twenty-nine patients (pts, 24 male 57 f 9 years) with prior 
(~2 weeks) myocardial infarction undergoing single- or multi-vessel PTCA 
were studied. Coronary angiography and laevocardiography were performed 
prior to PTCA and at 6 month follow up. For regional wall motion analysis the 
centerline method was used and regional wall motion expressed as SD/chord. 
Prior to PTCA, endocardial electrograms were mapped using the NOGA”” 
system. The left ventricle was divided into 12 regions and the regional mean 
amplitude of the unipolar electrogram was calculated. Based on previous 
validation studies using FDG-PET, a regional mean amplitude of 7 mV was 
used as threshold for viability assessment. 
Results: Twenty-two patients had a good PTCA result at 6 month follow-up 
angiography. Regional wall motion improved from -2.4 ?I 0.9 SD/chord to 
-1.4 f 0.9 SD/chord (p < 0.01) in infarct regions with electrogram amplitudes 
>7 mV (n = 12), whereas regional wail motion worsened from -2.3 i 0.5 
SD/chord to -2.6 i 0.5 SD/chord (p < 0.01) in infarct regions with amplitudes 
~7 mV (n = 10). Similarly, left ventricular ejection fraction improved from 50 
f 18% to 60 A 11% (p = 0.03) in patients with preserved electrical function 
whereas ejection fraction did not change (54 f 8% to 51 f ll%, p = 0.41) in 
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the remaining patients. The positive predictive value of NOGA for wall motion 
recovery ~0.5 SD/chord was 88% and the negative predictive value was 80%. 
Conclusion: These data suggest that the mean regional amplitude of the 
electrogram, derived from NOGA’” mapping, may predict improvement in wall 
motion abnormalities after successful revascularization. 
/ 1095-I 43 ( Validation of Real-time 3D Echocardiography for 
Quantifying LV Volumes in the Presence of a LV 
Aneurysm: In Vitro and Clinical Studies 
Jian Xin Gin, Takahiro Shiota, Hiroyuki Tsujino, Michael S. Firstenberg, Lisa 
A. Cardon, Jill A. Odabashian, Richard D. White, James D. Thomas. The 
Cleveland Clinic Foundation, Cleveland, OH, USA 
Although LV volume can be obtained satisfactorily in many patients by 2DE, 
it is limited when applied for patients with LV aneurysm. The purpose of this 
study was to validate the accuracy of real-time 3D-echo (3DE) for quantifying 
aneurysmal LV volumes. 
Methods: 3DE and 2DE systems were used to acquire images of 7 
aneurysmal balloons and of 34 patients (14 with chronic LV aneurysms and 20 
with normal LV). LV volume was measured with rotated apical B-plane method 
by 3DE and with Simpson’s rule by 2DE. Magnetic resonance imaging (MRI) 
was used for validation in the patient study. 
Results: In the in vitro study, The volume range of aneurysmal balloons 
was 150 to 395 ml. The volumes calculated by 3DE and 2DE correlated 
well with actual values. However, 3DE was more accurate than 2DE (mean 
difference (A): -7 f 7 ml vs 27 i 12 ml, p = 0.0002). In the clinical study, LV 
end-diastolic and end-systolic volumes were 142 f 47 ml and 59 i 24 ml in 
control group, and 250 * 89 ml and 159 i 83 ml in aneurysm group. Excellent 
correlations and agreements between 3DE and MRI for LV volumes were 
found. Although 2DE correlated well with MRI in patients without aneurysms, 
the r-value decreased and A increased in patients with aneurysm (Table). 
r-value 
A fmll 
3DE “s MRI 
Control Aneurysm 
0.96 0.99 
-13i18 -28 f 25 
2DE “s MRI 
Control A,neurysm 
0.92 0.84 
-27 i 23* -53 f 53* 
I: Comparison with 3DE, p < 0.01 
Conclusions: For geometrically asymmetric LVs associated with ventric- 
ular aneurysms, real-time 3DE can accurately quantify LV volumes. 
L-L-. 1095 144 Elevated Levels of Serum C-Reactive Protein may Predict Prognosis of Patients With Chronic 
Heart Failure 
Yasuhiko Mitsuke, Jong-Dae Lee, Hiromasa Shimizu, Hiroyasu Uzui, 
Taketoshi Yamazaki, Takanori Ueda. First Department oflnternal Medicine, 
Fukui Medical University Fukui, Japan 
Background: Several circulating neurohormones and inflammatory. markers 
have been shown to have a prognostic significance in chronic heart failure 
(CHF). We evaluated the serum levels of C-reactive protein (CRP) in CHF pa- 
tients to examine whether serum levels of CRP are correlated with the severity 
of CHF, circulating levels of pro-inflammatory cytokines or neurohormones. 
Methods: Eighty-six Japanese patients with CHF (38 with nonischemic 
cardiomyopathy, 28 with ischemic cardiomyopathy and 20 with valvular heart 
diseases) were included in this study (left ventricular ejection fraction <45%, 
NYHA functional class II (n = 46), Ill (n = 25) IV (n = 15)). Age-matched 36 
healthy persons were used as control. None had evidence of unstable angina, 
inflammatory disease or cancer at the time of evaluation. Levels of CRP, 
interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-or), and atrial natriuretic 
peptide (ANP), brain natriuretic peptide (BNP) and norepinephirine (NE) were 
measured in each subject using obtained from peripheral blood samples 
Results: The serum CRP concentrations were significantly higher in CHF 
than in controls (0.43 f 0.06 mg/dl vs. 0.05 i 0.01 mg/dl, p < 0.01). In 
CHF, serum CRP was increased along with NYHA functional class, and was 
correlated with circulating levels of IL-6 (r = 0.69, p < O.Oi), TNT-a (r = 0.58, 
p < O.Ol), ANP (r = 0.50, p < O.Oi), BNP (r = 0.51, p < O.Ol), and NE (r = 
0.42, p < 0.03). In stepwise regression analysis, Serum CRP emerged as the 
independent strongest predictor of IL-6 and BNP. In addition, univariate Cox 
proportional hazards analysis showed that serum level of CRP was also a 
significant predictor of mortality in this group of patients (p = 0.0002). 
Conclusion: Our data indicated that elevated serum CRP was related 
to the levels of circulating pro-inflammatory cytokines, neurohormones, and 
mortality of patients with heart failure syndrome. 
~1095-145 ( Variability of Ventricular Extrasystoles and 
Survival in Patients With Postinfarction Left 
Ventricular Dysfunction 
Maciej Sosnowski, Zofia Czy, Jan Skrzypek-Wa ha, Michael Tendera. 3rd 
Division of Cardiology: Silesian School of Medicine, Katowice, Poland 
Objective: Left ventricular (LV) dysfunction and frequent/complex ventricular 
extrasystoles (VES) are established, but not sensitive predictors of cardiac 
mortality in patients afler myocardial infarction (Ml)., We examined a new 
approach to identifying post-MI patients at highest risk of sudden cardiac 
death. 
Methods: 56 patients (52 men, 4 women, mean age 58 f IO years) were 
selected, who had echo signs of LV dysfunction (mean LVEF 33 f 12%, mean 
LVID 62 & 8 mm) and frequent’complex VES (log VES 7.1 f 1 .l, episodes 
of non sustained VT[nsVT] 6 i 19) during Holter ECG monitoring. In each 
patient, a standard VES evaluation, and an analysis of heart rate and VES 
variability were performed to obtain the total VES, number of runs of nsVT, 
NNI -mean R-R interval, SDNN-standard deviation of normal R-R intervals, 
NVI - mean coupling interval of VES, SDNV - its staandard deviation, as well 
as LVEF and LVID. 
Kaplan-Meierumulativesurvival 
r_l ______-________--_ d 
109 rank 3.501,p=0.0004 
Results: During 12.months follow-up, eight patients died suddenly (14.3%) 
As compared to the survivors, the victims had significantly shorter NNI (714 
* 89 vs 848 f 134 ms, p < 0.05, Kolmogorov-Smirnov), and greater SDNV 
(85 f 30 vs 65 i 26 ms, p < 0.05). When an 80 ms cut-off value of SDNV 
was chosen, the one-year mortality rate was 42.9% in those with SDNV ? 80 
ms, as compared to 4.8% in those with SDNV < 80 ms (figure). The sensitivity 
reached 80%, specificity 83%, positive predictive value 43%, negative predic- 
tive value 95% and relative risk 2.04. The SDNVshowed asignificant positive 
correlation with LVID (Spearman R = 0.40, p < 0.01) and with the number 01 
nsVT episodes (R = 0.45, p < 0.001). 
Conclusion: Analysis of variability of ventricular arrhythmia may improve 
risk stratification in patients with LV dysfunction and frequent ventricular ar- 
rhythmia following myocardial infarction. 
1095-I 46 Quantitative General Theory for Periodic 
Breathing in Chronic Heart Failure and Its 
Clinical Implications 
Darrel P. Francis, Keith Willson, L. Ceri Davies, M.F. Piepoli, Andrew 
J.S. Coats. Nation&Heart & Lung Institute, London, UK 
Background: Periodic breathing is frequently seen in patients with chronic 
heart failure and carries a poor prognosis. The dynamics of respiratory con- 
trol involve equations which cannot be solved in general using conventional 
mathematical formulae, so that a general quantitative theory explaining peri- 
odic breathing and its treatment has been elusive. 
Methods: We show how the introduction of a transcendental function al- 
lows, for the first time, a general solution of the fundamental delay differential 
dynamics of respiratory control physiology, using only widely-understood clin- 
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ical concepts, Measurements are made on an indicative group of 20 patients 
and IO controls. 
Results: This gives a quantitative explanation of mechanisms in the cau- 
sation and treatment of periodic breathing. The graph shows show the com- 
plex dependency of the instability of the system upon the chemoreflex gain 
(S), end-tidal COa concentration (C), time delay (S), lung volume (VL), mean 
alveolar ventilation (VA), cardiac output (Q) and solubility of CO2 in blood (p). 
A validation study suggests that the major contributing factors to PB in CHF 
are principally chemoreflex gain (p < 0.001) and delay time (p < 0.05). 
Conclusion: This time-domain mathematical approach to periodic breath- 
ing allows its pathophysiology to be considered quantitatively, and underlines 
the importance of chemosensitivity. It explains the mechanisms of all known 
effective treatments and has the potential to become a framework for rational 
therapy. 
1095-l 47 An Exaggerated Ventilatory Response to 
Exercise is Related to Abnormal Exercise 
Hemodynamics in Patients With Chronic Heart 
Failure 
Michee de Guise, Claire E. Snader, Alyce Venditti, James B. Young, Michael 
S. Lauer. C/eve/and Ciinic Foundafion, C/eve/and, O/-/, USA 
Background: In congestive heart failure (CHF), an increased ventilatoty 
response to exercise had been demonstrated, characterized by the rela- 
tion between ventilation (Vs) and CO* production (VsN~oa). This has been 
linked to autonomic imbalance and predicts mortality. Exercise hemodynam- 
its, namely heart rate (HR) and systolic blood pressure (SBP) responses, 
also predict mortality. We analyzed the impact of VsN~os on exercise hemo- 
dynamics in chronic CHF. 
Methods: Metabolic stress tests of 426 consecutive CHF patients (mean 
age 52 rt 11, 72% male, 42% with hypertension, 36% with coronary disease 
(CAD), mean LVEF21 i 8) in sinus rhythm (none had pacemakers), not taking 
B-blockers, amiodarone or intravenous inotropes were reviewed. The patient 
population wasdivided in quintiles according to VsNcoa at peak exercise. HR 
and SBP responses were analyzed for each of the first 4 stages of exercise 
and at peak exercise of a modified Naughton protocol. HR response was 
assessed by calculating the proportion of heart rate reserve (HRR) used while 
SBP response was measured by rise of SBP in nun Hg. 
Results: Patients with higher V s N cop had attenuated HRR used (P 4 
0.0001) and SBP rise (P < 0.0001) at peak exercise (Figure relates these to 
VsNcoa quintiles). Similarly, a higher VsNcoa predicted an attenuated SBP 
response at Stage 1 of exercise (P = 0.001). Even after adjusting for age, 
gender, CAD, peak VOa, and other possible confounders, a higher VsNcos 
was associated with lower HRR used (P = 0.04) and SBP rise (P x 0.0001) at 
peak exercise and with a lower SBP response at Stage 1 (P = 0.08). 
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Conclusion: In patients with chronic CHF, a higher VsNcoa is strongly 
associated with attenuated heart rate and blood pressure responses to ex- 
ercise; SBP responses are attenuated even at very low levels of exercise. 
These observations may reflect impaired sympathetic reserve and may partly 
explain the strong and independently additive value of VsN~oa in predicting 
mortality in CHF patients. 
at rest (QTcd(R)) and QTcd just after Master double stress test (QTcd(E)) for 
all study patients. They were divided into two groups based upon QTcd(E) > 
QTcd(R) (Group 1, n = 42) or not (Group 2, n = 46) and were followed up for 
three years, During the follow-up period of 1-36 months, seven patients died 
suddenly (six in Group 1 and one in Group 2). There were no significant differ- 
ences in age, sex, EF, NYHA classification. Kaplan-Meier analysis revealed 
that the rate of sudden death in Group 1 was significantly higher than that in 
Group 2 (p = 0.038) (Fig.). These results suggest that an increase in QTcd by 
exercise might be a potent predictive implication for sudden death in patients 
with CHF. 
1095-149 Increased Risk of Infection in Patients With 
Congestive Heart Failure 
Amr Morsi, Chun Kwan, Heather Ross, Elaine Wang, Peter Liu. The Toronro 
Hospital (TTH), University of Toronto, Canada 
Background: Circulating cytokine levels are increased in patients with heart 
failure (HF), and this may imply abnormal immune modulation and immune 
compromise. To determine if HF patients are prone to infection, a case control 
study was conducted. 
Methods: The cases consisted of consecutive patients admitted to TTH 
with the primary diagnosis of heart failure during a fixed period, and the con- 
trols were consecutive patients admitted with the primary diagnosis of acute 
myocardial infarction (Ml) without HF during precisely the same period. The 
presence of infection was established from clinical diagnosis by the attending 
medical team with documented clinical sequelae requiring antibiotic treatment 
and/or positive cultures. 
Results: Overall there were 75 pts with the isolated diagnosis of HF (mean 
age 73.2 yr), and the controls were 91 pts with MI (mean age 61.3 yr). Infection 
rate in the HFcases was41.3% (31/75), vs. 12.1% (11/91) in thecontrol group 
(Odds ratio 3.3, 95% Cl = 2.9-3.7 p < 0.001). HF pts were also at greater 
risk of developing nosocomial infection [18.5% vs. 8.0% O.R. 2.6, 95% Cl = 
2.6 (1.3-3.8) p < 0.05]. In hospital mortality in HF patients with infection was 
41.9% compared to 9.1% (p < 0.001) in pts without infection. Interestingly, the 
patients with refection in the HF group showed no significant rise in leukocyte 
count at the time of diagnosis compared to non-infected HF pts (9.5 & 5.7 
vs. 7.9 i 44 x IO”, p = NS). The infections in HF pts were mainly pulmonary 
(63.6%) whereas the control developed a broad spectrum of infections. 
Conclusions: Patients with HF are at clearly increased risk of infection, 
and this may contribute both to the high morbidity and mortality in these 
patients. HF pts are particularly susceptible to pulmonary infection, and may 
constitute a newly recognized immune compromised population. 
1 1095-l 50 1 Going Gone! The Relationship Going 
Between Atrial Fibrillation Duration and Atrial 
Stunning 
Jeanne M. DeCara, Simon Dubrey, Rodney H. Falk. Bosfon Medical Cenfer, 
Boston, MA, USA 
1 1095-l 48 / An Increase in Corrected QT Dispersion on 
Exercise Predicts Sudden Death in Patients With 
Chronic Heart Failure - A Prospective Study 
Hisakazu Ogita, Masatake Fukunami, Tsuyoshi Shimonagata, 
Kazuaki Kumagai, Takahisa Yamada, Yoshihiro Asano, Akio Hirata, 
Mitsutoshi Asai, Noritake Hoki. Osaka ?refectura/ Genera/ Hospital, Osaka, 
Japan 
Prolonged QT dispersion (QTd) was reported to be related to malignant ven- 
tricular arrhythmias in patients with chronic heart failure (CHF). However, little 
data showed whether heart rate corrected QTd (QTcd) on exercise was re- 
lated to sudden death. Then, we hypothesized that the prolonged QTcd would 
be more prominent on exercise than at rest in patients with CHF. We prospec- 
tively studied 88 CHF patients Without atrial fibrillation whose left ventricular 
ejection fraction (EF) was less than 40%. QTcd was determined by subtracting 
the shortest corrected QT interval by Bazett’s formula from the longest one in 
the standard 12slead ECG. Before the entry of this study, we calculated QTcd 
Background: Previous investigators have shown that AF of brief (12 wks) 
duration is associated with less atrial mechanical dysfunction post-cardiover- 
sion (CV) than prolonged AF (>2 wks). The point at which the relationship 
between AF duration and atrial stunning ceases is unknown. We therefore 
sought to better define the duration of AF after which the degree of post-CV 
atrial stunning remains constant. 
Methods and Results: Doppler A-wave velocity was measured within 
24 hours of CV in 170 patients with AF of 2-6 months duration. Regression 
analysis was performed starting with patients with AF 2-4 weeks in duration 
and was repeated as the patient group was expanded in 1 week increments 
to include those with longer AF duration. An inverse relationship between 
AF (weeks) 2-4 4-6 6-8 8-10 
n 18 43 24 16 
r value -0.524 -0.103 -0.090 -0.341 
p value 0.03 0.51 0.68 0.20 
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pre-CV AF duration and post-CV peak A wave velocity was found. Though this 
association was statistically significant for AF durations up to 9 weeks, further 
regression analyses in 2 week blocks proved that the apparent relationship 
was entirely driven by a strong correlation in patients with AF of 2-4 weeks 
duration. 
Conclusions: Contrary to prior belief, the effect of pre-cardioversion AF 
duration on post-cardioversion atrial stunning persists even after 2 weeks of 
arrhythmia. However, this effect rapidly dissipates by one month, after which 
the degree of atrial stunning remains constant. 
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) 1096-l 51 1 Age Related Acute Results of Percutaneous 
Septal Ablation in Hypertrophic Obstructive 
Cardiomyopathy 
Hubert Seggewiss, Lothar Faber, Peer Ziemssen, Werner Meyners, 
Leon Krater, Axel Meissner, Juergen Schlichting. Dept of Cardiology, Heart 
Center NRW; Ruhr-University Bochum, Bad Oeynhausen, Germany 
Background: Elderly pts. with HOCM have significant differences in baseline 
characteristics and increased risk after surgical myectomy. 
Methods: We compared baseline data and acute results of PTSMA in 
younger (~40 years), middle aged (40-59 years), and elderly (?60 years) 
pts. with HOCM who underwent alcohol-induced septal branch occlusion 
(PTSMA). 
Results: Since l/l 996 241 symptomatic pts. with HOCM were treated. 
Group 
Patients (n) 
Women (,)*** 
NYHA (Class)*‘* 
Family history (,)*** 
Septal thickness (mm)’ 
LVOTG at rest (mmHg) 
-Baseline 
-After PTSMA 
LVOTG > 50% $ (%)** 
CK max. (U/l) 
Complications (%) 
-DDD pacer (%) 
-Death 1%) 
<40 years 
48 
33 
2.5 i 0.5 
52 
22.3 zk 3.7 
71.9 zt 27.7 
25.8 * 22.1 
67 
639h310 
2 
2 
0 
40-59 years 
102 
41 
2.7 + 0.5 
31 
20.5 * 3.7 
69.6 * 34.7 
16.7zk21.1 
87 
570 zk 267 
7 
0 
?60 years 
91 
62 
3.0 * 0.5 
21 
20.6 i 3.8 
74.4 l 39.7 
21.4 + 23.5 
86 
525 zk 294 
11 
8 
3.3 
Differences of baseline data as well as acute results are listed in a table i”p < 0.05; **p 
< 0.01: **‘p < 0.001; LVOTG = lefl ventricular outflow tract gradient; $ = reduction). 
Conclusion: Younger pts. show lower LVOTG reduction after PTSMA. 
But, like in surgical myectomy complications are more often seen in elderly 
pts. and mandate a careful monitoring during hospital stay. 
l-4 1096 152 Improvement of Acute Results After Percutaneous Transluminal Septal Myocardial 
Ablation in Hypertrophic Obstructive 
Cardiomyopathy During Mid-Term Follow-Up 
Hubert Seggewiss, Lothar Faber, Axel Meissner, Werner Meyners, 
Leon Krater, Peer Ziemssen. Dept. of Cardiology: Heart Center NRW; 
Ruhr-University Bochum, Bad Oeynhausen, Germany 
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) 
by alcohol-induced septal branch occlusion in pts. with HOCM results in acute 
reduction of left ventricular outflow tract gradients (LVOTG) in >90% of the 
pts.. 
Methods: We report on 197 symptomatic pts. (103 men; age 52.1 f 15.5 
years; 9 pts. with prior myectomy, 13 pts. with prior DDD-pacer (PM); NYHA 
2.8 i 0.5; LVOTG at rest 60.3 f 34.0 and Bt stress 125.1 f 48.9 mmHg) 
with 3 months follow-up. 15 (7.6%) pts. required DDD-PM due to permanent 
AV-block. 141 (71.6%) pts. had additional 1 year follow-up. 
Results: 2 pts. had temporary atrial fibrillation 2 and 9 months after 
PTSMA. 2 pts. died 3 weeks (plaque rupture of a preexisting 25&O% RCA 
lesion with acute Ml) and 9 months (86 year old woman with stroke) after 
PTSMA. No other cardiac complications were seen during follow-up. Symp- 
tomatic improvement was impressive to NYHA 1.2 & 1 .O (p < 0.0001). 
Acute results 3 months 12 months 
LVOTG (mmHg): 
-Rest 27.2 zt 26.1 16.55 19.1** 9.7 i 16.6** 
-stress 61.8 i 45.9 42.5 zt 38.8** 28.6 zk 33.8** 
No LVOTG (%) 24 39 61” 
IVS (mm) BL: 21.1 i 3.6 16.9f4.1** 14.7 l 4.1** 
LVPW (mm) BL: 13.7 * 2.4 12.8 zt 2.0** ll.Q* 1.8** 
X-ECG: 
-Capacity (Watts) BL: 84.9 zk 54.6 110.0 zt 42.6** 119.9 S 37.1 
-lime (min.) BL: 5.6 + 3.6 7.4 * 3.3x* 8.8 * 3.0%” 
Echo and X-KG data are listed in the iable (BL = baseline; p-values vs. previous control: 
*p < 0.01; **p < 0.0001). 
Conclusion: Pts. show ongoing symptomatic improvement after PTSMA 
without significant risk of cardiac complications. Remodeling after circum- 
scribed septal infarction results in further LVOTG reduction in ~50% of the 
pts. and significant reduction of LVPW thickness. 
1096-l 53 Investigation of the Prevalence of Exercise 
Stress Induced Outflow Tract Obstruction in 
Hypertrophic Cardiomyopathy 
Munmohan S. Virdee, Yoshihisa Matsumura, Paul Sorajja, Sanjay Sharma, 
.Perry M. Elliott, William J. McKenna. St George’s Hospital MedicalSchool, 
London, UK 
Background: Although a proportion of patients (pts) with Hypertrophic Car- 
diomyopathy (HCM) have outflow tract obstruction (LVOTO) during pharma- 
cological stress, the prevalence and significance of provokable LVOTO during 
exercise is poorly understood. 
Methods: Fifty one pts with HCM were studied (44 f 14 yrs, 63% male). 
Echocardiography was performed supine and before, during and after maxi- 
mal upright bicycle exercise. 
Results: Forty two (82%) pts had asymmetric septal hypertrophy, the rest 
concentric hypertrophy. Mean septal thickness was 20 f 5 mm and atrial size 
44 & 8 mm. There was no difference between supine and erect resting LVOTO 
(p=O.31). Twenty sevenpts (53%) had no resting LVOTO (Group A), 24 (47%) 
had resting LVOTO > 30 mmHg, (61 i 23 mmHg, Group 6). There was no 
significant difference between groups A and B for age, symptoms, functional 
class, septal thickness, atrial size and cavity dimensions. In Group A, LVOTO 
> 30 mmHg developed during exercise in IO (37%) pts (peak LVOTO 53 f 
28 mmHg, mean rise 34 f 29 mmHg), with further increases (II-64 mmHg) 
during recovery in 4 pts. In two pts, LVOTO developed only in recovery (peak 
LVOTO 33 and 49 mmHg). There was no significant difference between those 
with and without inducible LVOTO for pattern of hypertrophy (p = 0.6), septal 
thickness (p = 0.4), atrial size (p = 0.06), resting mitral regurgitation (p = 0.3), 
symptoms (p = 0.49), NYHA class (p = 0.2), exertional chest pain (p = 1) 
or exertional pre-syncope (p = 1). Patients with inducible LVOTO were more 
likely to have incomplete SAM (p = 0.006) and an ejection systolic murmur 
(p = 0.047) at rest. In Group B, resting LVOTO increased by 210 mmHg.in 
21 (88%) pts during exercise (mean 28 -+ 13 mmHg), and by a further 24 i 
11 mmHg during recovery in 9 pts. In 2 further patients, increases in LVOTO 
occurred exclusively during recovery (16 and 18 mmHg). The peak gradient 
during exercise and recovery correlated strongly with resting LVOTO (r = 0.88, 
p < 0.001). 
Conclusions: Significant LVOTO develops in 37% of patients with no 
resting LVOTO, and increases in 88% patients with resting LVOTO during 
exercise. LVOTO provoked during exercise was not, however, associated with 
greater functional limitation, exertional chest pain or exettional pre-syncope. 
1096-l 54 Delineation of Prognostic Blood Pressure 
Values for Abnormal Blood Pressure Response 
to Exercise in Hypertrophic Cardiomyopathy 
Paul Sorajja, Perry M. Elliott, Jan Poloniecki, Shaughan Dickie, Munmohan 
S. Virdee, Sanjay Sharma, William J. McKenna. St. George’s Hospital 
Medical School, London, UK 
Background: Abnormal blood pressure (BP) response to exercise in hyper- 
trophic cardiomyopathy (HCM) is linked to increased risk of sudden death 
(SD). The precise changes in BP during exercise that are related to SD risk, 
however, are uncertain. This study aimed to delineate these BP values. 
Methods: We examined 247 HCM patients aged ~40 yrs who under- 
went maximal exercise testing off cardioactive drugs. Patients receiving amio- 
darone (n = 22) were excluded. For each exercise study, the systolic blood 
pressure (SBP) rise was defined as the maximum SBP in exercise minus the 
SBP at rest. The SBP fallwas defined as the maximum SBP in exercise minus 
the SBP at peak exercise. Each study was then classified as a positive test if a 
SBP fall greater than xoccurred orthe SBP failed to rise by more than L: where 
xand yrefer to SBP cut-off values from 0 to 50 mmHg. True and false positive 
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rates for each x-ycombination were examined with respect to the occurrence 
of SD. During follow-up (96% complete; median = 48 mos), 14 SD’s occurred. 
Results: The presence of a SBP fall >I0 mmHg yielded the greatest 
positive predictive accuracy for SD occurrence. A failure of the SBP to rise by 
>30 mmHg, however, yielded the greatest sensitivity and negative predictive 
value (NPV). A table of representative SBP fall (x) and rise (y) cut-off values is 
shown below. 
x (mmHQ) 0 15 30 45 
sensrtivity 50.0 42.8 28.5 21.7 
NPV 94.7 95.4 94.8 97.0 
LR 1.35 2.54 3.56 7.14 
P (XT 0.33 0.01 0.01 <O.OOl 
vrmmHol 0 15 30 45 
sensitivity 50.0 
NPV 94.7 
LR 1.35 
P (x2) 0.33 
LR = likelihood ratio. 
64.2 92.8 92.8 
95.6 98.6 97.9 
1.44 1.47 1.24 
0.15 0.02 0.12 
Canclusions: A range of BP changes during exercise identifies persons 
with HCM who are at increased risk for SD, The presence of a SBP fall greater 
than 10 mmHg during exercise suggests an adverse prognosis. The threshold 
of a SBP rise of less than 30 mmHg for an abnormal exercise test provides the 
greatest sensitivity and NPV for SD. 
1096-I 55 1 Variants of Tumor Necrosis Factor-a, 
’ Insulin-Like Growth Factor-2, Transforming 
Growth Factor& and Aldosterone Synthase and 
the Extent of Hypertrophy in Patients With 
Hypertrophic Cardiomyopathy 
Deepa Reddy, Do-Sun Lim, Sherif Nagueh, Miguel Quinones, 
William Zoghbi, Michael Sole, Robert Roberts, Ali J. Marian. Baylor co//ege 
of Medicine, Houston, Texas, USA 
Background: Patients with hypertrophic cardiomyopathy (HCM) exhibit vari- 
able degree of left ventricular hypertrophy (LVH). Causal mutations account 
for a small fraction of the variability of LVH and genetic background plays a 
major role. We investigated association of variants of 4 genes, implicated in 
cardiac hypertrophy, with the extent of LVH in 140 genetically independent 
subjects with HCM. 
Methods: Genotypes were determined by polymerase chain reaction and 
restriction mapping. Septal thickness (ST), mass index (LVMI) and LVH score 
were calculated from echocardiograms. 
Results: 
ST (mm) LVMl (9) 
Tumor necrosis factor (TNF)-cr G-308A 
GG (n = 96) 2.0 i 0.4 141.3 i47.5 
GA (n = 33) 2.0 * 0.4 133.1 & 32.4 
AA (n = 6) 2.0 i 0.4 19o.oi 74.7 
Aidosterone Synthase (CYPllW) (+%) 
-m(n = 37) 1.9 + 0.5 141.0142.6 
TC(n=77) 2.0 5 0.4 142.9zt 52.7 
CC@= 23) 1.9 * 0.3 125.3 * 29.5 
Insulin-like growth factor-2 (IGF-2) G’s’A 
GG (n =.56) 2.0 i 0.4 142.7 5 40.0 
GA (n = 52) 1.9 * 0.4 138.2 + 58.7 
AA (n = 22) 1.9 zk 0.4 140.5 i40.6 
Transforming growth factor (TGF)-B C-sogT 
CC(rl= 55) 2.0 i 0.5 142.3 f 50.0 
CT (n = 65) 2.0 i 0.4 138.7 * 41.6 
TTln=16) 1.9 * 0.3 133.6iBl.O 
score (l-10) 
5.8 h 2.3 
5.7 i 2.0 
7.0 i 0.6 
5.5 dc 2.3 
6.0 z!c 2.3 
5.4 zt 1.8 
6.1 i 2.4 
5.4 zt2.2 
5.7 * 2.0 
6.1 i 2.1 
5.8 i 2.3 
4.8 f 2.0 
Conclusion: HCM subjects with a functional mutation in the TNF-a pro- 
moter have greater LVMI than those without (p = 0.024). Thus, TNF-ru, but not 
CYPIIBZ, TGF-B, and IGF-2 variants, modify the extent of LVH in patients 
with HCM. 
1 1096-l 56 1 Systolic Anterior Motion Begins at Low Left 
Ventricular Outflow Tract Velocity in Obstructive 
Hypertrophic Cardiomyopathy 
Mark V. Sherrid, David Z. Gunsburg, Sonja Moldenhauer, Gretchen Pearle. 
Echocardiography, St. Luke’s-Roosevelt Hospital Center, New York, Nr; USA 
Background: In obstructive hypertrophic cardiomyopathy (HCM) systolic an- 
terior motion (SAM) of the mitral valve with mitral-septal apposition is the most 
common cause of outflow obstruction. If SAM were caused predominantly by 
the Venturi mechanism, high flow velocity in the left ventricular outflow tract 
should be found at the time of SAM onset. If, however, the velocity were found 
to be normal, this would support an alternate mechanism. 
Methods: We studied with echocardiography 25 patients with obstructive 
HCM who had a mean outflow tract gradient of 82 f 6 mm Hg. We compared 
mitral valve M-mode tracings with continuous wave (CW) and pulsed (PW) 
Doppler tracings recorded on the same study. A total of 98 M-mode, 159 CW 
and 151 PW Doppler tracings were digitized and analyzed. For each patient 
we determined the left ventricular outflow tract CW velocity at the time of SAM 
onset. For each patient we first determined the mean time interval from Q 
wave to SAM onset from multiple M-mode tracings. Then, CW velocity in the 
outflow tract was measured at that same time interval following the Q wave. 
Results: SAM began mean 71 i 5 msec after Q wave onset. Mean CW 
Doppler velocity in the left ventricular outflow tract at SAM onset was 89 i 8 
cmisec. In 68% of cases SAM began before onset of CW and PW Doppler left 
ventricular ejection, 
Conclusions: SAM begins at normal left ventricular outflow tract velocity. 
At SAM onset, though Venturi forces are present in the outflow tract, their 
magnitude is much smaller than previously assumed: the Venturi mechanism 
cannot explain SAM. This velocity data, along with shape, orientation and 
temporal observations, indicate that drag, the pushing force of flow, is the 
dominant hydrodynamic force that causes SAM. 
( 1096-l 57 ( Hemodynamic Determinants of 
Exercise-Induced Hypotension in Hypertrophic 
Cardiomyopathy 
Quirino Ciampi, Sandro Betocchi, Anna Violante, Fiore Manganelli, Maria 
Angela Losi, Giulia Sica’ , Carlo Gabriele Tocchetti, Filippo Finizio, 
Elpidio Pezzella, Raffaella Lombardi, Marco Boccalatte, Albert0 Cuocolo’ , 
Massimo Chiariello. Departments of Clinical Medicine & Cardiovascular 
Sciences; ‘Radiological Sciences, “Federico I/” University Nap/es, ltaly 
Background: Blood pressure (BP) drops during exercise in about i of pa- 
tients (pts) with hypertrophic cardiomyopathy (HCM), and may lead to hemo- 
dynamic instability, which is associated with a high incidence of sudden car- 
diac death. We analyzed the hemodynamics of exercise-induced hypoten- 
sion. 
Methods: 43 HeM pts (age 38 f 14 years, 34 men) and 10 controls (age 37 
f 15 years, 7 men) underwent maximal symptom-limited exercise treadmill, 
during ambulatory radionuclide monitoring (VEST). Fourteen HCM pts had 
hypotension (>20 mmHg decrease) during exercise (HypoBP), 24 had normal 
(?20 mmHg) increase in BP (NIBP), the remaining 5 pts had an intermediate, 
flat BP response and were excluded. VEST data were averaged for 1 min. 
Baseline I’ 3 6 Peak 
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and analyzed at baseline, at 1, 3,6 min. and at peak exercise. Left ventricular 
stroke volume (SV), cardiac output (CO) and peripheral resistance (PR) were 
expressed as % of the baseline value. 
Results: Ejection fraction, SV, CO (figure) increased significantly during 
exercise in all groups but more in controls (p < 0.001); in contrast, there was 
a similar increase in heart rate and decrease in PR in the 3 groups. HypoBP 
ware younger (p = 0.015), more symptomatic for angina (p = 0.03), and had 
less left ventricular hypettrophy (p = 0.005), as compared to NIBP. 
Conclusion: Exercise-induced hypotension in HCM depends on a blunted 
increase in CO during exercise, and on an impairment in systolic function. 
This latter may be due to excessive increase in wall stress, consequence 
of a lesser degree of left ventricular hypertrophy, and/or to exercise-induced 
ischemia. This hypothesis could explain higher incidence of angina. A pe- 
ripheral mechanism for exercise hypotension is unlikely because PR did not 
change. 
1 1096-l 58 1 Gender-Specific Cardiac Phenotypic Differences 
Detected by Magnetic Resonance Imaging in 
Hypertrophic Cardiomyopathy Caused by 
Sarcomeric Gene Mutations 
David Begley, Glen Plexico, Andrew Arai, Saidi Mohiddin, Lameh 
Fananapazir. National lnstifutes of Health, NH/B/, Bethesda, MD, USA 
Background: Increased left ventricular mass (LVM) in hypertrophiccardiomy- 
opathy (HCM) is secondary to impaired sarcomeric function. The cardiac phe- 
notype is highly variable even in patients with the identical mutation. There- 
fore, the cardiac responses to the molecular defect are probably modified by 
several undetermined factors. In most studies the number of men who present 
with HCM is higher than women. We therefore tested the hypothesis that this 
is due to gender differences in clinical expression of HCM. 
Methods and Results: Cardiac Magnetic Resonance Imaging (MRI) and 
echocardiograms (echo) were performed off all drugs in 34 adult patients 
(aged > 20 years; 16 men) with HCM caused by sarcomeric mutations: actin 
(n = 2); B-myosin heavy chain (n = 21); atropomyosin (n = 7); myosin-binding 
protein-C (n = 3); myosin light chain (n = 1). LVM and LV volumes (-I denotes 
indexed to body surface area) were smaller in the women. Ejection fractions 
(EF) were lower in men despite higher LVM and hence, lower wall stress: 
Echo MRI 
Gender Septum WTmax LVM LVD LVS EF 
men 1817 22 zt 6 176*52 131 * 39 36110 71*7 
women 1617 20 zk 6 118&43*” 96 zt 21*** 21 f 9”*” 78 * 8* 
Mean BP LVM-I LVD-I LVS-I SW 
men 89513 86zk22 64*16 la-c5 44*19 
WOWS” 83zk9 67121” 55*9* 12 z!c 5*** 43f8 
WTmax, max. LV wall thickness; LVD, LV diastolic and LVS, LV systolic volumes; BP, 
blood pressure (mm Hg); SV, stroke volume; * = p < 0.05; ** = p < 0.01; *** = p < 0.005 
Conclusions: 1) Wall thickness is a poor indicator of LVM; 2) The mal- 
adaptive increased LVM may be associated with impaired LVfunction in men; 
And 3) Gender-specific hormones may affect cardiac responses significantly 
in HCM. Our findings have important implications for design of studies that 
examine genes/therapies that may modify phenotypic expression in HCM. 
1 1096-l 59 1 Risk Identification by Microvolt-Level T Wave 
Alternans in Hypertrophic Cardiomyopathy 
Nami Kuroda, Yoshio Ohnishi, Kouhei Yamashiro, Katsunori Okajima, 
Akihiko Ishida, G.E. Javier, Mitsuhiro Yokoyama. Kobe University Schoolof 
Medicine, Japan 
Background: Identification of the high risk patients in hypettrophic cardiomy- 
opathy (HCM) is an important current issue. Microvolt-level T wave alternans 
(TWA) has been proposed as a useful noninvasive tool for assessment of the 
ventricular tachycardia (VT). 
Methods: Fifty patients (pts) with HCM experienced TWA during bicycle 
exercise testing using a CH2000 system (Cambridge Heart, Inc.). We exam- 
ined the SVI + RV5 and QTdispersion (QTd) on the ECG, late potential (LP), 
intraventricular septal thickness, posterior wall thickness, diastolic dimension 
and % fractional shortening of the left ventricle detected by echocardiogram. 
The maximum number of successive ventricular beats (VE) and nonsustained 
VT (NSVT 1 5 VEs) were measured by Holter monitoring. We also evaluated 
the presence of a family history of HCM (FH), sudden death (SD) and genetic 
abnormality. Twelve pts underwent right ventricular biopsy within 1 month of 
TWA assessment. Histological evaluation was performed to determine hyper- 
trophy of myocytes, disarray and fibrosis by a scoring method (0 to 3 points 
each). 
Results: TWA was positive (TWA+) in 28 pts, negative (TWA-) in 15 pts 
and indeterminate in 7 pts. There was no significant difference in the QTd, LP 
and those parameters determined by echocardiogram between two groups. 
The maximum number of successive ventricular beats and the percentage 
of pts with NSVT in the TWA+ group were significantly higher than those in 
the TWA- group (3.6 13.2 vs 1.2 * 0.8; p < 0.01, 100% vs 0%; p < 0.01). 
Eleven of 17 pts (65%) with FH and five of 8 pts (75%) with SD showed TWA+. 
No significant difference was observed in the histological score between the 
two groups (4.0 i 2.4 vs 2.3 & 1.5). Among the eight pts with FH, a genetic 
abnormality was detected in 5 pts (4 pts; B-myosin heavy chain, 1 pt; car- 
diac myosin-binding protein C). TWA was positive in two pts with a genetic 
abnormality and NSVT. 
Conclusion: TWA is a noninvasive useful marker for detecting high risk 
patients for VT and is closely correlated with a family history of sudden death 
in HCM. 
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845-l Heart-Type Fatty Acid Binding Protein: An Important 
Predictor of Cardiac Events in Heart Failure 
Kazuo Komamura, Naotaka Ohta, Akihisa Hanatani, Keiji Hirooka, 
Yoshio Yasumura, Satoshi Nakatani, Masakazu Yamagishi, Kunio Miyatake. 
National Cardiovascular Center, Suita, Japan 
Background: Heart-type cytoplasmic fatty acid-binding protein (hFABP) has 
been proposed as an early marker- of myocardial infarction. The protein is 
abundant in myocardial cells and is involved in the uptake, transport and 
metabolism of fatty acids, hFABP has been found to provide a higher level 
of accuracy than creatine kinase or myoglobin for early diagnosis of acute 
myocardial infarction. We tested the clinical importance of hFABP as a marker 
for long-term cardiovascular prognosis in idiopathic dilated cardiomyopathy 
(DCM). 
Methods: We measured serum hFABP by means of enzyme immunoas- 
say in peripheral venous blood of consecutive 50 patients with DCM. As a 
control group, hFABP was measured in 75 normal men and women. Clinical 
courses of DCM were followed by 28 i 13 months. Primary endpoint included 
cardiac death. 
Results: 1) Normal values were distributed according to lognormal distri- 
bution and mean + 2SD was equal to 5.25 ng/mL; 2) There were no differences 
in age, sex, NYHA class, LV ejection fraction and plasma BNP levels between 
the normal range (N) group (~5.25 ng/mL) and elevated (E) group (>5.25 
ng/mL); 3) Cardiac events occurred frequently in E group (12/14 = 85.7%) 
than in N group (7/36 = 19.4%) during the follow-up: 4) The Kaplan-Meier sur- 
vival curves demonstrated that the patients in E group had a significantly lower 
survival rate than those in N group (log-rank test, p < 0.05); 5) The cardiac 
event free curves demonstrated that the patienti in E group had a significantly 
lower event free rate than those in N group (log-rank test, p c: p.05). 
Conclusions: These results suggest that elevation of hFABP in idiopathic 
dilated cardiomyopathy is an important clinical marker related with increased 
cardiac events. 
2:15 p.m. 
845-2 Baseline Plasma Levels of Tumor Necrosis Factor-a 
Predicts Response to Treatment With Pentoxifylline 
in Patients With Idiopathic Dilated Cardiomyopathy 
Daniel Skudicky, Karen Sliwa, Anette Bergemann, Geoffrey Candy, 
Pinhas Sareli. Heart Failure Research Unit, Department of Cardiology, 
Baragwanath Hospital, Johannesburg, South Africa 
Background: We have previously reported beneficial effects of pentoxifylline, 
a xanthine derived agent known to inhibit the production of TNF-ol in patients 
with idiopathic dilated cardiomyopathy. However, if the clinical improvement 
and the increment in the left ventricular ejection fraction are related to the 
changes in the TNF-r* levels has not been established. 
Methods: In a prospective, randomized, double blind, placebo control 
study we enroled 49 patients (mean age 52 f IO years, 60% male) with 
idiopathic dilated cardiomyopathy. Patients were randomized to pentoxifylline 
400 mg TDS or placebo. All patients received treatment with digoxin, diuretics 
and ACE inhibitors. Echocardiograms, radionuclide studies and cytokine level 
determinations were performed at baseline and after 6 months. 
Results: 8 patients died during the 6 months study period (6 in the placebo 
group). Patients treated with pentoxifylline, significantly improved the func- 
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tional class, with an improvement in ejection fraction from 21 f 8% to 35 
f 6%, p c 0.0001, and a reduction in TNF-LY levels from 6.5 rt 5 to 1.9 f 1 
pg/ml, p = 0.0005. No significant changes were observed in the placebo group. 
Twelve of the pentoxifylline treated patients improved the ejection fraction > 
IO absolute units. These patients had higher baseline TNF-a levels compared 
to rest of the patients in that group (7.3 + 3vs 3.7 + 2 pgiml, p = 0.01). There 
were no other baseline differences between these two groups. 
IZonclusion: In patients with idiopathic dilated cardiomyopathy, baseline 
levels of TNF-a may identify a group of patients with a better response to 
treatment with pentoxifylline. 
2:30 p.m. 
845-3 Brain Natriuretic Peptide in Hypertrophic 
Cardiomyopathy Caused by Sarcomeric Gene 
Mutations: A Marker for Poor Outcome? 
David Begley, Judith Winkier, Glen Plexico, Dorothy Tripodi, Andrew Arai, 
Saidi Mohiddin, Lameh Fananapazir. National lnstifufes of Health, NHLBI, 
Befhesda, MD, USA 
Background: Familial hypertrophic cardiomyopathy (FHC) is characterized 
by maladaptive left ventricular hypertrophy (LVH) in response to mutations 
that impair sarcomeric function. Some of these mutations are associated with 
a high incidence of sudden death (SD), but others have a benign prognosis, 
Brain natriuretic peptide (BNP) is secreted by ventricular myocytes and is 
reported to be a specific marker of LVH in several disease states. We tested 
the hypothesis that in FHC, the relation of BNP to the increased cardiac mass 
depends on the prognostic significance of the causative mutation. 
Methods and Results: Serum BNP levels and LV mass (using magnetic 
resonance imaging), corrected for body surface area (LVM-I), were measured 
in 53 subjects: 13 patients with FHC caused by 3 mutations associated with 
a poor prognosis (group 1); 23 patients with FHC caused by 6 mutations 
associated with a good prognosis (group 2); and 17 normal relatives without 
mutation (controls). BNP correlated with LVM-I but the significance was low (r 
= 0.29; p = 0.03). Ejection fractions were similar in groups 1 and 2. BNP levels 
related to LVM-I in the 3 groups were: 
Subjects Age WTmax LVM-I BNP BNP t LVM-I 
group 1 251 11 20 * 5** 72 * 19*’ 288 zk 320*** 3.8 i 4x”* 
group 2 28i15 l7%7* 64 + 25 48 i 80”” 0.8 i 1.1- 
Controls 20*13 12+3 54111 25&17 0.5 + 0.4 
WTmax, maximum wall thickness by MRI; =, p < 0.01; **p < 0.005; ***p 5 0.0001 com- 
pared to controls; w , p c: 0.0001 compared to group 1, 
Conclusions: 1) Mutations associated with poor prognosis tended to have 
higher LVM; 2) Severity of LVH is associated with increased BNP levels but 
the correlation between BNP levels and LVM is poor: And 3) Importantly, 
BNP levels were several fold higher in FHC caused by malignant mutations. 
Further studies are necessary to confirm the intriguing finding that BNP levels 
may predict adverse outcome in FHC. 
245 p.m. 
845-4 Hypertrophic Cardiomyopathy and Premature Death 
in the Young: The Histological Characteristics of 
Patients Aged 21 Years and Under 
Amanda M. Varnava, Perry M. Elliott, Niall Mahon, William J. McKenna, 
Michael J. Davies. St George’s Hospital Medical School, London, UK 
Background: Premature death is a significant risk in patients with HCM, 
especially in the young. It is likely that the mechanisms of death in these 
patients is different from the adult population, however little is known of the 
pathological findings in this group. We examined in detail the histology of 
patients aged 21 years and under and correlated these results with the clinical 
findings. 
Methods: The symptoms, echo data and risk profile were noted in 18 HCM 
patients aged 21 and under who had suffered sudden cardiac death (SCD) or 
cardiac failure. Hearts were weighed after fixation and % fibrosis, % disarray 
and degree of small vessel disease noted in 6 sections (LV anterior, posterior 
and lateral free wall, anterior and posterior septum, and RV free wall), at 3 
levels (base, mid section and apex). Pathological data were compared to 
HCM patients over 21 years (range 22-72 years). 
Results: There were 12 males, 6 females, mean age 14.6 years (range 
6-21). IO suffered premorbid symptoms, including syncope in 3.7 of 7 had an 
abnormal ECG, 1 of 7 had a resting gradient on echo, none of 4 had NSVT 
on bolter and 4 of 4 had an abnormal blood pressure response to exercise. 13 
suffered SCD. Mean hear? weight, % microscopic fibrosis, and small vessel 
disease did not differ significantly from the adult group. 15% had marked 
scarring compared to 47% of the adult group, p = 0.01, whilst disarray was 
significantly greater (35.5% vs 20.7% respectively, p = 0.002). 
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Conclusion: Young patients who die with HCM are characterised by 
markedly less macroscopic scarring and a greater degree of myocyte dis- 
array. Of those assessed all had an abnormal vascular response. We have 
previously reported that disarray is not associated with episodes of NSVT, but 
did correlate with an abnormal vascular response. It is likely that sudden car- 
diac death in the young is related to hemodynamic collapse rather than fatal 
arrhythmias. 
3:00 p.m. 
845-5 Investigation of the Relation Between Outflow Tract 
Obstruction, Exercise Capacity and Blood Pressure 
Response During Exercise in Hypertrophic 
Cardiomyopathy 
Munmohan S. Virdee, Yoshihisa Matsumura, Paul Sorajja, Sanjay Sharma, 
Perry M. Elliott, William J, McKenna. St George’s Hospital Medical School, 
London, UK 
Background: Patients (pts) with Hypettrophic Cardiomyopathy have impaired 
exercise capacities and abnormal blood pressure responses (BPR) on exer- 
cise. The influence of resting and inducible outflow tract obstruction (LVOTO) 
on exercise capacity and BPR is poorly understood. 
Methods: Fifty one pts with hypertrophic cardiomyopathy (44 f 14 yrs, 
63% male, 86% symptomatic) underwent maximal, symptom-limited upright 
bicycle exercise with simultaneous respiratory gas analysis and echocardio- 
wvhy. 
Results: Twenty seven pts had no resting LVOTO (group A), 24 pts had 
resting LVOTO > 30 mmHg (61 & 23 mmHg, group 5). There was no signifi- 
cant difference between groups A and B for age, septal thickness, atrial size, 
cavity dimensions, peak systolic blood pressure during exercise (pSBP) (p = 
0.62), change in SBP (ASBP) (p = 0.67), peak oxygen consumption (pVOn) (p 
= 0.33) and % predicted pVOn (%pVOn) (p = 0.07). Ten pts in group A with in- 
ducible LVOTO P 30 mmHg during exercise had a higher %pVOn (85 i 16 vs 
67 & 22%, p = 0.03) than 17 pts without inducible LVOTO. The 10 pts with in- 
ducible LVOTO also had a higher pVO* (25 & 7 vs 19 f 6 mlikglmin, p = 0.02) 
and %pVOn (85 i 16 vs 62 + 18%, p = 0.03) than pts in group B. Their peak 
LVOTO during exercise was significantly lower than those with resting LVOTO 
(53 -+ 28 vs 85 i 32 mmHg, p = 0.01). Pts with LVOTO > 70 mmHg during 
exercise had lower ASBP (32 f 15 vs 45 i 20 mmHg, p = 0.03) than those 
with LVOTO < 70 mmHg. Pts with LVOTO > 100 mmHg during exercise had 
lower ASBP (24 i 13 vs 45 i 18 mmHg, p = 0,003) than those with LVOTO < 
100 mmHg, and were more likely to have exettional pre-syncope (719 vs 1 i/42 
pts, p = 0.006). No correlations were found for resting LVOTO, peak-exercise 
LVOTO or change in LVOTO and pSBP, ASBP, pVO* and %pVOa for any pt 
group. 
Conclusions: Exercise induced LVOTO in pts without resting obstruction 
is associated with a better exercise capacity, and may reflect better systolic 
functional reserve. LVOTO > 70 mmHg during exercise is associated with a 
lower blood pressure response and if >I00 mmHg, exettional presyncope, 
suggesting LVOTO is of hemodynamic significance. 
3:15 km. 
845-6 Comparison of Percutaneous Transluminal Septal 
Myocardial Ablation and Septal Myectomy in 
Hypertrophic Obstuctive Cardiomyopathy 
Jian Xin Qin, Takahiro Shiota, Harry M. Lever, David N. Rubin, 
Fabrice Bauer, Hiroyuki Tsujino, Jeanne K. Drinko, Maureen Martin, James 
D. Thomas. The Cleveland Clinic Foundation, Cleveland, OH, USA 
Controversy exists about the choice of treatment for patients with hypertrophic 
obstuctive cardiomyopathy (HOCM). The purpose of this study was to evalu- 
ate 3-month follow-up results in patients with HOCM after septal ablation and 
myectomy by 2-D echo. 
Methods: Thirty-three consecutive patients with HOCM underwent either 
septal ablation (19 cases) or myectomy (14 cases). 2-D ethos were performed 
pre-, immediately post- procedure and at a mean follow up was 101 i 30 days. 
Results: The patients in ablation group were much older than them in 
myectomy group (63 i 13 y vs. 44 j, IO y, p < 0.0001). Interventricular septal 
thickness was significantly decreased after the procedures in both group (2.2 
f 0.4 cm vs 1.8 f 0.4 cm for ablation, and 2.4 & 0.5 cm vs 1.6 f 0.3 cm for 
myectomy, both p < 0.001). The pressure gradient (PG) across LV outflow 
tract (LVOT) estimated by CW Doppler decreased significantly after the pro- 
Pre-PG (mmHg) Post-PG (mmHg) Follow-up PG (mmHg) 
Rest Amy1 Rest Amy1 Rest Amy1 
Ablation 69 zk 41’ 107+33 27i26 46 + 29 30133 68 i 54 
Myectomy 62 i 45* 86 i 23” 7*10 15ii@ 12rt6 33122 
j: Pre- vs post- and follow-up, p < 0.01. #. lsoproterenol infusion instead of amyl. 
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cedures in both groups at rest and amyl nitrate study (table). During follow-up, 
PG tended to increase in both groups. However, no patient showed PG higher 
than 40 mmHg after myectomy. In’ ablation group, 5 patients showed PG 
higher than 40 mmHg at rest after 3-month. 
Conclusions: Both septal ablation and myectomy reduce LVOT obstruc- 
tion significantly in patients with HOCM. While septal ablation is recom- 
mended in elderly, follow-up study revealed that myectomy could normalize 
the PG more often than ablation. 
ORAL 
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847-l Aortic Distensibility is Severely Reduced and 
Correlates With Exercise Intolerance in Older 
Patients With Diastolic and Systolic Heart Failure 
W. Gregory Hundley, Stephen N. Darty, Craig A. Hamilton, Kathryn 
P. Stewart, Timothy M. Morgan, Kerry M. Link, William C. Little, Dalane 
W. Kitzman. Departments of internal Medicine (Cardiology Section) and 
Ra&ology at the Wake Forest University Baptist Medical Center, 
Winston-Salem, NC, USA 
Background: Elderly patients with heart failure have reduced exercise tol- 
erance and increased left ventricular (LV) mass regardless of whether their 
LV ejection fraction is reduced or normal. Aortic distensibility and exercise 
tolerance are reduced with aging, but it is not known if an exaggerated reduc- 
tion in aortic distensibility may play a role in both exercise intolerance and LV 
hypertrophy in older patients with heart failure. 
Methods: We studied 29 subjects aged 360 years: 10 healthy normals 
(HN), 10 with diastolic heart failure (DHF), and 9 with systolic heart failure 
(SHF). We measured with magnetic resonance imaging thoracic aortic disten- 
sibility and wall thickness, as well as left ventricular mass and ejection fraction: 
in addition, with bicycle ergonometry, we measured maximal exercise capacity 
(VOs max). To measure LV mass and ejection fraction, multi-slice multi-frame, 
gradient echo acquisitions (acquired from base to apex of the left ventricle) 
were performed and values were calculated according to Simpson’s rule. Aor- 
tic wall thickness was measured with double inversion recovery images that 
were positioned perpendicularly across the ascending aorta approximately 4 
cm above the aortic valve. Aortic distensibility was calculated by the standard 
formula of: (cardiac cycle dependent changes in aortic area)/(pulse pressure 
- aortic area at end-diastole). Aortic area determinations were assessed with 
single-slice multi-phase gradient echo acquisitions placed at the same slice 
position as the aortic thickness determinations. Pulse pressure was measured 
in the brachial artery. 
Results: Compared to the HN patients, those with DHF and SHF had 
significant exercise intolerance (DHF: 12 i 2, and SHF: 12 * 2, vs. HN 20 i 
2 mllkgimin), reduced aortic distensibility (DHF: 0.03 f 0.01, and SHF: 0.03 
f 0.02, vs. HN 0.12 f 0.07 mmHg-I), elevations of LV mass index (DHF: 
70 i 14, and SHF: 128 i 24, vs. HN 52 f IO grams/m2), and aortic wall 
thickness (DHF: 3.5 + 1.3, and SHF: 3.6 f 0.7, vs. HN 2.9 f 0.4 mm). Aortic 
distensibility correlated with VOpmax (r = 0.70) & LV hypertrophy (r = 0.45). 
Conclusions: Aortic distensibility is reduced in elderly patients with heart 
failure (regardless of etiology) and is strongly related to VOsmax and LV 
hypertrophy. This suggests that reduced aortic distensibility contributes to 
exercise intolerance and LV hypertrophy in elderly patients with heart failure. 
2:15 km. 
847-2 Pulse Pressure Rises Exponentially With Age by 
Longitudinal Analysis 
Susan J. Zieman, Edward G. Lakatta, Jerome L. Fleg, Gary Gerstenblith, 
Frances C. O’Connor, Larry J. Brant, Angelo J.-G. Boa Gerontology 
Research Center/N/A/N/H and the Division of Cardiology, Johns Hopkins 
Medical Institutions, Baltimore, Maryland, USA 
Background: Pulse pressure (PP) is a major risk factor for cardiovascular 
disease and is described by cross-sectional analyses to increase linearly 
with age beyond age fifty. Age changes are best described using longitudinal 
analyses however, and it is unknown whether the PP changes are indeed 
linear over the adult age span using a longitudinal model. 
Methods: Longitudinal data were collected from Baltimore Longitudinal 
Study on Aging participants (1017 males and 572 females, follow-up = O-38.8 
yrs., mean = 9.9) excluding those on vasoactive medications and those with 
cardiovascular disease including hypertension. Normative aging changes m 
PP were estimated using a mixed-effects linear regression model control- 
ling for gender, body mass index, cholesterol, reported exercise and smoking 
habits, and diabetes. Cross-sectional PP differences were predicted using 
age at first visit whereas longitudinal PP changes were predicted using fol- 
low-up time and as interaction with other variables. 
Results: The percent change of predicted PP per 10 year follow-up for 
each starting age decade using cross-sectional (open circles) and longitu- 
dinal (solid circles) models are shown in the figure. Beyond age 60, and in 
contrast to the linear rise in PP predicted by the cross-sectional analysis, an 
exponential rise in PP is predicted by the longitudinal analysis. The inset de- 
picts mixed-effects estimates of the longitudinal changes in PP by starting age 
decades and demonstrates that the rate of rise of PP increases with age. 
Conclusions: In older individuals, the linear rise in PP predicted by cross- 
sectional analyses may underestimate the longitudinal age-associated expo- 
nential rise in PP and may therefore underestimate the risk of cardiac disease 
associated with this variable. 
2:30 u.m. 
847-3 Assessment of Leg Arterial Vasodilatory Capacity in 
Elderlv Heart Failure Patients and Normals Usina 
PhaseContrast Magnetic Resonance Imaging - 
Shazia Khaliq, Dalane W. Kitzman, Craig A. Hamilton, Kerry M. Link, David 
M. Herrington, W. Gregory Hundley. Wake Forest University Schoolof 
Medicine, Winston-Salem, North Carolina, USA 
Background: Leg arterial vasodilation appears to be an important determi- 
nant of exercise capacity, which is reduced with normal aging and heart failure 
(HF). However, most previous studies of flow-mediated arterial dilatory re- 
sponse (FMAD) were performed in the arm with ultrasound in middle aged 
men. The leg arterial vasodilatory response has not been characterized in el- 
derly normal subjects or in elderly HF patients and its relationship to exercise 
capacity in the elderly is unknown. 
Methods: We studied 24 subjects 1 60 years (61 to 88 years), including 
15 women and 9 men. There were 3 groups: normal elderly subjects (NL, n = 
9); NYHAclass Ill heart failure with EF 5 30% (systolic HF, n = 6); and NYHA 
class Ill heart failure with EF > 50% (diastolic HF, n = 9). Leg FMAD response 
was assessed with measurements of femoral artery cross-sectional area at 
30 second intervals before, during and after an ischemic stimulus (4 minute 
suprasystolic thigh cuff inflation), using a new technique based on phase 
contrast magnetic resonance imaging (PC-MRI). Subjects also underwent 
maximal bike exercise with expired gas analysis for measurement of maximal 
oxygen consumption (VOs) on a separate day. 
Results: lnterday reproducibility of leg FMAD in 5 subjects was excellent 
(r = 0.99, difference = 2 i 1 mm*). Femoral artery area increase after the 
ischemic stimulus was 12.9% in NL and 13.0% in diastolic HF patients but 
only 2.7% in systolic HF patients (p < 0.01). Maximal exercise VOs was 19.4 
in NL, and was 13.4 and 10.8 ml/kg/min in diastolic and systolic heart failure 
patients, respectively. Leg FMAD response correlated moderately well with 
exercise VOs response in the overall group (r = 0.45, p < 0.03) and correlated 
better in systolic than in diastolic heart failure patients. 
Conclusions: Leg arterial vasodilatory capacity by PC-MRI: 1) is highly 
reproducible; 2) is severely reduced in elderly systolic HF patients; 3) may 
be preserved in elderly diastolic HF patients; and 4) is moderately related 
to exercise capacity. These data indicate that elderly systolic heart failure 
patients have severe leg artery endothelial dysfunction and that this may 
contribute to their exercise intolerance. 
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847-4 The impact of Aging on Myocardial Intermediary 
Metabolism 
Andrew M. Kates, Pilar Herrero, Carmen S. Dence, Ali A. Ehsani, Robert 
J. Gropler. Washington University School of Medicine, St. Louis, MO, USA 
Background: Results of studies in experimental animals have shown that 
there is an age-related decrease in myocardial fatty acid utilization (MFAU) 
and an increase in myocardial glucose utilization (MGU). However, it is un- 
known if this shift in intermediary metabolism occurs in humans. 
Methods: Myocardial intermediary metabolism was measured under rest- 
ing conditions following an overnight fast in 4 healthy young adults (Y; 3 men, 
25 f 6 yrs) and IO healthy older adults (0; 5 men, 62 * 5 yrs; no history 
of diabetes mellitus, hypertension, smoking, or hyperlipidemia; normal rest- 
stress echocardiogram). Measurements of myocardial perfusion (ml/g/min), 
oxygen consumption (MV02), MFAU, and MGU (all in @mol/g/min) were per- 
formed by PET with ‘so-water, “C-acetate, “C-palmitate, and “C-glucose, 
respectively. 
Results: Levels of myocardial perfusion, MVOZ, plasma glucose and in- 
sulin levels (mmol/L) were similar between groups (p = NS for all). Plasma free 
fatty acid levels tended to be higher in Y than 0 (0.86 f 0.30 vs. 0.58 It 0.13, 
p = 0.053). Levels of MFAU/MV02 were higher in Y (0.049 + 0.18) than in 0 
(0.033 i 0.008, p = 0.04). Conversely, MGUiMVOP was higher in 0 (0.067 
f 0.008) versus Y (0.017 f 0.004, p = 0.03). Assuming that fatty acids and 
glucose are the only substrates used by the myocardium, there was a greater 
contribution of MFAU to overall substrate utilization in Y compared with 0 (71 
+ 7%vs. 35 i 17%, p = 0.015). Conversely, there was a greater contribution 
of MGU to overall substrate utilization in 0 compared with Y (62 i 17% vs. 29 
15%, p= 0.015). 
Conclusion: Although differences in the substrate environment may be 
contributory, it appears that with age there is a decrease in myocardial fatty 
acid utilization and increased reliance upon glucose as a myocardial energy 
fuel. This shift in metabolism may provide a partial explanation for the di- 
rect relationship between age and the manifestestation of numerous cardiac 
diseases. 
3:00 p.m. 
847-S Isolated Diastolic Heart Failure: Does It Exist? 
Characterization of an Important Svndrome Amono 
the Elderly 
Dalane W. Kitzman, Peter Brubaker, Roger T. Anderson, Bridget Brosnihan, 
Kathryn P. Stewart, Deborah K. Wesley, W. Gregory Hundley, William 
C. Little. Wake Foresf University School of Medicine, Winston-Salem, NC, 
USA 
Background: Many older patients with clinical heart failure (HF) have pre- 
served LV ejection fraction (EF). However, the pathophysiology of this dis- 
order is not well characterized and it is unknown whether it represents ‘real’ 
HF. 
Methods: We studied 147 subjects > 60 years old: 59 with isolated di- 
astolic HF (DF) defined as documented HF, EF z 50%, and no evidence of 
significant coronary, valvular, or pulmonary disease; 60 with typical systolic 
HF (SF, EF < 45%) and 28 healthy, normals (NO). LV structure and function, 
exercise capacity, neuroendocrine function, and quality of life were evaluated. 
Results: l.LVfuncfion.Byecho,EFwas6Of7%inDFvs31 12inSFand 
54 * 6 in NO. LV mass/volume ratio was markedly increased in DF (2.1 i 0.1 
gm/ml; p < 0.01) vs SF (1.2 f 0.1) and NO (1.5 f 0.2). 2. Exercise capacity 
Peak oxygen consumption by expired gas analysis during cycle ergometry 
was similar in DF and SF (14.2 f 0.5 and 13.1 i 0.5 mlikglmin respectively, p 
= n.s.) and in both was markedly reduced compared to NO (19.9.1 i 0.7; p 4 
0.001). Anaerobic threshold was similar in DF and SF (9.1 & 0.3 and 8.7 f 0.3 
mlikglmin, respectively, p = ns.) and in both was reduced compared to NO 
(11.5 & 0.4; p 5 0.001). 3. Neuroendorine function. Brain natriuetic peptide 
was significantly increased in both DF (56 f 30) and SF (154 i 28) compared 
to NO (3 i 38 pgiml; p < 0.01). Norepinephrine was similar in DF (306 f 64) 
and SF (287 f 62) and in both was markedly increased vs NO (169 & 80 pg/dl; 
p 5 0.01). 4. Qualifyoflife. Total quality of life by the Minnesota Living with HF 
survey was severely reduced in DF (29 & 3) and SF (41 + 3). 
Conclusions: Despite markedly different LV structure and function, el- 
derly patients with isolated diastolic HF have similar pathophysiologic de- 
rangements as systolic HF, including neuroendocrine activation and severely 
reduced exercise capacity and quality of life. Thus, isolated diastolic dysfunc- 
tion produces the typical syndrome of HF. 
1847-6 j 
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Screening for Treatable Left Ventricular Systolic 
Dysfunction in Stroke, Transient lschaemic Attack, 
and Peripheral Vascular Disease Patients: 
A Case-Control Study 
Robert Kelly’, Ron McWalteP, Peter Stonebridge3, Hugh Tunstail-Pedoe4, 
Allan D. Struthers’ ‘Departments of Clinical Pharmacology; ‘Medicine; 
3Surgery; 4 Cardiovascular Epidemiology, University of Dundee, Ninewells 
Hospital, Dundee, Scofland, UK 
Background: Asymptomatic left ventricular dysfunction (LVSD) is both com- 
mon and treatable. So we ought to somehow be identifying these patients. 
A cost-effective way to detect LVSD patients who would normally be missed, 
might be to screen patients who present with their first noncardiac vascular 
episode, i.e. stroke, oven peripheral vascular disease (PVD), or a transient 
ischaemic attack (TIA). 
Methods: A consecutive series of 180 Stroke, TIA, and PVD patients, 
aged between 45-86 years, were identified at first noncardiac presentation. 
60 age and sex matched controls were recruited from general practice. Each 
patient underwent echocardiography to assess Left ventricular function. The 
ejection fraction (LVEF) was calculated using The Modified Simpson’s Rule. 
Results: 57 (32%) patients had LVEF < 40%, of whom 75% were asymp- 
tomatic. 34 (19%) had LVEF < 35%, IO (5.5%) had LVEF < 30%. Among the 
control group, 3 patients had LVEF < 40%, of whom 66% were asymptomatic. 
Pre-screening these patients for LVSD using major ECG abnormalities: (Atrial 
fibrillation or atrial flutter; ischaemic ECG changes, including previous Ml; and 
LBBB) identified 63% of LVSD patients, compared with 66% LVSD among 
control patients. 
Conclusion: LVSD is more prevalent among Stroke, TIA, and PVD pa- 
tients than in the general population. Our data would suggest that there is 
enough LVSD in such patients to warrant routine screening. Our data also 
suggests that such echo screening is likely to be even more cost-effective if it 
is limited to those patients with major ECG abnormalities. 
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L-L-I 1115 142 Noninvasive, Quantitative Detection of Left Ventricular Wall Dysfunctional Areas in Patients 
With lschemic Cardiomyopathy Using Magnetic 
Resonance Imaging With Tissue Tagging and 
Finite Element Modeling 
Pavlos Moustakidis, Randall P. Scheri, Giridhar Vedala, Brian P. Cupps, 
Andrew M. Kates, Thoralf M. Sundt Ill, Robert J. Gropler, Victor 
G. Davila-Roman, Michael K. Pasque. Washingfon University, St. Louis, 
Missouri, USA 
Background: Left ventricular (LV) function and regional contractility are de- 
creased in LV ischemia. The regional determination of myocardial systolic 
stress (g) and strain (E, measure of contraction) has been greatly enhanced 
by the application of MRI and Finite Element Analysis (FEA). In this study we 
tested the hypothesis that the end-systolic stress/systolic strain ratio (U/E) de- 
termined by these methodologies is significantly increased in left ventricular 
dysfunctional areas in ischemic cardiomyopathy (ICM). 
Methods: MRI radiofrequency tissue-tagging was performed to measure 
global and regional (anterior, lateral, posterior, inferior, inferoseptal and an- 
teroseptal) systolic strain at rest and with dobutamine administration (IO 
pg/kg/min) in 14 normal volunteers (Age: 35 f 17) and 12 ICM patients (Age: 
57 f 6, EF: 29 i 12%). Accurate non-axisymmetric Finite Element cardiac 
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models were constructed from the MR images. End-systolic stress was cal- 
culated by FEA with systolic model loads determined by noninvasive Miller 
carotid artery pressures. 
Results: The global LV g./& ratio (dynes/cmz, x 1 O5 for all) was significantly 
higher in ICM patients (chart) at rest (13.45 f 4.12 vs. 4.33 & 1.11, p < 0.001) 
and with dobutamine (il.8 & 4.65 vs. 3.28 & 1.76, p < 0.001). In the regional 
analysis (312 LV wall segments) this methodology accurately differentiated 
normal from abnormally contracting regions. Comparison to echocardiogra- 
phy at rest, demonstrated an 88% sensitivity and 85% specificity (normal 
regional ratio defined as mean f 2SD in the normal volunteers). 
Conclusion: U/E ratio, is a sensitive, noninvasive, clinically applicable 
index that may help in the quantitative identification of the dysfunctional areas 
in ICM. 
I 1115 143 Jugular Venous Pressure Predicts Septal Function and Left Ventricular Performance in 
Heart Failure 
S. Gabrielle Horne, Robert N. Anderson, Chris Koilpillai, David E. Johnstone; 
Eldon R. Smith. Dalhousie Univers& Halifax, Nova Scotia; University of 
Calgary, Calgary, Alberta, Canada 
Background: In animal models of heart failure (CHF), and CHF patients with 
normal conduction, septal function is better preserved than that of the LV 
freewall. We hypothesised that high RV filling pressure would adversely affect 
septal systolic function in heart failure through impairment of septal diastolic 
loading. To test this, we analysed echocardiographic data from 50 patients 
with stable CHF and normal electrical conduction, with and without elevated 
JVP. 
Methods: LV parasternal shori axis end-diastolic and end-systolic frames 
were digitized and endocardial borders traced. After correction for systolic 
translation and rotation, a floating centroid and 32 radial chords were con- 
structed. Shortening from end-diastole to end-systole along each chord was 
measured. 
Results: Patients with elevated JVP (n = 18) and normal JVP (n = 32) had 
similar LV end-diastolic areas (41 f 11 vs 44 Z!C 9 cm*, p = ns) and % of patients 
with septal infarction on ECG (39 vs 31), but patients with elevated JVP had a 
worse NYHAclass (3.1 f 0.2~~2.7 i- 0.7), and IowerLV strokearea (5 * 3vs8 
i 5 cm2) than those with normal JVP (both p < 0.05). Septal chord shortening 
(sum % shortening chords 22-31) was similar to that of the LV freewall (sum 
% shortening chords 7-16) in patients with elevated JVP (54 i 34 vs 69 f 
22%, p 5 ns), but considerably greater than that of the LV freewall in patients 
with normal JVP (147 f 17 vs 55 i 16%, p < 0.001). Comparing individual 
chords between groups, % shortening of IO septal chords was significantly 
less in patients with elevated JVP compared to those with normal JVP (see 
figure). 
Conclusion: In CHF patients with normal JVP, septal contribution to LV 
systolic function is enhanced, but with elevated JVP this is lost, and is as- 
sociated with a lower index of LV systolic performance and worse functional 
class. 
1115-i 44 Subclinical Atherosclerosis Detected by Lumbar 
Aortic Calcification is an Important Predictor of 
. Congestive Heart Failure 
Craig R. Walsh, L. Adrienne Cupples, Daniel Levy, Peter W.F. Wilson, 
Christopher J. O’Donnell. N-/LB/3 Framingham Heart Study Framingham, 
MA, USA 
Background: Coronary artery disease is a major cause of congestive heart 
failure (CHF). Detection of subclinical extracoronary atherosclerosis may 
identify subjects at risk for development of CHF. 
Methods: Aortic vascular calcifications seen on lateral lumbar radiographs 
were studied as a predictor of CHF over 22 years of follow-up. Films were orig- 
inallyobtained in 1030 men (mean age 60 years) and 1437 women (mean age 
61 years) free of CHF as part of an osteoporosis study conducted in 1968 in 
the Framingham Heart Study. Anterior and posterior wall calcific deposits in 
the LI -L/I region of the aorta were graded according to increasing severity. 
Tettiles of lumbar aortic calcification (UC-range O-24 points) were defined 
after summing the anterior and posterior gradings. Proportional hazard mod- 
els were used to test for associations between LAC score and CHF risk in men 
and women. 
Results: There were 141 cases of CHF in men and 169 cases of CHF in 
women. In comparison with the lowest LAC tertile, age-adjusted risk for CHF 
was increased in tertile 2 and tertile 3 in both men and women. Risk of CHF 
was proportional to extent of LAC, .and was not materially altered by a multi- 
variable model including age, smoking, diabetes, systolic blood pressure, left 
ventricular hypertrophy, body mass index, total and HDL cholesterol (table). 
Table. CHF risk by LAC score in men and women (multivariable model) 
LAG score CHFiat risk HR 95% Cl 
Men 
0 
14 
B/336 1.0 Referent 
521371 2.2 1.2-3.8 
5-24 611323 2.8 1.5-5.2 
Women 
0 32/601 1.0 Referent 
l-4 461397 1.8 1.0-3.0 
5-24 91/439 3.0 1.7-5.1 
Conclusions: Subclinical atherosclerosis, detected by the presence of 
calcification of the lumbar aorta on simple lumbar radiographs, predicts risk of 
CHF. 
1 1115-l 45 1 Differential Prognostic Value of Neurohumoral 
Activation in Left Ventricular Dysfunction: 
Coronary Heart Disease Versus Dilated 
Cardiomyopathy in 428 Nonselected Patients 
T. Kottmann, C. Bergmeier, G. Taubert, T. Kleemann, A. Kilkowski, 
M. Bangert, D. Nagel’, D. Seiler’ , J. Senges. Department of Cardiology: 
Ludwigshafen; ‘Institute for Clinical Chemistry: Ludwigshafen, Germany 
Background: Left ventricular dysfunction (LVD) is associated with neurohu- 
moral activation. The impact of etiology on the neurohumoral activation is 
unknown. 
Question: Are there differences in prognostic meaning of various neu- 
rohumoral parameters (NP) in patients with coronary heart disease (CHD) 
versus dilated cardiomyopathy (DCM)? 
Methods: 428 consecutive nonselected patients with ejection fraction (EF) 
5 45% were registrated. Follow-up time was 498 i 287 (median 454) days. NP 
at discharge were measured. Relationship between mortality were compared 
in CHD vs. DCM. Medians of NP were taken as cut-off points. Patients: 78% 
male, age 64 f 11 years, EF 29 f 9%. Etiology: 60% CHD, 29% DCM, 11% 
other. 
Results: Mortality was 24% in CHD and 16% in DCM (p = 0.02). 
n = 428 
Norepinephrine 
ANP 
Vasopressin 
Endothelin 
Renin 
Aldosteron 
*: p < 0.05 
Median 
298 pgiml 
314 pgiml 
2.8 pgiml 
7.6 pg/ml 
37 @/ml 
58 pglml 
Mortality in CHD Mortality in DCM 
>Median +edian >Median SMedian 
37% 1 1 %* 25% 9%* 
32% 17%* 32% 5%* 
28% 21% 28% 5%” 
29% 20% 27% 5%” 
26% 21% 20% 12% 
27% 21% 21% 10% 
Conclusion: 
(1) Increased norepinephrine- and ANP-values are associated with higher 
mortality in LVD caused by both CHD or DCM. 
(2) Vasopressin and endothelin are of large prognostic importance in LVD 
caused by DCM but not in CHD. 
(3) There is no prognostic value of renin and aldosteron in patients with LVD 
caused by both CHD or DCM. 
/ 1115-l 46 ] A Parameter of Recovery After a Maximal 
Exercise is an Independent Predictor of Survival 
in Patients With Left Ventricular Systolic 
Dysfunction 
Pascal de Groote, Valerie AumPlgeat, Thibaud Meurice, Olivier Nugue, 
Alain Millaire, Nicolas Lamblin, Jean-Marc Lablanche. University of LiNe, 
France 
Background: Peak V02 is a powerful prognostic parameter in patients (pts) 
with congestive heart failure (CHF) but particularly in pts with severe exercise 
intolerance (peak VO2 < IO ml/min/kg). In order to improve the prognostic 
information of the cardiopulmonary exercise test, other parameters must be 
defined. 
Methods: We prospectively analyzed the kinetics of V02 during exercise 
and recovery (Ret) in 411 consecutive pts with stable CHF (53 women, mean 
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age: 53 i 11 years, NYHA: 2.29 i 0.55, ischemic cardiomyopathy: 178 pts). 
We determined the ratio between total V02 during exercise and during Ret, 
the half Ret time of peak V02, the duration of Ret, the kinetics of V02 at 
1, 3, 5 and 7 min of Ret and the VENC02 slope during exercise and Rec. 
Speak-3% was defined as peak V02 - V02 at 3 min of Ret divided by peak 
vm. 
Results: Left ventricular ejection fraction (LVEF) was 30.5 k 10.2%, peak 
VO2 was 16.6 + 5.3 ml/min/kg, % of maximal predicted V02 (%VO2) was 60.8 
i 18.6%, Speak-3% was 59 + 14%. During a median follow-up period of 851 
days, there were 80 cardiac related deaths (CD), 8 urgent transplantations 
(UNQSI), 32 transplantations, 11 non-CD. No pt was lost to follow-up. Inde- 
pendent predictors of CD + UNOSI (Cox analysis) were: %VO2 (p < O.OOOl), 
NYHA (p = O.OOOl), Speak-3% (p = 0.0007), LVEF (p = 0.004) cardiac rhythm 
(p = 0.03) and peak blood pressure (p = 0.035). Peak V02/kg, VENCO2 
slope and other parameters of recovery were not independent predictors of 
survival. Mortality rates in subgroups of pts divided according to %VO2 and 
to Speak-3% were: in pts with %VO2 > 50% and Speak-3% > 60% or ~60%: 
10% and 21%, respectively; in pts with %VO2 < 50% and Speak-3% > or 
~60%: 19% and 46%, respectively, Speak-3% could identify subgroups of pts 
at higher risk of cardiac events, whatever the value of %VO2. 
Conclusion: Speak-3%, an easy new parameter to determine, is an inde- 
pendent predictor of cardiac survival in pts with stable CHF. The kinetics of 
V02 during recovery must be determined in all pts with stable CHF in order to 
improve the prognostic information of the cardiopulmonary exercise test. 
1 1115-I 47 1 Effect of Right Ventricular Size on Prognosis in 
Pabents With LV Dysfunction: Results From a 
Cohort of 2265 Patients With LV Ejection 
Fraction 5 40% 
Helme Silvet, Jatin Amin, Sriram Padmanabhan, Ramdas G. Pai. Loma 
Linda VA Medical Cfr, Loma Linda, CA, USA 
The right ventricular (RV) function has been associated with prognosis m 
relatively small cohorts of patients with heart failure, valvular problems and 
congenital heart diseases. But, RV function assessment is difficult due to its 
complex geometry. We investigated the prognostic significance of visually 
assessed RV size in a large cohort of patients (n = 2265) wrth LV ejection 
fraction (EF) 5 40%. Mean age was 68 * 11 years, mean follow up of 855 
days, and there were 743 deaths. RV enlargement (RVE) and EF were visually 
quantified by a level Ill trained echocardiographec Analysis was performed 
using Kaplan-Meier method and log rank tests. 
Results: The RV size was normal in 1452 patients. Mild, moderate and 
severe degrees of RV enlargement (RVE) were present in 554 (24%) 220 
(10%) and 39 (2%) of the patients respectively. Presence of moderate or 
severe RVE was associated with a higher 5 year mortality compared to those 
with no or mild RVE (80% vs 60%, p = 0.02). Mortality was also a function 
of the degrees of RVE (p = 0.01). Effect of RVE on mortality was greater in 
patients with better EF, those with atrial fibrillation and in younger individuals. 
Conclusions: (1) Visually estimated RV enlargement is astrong predictor 
of mortality in those with moderate and severe LV dysfunction. (2)). Mortality 
was also a function of the degrees of RV enlargement. (3) The interaction 
between LV enlargement and mortality is affected by the level of LV systolic 
function, age and presence or absence of atrial fibrillation. 
1115-148 improvement of Right Ventricular Function After 
Acute Vasoclilator Administration is Critical for 
Risk Stratification of Patients With Severe Heart 
Failure and Pulmonary Hypertension 
Antonello Gavazzi, Stefano Ghio, Carlo Campana, Corinna Inserra, 
Andrea Giusti, Maria L. Laudisa, Catherine Klersy, Luigi Tavazzi. Depf. of 
Cardiology, /RCCS S. Matte0 Hospital, favia, /h/y 
Background: In pts with severe chronic heart failure (CHF) and elevated 
pulmonatyarterypressure (PAP), testing ofpotential reversibility of pulmonary 
hypertension (PH) with vasodilators is useful to predict early mortality after 
heart transplantation. However, it is still unknown whether this test is useful 
for a prognostic stratification of CHF patients. 
Methods: Between 1994 and 1998, 76 pts with advanced CHF due to is- 
chemic heart disease or primary dilated cardiomyopathy and secondary, PH 
(pulmonary vascular resistance (PVR) > 2.5 Wood units and/or systolic PAP 
> 40 mmHg) underwent right heart catheterization. In all pts the hemodynamic 
measurements, including termodilution-derived right ventricular ejection frac- 
tion (RVEF) were repeated after an i.v. bolus of nitroglycerin (NTG, mean dose 
3.1 mg). 
Results: After NTG, mean PAP acutely decreased from 42 f 8 to 28 i 
IO mmHg; PVR decreased from 4.8 & 2.9 to 2.7 f 2 units; RVEF increased 
from 14 f 8 to 22 i 11% (all p x 0.05). During a follow-up period of 13 i 11 
months, 39 pts had a cardiac event (death or urgent heart transplantation). At 
Cox survival analysis NTG induced reduction of pulmonary resistance below 
2.5 units was not associated with a better outcome. However, the event rate 
was 22% per year in pts with a baseline RVEF > 30%, 21% per year in pts 
whose RVEF increased after NTG to ~30% and 60% per year in pts whose 
RVEF did not increase to >30% (p = 0.03). 
Conclusion: These data show that in pts with severe CHF and pulmonary 
hypertension, a valid risk stratification should include the evaluation of the 
changes of right ventricular function after acute vasodilator administration. 
1115-l 49 Elevated Circulating Levels of Tumor Necrosis 
Factor Correlate With Cardiac Remodeling in 
Patients With Heart Failure 
Hector A. Malave, Dorellyn Lee-Jackson, Pamela D. Samuels, Debbie 
K. Smith, Alvin S. Blaustein, Douglas L. Mann. Veterans Affairs Medical 
CenferandBaylor College of Medicine, Houston, Texas, USA 
Background: Previous experimental heart failure models have invoked a 
possible role for tumor necrosis factor-alpha (TNF) in the process of cardiac 
remodeling. However, it is not known whether expression of TNF is involved in 
the remodeling process affecting human subjects with heart failure. Therefore, 
the purpose of this study was to investigate whether there was a significant 
relationship between expression of TNF and cardiac chamber geometry in 
patients with heart failure. 
Methods: We studied 15 patients with mild heart failure (NYHA class I and 
II), 14 patients with moderate heart failure (NYHA class Ill-A) and 10 healthy 
controls free of cardiovascular disease. We measured plasma TNF and TNF 
soluble receptors type I and II (TNFRl and TNFRP) by ELISA. We also ob- 
tained 2D echocardiograms on patients and controls, and measured absolute 
values and values normalized for body surface area (index), of left ventricular 
end diastolic dimension (LV&), left ventricular end systolic dimension (LV,,) 
and left atrial dimension (LA). 
Results: There were significant correlations between TNF levels and LV& 
(r = 0.57, p = 0.00013), LV& index (r = 0.63, p = 0.000016), LV,, (r = 0.60, p = 
0.000057), LV,, index (r = 0.57, p = 0.00015), LA (r = 0.59, p = 0.000067) and 
LA index (r = 0.59, p = 0.000083). Insofar as the datafor TNFRI and TNFR2 
were not normally distributed, analyses with log transformation and non-para- 
metric tests were performed. There were significant correlations between LA 
and both log-TNFRI (r = 0.4, p = 0.013) and log-TNFR2 (r = 0.45, p = 0.0039). 
Similarly, when the untransformed data were examined (Spearman rank or- 
der correlation) there were also significant correlations between LA and both 
TNFRI (r = 0.4, p = 0.011) and TNFR2 (r = 0.43, p = 0.0060). 
Conclusion: Serum levels of TNF and TNF soluble receptors increase 
with progressive cardiac remodeling (dilatation) in heart failure patients. While 
it is not possible to establish a cause and effect relationship, these findings 
suggest that cytokine expression may play a role in the remodeling process in 
heart failure. This question is now being addressed in the ongoing randomized 
etanercept study to the antagonism of cytokines (RENAISSANCE). 
1115-l 50 Evaluation of Flow Mediated Vasodilation in 
Upper and Lower Limbs of Patients With 
Congestive Heart Failure 
Rajiv N. Patni, Pierre V. Ennezat, llya V. Kaplan, Tim Chang, Thierry 
H. LeJemtel. Albert finsfein College of Medicine, Bronx, New York, USA 
Background: Flow mediated vasodilation is known to be reduced in the 
brachial and femoral artery in patients with congestive heart failure (CHF). 
Whether the extent of this reduction is the same in the upper and lower limbs, 
suggesting a systemic (i.e. enhanced nitrous oxide metabolism) ratherthan io- 
cal (Le. reduced shear stress) mechanism, is currently unknown. Accordingly, 
flow mediated vasodiiation in the brachial and popliteal arteries (following 
reactive hyperemia) was compared in 20 patients with CHF. 
Methods: All patients had similar clinical characteristics (EF < 30%, NYHA 
11-111, on ACEI, diuretics, digoxin; no history of peripheral vascular disease). 
Brachialipopliteal artery diameter (BAD and PAD, respectively), heart rate and 
velocity time integral were determined using 2D/doppler echography at rest 
and following 1, 2, and 4 minutes of artery occlusion (reactive hyperemia). 
Brachial/popliteal artery blood flow (BABF and PABF, respectively) and % 
change in BAD/PAD were then calculated at these time points. 
Results: 
BABF (mllmin) 
increase in BABF (ratio) 
%Change BAD (mm) 
PABF (mlimin) 
Increase in PABF (ratio) 
%Change PAD (mm) 
Rest 1 min 2 min 4 min 
301.4 369.6 443.1 631.8 
1.2 1.5 2.0 
1.3 5.9 9.7 
428.6 471.5 600.4 780.1 
1.1 1.4 1.8 
1.1 6.6 8.9 
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Conclusion: There is a similar reduction in flow mediated vasodilation in 
the upper and lower limbs of patients with CHF. Our data therefore suggest 
that a systemic rather local mechanism is responsible for the reduction in flow 
mediated vasodilation seen in the skeletal muscle vasculature of patients with 
CHF. 
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I 1116 120 Diabetes Mellitus in Cardiogenic Shock Complicating Acute Myocardial Infarction: 
Report From the SHOCK Registry 
Daniel M. Shindler, Sebastian T. Palmeri, Tracy Antonelli, Lynn A. Sleeper, 
Jean Boland, Maryhelen Hosler, Thomas P. Cocke, Emilie Godfrey, Sonja 
M. McKinlay, Thierry H. LeJemtel, James N. Slater, Judith S. Hochman. For 
the SHOCKInvestigators; UMDNJ-Robert Wood Johnson Medical School, 
New Brunswick, New Jersey, USA 
The international prospective SHOCK Trial Registry included 1 ,I 90 patients 
(pts.) with cardiogenic shock (CS) complicating acute myocardial infarction 
(Ml). Diabetes mellitus (DM) status was determined in 1 ,I 63 pts; 379 (33%) 
had history of DM. DM pts. were more likely to be female (49% vs. 36%, p 
< 0.001) and less likely to be Caucasian (77% vs. 85%, p = 0.001). DM pts. 
had a higher incidence of previous Ml (43% vs. 34%), hypertension (66% 
vs. 47%), CHF (30% vs. 15%), and peripheral vascular disease (28% vs. 
13%), all p < 0.002. Mean age was similar (69 f 12 yr.), as were rates 
of smoking, previous PTCA, and previous CABG. Management for C&was 
similar for DM and non-DM pts. with regard to intra-aortic counterpulsation 
and pulmonary artery catheterization, but DM pts. were less likely to receive 
thrombolytic therapy (28% vs. 37%, p = 0.002) and less likely to undergo 
attempted revascularization (40% vs. 49%, p = 0.008). PTCA was attempted 
in 28% DM pts. vs. 32% non-DM, p = 0.174. CABG was attempted in 16% 
DM pts. vs. 20% non-DM, p = 0.108. Survival in DM pts. undergoing PTCA 
was 48% vs. 56% in non-DM, p = 0.217. Survival in DM pts. undergoing 
CABG (including those with primary PTCA attempt) was 65% in DM vs. 64% 
in non-DM, p = 0.875. Survival benefit in DM pts. selected for PTCA and/or 
CABG (55% vs. 19% when no revascularization was attempted) was similar 
to that of non-DM pts. (59% vs. 25%). In-hospital survival was lowerfor all DM 
pts. (34% vs. 42%, p = 0.007) and DM remained an independent riskfactorfor 
in-hospital mortality after adjustment for patient differences between DM and 
non-DM (odds ratio 1.4, p = 0.008). 
Conclusion: DM is an independent risk factor for in-hospital mortality 
in cardiogenic shock complicating acute MI. DM pts. who undergo PTCA 
and/or CABG revascularization derive survival benefits similar to those of 
non-diabetics. 
1116-l 21 Left Ventricular Assist Device Preserves Nitric 
Oxide Dependent Control of Mitochondrial 
Flespiratibn in Failing Human Hearts 
Seema Mital, Kit E. Loke, Linda Addonizio, Mehmet Oz, Thomas H. Hintze. 
Columbia University College of Physicians and Surgeons, New York, NY; 
New York Medical Co//ege, Valhalla, N): USA 
Background: Ventricular unloading using left ventricularassistdevices (LVAD) 
can improve mitochondrial function in end-stage heart failure. Nitricoxide reg 
ulates myocardial oxygen consumption by modulating the activity of the mito- 
chondrial electron transport chain. We investigated the role of nitric oxide in 
the beneficial effect of LVADs in end-stage heart failure. 
Methods: Myocardial oxygen consumption was measured in isolated left 
ventricular myocardium from 26 explanted failing human hearts obtained at 
the time of heart transplantation using the Clark type oxygen electrode. 
Results: Rate of decrease in oxygen concentration is expressed as per- 
centage of baseline and results of the highest dose are indicated. Bradykinin 
(10m4 mol/L, -24 f 5%), enalaprilat (IO-“ moliL, -23 f 5%), amlodipine 
(10-s mol/L, -16 f 5%), diltiazem (1 O-“ mol/L, -22 i 5%), and nitroglycerin 
(2.5 x 1 O-3 mol/L, -30 f 3%) caused dose-dependent decreases in myocar- 
dial oxygen consumption (p < 0.05). In LVAD hearts, bradykinin (-34 & 3%), 
enalaprilat (-37 f 5%) and amlodipine (-43 i 13%) caused larger reductions 
in myocardial oxygen consumption (p < 0.05). The response of LVAD hearts to 
diltiazem (-22 rt 5%), and exogenous nitric oxide donor, nitroglycerin (-33 & 
7%) was not significantly different from non-LVAD hearts. Inhibiting endoge- 
nous nitric oxide synthesis with l\IW-nitro-L-arginine methyl ester (L-NAME) 
attenuated the response to bradykinin, enalaprilat and amlodipine in both 
groups indicating a nitric oxide-dependent mechanism of action. Reductions 
in tissue oxygen consumption in response to diltiazem and nitroglycerin were 
not significantly affected by L-NAME. 
Conclusions: Nitric oxide mediated regulation of myocardial oxygen con- 
sumption can be pharmacologically modulated with ACE inhibitors, amlodip- 
ine and nitroglycerin in failing human hearts. Pretransplant LVAD support 
potentiates endogenous nitric oxide mediated regulation of mitochondrial res- 
piration and likely facilitates the pharmacological actions of ACE inhibitors and 
amlodipine. 
lxzl 1116 122 Age Related Outcome for Patients Bridged to Heart Transplantation With HeartMate Left 
Ventircular Assist Devices 
G. Martin Mullen, Krystyna Malinowska, Christine E. Lawless, Barbara 
A. Pisani, Jose C. Mendez, Jbhn A. Robinson, Roque Pifarre, Bryan K. Foy, 
Mamdouh Bakhos. Loyofa University of Chicago Health System, Heart 
Transplant/Heart Failure Program, Maywood, Illinois, USA 
Background: Chronic immunosuppression, allograft coronary disease and 
decreasing availability of the donor hearts continue to limit the benefits of 
the heart transplantation (HT) in patients with the end stage of heart failure 
in whom HT is deemed the only hope for survival. At the same time, there 
is a growing number of successfully supported left ventricular assist devices 
(LVAD) patients surviving and awaiting HT necessitating longer LVAD implant 
times. We hypothetized that older patients may not be able to withstand LVAD 
surgery and prolonged implant times pre and post FIT as well as younger 
patients. We would like to predict which age group would benefit the most 
from the LVAD bridge to HT. 
Methods: We reviewed our experience with the pneumatic and vented 
electric HeartMate left ventricular assist devices (LVAD) implanted in our in- 
stitution behveen 6/l/92 to 3/31/99. Twenty seven patients were implanted 
with pneumatic LVADs and twenty eight patients were implanted with electric 
HeartMate LVADs, of whom one is still waiting for donor heart. The younger 
LVAD recipients between 14-50 years old comprised Group I and the older 
LVAD recipients comprised Group II. 
Results: 
Mortality on LVADs prior to HT 
1 Year Survival after HT 
Overall Survival after HT 
*p < 0.05 
Group I (N = 22) 
2/22 (9.1%) 
18120 (90%) 
15120 (75%) 
Group II (N = 32) 
11/32 (34.4%)* 
18/22 (81.8) 
12/22 (54.5%) 
Conclusions: The above data demonstrates that older patients had a 
statistically significant higher mortality while on LVADs. Even if they fortunate 
enough to receive a donor heart and undergone HT, older patients seen to 
do worse than younger patients. Especially at the time of the REMATCH trial, 
there should be special emphasis on careful patient selection for implantation 
of LVAD and special caution and restrained enthusiasm for LVAD as hope for 
permanent cardiac support in older patients. 
1 1116-l 23 / Cardiogenic Shock After Acute Myocardial 
Infarction in the Elderly: The Michigan 
Cooperative Cardiovascular Project Experience 
Rajendra H. Mehta, Erik J. Stalhandske, Patricia A. McCargar, 
Pamela Russman, Thomas Ruane, Kim A. Eagle. VniversityofMichigan 
Heart Care Program, Ann Arbor, Michigan, USA 
Background: Few data exist on the clinical outcomes of elderly patients with 
cardiogenic shock complicating acute Ml. 
Methods: We analyzed 7,874 consecutive patients 2 65 years old with 
acute Ml from the Michigan Cooperative Cardiovascular Project. Patients 
were divided into three groups (A < 70 yrs, B 2 70 but ~80 yrs, and C z 80 
yrs). 
Results: (see table, * = p x 0.001, LOS = length of stay): Cardiogenic 
shock occurred in 540 Ml patients (6.9%) with the incidence increasing with 
age (A= 5.4%, B= 7.0%, C=7.6%). There were nodifferences in the incidence 
of diabetes, time to presentation, anterior MI, non-Q MI, or prior Ml among 3 
groups. Older patients were less likely to smoke (A = 38%, B = 15%, C = 5%; 
p < O.OOl), have prior CABG (A = 16.8%, B = 16%, C =4.3%, p < O.OOl), or 
be transferred to tertiary care centers (A = 21%, B = 16%, C = 4%, p < 0.001). 
The percentage of women (A = 50%, B = 51%, C = 59%; p c: 0.01) increased 
with age. Procedural use declined with increasing age [cardiac catheterization 
(A=55%, B=43%, C= 17%, p < 0.001); PTCA(A=23%, B= 19%, C= II%, 
p=O.O3); and CABG (A= 14.7%, B= 11.2%, C=2.7%, p < O.OOl)]. 
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N Median Age LOS In-hosp Mortality 30 Day Mortality 
Group A 95 67 years 10.1 days 54.7% 59% 
Group B 259 75 years 9.4 days 66% 69% 
Group C 186 a4 years 5.v days 77.4%* 81% 
Conclusions: increasing age is associated with increasing mortality rates 
resulting in shorter hospital length of stay in patients with cardiogenic shock 
complicating acute MI. Older patients are less likely to undergo invasive pro- 
cedures Whether more frequent transfer to tertiary care centers and/or ag- 
gressive revascularization in the vety elderly would improve outcomes needs 
further investigation. 
11116-l 24 / Intra-Aortic Balloon Counterpulsation in Patients 
With Cardiogenic Shock: The BENCHMARK 
Registry Experience 
James J. Ferguson, Marc Cohen, Michael F. Miller, Debra L. Joseph, Robert 
R. Cuffey Jr., Robert Freedman Jr., E. Magnus Ohman. Texas Heart Institute, 
Houston, Texas, USA 
Background: Patients treated with intra-aortic balloon counterpulsation (IABC) 
for cardiogenic shock (S) are at high risk for adverse outcomes, 
Purpose: To document outcomes and balloon-related complications of 
modern-day IABC therapy in patients with and without cardiogenic shock. 
Methods: The BENCHMARK registty is a prospective series of all patients 
undergoing IABC at 132 participating institutions. We compared the outcomes 
(duration of IABC, LOS, mortality) and balloon-related complications (severe 
bleeding, major limb ischemia, balloon failure) with/without shock as the pri- 
mary indication for IABC, in patients not undergoing revascularization, pa- 
tients treated with percutaneous intervention (PCI) only, and patients treated 
with CABG. 
Results: 
No Revasc PCI CABG 
(n = 967) (n = 2543) (n = 5707) 
S NoS S No S S NoS 
Duration of IABC (hours) 66 68 55 48 68 58 
LOS (days) 10.2 10.9 9.8 8.7 16.9 13.7 
In-hospital mortality 53% 21% 39% 11% 31% 15% 
Severe bleeding 0.7% 1 .O% 0.9% 1.1% 0% 0.6% 
Major ischemia 0.7% 0.9% 0.7% 0.5% 1.7% 1.5% 
Balloon failure 2.7% 2.2% 1.3% 1.9% 3.6% 2.8% 
Conclusions: In the modern-day practice of IABC, the in-hospital mortality 
of cardiogenic shock is approximately 30-40% in CABG and PCI patients, and 
>50% in patients not undergoing intervention. IABC-related complications are 
not more frequent in shock patients (p > 0.05). 
1116-l 251 Assessment of Coronary Bypass Flow During 
lntraaortic Balloon Pumping 
Beat t-l. Walpoth, Dirk Springe, Pascal Berdat, Beat Kipfer, Peter Neidhart, 
Franz Eberli, Otto M. Hess, Thierry Carrel. Cardiovascular Surgery, 
Cardiology and Anaesthesia, University Hospital, Bern, Switzerland 
Background: lntraoperative balloon pumping (IABP) has been shown to im- 
prove cardiac output and to reduce morbidity and mortality. IABP augments 
aortic pressure mainly during diastole and improves coronary artery flow. 
Thus, the aim of the present study was to assess changes in coronary bypass 
flow with intraaottic balloon pumping. 
Method: Ten male patients (56 f 12 years) underwent emergency coro- 
nary artery bypass surgery. In two patients the IABP was implanted as a 
prophylactic (preoperative) measure and in 8 a therapeutic (intraoperative) 
intervention from the femoral artery (Datascope 95) was necessary. All had 
prior myocardial infarction and were under maximal medical therapy. Mean 
ejection fraction was 41 i 15%. Coronary bypass flow was measured simul- 
taneously in the left internal mammary artery (n = IO) respectively free radial 
artery grafts (n = 3) as well as saphenous vein grafts (n = IO) using the transit 
time volume flow technique (CardioMed 4008, Medi-Stim, Norway). Measure- 
ments (n = 60) were performed on and off cardiopulmonary bypass with and 
without IABP. 
Results: There was a significant increase of 33% in mean diastolic blood 
pressure (diastolic augmentation = 28 f 25 mmHg; p = 0.001) and rate-pres- 
sure product (7263 f 954 vs 8026 f 1148; p = 0.003) during IABP. At the 
same time coronary blood flow increased from 33 f 12 to 39 & 13 ml/min. (p = 
0.001) in the left internal mammary artery and from 58 f 35 to 70 f 39 ml/min. 
(p = 0.002) in the saphenous vein graft but remained unchanged in the radial 
artery (29 & 4 vs 32 i- 4 mllmin.; ns). The percent increase amounted to 20% 
for the LIMA respectively SVG and 14% for the radial artery. The systolic flow 
decreased by 22% and the diastolic flow increased by 49% during IABP (p = 
0.001). The increase in diastolic flow was directly correlated to the increase 
in mean diastolic pressure (r = 0.62; p = 0.001). There were similar results for 
flow increase during IABP on and off cardiopulmonary bypass. One patient 
died however postoperatively of multi organ failure and one patient required 
arterial desobliteration for arterial thrombosis secondary to IABP. 
Conclusion: Coronary bypass flow increases significantly during intraaor- 
tic balloon pumping and thus, may improve patients with cardiogenic shock 
after myocardial revascularisation. 
1 1116-l 26 / The Effects of Different lntraaortic Balloon Pump 
Volumes on Cardiac Performance in Humans 
Varinder P. Singh, Binoy K. Singh, Ruth McBride, William G. Kussmaul Ill, 
Marc Cohen. MCP Hahnemann School of Medicine, Philadelphia, 
Pennsylvania, USA 
Background: lntraaortic balloon (IAB) counterpulsation has been shown to 
be an effective technique for hemodynamic stabilization for patients (pts) in 
cardiogenic shock. The effect of different IAB inflation pressures and size on 
cardiac hemodynamics has not been evaluated in humans. 
Methods: Eighty-two patients (52 males (63%), mean age 65 i 12, mean 
body surface area [BAS] 1.8 f 0.2 m”) had IAB counterpulsation for car- 
diogenic shock, refractory angina, and preoperatively for high risk cardiac 
surgery. Cardiac hemodynamics were prospectively studies in these patients 
with inflation volumes of 32 cc and 40 cc. Hemodynamic data collected for 
each cardiac cycle was as follows: aortic pressure (systolic, diastolic, mean), 
pulmonary arterial pressures, and systemic and mixed venous oxygen satura- 
tions. Transthoracic echocardiography (TTE) was used to obtain both velocity 
time integrals and the area of the LVOT. Left ventricular stroke volume was 
then calculated (LVOT area X VTI). 
Results: Cardiac output (COjdetermined by the Fick method did not differ 
significantly (p = NS) between the two inflation volumes (see Fig., y = 0.002 
+ 0.97 x). In a subgroup of 33 pts with BSA 5 1.8 ms, there is a significant 
difference in CO determined by TTE between 32 cc and 40 cc inflation volumes 
(p = 0.05, Table). 
BSA(1.8m2 BSA> 1.8m’ 
40 cc 30 cc P 40 cc 30 cc P 
CO VTI (Umin) 5.23 4.96 0.05 5.85 5.85 0.74 
CO Fick (Umin) 5.24 5.15 0.55 5.47 5.51 0.80 
Conclusions: Overall, smaller IAB inflation volumes do not affect hemo- 
dynamic improvement afforded by IAB counterpulsation. However, in pts with 
smaller BSA, larger inflation volumes may provide improved CO. 
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L-L! 1117 151 Serum Uric Acid and Risk of Coronary Heart Disease in Older Adults: A 7-Year Prospective 
Study 
Abraham A. Ariyo, Richard Kronmal, John Robbins, Gregory Burke. Forthe 
Cardiovascular Health Study Investigators; Johns Hopkins Hospital, 
Baltimore, MD, USA 
Background: Uric acid is the final breakdown product of purine metabolism 
in humans. Several epidemiologic studies have suggested that elevated uric 
acid level predisposes to coronary lheart disease (CHD). We investigated this 
relationship among older adults. 
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Methods: In a prospective study of 5,888 elderly (~6.5 years) men and 
women, we assessed the uric acid level in blood samples of 4249 participants 
who were free of cardiovascular disease at baseline and followed them for a 
median of 7 years for the development of CHD. 
Results: We used Cox-proportional hazards models to assess the risks 
associated with each quintile level of uric acid, using the first quintile as the 
reference group. The unadjusted hazard ratios for the development of CHD 
for the 2nd, 3rd, 4th and 5th quintiles of uric acid were 1.0 (p = 0.94) 1.2 (p 
= 0.26), 1.4 (p = O.Ol), and 1.8 (p = O.OOl), respectively. After adjusting for 
age, gender, total cholesterol, high-density cholesterol, alcohol use, diabetes, 
physical activity, systolic and diastolic hypertension, the hazard ratios were 
0.8, (p=O.3), 0.9 (p=O.6), 1.0 (p= 1.0) and 1.1, (p=O.5), respectively. 
Conclusions: Among apparently healthy older adults, elevated uric acid 
was not associated with increased risk of CHD. This data does not support 
the measurement of serum uric acid level as a screening tool for CHD in this 
population. 
1 1117-l 52 ( Association of Plasma Homocysteine With 
Increased Incidence of New Coronary Events in 
Older Persons 
Wilbert S. Aronow, Chul Ahn. Mount Sinai School of Medicine, New York, 
New York, USA 
Background: Increased plasma homocysteine has been associated with 
coronary artery disease. 
Methods: We investigated in a prospective studythe association of plasma 
homocysteine and other risk factors with the incidence of new coronary events 
(CE) (myocardial infarction or sudden cardiac death) in 153 men and 347 
women, mean age 81 & 9 years. Follow-up was 31 f 9 months. 
Results: CE developed in 194 of 500 patients (pts) (39%). Univariate 
analysis showed that risk factors for new CE were plasma homocysteine (p 
< O.OOi), vitamin 812 (inverse association) (p < O.OOi), folate (inverse asso- 
ciation) (p < O.OOi), prior coronary disease (p < O.OOl), cigarette smoking 
(p < O.OOi), diabetes mellitus (p < O.OOl), hypertension (p < O.OOl), obe- 
sity (p = 0.012) total cholesterol (p < O.OOl), high-density lipoprotein (HDL) 
cholesterol (p < O.OOi), and triglycerides (p = 0.005). Stepwise Cox regres- 
sion analysis showed that significant independent predictors of new CE were 
age (p < 0.001, risk ratio = 1.041); plasma homocysteine (p < 0.001, risk ratio 
= 1.073); cigarette smoking (p < 0.001, risk ratio = 2.524); hypertension (p < 
0.001, risk ratio = 2.032); diabetes mellitus (p < 0.001, risk ratio = 2.022); total 
cholesterol (p < 0.001, risk ratio = 1.013); HDL cholesterol (p < 0.001, risk 
ratio = 0.925); and triglycerides (p = 0.022, risk ratio = 1.004). 
Conclusions: Significant independent risk factors for new CE in older 
persons were age, plasma homocysteine, cigarette smoking, hypertension, 
diabetes mellitus, total cholesterol, HDL cholesterol (inverse association), and 
triglycerides. 
1117 153 Is Cholesterol Reduction as Effective in the 
/ Elderly? 
Celia J. Fang, Thomas A. Pearson, Kecia Brown. University of Rochester 
School of Medicine and Dentistry, Rochester, NY; USA 
HMGCoA reductase inhibitors (statins) have been shown to be effective in 
prevention of coronary heart disease (CHD) for which the elderly are at greater 
risk. However, it is unclear if statins are as effective or if response to statins 
changes with age. To study this, 7166 patients (pts) were enrolled in the 
TARGET study and randomly allocated to atorvastatin IO mg/day (A) + diet 
(D) (n = 4347) vs D alone (n = 2819) after recruitment by 1236 primary care 
physicians. The population ranged in ages 18-91 with good representation 
of all age strata, especially the elderly (n = 1686 aged 70+ years). The % 
change in LDL-C after A + D vs D alone did not vary over age for men and 
declined with age for D alone in women. However, the % reaching LDL-C 
goal of the National Cholesterol Education Project (NECP) declined markedly 
in both sexes. [See table for mean LDL (mg/dL) % change/% pts achieving 
LDL-C goal]. 
Age Strata 
<39 40-49 50-59 60-69 >70 
Male/A + D -33.9/68 -35.7166 -36.1163 -37.5162 -37.5160 
Male/D -7.5117 -&l/19 -9.6/16 -7.2/14 -7.8/14 
Female/A + D -36.1/71 -38.2'76 -39.3169 -38.2/67 -39.4165 
Female/D -11.9133 -9.2/23 -7.7118 -6.0114 -5.6114 
D alone was less effective in lowering LDL-C in the elderly, with a smaller % 
reaching LDL-C goal by D alone. The proportion of elderly in high risk or CHD 
risk groups was much greater than in younger age groups. Within NCEP risk 
strata % reaching LDL-C goal on A + D actually increased in the elderly (p = 
0.0001). These data suggest that a standard dose of atotvastatin (10 mg/day) 
is equally if not more effective in the elderly. The elderly may require higher 
doses of statins, however, not because statins are less effective, but because 
a greater % of elderly are in higher NCEP risk groups. 
1 1117-l 54 1 Differing Effects of Age on Circadian Profile of 
Heart Rate Variability 
Hendrik Bonnemeier, Nina Kluge, Axe1 Brandes, Uwe K.H. Wiegand, 
Jiirgen Potratz, Hugo A. Katus. Medical University Luebeck, Germany 
Background: Heart rate variability (HRV) has been reported to decrease with 
normal aging, however, there is almost no data available on circadian profile 
of HRV over different decades in healthy subjects. 
Methods: We investigated 139 healthy subjects (76 females, 63 males; 
age 41.7 & 15.3 years). Time domain HRV (SDNN, SDNNi, SDANN, rMSSD, 
pNN50, sNN50, TI) and mean RR-interval were determined from 24-hour 
Holter monitoring after manual exclusion of artefacts and premature beats 
and were calculated as hourly mean values and mean 24-hour values. All vol- 
unteers were fully mobile, woke up around 7 AM and had 6 to 8 hours of sleep. 
Results: Mean 24-hour values of all HRV parameters were significantly 
lower in older subjects. Circadian profile of HRV revealed a marked day-night 
pattern with a peakat nighttime and a plateau at daytime. According to decade, 
the characteristic peak deminished with aging. Mean 24-hour RR-interval de- 
creased from the second to the fourth decade and consecutively increased 
again to the sixth decade. However, the day night difference constantly de- 
creased with aging. Mean 24-hour HRV and RR-interval as well as their hourly 
profiles were higher in male subjects. 
Conclusion: Mean 24 hour HRV of healthy subjects significantly de- 
creased with aging and was higher in males. Circadian profile of HRV exhibited 
that the significant vagal modulation at nighttime constantly declined with ag- 
ing. At daytime sympathetic predominance age-related increased. Thus, age 
and gender affect time domain HRV, which has to be considered using HRV 
for rise stratification. 
L-2 1117 155 Influence of Aging on Baroreflex Sensitivity 
Determined Noninvasively by Transfer Function 
Analysis 
Gianfranco Piccirillo, Marialuce Nocco, Marco Lionetti, Antonio Moise, 
Sabrina Tarantini, Camilla Naso, Vincenzo Marigliano. lsituto di Prima Clinica 
Medica, Universit8 “!-a Sapienza”, Roma, Italy 
Our aim in this study was to assess the effect of aging on baroreflex sensitivity 
determined by transfer function analysis (a index) in a large population of 
healthy subjects. 
We studied 154 subjects (M:F = 83:71), age range 9-94 years, in three 
age ranges: 39 years or younger (58 subjects); 40 to 59 years (52 subjects) 
and 60 years or older (44 subjects). Transfer function analysis yields three CI 
indexes: an cx low-frequency (LF) index of baroreflex sensitivity that ranges 
around 0.1 Hz; an 01 high-frequency (HF) index reflecting baroreflex sensitivity 
corresponding to the respiratory rate; and the 01 total frequency (TF), a new 
index whose spectral window includes all the power in the range 0.03-0.42 
Hz. All three u indexes were higher in the youngest age group than in the two 
older groups. No significant difference was found for baroreflex sensitivity in 
the two older groups. All the a indexes correlated inversely with age (a LF, 
r: -0.55, p < 0.001; (Y HF, r: -0.46, p < 0.001; olTF, r: -0.56, p < 0.001). 
Multiple regression analysis showed a negative association only between CI 
TF and systolic blood pressure (r = 0.37, B: -1.04, p < 0.0001). 
Youngest Middle age Elderly 
01 LF resp, ms/mm Hg 11.6 * <0.8* 7.7 i 0.6 5.9 4 0.5 
ol HF resp, ms/mm Hg 16.1 zk l.l* 11.1 f0.9 9.6 i 0.8 
01 TF resp, ms/mm Hg 12.7 i 0.9* 8.3 zt 0.6 6.7 4 0.5 
*p < 0.001 Youngest group 1 versus middle age and oldest groups. 
Baroreflex sensitivity in middle age remains substantially unchanged in the 
elderly, hence it predominant fall takes place not in advanced but in middle 
age (40-60 years). Diminished baroreflex sensitivity in the elderly could be 
linked more to the age-related increase in arterial pressure than to aging itself. 
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I 1117 156 Association of Atrial Fibrillation and Aortic Atherosclerosis: An Age-Related Phenomenon 
in the General Population 
Yoram Agmon, Bijoy K. Kandheria, Irene Meissner, Gary L. Schwartz, Tanya 
WI. Petterson, W. Michael O’Fallon, Federico Gentile, Jody L. Covalt, Jack 
P. Whisnant, David 0. Wiebers, James B. Seward. n/lay0 ClinicandMayo 
Foundation, Rochester, Minnesota, USA 
Background: Recent data suggest that atherosclerosis of the thoracic aorta 
(ATA) is associated with embolic events in high-risk patients with atrial fib- 
rillation (AF). The association of AF and ATA has not been evaluated in the 
general population. 
Methods: Transesophageal echocardiography was performed in 581 sub- 
jects, a random sample of the Olmsted County population aged 245 yrs (strat- 
ified by age and sex), as a part of the SPARC study (Stroke Prevention: As- 
sessment of Risk in a Community). The presence of ATA (any degree of ATA, 
in any segment of the thoracic aorta) and complex ATA (protruding atheroma 
> 4 mm in thickness and/or mobile debris or ulceration) was determined in 
42 subjects with electrocardiographically-documented AF (AF group), and 
compared with 539 subjects without AF (non-AF group). 
Results: AF subjects were much older than non-AF subjects (81 f IO 
vs 66 i 13 yrs, P < 0.001) and more commonly hypertensive (67% of AF vs 
53% of non-AF subjects, P= 0.097). Gender, diabetes, hypercholesterolemia, 
and smoking status were similar in both groups (all P values > 0.10). The 
frequencyofATA(of anydegree) was74%inAFvsSO%innon-AF(P=0.002). 
The frequency of complex ATA was 17% in AF vs 7% in non-AF (P = 0.03). 
The odds ratios for ATA and complex ATA were 2.87 (95% confidence interval 
[Cl] 1.41-5.83, P = 0.004), and 2.71 (Cl 1 .I 3-6.52, P= 0.03), respectively, in 
the AF group vs the non-AF group. Age was a significant predictor of ATA (P 
< 0.001) and complex ATA (P < 0.001). After adjusting for age, there was no 
significant difference in the odds of ATA or complex ATA in the AF vs non-AF 
groups (P= 0.13 and P =0.75, respectively). 
Conclusions: AF in the general population is associated with ATA and 
complex ATA. This association is primarily related to aging, since both AF and 
ATA are more frequent in the elderly population. The association between AF 
and ATA suggests that AF, which is primarily a disease of the very elderly, may 
not only be adirect cause of embolism, but may also serve as a riskmarkerfor 
high embolic potential due to multiple alternative mechanisms, including ATA. 
L-L-I 1117 157 Secular Trends in Atrial Fibrillation Over Three 
Decades in 2052 Older Men and Women in 
Rochester, Minnesota 
Teresa SM. Tsang, George W. Petty, Marion E. Barnes, JoRean D. Sicks, 
Michael W. O’Fallon, Jack P. Whisnant, James B. Seward, Bernard J. Gersh. 
Mayo Clinic, Rochester, MN, USA 
Objective: A significant increase in prevalence of atriai fibrillation (AF) was 
noted in men, but not women, in the Framingham Heart Study from 1968 to 
1989, Reasons for the rising trend and gender differences remain unknown. 
Secular trends in AF and cardiovascular comorbidity over a 30-year period in 
Rochester, MN, were determined. 
Method: The study population comprised the matched control group for a 
stroke case-control study. ECG evidence of AF and diagnostic confirmation 
of myocardial infarction (Ml), congestive heart failure (CHF), valvular heart 
disease (VHD) and diabetes mellitus (DM) were obtained for all. 
Results: An age-related increase in AF was present for both sexes in all 
time periods. A secular trend of increasing AF was identified for men and 
women p 65 y (Table). The AF increase occurred in association with a rise in 
VHD in women 65-84 y, and in both VHD and CHF in those ~85 y. In men 
65-84 y, the AF increase was associated with both Ml and VHD, and in men 
2 85 years, with Ml and CHF. No increase in DM was noted for either sex. 
Period Women Men 
Age 65-84~ Age>85y Age 65-83 y Age>85y 
n % " % " % n % 
1960-69 g/175 5 6149 12 11/177 6 4/20 20 
1970-79 221235 9 7161 11 171175 10 6125 24 
1980-89 301285 ii* 431191 231 35/241 15' 10136 28 
*p =0.03; lJp=o.o2~p = 0.003 
Conclusions: A secular trend of increasing AF was noted in older women 
as well as in men, which may be related to an increase in comorbid conditions 
which predispose to AF development. 
I 1117 158 Ambulatory Norepinephrine Infusion as a New 
Therapeutic Opt,ion in Severe Autonomic 
Orthostatic Hypotension 
Olaf Oldenburg, Andreas Kribben’ , Stefan Sack, Robert Seng, 
Thomas Philipp’, Raimud Erbel. University Hospital, Dept. of Cardiology; 
‘Dept. of Nephro/ogy and Hypertension, Essen, Germany 
Recurrent syncopes and severe orthostatic hypotension is the key problem 
in advanced Shy-Drager- (SDS) and Bradbuty-Eggleston-Syndromes (BES). 
Immobilization of patients can be the result of this orthostatic hypotension 
(OH). Oral antihypotensive therapy often fails in treatment of these patients. 
Aim of this study was the investigation of an ambulatory norepinephrine infu- 
sion therapy in these cases. 
Methods: We investigated 6 patients with therapy refractory OH (60-71 
years), 5 patients with SDS and 1 with BES. Beside of an oral antihyotensive 
therapy, 4 patients were bedridden b/o OH and 2 were unable to stay in an up- 
right position for more than 3 min. In all patients syncope occurred in less than 
15 min during tilt table testing (60” angulation). After a dose-finding study with 
i. v. application of norepinephrine, a port-a-cath system was implanted. Using 
a PCA-pump (Patient Controlled Anaesthesia), norepinephrine was infused 
in a dosage of IO to 30 rig/kg body weight/h. Every patient was individually 
instructed to use the system. 
Results: During continuous blood pressure and heart rate control, all pa- 
tients were mobilized and tolerated a 45 min tilt table test without any symp- 
toms. Self administration of norepinephrine leads to an almost normal daily life 
without syncope and dizziness. Today the longest therapy period is 5 years. 
Conclusion: In case of therapy refractory, primary autonomic OH, self 
administrated ambulatory norepinephrine infusion, using a pot-la-cath system 
in combination with a PCA-Pump, is a safe and well tolerated option. 
L--l- 1117 159 Platypnea Orthodeoxia: Management by Transcatheter Buttoned Device Implantation 
P. Syamasundar Rao, lgor F. Palacios, Richard G. Bach, E.B. Sideris. Saint 
Louis University School of Medicine, St. Louis, Missouri, USA 
Background: Arterial desaturation on upright or sitting position associated 
with or without prior pneumonectomy in elderly subjects is described as 
Platypnea-Orthodeoxiasyndrome (POS) and is due to right-to-left shunt across 
an interatrial communication, usually a patent foramen ovale (PFO). Hitherto, 
surgical closure of PFO is the only available treatment option. Buttoned de- 
vice has been used for occlusion of ostium secundum atrial septal defects 
(ASD), PFOs associated with paradoxical embolism and cerebrovascular ac- 
cidents and ASDs/PFOs in association with other congenital heart defects, 
causing right-to-left atrial shunt. The objective of this presentation is to de- 
scribe the use of buttoned device in effectively occluding PFOs, thus relieving 
hypoxemia associated with POS. 
Methods: During a two-year period ending July 1999, seven patients ages, 
71 f 9 (range 60-83) years with POS underwent buttoned device closure of 
their PFOs. 
Results: Echographic and balloon stretched ASD sizes were 8 f 3 mm 
and 12 * 3 mm respectively. The ASD/PFOs were occluded by devices rang- 
ing in size from 25 to 35 mm; all had an additional 25 mm occluder placed 
on the fight atrial side. The oxygen saturation improved (p < 0.001) from 76 
& 7% (range 69-86%) to 95 f 2% (range 92-98%). No complications were 
encountered. Symptomatic improvement was seen in all patients. Follow-up 
of 1 to 24 (median 6) mo revealed persistent relief of symptoms. 
Conclusion: Buttoned device closure of PFOs to relieve hypoxemia of 
POS is feasible, safe and effective and is an excellent alternative to surgical 
closure. 
ORAL 
18031 Effects of Load/Unload Neurohumoral 
Activation/Blockade on the Failing Heart 
Monday, March 13,2000,4:00 p.m.-5:30 p.m. 
Anaheim Convention Center, Room 304A 
4:15 p.m. 
I 803 2 Improved Responsivenes to Beta-Adrenergic Stimulation in Trabeculae From LVAD Supported 
Hearts 
John D. Madigan, Alessandro Barbone, Mehmet C. Oz, Jeffrey W. Holmes, 
Daniel Burkhoff. Columbia University, New York, N): USA 
Background: Left ventricular assist device (LVAD) support has been reported 
to normalize LV chamber geometry, unloaded myocyte shortening, and ex- 
200A ABSTRACTS - Cardiac Function and Heart Failure JACC February 2000 
pression of genes for major excitation-contraction coupling proteins. We in- 
vestigated the effects of LVAD support on the developed force-length curve, 
force-frequency relation, and response to p-adrenergic stimulation in isomet- 
rically contracting trabeculae. 
Methods: At the time of transplantation, trabeculae were dissected from 
the LV free wall of 5 patients with idiopathic dilated cardiomypathy and 2 pa- 
tients supported with an LVAD for48 and 82 days. The trabeculae were placed 
in an oxygenated muscle bath at 37”C, stimulated at 1 Hz, allowed to equili- 
brate for one hour, then prestretched to L,,,. The force frequency relationship 
was determined at 0.5-Hz steps between 1 .O and 3.0 Hz. Responsiveness to 
p-adrenergic stimulation was assessed at 1 .O Hz with a 4 x 10-s M dose of 
isoproterenol. 
Results: There was no difference in baseline muscle function between 
LVAD and non-LVAD trabeculae as assessed by the developed force-length 
curve. (Developed force 12.5 i 10.4 vs. 9.5 f 1.6 mN/mms at L,,,, p = 
0.49; il.52 i 11.8 vs. 7.0 f 1.6 mN/mms at 95% L,,,, p = 0.36). However, 
both the force-frequency relationship and responsiveness to isoproterenol 
1 improved with LVAD support. At L ,,,= developed force at 3 Hz was 91 & 23% 
’ and 65 f 7% of developed force at 1 Hz for LVAD and non-LVAD trabeculae 
(p = 0.048). At L,,, and 1 Hz developed force with isoproterenol was 328 f 
49% of baseline for LVAD compared to 167 f 53% for non-LVAD trabeculae 
(p = 0.015). Responsiveness within the non-LVAD group depended on the 
history of inotropic support (developed force 148% with history of dobutamine 
support, n = 4, vs. 246% without support, n = 1) 
Conclusions: The most dramatic improvement in muscle function follow- 
ing LVAD support was the increased responsiveness to fi-adrenergic stim- 
ulation The force-frequency relationship also improved significantly, while 
alterations in baseline function were not detectable with the small sample size 
reported here. Since LVAD patients did not require inotropic support while on 
LVAD, the altered p-adrenergic responsiveness may reflect reversal of de- 
sensitization rather than direct effects of mechanical unloading. These data 
suggest that much of the functional improvement observed during LVAD sup- 
port may be due to recovery of j+adrenergic pathways. Further, this recovery 
may be attributable more to decreased requirement for inotropic support dur- 
ing LVAD, rather than to the effects of mechanical unloading. 
4:30 nm. 
El 803 3 Mechanical Unloading Versus Neurohumoral 
Stimulation on Mvocardial Structure and Endocrine 
Function In Vivo - 
Ondrej Lisy, Margaret M. Redfield, Sofija Jovanovic, Michihisa Jougasaki, 
Aleksandar Jovanovic, Hanna Leskinen, Andre Terzic, John C. Burnett, Jr.. 
Mayo Clinic, Rochester, MIV, USA 
Background: Mechanical load and humoral stimuli such as endothelin (ET) 
and angiotensin II (ANG II) are potent modulators of cardiac structure and 
myocardial endocrine function, specifically the gene expression, production 
and release of the cardiac hormone atrial natriuretic peptide (ANP). While 
both mechanical load and neurohumoral mechanisms influence cardiomy- 
ocyte growth and function, it is unclear which predominates particularly when 
the heart is unloaded. Our study defines the contribution in vivo of mechanical 
load as compared to neurohumoral stimulation with a specific focus on my- 
ocardial and circulating ET and ANG II during chronic unloading produced by 
thoracic inferiorvenacaval constriction (TIVCC), which is characterized by the 
marked activation of circulating and cardiac ET and ANG II with a reduction in 
cardiac preload. 
Methods: TIVCC was produced by banding of the vena cava inferior for 
IO days in a group of 7 dogs while in the control group of 6 dogs the band was 
not constricted (SHAM). *p < 0.05 vs SHAM. 
Results: TIVCC group was characterized by a decrease in CO (2.3 f 0.2* 
vs 3.6 & 0.3, Urnin), RAP (-0.7 f 0.4* vs 3.0 f 0.4, mmHg) and a decrease 
in LVEDD (3.48 f 0.22” vs 4.08 f 0.15, cm) compared to the SHAM with a 
marked activation of ET and ANG II in plasma and in atrial and ventricular my- 
ocardium. Despite neurohumoral stimulation the LVMi was decreased in the 
TIVCC (3.5 f 0.2* vs 4.5 f 0.2, g/kg) reflecting myocyte atrophy. Laser con- 
focal microscopy of WGA-FITC-stained ventricular cross-sections revealed 
decreases in maximal (88.7 i 4.4” vs 128.1 f 4.4, @rn) and minimal (20.0 
i 0.1” vs 24.6 f. 0.9, pm) diameters of the myocytes and decreases in the 
cross-section areas (1292 f 98* vs 2217 f 135, pm*) and volumes (30000 
i 2000* vs 54000 * 3000, ym3) of the myocytes in the unloaded hearts com- 
pared to the sham operated. The total number of myocytes in the left ventricle 
remained unchanged. Plasma ANP did not change, while there was a trend to 
decrease ANP gene expression in the TIVCC group. 
Conclusion: These studies provide important insights into the seminal 
role of myocardial load versus neurohumoral mechanisms in the control of 
myocardial cell growth and endocrine function in vivo. The chronic mechanical 
unloading of the heart results in myocardial atrophy and a decrease in ANP 
synthesis despite marked neurohumoral stimulation. 
4:45 p.m. 
I 803 4 SERCAQ Expression is Decreased in the Unloaded Heart In Vivo 
Faisal Hasan, Ellen 0. Weinberg, Beverly H. Lorell, Michael D. Schneider. 
Beth Israel Deaconess Medical Center, Boston, Massachusetts; Baylor 
College of Medicine, Houston, Texas, USA 
Background: Prolonged space flight leads to cardiac unloading in humans. 
The effect on cardiac gene expression is unknown. Animal models demon- 
strate that cardiac unloading in viva induces a fetal/hypertrophic pattern of 
gene expression characterized by reexpression of growth factors and proto- 
oncogenes and down regulation of certain “adult” protein isoforms. We ex- 
amined the phenotypic adaptation of the heart to ventricular unloading by 
measuring the expression of fetal/hypertrophic markers, atrial natriuretic pep- 
tide (ANP) and B myosin heavy chain (fi MHC), as well as the critical calcium 
regulatory protein, sarcoplasmic reticulum Ca ATPase-2 (SERCAP). 
Methods: Ventricular unloading was achieved in rats by heterotopic heart 
transplantation to the abdominal aorta of an isogenic recipient. Five weeks af- 
ter surgery the animals were sacrificed, and LV tissue was dissected, weighed 
and frozen at -80 C. Total RNA was isolated from frozen LV tissue of control 
(n = 12) and unloaded (n = 12) hearts and Northern blot analyses (normalized 
to GAPDH) performed. 
Results: Compared with control hearts, the weight of unloaded hearts was 
significantly decreased (0.81 f 0.03 vs 0.24 z!= 0.02 g, p < 0.01). Expression 
of ,5 MHC was significantly increased in unloaded hearts compared to control 
hearts (220 X+Z 12 vs 118 & 6 units, p < 0.001). SERCA-2 mRNA levels were 
markedly decreased in unloaded hearts compared to control hearts (34 i 7 
vs 106 --t 11 units, p < 0.001). Preliminary results (n = 2/group) show that 
SERCA-2 protein levels are also decreased in unloaded hearts compared to 
controls. Expression of ANP was minimally changed in unloaded hearts (179 
i 48 vs 110 f 29 units, p = 0.2). These changes in 6 MHC and SERCA-2 gene 
expression were also noted as early as two weeks of unloading (n =4/group). 
Conclusion: Since SERCA-2 and fi MHC are proteins critical for LV con- 
tractile function, these findings may have implications for cardiac unloading in 
humans during microgravity space flight, and extreme unloading in patients 
on ventricular assist. 
5:00 p.m. 
803-5 Suppression of Cardiac Myocyte Hypertrophy by 
Adenoviral Gene Transfer of Cyclic GMP-Dependent 
Protein Kinase 
Kai C. Wollert, Beate Fiedler, Helmut Drexler, Stepan Gambaryan, 
Albert Smolenski, Suzanne M. Lohmann. Medizinische Hochschule 
Hannovel; Hannover; Universit2t Wikzburg, Wtirzburg, Germany 
Background: Cardiac hypertrophy represents an independent risk factor for 
cardiovascular morbidity and mortality. It is important, therefore, to develop 
molecular strategies to inhibit cardiac hypertrophy. In vascular smooth mus- 
cle cells (VSMCs), cyclic GMP (cGMP)-dependent protein kinase (PKG) has 
emerged as a mediator of the growth inhibitory effects of nitric oxide and 
cGMP. However, the concentration of PKG present in cardiac myocytes is 
approximately 1 Ofold lower as compared to VSMCs. 
Methods and Results: We used adenoviral gene transfer to investigate 
whether overexpression of PKG will inhibit cardiac myocyte hypertrophy in- 
duced by the 011 -adrenergic agonist phenylephrine (PE). Neonatal rat ventric- 
ular cardiomyocytes were transfected with emptyadenovirus (Ad), adenovirus 
encoding wild-type PKG type lb (Ad.PKG-wt), or adenovirus encoding a mu- 
tated, i.e. catalytically inactive, PKG type IB (Ad.PKG-K405A). After transfec- 
tion (M.O.I. = 20) cardiac myocytes were stimulated with the cell-permeable 
cGMP analogue 8pCPT-cGMP (500 FM) and PE (3 KM) for 24 h, as indicated 
(n = 3-4). Steady state mRNA levels of the embryonic marker gene atrial 
natriuretic factor were determined by Northern blot analysis: 
Control 
8pCPT.cGMP 
PE 
PE + 8pCPT-cGMP 
Ad 
100% 
115115 
255 i 75* 
295 zt 65* 
Ad.PKG-K405A 
83122 
loo+38 
166zk36* 
211 zk 61* 
Ad.PKG-wt 
55115 
22 + 3* 
151 i la* 
37 f 8# 
*p < 0.05 vs. control, #p < 0.05 vs. PE 
In addition, as shown by immunostaining using an anti-troponin T mAb, 
8pCPT-cGMP significantly reduced the increase in cell size induced by PE 
by 34 i 7% in cardiac myocytes transfected with Ad.PKG-wt, but not Ad or 
Ad.PKG-K405A. 
Conclusion: Adenoviral gene transfer of PKG suppresses molecular and 
morphological markers of a hypertrophic response in cultured cardiac my- 
ocytes. 
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El 803 6 Growth Hormone Attenuates Pathologic Remodeling 
in the Rats With Postinfarct Heart Failure 
Entela Bollano’ , Elmir Omerovic’ , Vuk Kujacic, ,&ke Hjalmarsson’ , 
Finn Waagstein’ , Jijrgen Isgaard’, ’ Wallenberg and Lundberg Laboratories, 
Sahlgrenska University Hospital; 2 Research Centrum for Endocrinology and 
Metabolism, Sahlgrenska University Hospital, Gdteborg, Sweden 
Background: Increasing experimental evidence suggests that growth hor- 
mone (GH) may have beneficial effects in the treatment of heart failure. How- 
ever, the mechanisms behind these positive effects are not well understood. 
The aim of this study was to investigate the effects of GH on cardiac function, 
remodeling and plasma levels of brain natriuretic peptide (BNP) in the early 
postinfarct phase. 
Methods: Myocardial infarction (Ml) of lefi ventricular (LV) anterolateral 
wall was induced by ligation of the left coronary artery in male Sprague-Dawley 
rats. Three different groups were studied: Ml rats treated with GH (GH, n = 
II) (3 mgikglday), MI rats placebo treated (P, n = IO), and sham operated rats 
(S, n = 7). All rats were investigated with transthoracic echocardiography at 3 
days and 3 weeks after Ml. The plasma concentration of (BNP) was measured 
using radioimmunoassay after the treatment. 
Results: The results are summarized in the table. Treatment with GH 
attenuated increase in LV volumes and improved LV.systolic function. Brain 
natriuretic peptide (BNP) was increased in P group while treatment with GH 
normalized the plasma level of BNP. 
AEF% AEDVml AESVml LV/BW ma/o BNP 
GH 6.6 It 5.2’ 15.1 i 2.1* 9.3 i I@ 2.5 zk 0.05 124 i 8.4” 
P -15.6 zt 6.6 24.3 zt 2.5” 17.6 I2.3# 2.4 f 0.06 203 i 35 
S 1.6 + 5.2 8.7 5 2.2 3.1 + 1.5 2.8 + 0.09 118f23 
EF = ejection fraction, EDV = end distolic volume, ESV = end systolic volume, LVBW = 
left ventricular index, * = p < 0.05 v. Placebo; # = p < 0.05 v. sham 
Conclusion: GH attenuates pathological remodeling and improves LV 
systolic function without induction of LV hypertrophy. This improvement was 
associated with normalization of plasma levels BNP. 
ORAL 
/855/ Dilated and Hypertrophic Cardiomyopathies: 
Genetic Aspects 
Monday, March 13,2000,4:00 p.m.-%30 p.m. 
Anaheim Convention Center, Room 213A 
4:00 D.m. 
855-l A De Novo Mutation of the Troponin T Gene in a 
Patient With Hypertrophic Cardiomyopathy 
Amanda M. Varnava, Fergus Davison, Leon de Cruz, Fabio Coccolo, Perry 
M. Elliott, Christina Baboonian, Michael J. Davies, William J. McKenna. St 
George’s Hospital Medical School, London, UK 
Background: Mutations in at least 8 genes have been associated with hyper- 
trophic cardiomyopathy (HCM). Animal transgene studies suggest that these 
gene mutations cause HCM, but definitive proof of causation in the form of de 
novo mutations in paiients with HCM is established only for the myosin and 
tropomyosin genes. Troponin T mutations have been linked to a particularly 
malignant form of the disease. We describe the first de novo mutation of this 
gene in a patient with HCM. 
Methods: The DNA was extracted from the blood of a 6 year old pa- 
tient with severe HCM who had undergone cardiac transplantation. Direct 
sequencing of exon 9 of the troponin T gene identified a missense mutation at 
codon 92, which resulted in the substitution of the amino acid tryptophan for 
arginine. The mutation was confirmed with restriction digest. 
Results: The Arg92Trp mutation was found in the proband, but not the un- 
affected parents who underwent DNA haplotyping to confirm genetic parent- 
age, nor in the DNA of 200 normal chromosomes. Pathological examination 
revealed widespread myocyte disarray (up to 80% of the myocardium). 
Conclusion: We present the first de novo mutation of the troponin T gene. 
This mutation was at a known hot spot and is at an evolutionary conserved 
site. At histology widespread myocyte disarray was found. This provides the 
most definitive evidence that mutations of the troponin T gene are indeed a 
cause of HCM. 
4:15 p.m. 
/ 855 2 Possible Role of Calcineurin in Etiology of Maladaptive Cardiac Hypertrophy in Familial 
Hypertrophic Cardiomyopathy Caused by Missense 
Sarcomeric Mutations 
Hae W. Lim, David Begley, Jeffery D. Molkentin, Lameh Fananapazir. 
Department of Pediatrics, Children’s Hospital Medical Center, University of 
Cincinnati, andNational institutes of Health, NHLBI, Bethesda, MD, USA 
Background: Familial hypettrophic cardiomyopathy (FHC) is characterized 
by left ventricular hypertrophy (LVH) and may be caused by mutations in one 
of several sarcomeric genes. The molecular mechanisms whereby mutations 
in sarcomeric genes lead to LVH is presently unknown. FHC has been asso- 
ciated with altered intracellular Ca2+ handling which may activate the calcium 
sensitive phosphatase calcineurin. 
Methods and Results: Activated calcineurin levels were quantified by 
calmodulin co-precipitation followed by Western blotting. To control for vari- 
ability in the immunoprecipitation procedure and to normalize calcineurin lev- 
els, the same blot was probed with calmodulin antibody. Cardiac biopsies 
were studied from IO adult patients (LV wall thickness 22 & 10 mm; range, 
17 to 50 mm) with FHC caused by mutations in ,!I-myosin heavy chain (8 pa- 
tients), myosin binding protein-C (1 patient), and myosin essential light chain 
(1 patient), as well as from 6 normal controls. Calcineurin levels (mean i SD, 
percent of normal values) were significantly higher in FHC patients: 356 i 
169%; range, 127 to 626% greater than controls, p < 0.001. The levels were 
>250% higherthancontrols in8ofthe IO FHC patients. Calcineurinenzymatic 
activity was measured in 4 of the FHC patients and compared with 4 normal 
controls. The calcineurin activity (mean & SD) was significantly greater in the 
FHC patients 6.42 f 1.20 pmollminl@g versus 2.9 + 0.34 pmoliminl~g in 
controls, p = 0.0013. 
Conclusions: Activated calcineurin may play a role in mediating LVH in 
FHC. Further studies are indicated to confirm the role of the calcineurin reg- 
ulatory pathway in FHC and to investigate the potential effectiveness of cal- 
cineurin antagonists. 
4:30 txm. 
855-3 Homozygous Mutation in Cardiac Troponin T: 
lmolications for Familial Hvoertroohic 
C&diomyopathy 
_. . 
Carolyn Y. Ho’, Harry M. Lever”, Carol M. Farve?, Roman DeSanctis, Jon 
G. Seidman’ , Christine E. Seidman’ ‘Harvard Medical School, Boston, MA; 
“The Cleveland Clinic Foundation, C/eve/and, OH 
Background: Mutations in the gone encoding cardiac troponin T (cTnT) ac- 
count for approximately 15% of cases of familial hypertrophic cardiomyopathy 
(HCM). These mutations are associated with a particularly severe form of 
HCM characterized by a high incidence of sudden death and a poor overall 
prognosis, despite inapparent to mild left ventricular hypertrophy. 
Methods: A family with HCM and multiple occurrences of sudden death 
in children was evaluated by history, physical examination, ECG and echo- 
cardiography. Genetic analysis was accomplished by automated sequencing 
of cTnT axons using DNA samples isolated from peripheral blood or paraffin- 
embedded tissue. 
Results: We identified a heterozygous sequence variant which alters a cy- 
tosine to a thymidine nucleotide in exon 11 of the cTnT gene. This is predicted 
to substitute a phenylalanine for serine at residue 179 (Serl79Phe) in cardiac 
troponin T. Both parents and three of four surviving, though clinically unaf- 
fected, children were heterozygous for this mutation; one child was clinically 
and genetically unaffected. Genetic analysis of DNA from paraffin-embed- 
ded tissue from a child who manifested profound left and right ventricular 
hypertrophy and suffered sudden death at age 17 years revealed that he was 
homozygous for this mutation. 
Conclusions: The genetic etiology of a virulent form of HCM is a novel 
homozygous mutation in cardiac troponin T resulting in an amino acid sub- 
stitution, Serl79Phe. The mild natural history of the heterozygote state in 
contrast to the severe phenotype conferred by homozygosity emphasizes the 
need to approach hypettrophic cardiomyopathy at a genetic as well as clinical 
level and provides a new perspective on the nature of troponin T mutations in 
this disorder. 
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855-4 Phenotypic-Genotypic Findings in Hypertrophic 
Cardiomyopathy in the ISAAC National Database 
Andre Keren, Vardiella Meiner, Marina Potekhin, Jakov Galimidi, Amos Katz, 
Jean M. Weinstein, Shimon A. Reisner, Dawod Sharif, Avraham Lorber, 
Joseph Shaheen, Ariel Roguin, Tzvi Klein, David Blondheim, Zvi Vered, 
David Leibowitz, Joseph Shemesh, Azaria J.J.T. Rein, Eli Peleg, Michel 
J. Dreyfus, Eran Leitersdorf. For the /SAAC investigators, lsrael 
Background: During 1998/99, the phenotypic features of 197 subjects, 55 
probands and 142 family members (belonging to 17 pedigrees) with hyper- 
trophic cardiomyopathy (HCM), were entered by 14 Centers in the ISAAC 
(Israeli Shared Action for Advancement of Cardiomyopathies) computerized 
database. DNA extraction was performed i all cases, and linkage analysis 
was started in the evaluated families. 
Results: The clinical diagnosis was: HCM in 74 (54 males, aged I-60, 
mean 43.6 years), 65 of them 120 years old, NO HCM in 66 and ULCER- 
TAlNin 57 (77% offhem children). Among the 74pf.s with HCM21 (28%) had 
a positive family history of premature sudden death. Presentation included 
chest pain (50%) dyspnea (49%) syncope (24%) and aborted sudden death 
(7%). ECG was abnormal in 87% of HCM cases, but ECGcrifeia forLVH were 
absent in 22 (33%) pts 120 years old and in 3 of the 9 HCM pts < 20 years old. 
LVH, by classical Echo criteria in probands and modified criteria in pedigrees, 
was found in 69 (93%) HCM pts. LV outflow obstruction was found in 21 of 
69 with LVH (31%). Holter showed atrial tachyarrhythmias in 12% and non- 
sustained ventricular tachycardia in 15%. Exersice test showed pathological 
blood pressure response in 21% of pts evaluated. The number of risk factors 
for sudden death was 0 in 26 (35%), 1 in 34 (45%) and ~2 in 15 (20%) pts. 
Genefic linkage analysis using microsatellite markers demonstrated that the 
disease-causing gene in 2 families was myosin-binding protein C. In addition, 
2 novel polymorphic sites in the myosin binding protein C gene (one in exon 5 
and one in exon 32) were identified. 
Conclusions: A shared-computerized database, specifically developed 
for HCM pts was successfully applied by Cardiology Centers in Israel, leading 
to standardization of the phenotyping process. Advances in genetic diagnosis 
should overcome the significant limitations of the clinical screening in children. 
Initial results of genetic testing showed that in 2 families the disease-causing 
gene was myosin-binding protein C. 
500 p.m. 
I 855 5 Histological and lmmunohistochemical Myocardial Abnormalities in Early Familial Dilated 
Cardiomyopathy 
Niall G. Mahon, Aldwyn J. Haven, Mirza K. Baig, Sanjay Sharma, Mark 
W. Norman, Perry M. Elliott, Brendan M. Madden, Michael J. Davies, William 
J. McKenna. St George’s Hospital Medical School, London, UK 
Background: Left ventricular enlargement (LVE) with preserved systolicfunc- 
tion is common in asymptomatic relatives of patients with familial dilated car- 
diomyopathy (DCM), progresses to overt DCM in a proportion and is postu- 
lated to represent early disease. Although inflammation is implicated in the 
pathogenesis of DCM, studies of human myocardium in early disease are 
lacking. We performed histological and immunohistochemical (IHC) analysis 
of endomyocardial biopsies (EMB) of asymptomatic DCM relatives with LVE. 
Methods: 18 relatives with LVE [mean age 32, left ventricular end-diastolic 
dimension 119% predicted, fractional shortening (FS) 31%)] and 3 patients 
with DCM underwent EMB for histology and IHC on snap-frozen specimens 
for leukocyte markers (CD68, CD3), adhesion molecules (ICAM-1) and HLA 
class II antigens (DR/DQ) by quantitative double immunofluorescence. 
Results: All patients with DCM and 7 (39%) LVE relatives demonstrated 
myocardial fibrosis. Seven (39%) LVE relatives had 21 4/mm2 interstitial UCHLI 
+ cells. IHC findings in LVE were: CD3 and CD68 7.2 (f5.2)/mm and 61 .I 
@38.7)/mm, DQ 11 (&65)/mm, DR (%total area) 6.6 (f2.4), ICAM (%total 
area) 2.3 (*I .2). While DCM patients had higher cell counts [CD3 and CD68: 
22.3 (h10.1) and 151 (122.5) respectively, p < 0.05], expression of DR, DQ 
and ICAM did not differ from LVE relatives. DR and ICAM expression corre- 
lated with deterioration in FS at follow-up (r = 0.5, p < 0.05). DR expression 
was higher in patients with cardiac antibodies [4.5 (*1.4) vO.5 (*1.2), p < 
0.051 and in patients without (5 & 2.3) vpatients with (3 & 1.3) fibrosis. 
Conclusion: There are significant morphological and IHC abnormalities in 
asymptomatic relatives with LVE. Expression of class II antigens and ICAM is 
associated with deterioration in systolic function at follow-up. DR expression 
is inversely correlated with fibrosis and likely precedes the development of 
fibrosis early in the pathogenesis of DCM. 
) 855-6 / 
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A Lamin A/C Gene Mutation Associated With Dilated 
Cardiomyopathy With Variable Skeletal Muscle 
Involvement 
Gary L. Brodsky, Francesco Muntoni, Marina R. Di Barletta, Snjezana Miocic, 
Gianfranco Sinagra, Caroline Sewry, Daniela Toniolo, Luisa Mestroni. 
W-WI, Denver, CO, USA; Imperial College, London, UK 
Background: Dilated cardiomyopathy (DCM) is a heart muscle disease char- 
acterized by impaired systolic function and ventricular dilation. Familial trans- 
mission of the disease is frequently observed and genetic heterogeneity is 
indicated by clinical and morphological variability in the disease phenotype. 
A phenotype recently described is characterized by mild inconstant skeletal 
muscle involvement in affected family members (MDDC). Cardiomyopathies 
have been found to be associated with skeletal muscle abnormalities in a 
number of forms of muscular dystrophy, including limb-girdle and Emery-Drei- 
fuss (EDMD) muscular dystrophy. Mutations in the lamin A/C gene have been 
shown to segregate with the disease phenotype in five autosomal dominant 
EDMD families. 
Methods: Fourteen family member of a MDDC family (MDDCI) under- 
went family screening. Clinical investigations in affected individuals included 
endomyocardial biopsy and skeletal muscle biopsy. DNA was obtained from 
affected and unaffected relatives. Genetic analysis included sequencing of the 
candidate gene lamin A/C, analysis of the cosegregation of the mutation within 
the family, and SSCP-heteroduplex analysis of 100 control chromosomes. 
Results: In family MDDCI, the DCM phenotype was severe and charac- 
terized by autosomal dominant pattern of transmission. In addition, the pheno- 
type of affected family members varied from an isolated DCM, to mild limb-gir- 
dle, or mild Emery-Dreifuss muscular dystrophies. Coding regions of the lamin 
A/C gene were PCR amplified from genomic DNA and sequenced. A single 
nucleotide deletion was identified within exon 6 (959delT) and all affected 
individuals were found to be heterozygous for this deletion. The frameshift 
mutation predicts a truncated protein with an altered structure, which abol- 
ishes signals critical for the protein assembly and localization. The mutation 
was not found 100 control chromosomes. 
Conclusions: Heterozygosity for a single nucleotide deletion in exon 6 of 
lamin A/C segregates with the disease in the MDDCI family. The phenotype 
heterogeneity observed in this family suggest that lamin A/C mutations can 
be involved in the pathogenesis of familial DCM, as well as of different forms 
of muscle dystrophies. 
ORAL 
El 863 Insights From Heart Failure Clinical Trials I 
Tuesday, March 14, 2000, 8:30 a.m.-l 0:OO a.m. 
Anaheim Convention Center, Room 213A 
8:30 a.m. 
863-l Beta-Blocker Evaluation of Survival Trial (BEST) 
Michael J. Domanski. The BESTlnvesfigafors; National Heart, Lung and 
Blood Insfifufe, Bethesda, MD 20892, USA 
Background: Data haveaccumulated suggestingabeneficial role for,&blocken 
in the treatment of heart failure. We conducted a randomized, placebo-con- 
trolled trial, the Beta-blocker Evaluation of Survival Trial (BEST), to determine 
whether patients with moderate or severe heart failure benefit from such ther- 
apy. BEST was sponsored by the National Heart, Lung, and Blood Institute 
and the Department of Veterans Affairs. 
Methods: We randomly assigned 2,708 patients in NYHA class Ill or IV 
heart failure with left ventricular ejection fraction (LVEF) 2 35% to treatment 
with bucindolol (a 3rd generation B-blocker) or placebo.,The primary endpoint 
was all-cause mortality. 
Results: A total of 1,354 patients were assigned to each treatment group 
and followed for an average of 2 years. Baseline characteristics are shown 
in the table. Means and standard deviations are reported for continuous vari- 
ables Proportions are presented for categorical variables. 
Table 
Treatment Age Class II l/IV lschemici Male Black LVEF PNE 
Group (YW % Nonischemic % % w/ml 
Placebo 6Ozk12 92l8 58142 77 23 23h7 502zk315 
Bucindolol 60 i 13 92/8 59141 79 24 2317 529zk371 
PNE = plasma norepinephrine level 
The median duration of heart failure at baseline was 3 years. Baseline 
co-therapies: ACE-inhibitor (91%), digitalis (92%), vasodilator (47%), diuretic 
(94%), anticoagulant (45%). The Data and Safety Monitoring Board recom- 
JACC February 2000 
mended termination of the trial based upon the totality of evidence from BEST 
and other B-blocker trials. There was no statistically significant difference in 
mortality between placebo and bucindolol-treated patients. 
Conclusion: Full results will be presented. 
8:45 a.m. 
ELI 863 2 Effect of Metoprolol CRIXL on Time in Hospital and Time Alive Outside Hospital: The MERIT-HF Study 
John Kjekshus, Bjdrn Fagerberg. On behalf of the MEFWHF Study Group; 
Oslo University, Oslo, Norway; Gdteborg University, Gdteborg, Sweden 
In the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart 
Failure (MERIT-HF) 3 991 patients with chronic heart failure in NYHA func- 
tional class II-IV and ejection fraction 5 0.40 stabilized with optimal therapy 
were enrolled in a double-blind randomized study. Randomization was pro- 
ceeded by a two-week single-blind placebo run-in period. The study medica- 
tion was up-titrated during 6-8 weeks starting with 12.5 mg (NYHA Ill-IV) or 
25 mg once daily (NYHA II). The target dose was 200 mg once daily. Analysis 
was by intention-to-treat. The mean follow-up time was 1 year. 
Altogether 581 patients (29.2%) randomized to metoprolol CR/XL were 
hospitalized at least once (any cause), the corresponding figure in the placebo 
group was 668 (33.4%) (risk reduction 18%; p = 0.0043). The corresponding 
figures for hospitalization due to worsening heart failure was 200 patients 
(10.1%) and 294 (14.1%), respectively (risk reduction 35%: p < 0.00001). The 
total number of hospitalizations in the metoprolol CRiXLgroup (all cause) was 
1 021 compared with 1 149 in the placebo group (p = 0.0050). Corresponding 
figures for worsening heart failure was 317 vs 451 (p < 0.00001). Patients 
randomized to metoprolol CR/XL spent a total of IO 172 days in hospital 
(any cause) and patients randomized to placebo a total 12 262 days (p = 
0.0042). Corresponding figures for days in hospital for worsening heart failure 
was 3 401 vs 5 303 days, respectively (p < 0.00001). The mean duration 
of hospitalization for worsening heart failure was 39% shorter on metoprolol 
CR/XL as compared with placebo (p < 0.00001). To account for the improved 
survival on metoprolol CR/XL (145 vs 217 deaths, p = 0.0062 adjusted p = 
0.00009 nominal) the number of days spent alive outside hospital was also 
calculated. Patients randomized to metoprolol CR/XL spent more time alive 
outside hospital compared with patients randomized to placebo (p = 0.0002). 
In patients with symptoms of heart failure and decreased ejection fraction 
treatment with metoprolol CFUXL decreased the need for hospitalization for 
worsening heart failure, and also decreased the mean number of days spent 
in hospital for worsening heart failure. This improvement in the patients’ con- 
dition has important implications for health economics related to this costly 
disease. 
9:00 a.m. 
El 863 3 Prevention of Heart Failure by Ramipril in High Risk 
Patients Without Heart Failure or Systolic 
Dysfunction 
Salim Yusuf, Malcolm Arnold, James Mathew, James Young, Alvaro Avezum, 
Victoria Bernstein, Jackie Bosch, Janice Pogue, Linda Richardson, 
David Johnstone. On behalf of the HOPE (Heart Outcomes Prevention 
Evaluation) Investigators; McMaster University: Hamilton, Canada 
Background: We evaluated if Ramipril, an ACE-inhibitor, as compared to 
placebo would prevent the development of heart failure (HF) in high risk pa- 
tients (255 years, previous vascular disease or diabetes plus one risk factor) 
without low ejection fraction or prior HF in a double blind randomized trial of 
9541 patients followed for 4.5 years. 
Results: 
Ramipril Placebo Relative Risk P 
(95% Cl) 
Any HF 7.4% 9.4% 0.76 (0.67-0.90) 0.0005 
Open label ACE-I 3.3% 4.5% 0.72 (0.58-0.88) 0.0017 
for HF 
HF Hosp. 3.2% 3.8% 0.84 (0.68-1.05) 0.13 
CV death + all HF 11.9% 15.3% 0.77 (0.69-0.86) 0.000003 
CV death + HF hosp 8.4% 10.7% 0.77 (0.68-0.88) o.oooi 
CV = cardiovascular, Hosp = hospitalization 
Benefits were observed in those with and without hypertension. diabetics 
and non-diabetics and among most other subgroups examined. 
Conclusions: Ramipril prevents the development of HF and reduces CV 
mortality in a broad range of high risk patients without evidence of HF or left 
ventricular dysfunction. 
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El 863 4 Do All Heart Failure Patients Benefit From High Dose 
Lisinopril? Results From the ATLAS Study 
L. Ryden, P.W.Armstrong, J.G.F. Cleiand, J.D. Horowitz, B.M. Massie, 
M. Packer, P.A. Poole-Wilson. On behalf of the ATLAS Investigators; 
Karolinska Institutet, Stockholm, Sweden 
Introduction: In the Assessment of Treatment with Lisinopril and Survival 
(ATLAS) study in heart failure (CHF) patients, a high 35 mg dose of the ACE 
inhibitor lisinopril produced a 12% risk reduction (p = 0.002) in the combined 
endpoint of mortality and hospitalisation, compared to a low 5 mg daily dose. 
Risk reduction for mortality was 8% (p = 0.128). Some patients are at higher 
cardiovascular risk than others, and might not benefit to the same degree from 
therapeutic interventions, We investigated whether certain patient subgroups 
within the mixed ATLAS population had a different response to high dose 
lisinopril. 
Materials and Methods: ATLAS was conducted over median 46 months 
in 3164 patients with NYHAclass II-IV CHF. Cox proportional hazards regres- 
sion models were used to identify possible interactions between the effect of 
treatment and clinically-relevant subgroups for both all cause mortality, and 
the combined endpoint, all cause mortality plus all cause hospitalisation. 
Results: Age, sex, etiology of CHF, NYHA class, systolic BP and heart 
rate at entry did not show any interaction with treatment effect. There were no 
consistent interactions with high or low sodium, potassium or creatinine. Thus 
these factors did not distinguish subgroups of patients in whom high dose 
lisinopril was associated with greater or lesser effect compared with the whole 
ATLAS population. However, there was some evidence that patients taking 
calcium channel blockers, short acting nitrates or other vasodilators at ran- 
domisation might gain less advantage from high dose lisinopril than patients 
not receiving these medications, High dose lisinopril was well-tolerated in all 
subgroups. 
Conclusion: With the possible exception of patients already receiving 
vasodilators, we have not identified any subgroup of patients in whom the 
outcome was meaningfully different to the overall study result. Upward dose 
titration should be attempted in all patients with CHF. 
9:30 a.m. 
czl 863 5 Survival Benefits of Spironolactone Therapy May Be Explained by the Limitation of the Excessive 
Extracellular Matrix Turnover in Patients With CHF: 
Insights From the RALES Trial 
Faiez Zannad, Francois Alla, Brigitte Dousset, Bertram Pitt. On behalf of the 
PALES Steering Committee and Investigator+; Centre d’lnvestigation 
Clinique (CIC) INSERM-CHU, Nancy, France 
Background: In congestive heart failure (CHF), extracellular matrix turnover 
is a major determinant of cardiac remodeling, diastolic function and pump- 
ing capacity. It may be monitored by measuring the serum level of procolla- 
gen type Ill aminoterminal peptide (PIIINP). Animal studies suggested that 
spironolactone (SPIRO), an aldosterone receptor antagonist may decrease 
cardiac and vascular fibrosis. Thus, we studied the prognostic significance of 
PIIINP and its changes during chronic treatment with SPIRO. 
Methods: A sample of 253 patients from the PALES trial participated in this 
substudy (CHF NYHA Ill and IV, mean age 69, LVEF = 26%, ischemic heart 
disease = 46%, all were on conventional therapy -92% on ACE inhibitors-). 
Patients were randomized to placebo or SPIRO 12.5 to 50 mg daily. Serum 
PIIINP was measured at baseline and 6 months after randomization (radioim- 
munoassay: 95%CI range in control subjects = 1.7-4.2 fig/l). Mean survival 
follow up was 24 months. ANOVA and multivariate Cox survival model were 
used. 
Results: Baseline serum PIIINP level was 4.6 (sd:2.5) and was simi!ar 
in the SPtRO and placebo group. At 6 months it decreased in the SPIRO: 
(changes: -17% [6-291 p = 0.005) but not in the placebo group. Baseline 
levels above the 95th percentile of control levels (>4.2 &I) were present in 
53% of the patients and were associated with an increased risk of death in the 
placebogroup: (RRz1.89 [1.12-3.201, p=O.Ol). Survival benefitfromSPlR0 
was clustered in those patients with excess mortality related to high baseline 
PIIINP levels: (RR = 0.54 [0.33-0.881, p < 0.02 vs 1.37 [0.78-2.411, p = 0.28 
in low risk patients). Among high risk patients SPIRO nearly suppressed the 
excess death risk related to high PIIINP level. These findings were unchanged 
after adjustment for other prognostic factors (NYHA class, serum creatinine 
and age). 
Conclusion: In patients with CHF, elevated serum PIIINP was significantly 
associated with excess mortality. SPIRO decreased serum PIIINP. It is sug- 
gested that limitation of the excessive extracellular matrix turnover is a major 
determinant of the beneficial effect of SPIRO on survival in patients with CHF. 
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I 863 6 Effect of Vesnarinone on Circulating Cytokine Levels in Patients With Congestive Heart Failure 
Anita Deswal, Nancy J. Petersen, Bill G. White’, Douglas L. Mann. Baylor 
College of Medicine, Houston, TX; ’ C2 R Gaithetsburg, MD, USA 
Background: Vesnarinone (VES) is a positive inotropic drug with phosphodi- 
esterase (PDE)-inhibiting effects, that has been shown to increase mortality 
in patients with heart failure. Experimental studies have suggested that VES 
may inhibit the production of cytokines including tumor necrosis factor (TNF) 
and interleukin-6 (IL-6) in vitro. The effects of VES on cytokine levels in vivo 
are not known. Therefore, the purpose of the study was to determine if VES 
changes circulating levels of cytokines in patients with heart failure. 
Methods: We measured circulating cytokine and cytokine receptor levels 
in 1044 patients with class Ill or IV heart failure enrolled in the Vesnarinone 
Trial (VEST) at baseline and at 24 weeks of follow-up. 
Results: There was no significant difference in TN F IL-6, soluble TNF 
receptors I & 2 and IL-6 soluble receptor levels at baseline and at 24 weeks, 
between patients receiving either placebo (n = 352), 30 mg VES (n = 366) or60 
mg VES (n = 326). Further analysis of the fold change (i.e. ratio) at 24 weeks 
from baseline, in survivors vs. nonsurvivors, revealed that in nonsurvivors 
there was a significant increase in IL-6 levels in the 60 mg VES group as 
compared to placebo (figure). There was however no significant difference in 
TNF or cytokine receptor levels between the placebo and drug groups in this 
analysis. 
peo.05 
Conclusion: Vesnarinone did not appear to significantly inhibit the produc- 
tion of cytokines or cytokine receptors in patients with advanced I hear-f failure. 
However, IL-6 levels increased in the nonsurvivors in the 60 mg VES group. 
Given that PDE inhibitors can raise IL-6 levels (through CAMP), the increased 
IL-6 levels in the nonsurvivors may have predicted a greater PDE-inhibitor 
response in these patients. 
ORAL 
Which Neurohumoral Mediators Really 
Control the Extracellular Matrix and Diastolic 
Function? 
Tuesday, March 14, 2000, 8:30 a.m.-IO:00 a.m. 
Anaheim Convention Center, Room 304A 
8:30 a.m. 
865-i Regulation of Systolic and Diastolic Function by 
Endogenous cGMP in Experimental Heart Failure 
Chari Y. Teramae, Donna M. Meyer, Margaret M. Redfield. Mayo C/inic, 
Rochester, Minnesota, USA 
Background: Heart failure (CHF) is characterized by systolic and diastolic 
dysfunction, ,&adrenergic hyporesponsiveness and activation of myocardial 
nitric oxide (NO) and the natriuretic peptides (NP). ,!I-adrenergic hyporespon- 
siveness is mediated, in part, by NO as NO synthase inhibition enhances 
B-adrenergic responsiveness in CHF. Both NO and the NP activate soluble 
(NO) or particulate (NP) guanylate cyclase and share cGMP as a 2nd mes- 
senger. In vitro studies suggest that cGMP has pro-lusitropic effects, but its 
effects on systolic function are controversial. We hypothesized that if the effect 
of NO on ,S-adrenergic responsiveness is mediated bycGMP, endogenous NP 
would also effect the B-adrenergic response. 
Methods: LV function and response to intravenous dobutamine (DOB: 
1 O-15 ug/kg/min) were assessed during sequential intracoronaty (ic) infusion 
of saline; HS-142-l (NP receptor antagonist) and finally HS-142-l + L-NMMA 
(NO synthase inhibitor) in anesthetized dogs with chronic CHF due to rapid 
pacing (n = 7). 
Results: The ic HS-142-I increased Tau by A = 9.6 f 1.6 ms, p < 0.05. 
Addition of L-NMMA further prolonged Tan by A = 10.1 h 1 .I ms, p < 0.05. 
Neither infusion altered load. HS-142-I had no effect on the inotropic response 
to DOB, but addition of L-NMMA enhanced the response (figure; **p < 0.01, 
***p i 0.001). 
Conclusion: In CHF, endogenous NP and NO provide pro-lusitropic ac- 
tions, likely mediated by their shared 2nd messenger cGMP. Disparate effects 
of NP and NO antagonism on B-adrenergic responsiveness support previous 
in vitro studies which suggest that NO may also alter myocardial function via 
cGMP-independent mechanisms. These findings have clinical importance in 
regards to NP and NO-targeted therapy for CHF. 
8:45 a.m. 
Left Ventricular End Diastolic Wall Stress and 
Endomyocardial Inducible Nitric Oxide Synthase 
Gene Expression in Human Dilated Cardiomyopathy 
Christopher J. Zeitz, Jean G.F. Bronzwaer, Christophe Heymes, 
Marc Vanderheyden, Walter J. Paulus. Cardiovascular Center, OLV 
Ziekenhuis, Aalst and University Hospital VU, Amsterdam, The Netherlands 
Patients with non-ischemic dilated cardiomyopathy (DCM) have altered en- 
domyocardial expression of nitric oxide synthase (NOS), as evident from in- 
duction of the calcium insensitive NOS isoform (iNOS). In experimental car- 
diac preparations, an elevation of LV diastolic wall stress reduces cytokine 
and iNOS gene expression. We investigated the relationship between LV 
end diastolic circumferential wall stress (EDWS) and iNOS expression in 29 
patients with DCM, with respect to their hemodynamic status, All patients 
underwent hemodynamic evaluation with LV microtip pressure recording, 
LV angiography, LV endomyocardial biopsy and echocardiographic LV wall 
thickness measurement. The iNOS mRNA was determined by quantitative 
reverse transcriptase polymerase chain reaction and expressed relative to 
EDWS. 
Results: 
Grouu A GrouD B Grouo C 
LVEF 36iZ 29zk3 
LV Stroke Work 136f14 98 zk Q* 
LVEDP 14h2 26 + 2* 
LV Compliance 37&18 7* 1* 
LV end systolic Vol 161 5 12 19Oh 15 
*p < 0.05 vs Group A; tp < 0.05 vs Group B 
13*3-t 
44 i a*t 
27 zk 3% 
5* 1” 
329 zk 63*t 
The iNOS/EDWS ratio was strongly correlated with LVEF (r = 0.47, p = 
O.Ol), LV stroke work (r = 0.41, p = 0.03) and LV compliance (r = 0.9, p < 
O.OOOl), and was negatively correlated with LVEDP (r = -0.6, p = 0.0006), 
LV minimum pressure (r = -0.47, p = O.Ol), pulmonary wedge pressure (r = 
-0.51, p = 0.004) and heart rate (r = -0.51, p = 0.0008). 
Conclusions: In patients with DCM, a high level of iNOS expression, 
relative to EDWS, is closely associated with superior hemodynamic status. 
9:00 a.m. 
EII 865 3 Endothelin-1 Increases Diastolic Distensibility of Human and Non-Human Myocardium in Conditions 
of Cardiac Overload 
A.F. Leite-Moreira’s*. A. Rocha-Sousa’ , C. Bras-Silva’ , C.A. Pedrosa’ , 
P. Pinho*, J. Pinheiro-Torresz, P. Bastoss. ‘Departments of Physiology; 
‘Cardio-Thoracic Surgery: Faculty of Medicine, University Hospital 90 Joso, 
Porto, Portugal 
Background: Endothelin-I (ET-I) has vasoconstrictor, growth promoting and 
positive inotropic properties, with increased plasma levels in heat-f failure. 
This study investigated the less well-known effects of ET-l on the diastolic 
properties of the myocardium. 
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Methods: The effects of ET-I (0.1, 1, IO nM) were tested in right atrial 
muscle strips (n = 7) from patients undergoing CABG surgery and in isolated 
rabbit papillary muscles (n = 14) (Krebs-Ringer; 1.25 mM Ca2+; 35°C). The 
papillary muscles were studied in the absence (n = 9) and in the presence 
(n = 5) of a nonselective endothelin ET us receptor antagonist, PD145065. 
Isotonic, afterloaded-isotonic and isometric twitches were recorded and ana- 
lyzed. Parameters for isometric contractions included: resting tension at the 
beginning (RT& and at the end (RT,,d) of the twitch, active tension (AT), 
peak rates of tension development (+dT/dt) and tension decline (-dT/dt), and 
time to half relaxation (tHR). Only significant results (mean & SE, p .Z 0.05) 
are given, expressed as A % baseline. 
Results: The figure shows four superposed isometric twitches of a rep- 
resentative papillary muscle. In papillary muscles, ET-I (10 nM) induced an 
increase of AT (147 i 33%), +dT/dt (154 f 39%) and -dT/dt (145 rt 38%). 
When compared to control and to RT beg, RTend decreased by 8 i 3% (0.1 nM), 
11 i 3% (1 nM) and 19 f 3% (10 nM). This effect was enhanced by afterload, 
being maximum in the isometric twitches. It showed no significant relation 
with AT. The analysis of atrial strips contractions yielded similar results. All the 
effects of ET-1 were abolished by PD145065. 
Conclusions: ET-I has a novel effect on the diastolic properties of the 
myocardium. It decreases resting tension, or conversely increases myocar- 
dial distensibility, when afterload is elevated. It is, therefore, tempting to sug- 
gest that ET-1 might contribute to cardiac dilatation when cardiac overload is 
present (e.g. in heart failure). 
9:15 a.m. 
865-4 Calcineurin Plays a Key Role in Development of 
Diastolic Heart Failure With Preserved Systolic 
Function in Hypertensive Rats 
Yasushi Sakata, Tohru Masuyama, Kazuhiro Yamamoto, Hiroya Kondo, 
Nagahiro Nishikawa, Keiko Ono, Tsunehiko Kuzuya, Takeshi Miwa, 
Masatsugu Hori. Osaka Univ. Graduate School of Medicine, Suita, Japan 
Background: It remains unclear how diastolic heart failure with preserved 
systolic function (DHF) develops in hypertension. We studied whether cal- 
cineurin is involved in the development of DHF by hemodynamic and patho- 
logic observation of hypertensive rats with and without chronic administration 
of calcineurin inhibitor (FK506: 1 mg/kg/day). 
Methods: Sixteen Dahl salt sensitive rats were placed on 8% NaCl diet 
from 7 wks old. FK were given from 8 wks in 8 rats (group FK(c)), and placebo 
were given in 8 rats (group FK(-)). Rats fed on 0.3% NaCl diet were defined 
as control rats (group N, n = 6). Systolic blood pressure (sBP), LV end-diastolic 
pressure (EDP), LV midwall fractional shortening (MFS), time constant (Tau), 
LV mass/body weight (LVMI) and LV hydroxyproline content (Pro-OH) were 
measured at 19 wks. 
Results: 
Group SSP LVEDP MFS Tall LVMI Pro-OH 
@mHg) (mmHg) (“4 (msec) mm (i.Lmollg) 
N 149+3 811 14il 23 * 2 2.2 f 0.1 2.0 * 0.2 
W-I 225 i 2* 14+2* 1611 3012” 3.8iO.l’ 4.0 i 0.2’ 
W+) 219*5* 6%l*t 16&i 24i1t 3.2 & O.l*t 3.7 * 0.2* 
Data are expressed as mean value f SEM (*p < 0.05 YS N tp < 0.05 vs FK(-)) 
FK506 administration shortened Tau and prevented the elevation of LVEDP 
in FK(-) without changes in sBP and MFS. In FK(+), LV hypertrophy was sig- 
nificantly milder than in FK(-), but LV fibrosis was not restrained by FK506 
administration. 
Conclusions: Administration of calcineurin inhibitor attenuated LV hyper- 
trophy and prevented the transition to DHF without any effect on LV fibrosis in 
hypertensinve rats. Calcineurin may play an important role in the development 
of DHF, mainly contributing to the development of LV hypetirophy rather than 
fibrosis. 
9:30 a.m. 
865-5 Phenotype Shift of Collagen Production and 
Enhanced Inhibition of its Degradation Contribute to 
Development of Diastolic Heart Failure in 
Hypertensive Rats 
Nagahiro Nishikawa, Tohru Masuyama, Kazuhiro Yamamoto, Hiroya Kondo, 
Yasushi Sakata, Keiko Ono, Tsunehiko Kuzuya, Takeshi Miwa, 
Masatsugu Hori. Osaka University: S&a, Japan 
Background: Structure of LV extracellular matrix is maintained by the regula- 
tion of both production and degradation of collagen (Col). Although increased 
collagen content is a well-established finding of failing hearts, its regulation is 
still unclear. Alteration in the regulation was investigated in hypertensive rats 
in which diastolic heart failure (DHF) developed following LV hypettrophy. 
Methods: Dahl salt sensitive rats were placed on 8% NaCl diet from 7 wks 
old (group DHF, n = 7) or on 0.3% NaCl diet as control rats (group N, n = 5). 
Hydroxyproline content (Pro-OH in or. mol/g) and mRNAof Col-I, Col-Ill, matrix 
metalloproteinase (MMP)-I, MMP-2 and tissue inhibitor of metalloproteinase 
(TIMP)-1 were quantified in the LV specimen at 19 wks old. 
Results: 
Pro-OH Cd-l COI-Ill MMP-1 MMP-2 TIMP-1 
N 2.3 h 0.3 1.0 * 0.1 1.0 + 0.1 l.OfO.l 1.1 * 0.1 1 .o i 0.2 
DHF 4.0 * 0.3* 4.7 i 0.5* 2.1 * 0.5 3.7 i 0.3* 2.5 zk 0.5” 5.8 f 0.7* 
Data are presented as mean i SEM (*p < 0.05 vs control) 
Collagen l/Ill ratio was higher in DHF rats than in control rats (1 .O f 0.1 vs 
2.3 i 0.2, p < O.Ol), indicating a shift in the ratio between Col-I and Col-Ill. 
Expression of both MMPs and TlMPs was greater in DHF rats than in control 
rats, but the enhancement was more evident for TlMPs than for MMPs. 
Conclusions: increased LV fibrosis in DHF rats is caused not only by the 
activation of collagen production but also bythe activated inhibition of collagen 
degradation. Besides increased fibrosis, phenotype shift from Col-Ill to Col-I 
may relate to stiffening of the myocardium and hence to the transition to DHF. 
9:45 a.m. 
I 865 6 Ticlopidine Stabilizes the Cardiac Extracellular 
Matrix. Evidence for a Cyclooxygenase-Mediated 
Effect 
Andreas V. Sigel, Chang-Fu Peng, Eckhard P. Kromer, Gunter A.J. Riegger. 
Khik und Poliklinik fur lnnere Medizin II, Universitat Regensburg, Germany 
Background: Ticlopidine serves as an important tool to prevent subacute 
stent thrombosis via inhibition of platelet aggregation. In addition, ticlopidine 
may affect proliferation andcollagen synthesis in cardiacfibroblasts, the cellu- 
lar source for the cardiac extracellular matrix. However, the underlying mech- 
anisms, which are responsible for these effects, are yet unknown. 
Methods: We, therefore, treated subconfluent rabbit cardiac fibroblasts 
with transforming growth factor beta 1 (TGF-,f?,), the major stimulus for colla- 
gen production in the heart, in the presence of therapeutical concentrations of 
ticlopidine (50 PM) and the cyclooxygenase-inhibitor indomethacine (50 PM). 
Results: Ticlopidine significanty increased prostaglandin E2 (PGEz) pro- 
duction by 20% (p < 0.05) but decreased proliferation (-25%, p < 0.05), 
DNA synthesis (-68%, p < 0.05) and protein synthesis (-37%, p < 0.05). In 
addition, immuno blot analysis, immunofluorescence and northern hybridiza- 
tion revealed a decrease in TGF-/$-induced collagen types I and Ill protein 
and mRNA expression by more than 30% (p < 0.05%) in ticlopidine treated 
cells. Finally, the effects of ticlopidine were blocked when fibroblasts were 
pretreated with 50 PM indomethacin. 
Conclusion: We, therefore, conclude that ticlopidine significantly inhibits 
cardiac fibroblast proliferation and collagen types I and Ill production in vitro. 
The effects of ticlopidine on PGE? production on one hand and the effects of 
PGE2 and indomethacin on collagen production on the other, may indicate 
an involvement of the cyclooxygenase pathway. Finally, given the fact that 
collagen type I represents the major extracellular matrix protein in the heart, 
ticlopidine may represent a powerful tool to prevent extracellular remodeling 
in vivo. 
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I 1137 142 Beneficial Effect of Spironolactone on Brain 
Natriuretic Peptide in Severe Congestive Heart 
Failure 
Michel F. Rousseau, Daniel Duprez, Walter Van Mieghem, Annie Robert, 
Franpois Van Linden, Sylvie Ahn, Jean Marie Ketelslegers. For the Belgian 
RALES Investigators, University of Louvain, Brussels, Belgium 
Background: In the RALES Trial, Spironolactone (S), an aldosterone-recep- 
tor blocker, decreased mortality in severe congestive heart failure (CHF). 
Methods: To clarify the mechanism of action in a subset of 107 pts (NYHA 
Ill-IV, mean ejection fraction 25%), the effect of S (25 mg daily) on the plasma 
concentration of brain natriuretic peptide (BNP), a neurohormonal marker of 
left ventricular (LV) function, was assessed at entry (TO) into study, at 3 months 
(T3) and at 6 months (T6) and the changes compared to the placebo (P) group. 
Results: Fesults were expressed in pg/mL-’ , geometric mean [95% Cl] 
and data were compared using a Mann-Whithney-Wilcoxon test. 
Placebo (n = 53) 
TO 
Spironolactone (n = 54) 
74 164-851 
p value 
67 159-761 0.33 
T3 68 i49-78j 52 [45-61 j 0.02 
T6 64 154-761 52 144-611 0.09 
Moreover, BNP changes from TO expressed by the ratios T3TTO and TGITO 
evidenced overtime, compared to the P group, a significant reduction of BNP 
concentration in the S group (0.99 vs 0.77, p = 0.004 and 0.96 vs 0.77, p = 
0.05, respectively). 
In conclusion, S decreases significantly the plasma levels of BNP reflect- 
ing the beneficial effect of S on the left ventricular remodeling through the 
reduction of myocardial stretching. This neurohormonal cardioprotection con- 
tributes to limit the progression of the disease and to explain the decreased 
mortality and hospitalizations observed with S in severe CHF. 
1 1137-i 43 1 Acute and Long-Term Haemodynamic and 
Neurohormonal Effects of Candesartan Cilexitil 
in Patients With Congestive Heart Failure 
Veselin Mitrovic. Kerkhoff-Klinik der Max-Planck Gesellschaft, Bad Nauheim, 
Germany 
Background: Candesattan cilexetil (CC) is an AT, receptor antagonist that 
produces dose dependant increases in exercise time and improvement of 
symptoms in congestive heart failure (CHF) patients. The present study in- 
vestigates haemodynamic, symptomatic and neurohormonal effects (PRA, 
angiotensin II, aldosterone, ANF, catecholamines) of four dose levels of CC 
versus placebo in patients with impaired left ventricular function (EF 40%, 
PCWP 13 mmHg, NYHA Class ll/lll). 
Methods: In a double-blind study, 218 patients were randomised after 2 
weeks of placebo run-in to placebo (n = 44) or CC 2 mg (n = 45), 4 mg (n = 
46), 8 mg (n = 39) or 16 mg (n = 44) once daily for 12 weeks. Haemodynamic 
measurements over 24 hrs were performed by right heart catheterisation with 
thermodilution technique after single and multiple doses. 
Results: Preliminary results demonstrate single and multiple doses of CC 
resulted in sustained, statistically significant and dose-dependant reductions 
in PCWP (primary parameter), PAP mean and SVR (regression analysis). How- 
ever, no consistent changes in Cl were apparent after single or multiple doses 
of CC or placebo. Significant decreases in aldosterone and ANF, as well as 
compensatory increases in PRA and angiotensin II were dose-dependent. 
There were also, statistically significant differences for CC versus placebo for 
CHF symptom scores (visual analogue scale) in categories “breathlessness” 
and “fatigue”. CC was well tolerated up to a dose of 16 mg once daily with no 
excess versus placebo nor dose dependency for serious adverse events. 
Conclusion: Haemodynamic, symptomtitic and neurohormonal effects 
in the present study demonstrated a consistent beneficial, dose-dependant 
effect of CC in CHF patients. 
I 1137 144 Plasma Atrial Natriuretic Peptide, Cyclic Guanosine Monophosphate, and Endothelin 
Response to Omapatrilat in Heart Failure 
John B. Kostis, Marc Klapholz, Ole Vesterqvist, Carol L. Delaney, 
Wei-chi Liao. UMDNJ-Robert Wood Johnson Medical School and New 
Jersey Medical School, New Brunswickand Newark, New Jersey; 
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New 
Jersey USA 
Background: Plasma levels of atrial natriuretic peptide (ANP), cyclic guano- 
sine monophosphate (cGMP), and endothelin are increased in patients with 
severe congestive heat-l failure. Omapatrilat, a novel vasopeptidase inhibitor 
(VPI), simultaneously inhibits neutral endopeptidase and angiotensin convert- 
ing enzyme (ACE). Effects of omapatrilat on ANP, cGMP, and endothelin were 
examined in patients with mild/moderate congestive heat-l failure. 
Methods: Fifteen New York Heart Association class ll/lll heart failure pa- 
tients (mean f SD left ventricular ejection fraction [LVEF] 23 f 10%) and 12 
controls (LVEF 61 f 6%) received a single oral dose of omapatrilat 25 mg 
after a i-month washout period from ACE inhibitors. Plasma concentrations 
of ANP, cGMP, endothelin-l&2 (ENDO) and ACE activity were measured at 
baseline and 4 hours after dose. Data (mean f SD) are presented. 
Results: Plasma ANP and cGMP concentrations increased and ACE ac- 
tivity decreased after omapatrilat dose in both heart failure and control pa- 
tients; plasma END0 concentration did not change (see table). 
Baseline After dose 
Heart-failure Control Heart-failure Control 
ANP (pg/mL) 107.3f70.0 61.6*25.5 130.3zk84.9 78.1 141.7 
cGMP (nmol/L) 14.7* 11.1 8.5 f 2.4 18.9 f 13.6 11.2i3.8 
END0 (pmol/L) 0.6 zt 0.4 0.6 zk 0.5 0.6 f 0.3 0.7 f 0.5 
ACE activity 7.8 i 3.5 7.2 + 1.7 0.5 i 0.4 0.4 * 0.3 
(% substrate hydrolyzedimin) 
Conclusion: Omapatrilat increased the vasodilator ANP and its second 
messenger, cGMP, by 20% and 30%, respectively, reflecting vasopeptidase 
inhibition. Omapatrilat did not affect levels of the vasoconstrictor endothelin in 
normals or mild to moderate heart failure patients. 
I 1137 145 Combination Therapy With Metoprolol and Felodipine in Comparison to Metoprolol Alone 
on Top of the Standard Medication in Severe 
Dilated Cardiomyopathy - A Randomized, 
Double Blind and Placebo Controlled Study 
Frank Edelmann, Markus Knapp, Gregor Simonis, Martin Braun, 
Carsten Schwencke, Christof Weinbrenner, Matthias Borst, Ruth H. Strasser. 
Department of Cardiology: University of Heidelberg, Germany 
Background: Long term B-blocker therapy with drugs such as Metoprolol has 
been shown to improve hemodynamics and survival in patients with CHF. In 
contrast, only a few calcium antagonists such as the high vascular selective 
agent Felodipine promoted benefitial effects in chronic therapy of CHF. How- 
ever with these drugs a slight reflectory sympathetic activation might impair 
their efficiency in long term treatment. To evaluate if a combination of Meto- 
prolol with Felodipine might improve the hemodynamic response the following 
study was designed: ’ 
Methods: 44 patients (dCMP, LVEF < 40%), stable on standard medica- 
tion (digitalis, diuretics, ACE-l), were prospectivly treated in a randomized, 
double blind an placebo controlled study with Metoprolol (up to 100 mg/d) 
combined with Felodipine (up to IO mg/d), MF n = 15 or with Metoprolol 
and Placebo, MP n = 16, the third group was on double Placebo, PP n = 
13. At baseline and after six months echocardiography and exercise testing 
was performed. Exercise hemodynamics were evaluated using right heart 
catheterization (supine bicycle ergometry) and maximal oxygen uptake was 
measured during treadmill exercise. 
Results: The EF increased after 6 months significantly (p < 0.05) only in 
the MP group (27% to 36%), the other groups showed only minor changes. 
Hemodynamics at rest and during exercise were significantly improved only 
under MP therapy (Clrest +21%, Clmax +13%, SVlrest +40%, SVlmax +44%, 
PAPrest -32%, PAPmax -25%), but not in the MP and PP group. In treadmill 
exercise after 6 months the peak oxygen uptake and the exercise duration 
were significantly increased only under Metoprolol, but not in the MF and the 
PP group. 
Conclusion: A marked improvement of resting and exercise variables oc- 
curred only under Metoprolol. Furthermore, the beneficial effects are blunted 
by the addition of Felodipine. These data suggest that a combined therapy 
with B-blockers and calcium antagonists is not advantageous in CHF. 
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/ 1137-I 48 / Tolerability and Side-Effect Profile of 
Beta-Blockers in Patients With Heart Failure: 
Differences Between Clinical Trial and Practice 
Setting 
Ghazzanfar Khadim, Javed Butler, Don 6. Chomsky, John R. Wilson. 
Vanderbilt Universifl: Nashville, TN, USA 
Background: Recent trials have shown a survival benefit with beta blockers 
(BB) in patients with heart failure (HF). These trials included a select group of 
patients and BB were well tolerated. Side effects profile in general population 
of HF patients remains unknown. The purpose of the current study was to 
assess the side effect profile and discontinuation rate of BB and compare 
it with ciinicai trials, and compare the side effects profile of metoprolol with 
carvediloi. 
Methods: Ail patients with HF and ejection fraction of 540% started on BB 
during 6/98 to 12/98 were included in the study. A total of 150 encounters with 
BB on 107 patients were studied. 
Results: The mean age of the study population was 54 f 11 yr., with 
predominantly class 11-111 symptoms. Mean EF was 24 i 8%. 
Side Effect VUMC 
ma) 
Carvedilol 
Studv i%) 
Side Effects VUMC 
(%) 
Carvedilol 
Studv (%) 
Commonest Side Effects 
Wt Gain 65 10 Fatiaue 61 25 
Drzziness 35 33 D)&G!Cl 
Hypotension 22 09 Hyperglycemia 
Bradycardia 17 09 Impotence 
Commonest Side Effects Leading to Discontinuation 
Fatigue 8 0.7 Hypotension 
Worse HF 2.7 1.6 Bradvcardia 
27 22 
22 13 
5 Unknown 
5.5 0.3 
2.7 0.9 
Patients on metoprolol were more likely to complain of impotence and 
those on carvedilol had more frequent hypotension, nausea and diarrhea. 
Discontinuation rate for any BB was 26.6% as compared to 5.7% in the US 
Carvedilol Study. Carvedilol was discontinued in 34% as compared to 20% 
for metoprolol. All 40 patients intolerant to one BB were switched to another 
and 33 of these were able to tolerate the change. Therefore, overall rate of 
intolerance leading to discontinuation to either of the BB was only 4%. 
Conclusion: Side effects and discontinuation rate with BB therapy in a 
general population of patients with HF is much higher then that reported in the 
clinical trials. However, with appropriate adjustment of BB and other medica- 
tion dosages, trial with different BB and a close follow-up, most patients can 
eventually tolerate BB therapy. 
i-i 1137 147 Bucindolol Has No intrinsic Sympathomimetic Activity (ISA) in Nonfailing Human Ventricular 
Preparations 
J. Sederberg, SE. Wichman, J. Lindenfeld, E. Wolfel, B. Lowes, S. Shakar, 
Ft. Roden, MR. Bristow. UnivColomdo HSC, Denver, CO80262. USA 
Based on data derived from 24 hour Holter-monitored heart rates, hemody- 
namic effects, adenylyl cyclase (AC) stimulation in membrane preparations 
and muscle contraction data in isolated tissue preparations we have previ- 
ously reported that the 3rd generation, low inverse agonist B-blocker bucin- 
dolol (B) has no ISA in failing human hearts. Because B has weak ISA in 
some animal models and because this compound is in clinical development 
for heart failure we have extended the isolated tissue studies to nonfailing 
human hearts. Isolated right ventricular (RV) trabeculae of uniform size were 
dissected free and mounted in 14-16 individual tissue baths at 36” C. Prepa- 
rations were paced at 1 Hz, and preload was adjusted to 75% of Lmax. In 
order to detect weak ISA, preparations were preincubated with the AC cat- 
alytic activator forskolin (F) for 15-20 min at a concentration of 10m6 or 3 x 
10-s M. Dose-response curves to B or the partial agonist xamoterol (X) were 
performed in F pretreated trabeculae and compared to trabeculae given F+ 
vehicle. Responses to B, X, and isoproterenol in the absence of F were also 
determined. RVs were divided into those that gave a high (2800 mg) or low 
maximum tension response to isoproterenol (ISO). The High IS0 group in- 
cluded 3 nonfailing organ donor hearts and 2 RVs from transplant recipients 
who had relatively well preserved RVfunction. Results are in mg f SEM. *, p 
< 0.05 vs. Low ISO. #, p < 0.05 vs. F alone. 
Group IS0 X B X+F B+F 
High IS0 (n = 5) '1213f 117 101 i 108 35 i 177 *e?97 + 96 74 It 70 
LOW IS0 In = 81 309 * 55 -10119 -41 + 47 52 zt 42 29 i 48 
/ . 1137 148 Baseline Clinical Parameters Do Not Predict Left Ventricular Ejection Fraction Improvement 
Following Carvedilol Therapy in Heart Failure 
W.H. Wilson Tang, Umesh N. Khot, Mary S. Larson, Lisa Prikazsky, Bob 
S. Hu, John L. Tan, Michael B. Fowler. Stanford Universify, Stanford, 
California, USA 
Background: Left ventricular ejection fraction (LVEF) may serve as a marker 
for the benefits seen in large populations treated with B-blockers with improve- 
ments in sutvival and decreased risk of hospitalization. We examined the im- 
provement in LVEF following carvedilol therapy in 266 patients treated for a 
mean follow-up of 1.7 years (range 0.8-5 years) in order to evaluate predic- 
tors of LVEF improvement following ~carvedilol therapy. We were particularly 
interested to determine whether an especially low LVEF (~20%) predicted a 
lack of subsequent response or intolerance to carvedilol. 
Methods: 235 of the 266 patients had serial echocardiographic data be- 
fore and after carvedilol therapy. Patients were divided into 2 groups based on 
their LVEF response to carvedilol (~8% versus >8% units). Various clinical 
parameters were compared using t- and chi-square statistics to determine of 
they predictLVEF improvement following carvedilol therapy. 
Results: Overall, 31 patients (12%) did not complete or did not tolerate 
carvedilol therapy. Among the 235 patients remaining, 122 (52%) had signifi- 
cant response to carvedilol therapy (LVEF improvement ? 8% units). Overall, 
the mean baseline LVEF was 25 rt 8% (range g-45%). Neither baseline LVEF, 
heart rate, blood pressure, left ventricular end-diastolic dimensions or degree 
of mitral regurgitation predicted responders or intolerance to carvedilol ther- 
apy. 
Conclusions: LVEF improvement (a possible surrogate for the clinical re- 
sponse) or tolerance to carvedilol therapy could not be predicted by simple 
baseline variables such as LVEF, heart rate, blood pressure, left ventricular 
end-diastolic dimensions or degree of mitral regurgitation. More sophisticated 
parameters are necessary to predict which patient will have LVEF improve- 
ment with carvedilol therapy. 
/ 1137 149 Vitamin C Increases Baroreflex Sensitivity in Chronic Heart Failure but has No Effect on 
Arterial Stiffness 
Angus K. Nightingale, Daniel J. Blackman, Catherine Mumford, Jayne 
A. Morris-Thurgood, Gethin R. Ellis, John R. Cockroft, Michael P. Frenneaux. 
Wales Heart Research Insfitute, Car-M, UK 
Background: Baroreflex sensitivity (BRS) is impaired in patients with chronic 
heart failure (CHF) and is a strong predictor of cardiac death. We hypothesised 
that vitamin C (VC) would acutely improve BRS in patients with CHF via 
decreased arterial stiffness. 
Methods: 21 CHF patients were studied. A venous cannula was inserted 
and 20 mls of saline injected. After 30 min patients were randomised to re- 
ceive either a second bolus of saline or 20 ml VC (2 g). BRS and arterial 
stiffness were measured after each intervention. BRS was assessed from the 
ECG and BP (Finapres) using spontaneous sequence analysis. Arterial stiff- 
ness was assessed using the SphygmoCor (PWV Medical) system to give 
augmentation index (Alx). 
Results: (Data expressed as mean + SEM). Both groups had similar 
BRS (7.7 & 0.8 ~5.6 rt 1.2 ms/mmHg) and Alx (17.6 i 2.8 ~13.0 f 6.8%) 
at baseline. BRS significantly improved in those patients who received VC 
compared to saline (A BRS 2.4 f 0.7 v -0.3 i 0.9 ms/mmHg, p = 0.02). 
There was no significant change in Alx from baseline in either group (A Alx 
2.9i0.6~1.6f1.2%,p=0.9). 
Conclusion: We show a significant improvement in BRS after an intra- 
venous bolus of VC in patients with CHF. VC has been shown to improve 
endothelial function both acutely and chronically in heart failure. Despite this 
we did not demonstrate any measurable change in arterial stiffness. It is pos- 
sible that VC has its beneficial effec? through the direct action of a reduction 
in free radicals on baroreceptor nerve endings, This is supported by a recent 
study in an animal model showing that free radicals may inhibit baroreceptor 
firing. This result raises the possibility of a novel therapy to reduce cardiac 
death in CHF. 
Conclusions: 1) As we and others have previously reported, F can en- 
hance the efficacy of partial agonists in preparations of human ventricular my- 
ocardium; 2) with F preincubation X has an intrinsic activity of 24%, detectable 
against the F+ vehicle control only in High ISO; 3) B has no detectable ISA in 
High IS0 or Low IS0 RVs. 
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1_1 1138 151 Screening for Hypertrophic Cardiomyopathy in a Young Male Military Population 
Stefano Nistri, Gaetano Thiene, Cristina Basso, Domenico Corrado, 
Antonio Vitolo, Roldano Scognamiglio, Barry J. Maron. University of Padova, 
Padova, Da/v; Minneapolis Heart Institute Foundation, Minneapolis, MN, USA 
Background: Hypertrophic cardiomyopathy (HCM) is an important cause of 
sudden death in young people. Identification of HCM during athletic screening 
and disqualification from sports can prevent sudden death. 
Methods: Military duty in Italy is compulsory and males 2 17 yrs undergo 
screening, including 12-lead ECG; echocardiography is performed if clinical 
findings are positive. This study evaluates prevalence of the HCM phenotype 
by echo in a large cohort of healthy male conscripts examined at Military 
Hospital (Verona), 1992-96. HCM was identified by maximal left ventricular 
(LV) wall thickness 2 15 mm, in absence of cavity enlargement. 
Results: Of 9264 conscripts, 2698 (29%) were referred for echo because 
of positive initial screening. Nineteen conscripts (age 19 !I 2 yrs) showed 
definitive echo evidence of HCM, for a prevalence of 0.2%. In 13/i 9 conscripts, 
HCM was diagnosed during military screening (8 by abnormal ECG). In 6/19, 
HCM had been previously diagnosed, including 5 during athletic screening; 2 
had mild symptoms and 17 had none. LV thickness was 21 f 5 mm (range 
15-35): hypertrophy was localized to 1 LV segment in 11 and diffuse in only 3. 
All subjects were without outflow gradients. 
Conclusion: Cardiovascular screening of a large male military popula- 
tion showed prevalence of phenotypic (echocardiographic) HCM to be 0.2%, 
similar to reports in other general populations. Large screening programs rep- 
resent an effective means of detecting HCM using 12-lead ECG as a primary 
test. 
j 1138-153 1 Preclinical Diabetic Cardiomyopathy: 
Association Between Asymptomatic Left 
Ventricular Diastolic Dysfunction and 
Sub-Clinical Cardiac Autonomic Neuropathy in 
Men With Type 2 Diabetes 
Paul Poirier, Caroline Garneau, Peter Bogaty, Claudette Fortin, 
Louise Marois, Franpois Philippon, Jean-Gaston Dumesnil. Quebec Heart 
Institute, Quebec CirY, Quebec, Canada 
Background: Previous studies suggests that left ventricular diastolic dys- 
function (LVDD) and cardiac autonomic neuropathy (CAN) may be early sub- 
clinical manifestations of diabetic cardiomyopathy. 
Methods: We studied 3 groups of age-matched men with type 2 diabetes. 
These groups were defined as subjects with normal diastolic function (n = IO), 
subjects with impaired relaxation (n = IO) and subjects with a pseudonormal- 
ized pattern of ventricular filling (n = IO). None had evidence of clinical diabetic 
complications, coronary artery disease, hypertension, congestive heart fail- 
ure, thyroid or overt renal disease and a negative treadmill maximal exercise 
test. Diastolic function was evaluated by standardized Doppler echocardio- 
graphy criteria and CAN was evaluated using spectral analysis of heart rate 
variability (time and frequency domains) from 24-hr Holter recording. 
Results: Glycated hemoglobin levels were within normal limits among 
groups. High frequency (0.15-0.4 Hz) decreased as the diastolic function 
worsened (p 2 0.03); 5.0 f 0.2 ms* in controls, 4.2 f 0.3 ms2 in subjects 
with impaired relaxation and 3.9 f 0.4 ms2 (mean + SE) in subjects with a 
pseudonormalized pattern of ventricular filling and was decreased in subjects 
with a pseudonormalized pattern of ventricular filling compared to controls (p 
< 0.03). Low frequency (0.04-0.15 Hz) was comparable among groups. In 
the time domain, rMSDD also showed the same phenomenon; 31.0 i 2.8 
ms, 23.8 f 1.6 ms and 21.5 & 2.9 ms, respectively. Controls were different 
compared to subjects with a pseudonormalized pattern of ventricular filling (p 
< 0.03). 
Conclusion: These results suggest an association between degree of left 
ventricular diastolic dysfunction and cardiac dysautonomy in subjects with 
well-controlled normotensive type 2 diabetes free of clinically overt heart 
disease. Although the pathophysiological link remains to be elucidated, left 
ventricular diastolic dysfunction might represent an expression of subclinical 
cardiac dysautonomy in this population. 
1138-I 52 Haemochromatosis Gene Mutations in Idiopathic 
Dilated Cardiomyopathy 
Niall G. Mahon, Aman S. Coonar, Stephen Jeffery, Fabio Coccolo, 
Richard Houlston, Julius Akiyu, Behnam Zal, Christina Baboonian, William 
J. McKenna. Sf George’s Hospital Medical School, London, UK 
Background: Recently 2 mutations [i. a substitution of cysteine for tyrosine 
at amino acid 282 of the gene product (C282Y) and ii. of histidine for aspar- 
tate at amino acid 63 (H63D)] have been identified in the hemochromatosis 
(HH) gene. Since cardiomyopathy is a feature of HH, the frequency of these 
mutations in idiopathic dilated cardiomyopathy (DCM) was determined. 
Methods: Two hundred seven unrelated Caucasian patients with DCM 
and 200 controls were tested for C282Y and H63D mutations. 
Results: 31/207 (15%) DCM v 24/200 (12%) controls carried C282Y 
[ORI .2 (0.7-2.2)], 74/207 (36%) v53/200 (27%) carried H63D [ORI .6 (1 .I-2.5) 
and IO/207 (4.8%) v4/200 (2%) were compound heterozygotes (CH) [OR2.6 
(0.8-8.5)]. Four DCM and 6 controls were H63D homozygous and 1 DCM 
was C282Y homozygous. There was a progressive increase in mean serum 
iron[Fe] and transferrin saturations (TS) from patients with no mutation ([Fe] = 
16.3 mmol/l, TS = 23.7%) through H63D heterozygotes (17.5 mmol/l, 25.8%), 
C282Y heterozygotes (17.1 mmol/l, 26.6%), H63D homozygotes (20.0 mmol/l, 
33.5%), CH (26.8 mmol/l, 41.7%) and C282Y homozygotes (34 mmol/l, 71%). 
At follow-up (median 90 months) the rate of death or cardiac transplanta- 
tion was 52/207 (25%). C282Y heterozygotes had less ventricular dilatation 
[59.9 (fl.7) mm v64.9 (f0.9) mm, p < 0.051, better fractional shortening 124 
(fl.7)% ~18.8 (*I .4)%, p 4 O.Oi] and a trend towards improved survival free 
from death or transplantation. [Fe] and TS did not correlate with severity of 
disease and were not associated with reduced survival. 
Conclusion: 1. The frequency of HH mutations is significantly increased 
in patients with idiopathic DCM. 2. Although C282Y and H63D increase iron 
levels and transferrin saturations additively, there is no clear relation between 
iron levels and disease severity or progression. 3. The presence of C282Y is 
associated with clinically milder disease and a trend towards better survival. 
l---L-l 1138 154 Morphologic and Hemodynamic 
Characterization of Cardiac Involvement in the 
ALA-60 Genotype of Familial Amyloidosis by 2-D 
and Doppler Echocardiography: Poor Prognosis 
in Advanced Disease 
Nalini M. Rajamannan, Lyle J. Olson, David A. Foley, Kent R. Bailey, Lynn 
A. Urban, Morie A. Gertz, A. Jamil Tajik, James 6. Seward. Mayo C/ink, 
Rochester, Minnesota, USA 
Background: Familial amyloidosis (AF) is a heritable disorder of abnormal 
transthyretin production and the most rare cause of systemic amyloidosis in 
North America. Unlike primary systemic amyloidosis (AL) which is caused by 
overproductionof monoclonal immunoglobulin, echocardiographicfeatures of 
AF have not been well characterized. We describe 2-D and Doppler echocar- 
diographicfindings and survival in 16ALA-60 genotype AF patients diagnosed 
at our institution between 1985-1997. 
Methods: All ALA-60 AF patients who underwent echocardiography were 
identified from a registry of over 2000 patients with systemic amyloidosis. 
Echocardiography was performed within 2 months of diagnosis. Patient age, 
gender, genotype, echocardiographic data and survival were analyzed. 
Echo findings 
Median Range 
Ejection fraction 51 33-52 
Posterior wall thickness 15 11-25 
Septal wall thickness 18 11-21 
End diastolic dimension 45 33-52 
Deceleration time 157 120-330 
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Results: Patient age ranged from 55-82 years (mean 66 years); there 
were 13 man and 3 women. Only 26% of patients survived 4 years after 
diagnosis (graph: p < 0.0001). 
Conclusion: Morphologic and hemodynamic characterization of ALA-60 
AF patients by echocardiography demonstrated findings similar to those pre- 
viously reported for AL patients including increased wall thickness, reduced 
systolic function and decreased deceleration time. The echocardiographic 
manifestations of ALA 60 AF and AL are very similar despite cardiac deposi- 
tion of different amyloid protein substrates. There were no distinctive hemody- 
namics or morphological features to distinguish AF from AL. Like AL, evidence 
of advanced cardiac involvement is associated with poor prognosis. 
I 1138 155 Cardiac Arrest in Pressor Dependent Primary Systemic Amyloidosis Patients Awaiting Heart 
Transplantation 
Janak H. Bhavsar, Lyle J. Olson, Christopher G.A. McGregor, Morie A. Gertz, 
Richard J. Rodeheffer, Win K. Shen. Mayo C/ink, Rochester, Minnesota, USA 
Background: Sudden death is frequent in primary systemic amyloidosis (AL) 
patients; the mechanism has not been well characterized. We perform heart 
transplantation (HT) for selected patients with cardiac AL. We reviewed the 
arrhythmias associated with cardiac arrest in AL patients awaiting HT. 
Methods: The study group was comprised of AL patients awaiting HT who 
had cardiac arrest. All patients were rhythm monitored. Clinical histories were 
reviewed and data including age, gender, echo findings, pressor dosage, and 
rhythm abnormalities were recorded. Cardiac arrest was defined as hemody- 
namic instability requiring cardiopulmonary resuscitation. 
Results: 15 men and 7 women with AL required pressor support while 
awaiting HT; all had Class IV congestive heart failure. 12 of the 22 patients 
had monitored cardiac arrest; 9 were male and 3 female. Echo demonstrated 
advanced AL including increased ventricular wall thickness (mean septal 
thickness 18 mm; range 15-22 mm) and decreased left ventricular ejection 
fraction (mean 35%; range 1567%). Pressor dosage was obtained for 10 
of 12 patients who had cardiac arrest. The mean dose of dopamine (n = 5) 
was 2.5 uglkgimin; range 1.3-4.6, and the mean dose of dobutamine (n = 8) 
was 3.7 uglkgimin; range I-9.6. 3 patients were on combined dopamine and 
dobutamine. 18 episodes of cardiac arrest occurred including electromechan- 
ical dissociation (EMD) (9), sinus bradycardia (5), ventricular fibrillation (2), 
and complete heart block (2). Six patients underwent permanent pacemaker 
(PPM) implantation, four of whom later died due to EMD. Of the group with 
cardiac arrest 3 of the 12 patients survived to transplant, including 2 who had 
PPM insertion. EMD was the terminal event in 5 patients, two more died after 
withdrawal of support after EMD arrests, one died from ventricular fibrillation, 
and one died of pulmonary emboli. Of those AL patients who did not have a 
pre-transplantation cardiac arrest, all survived to HT. 
Conclusion: In contrast to patients with coronary artery disease, where 
the most common cause of cardiac arrest is ventricular tachyarrhythmia, the 
most frequent causes of cardiac arrest in pressor dependent cardiac AL pa- 
tients were EMD and sinus bradycardia. EMD was lethal; no patient with EMD 
survived to HT. PPM insertion may serve as a bridge to HT for AL patients with 
hemodynamically significant sinus bradycardia. 
/ 1138-l 56 1 Adverse Effects of Dietary Fish Oil 
Supplementation Against Doxorubicin-Induced 
Cardiomyopathy 
Hideo Matsui, Kazunori Hayashi, Hiroki Kamiya, Yoshihiro Saburi, Yukio Toki, 
Takayuki Ito, Kenji Okumura. Nagoya University, Nagoya, Japan 
Background: Dietary fish oil (FO) potentiates susceptibility of cellular mem- 
branes to lipid peroxidation although it has been shown to have beneficial ef- 
fects on the development of cardiovascular diseases. We investigated possi- 
ble adverse effects of dietary FO supplementation against Doxorubicin (DOX) 
cardiomyopathy in which free radicals and lipid peroxidation may be involved. 
Methods: Sprague-Dawley rats (100 g) were fed a standard diet or an FO 
diet (containing 10% FO) during all the experimental period. Four weeks after 
starting the special diet, each rat was treated with DOX (cumulative dose: 15 
mg/kg) or the vehicle. After 3 weeks of DOX treatment, cardiac performance, 
Control DOX FO FO + DOX 
Mortality (%) 0 33.3* o+ 56.3#5 
BP(mmHg) 120*2 94*7# 119+3* go+ lO#§ 
FS ("'o) 57.4 * 0.7 42.4 + 1.6' 57.0+ 1.0* 44.0 * l.O#§ 
u-tocopherol (ng/mg) 173+5 156111 141 559 143*3" 
TEARS (&mol/mg) 619+15 71917f 811 + l@* 911 i 5#*5 
BP: blood pressure, FS: fractional shortening, TSARS: thiobarbituric acid reactive sub- 
stances. Mean i SEM. *p < 0.05, ‘p < 0 01 vs Control. tp < 0.05, *p < 0.01 vs DOX. 
§p < 0.01 "s FO. 
myocardial lipid peroxidation, and myocardial a-tocopherol content were as- 
sessed. 
Results: As shown in the table, dietary FO did not prevent cardiomyo- 
pathic changes caused by DOX, but rather increased the mortality. Dietary 
FO also enhanced myocardial lipid peroxidation, which was associated with 
decreased myocardial a-tocopherol content. 
Conclusion: These results suggest a possibility that dietary FO supple- 
mentation may 1) reduce antioxidant defenses, 2) accelerate susceptibility of 
the myocardium to lipid peroxidation, and 3) exacerbate the cardiomyopathy 
in patients under DOX treatment. 
L--l 1138 157 Remodeling of Cardiac Collagen and Extracellular Matrix in Keshan Disease 
Sujuan Qian, .&Xi Yu, Weihan Yu, Kazuyo Takeda, Guangyi Chen, 
Xuekuan Zhong, Xianhui Zeng, Victor J. Ferrans. National lnsfitutes of 
Health, Bethesda, MD, USA; Harbin Medical University, Harbin, RR. China 
Background: Keshan disease is a cardiomyopathy related to deficiency of 
selenium in China and occurs in acute, subacute and chronic forms. The 
latter resembles dilated cardiomyopathy clinically. The present study explores 
the mechanisms of remodeling of the cardiac extracellular matrix in Keshan 
disease. 
Methods: lmmunohistochemical staining techniques were performed on 
paraffin sections of formalin-fixed hearts from patients with subacute (n = 5) 
and chronic (n = 7) Keshan disease. Dual fluorescent labeling techniques 
were used to demonstrate the immunoreactivity (IR) for type I, Ill and IV col- 
lagen, matrix metalloproteinases (MMPs), including MMP-I, MMP-2, MMP-9, 
and membrane-type-l MMP (MT-I-MMP), tissue inhibitors of MMPs (TIMP-1 
and TIMP-2) and angiotensin-converting enzyme (ACE), followed by nuclear 
counterstaining with DAPI and examination by confocal microscopy. 
Results: In subacute Keshan disease, the cardiac lesions were focal and 
characterized by myocyte loss and developing fibrosis. IR for collagen types I 
and IV and MMP-I, MMPP, MMP-9, MTI-MMP and ACE was stronger than 
in normal control heart. The IR for TIMPP was increased in the collagen in 
fibrotic areas. Staining for type Ill collagen was decreased, and the proportion 
of type I collagen was increased in the lesions. Type IV collagen was increased 
in some areas and partially lysed in others. In chronic Keshan disease, cardiac 
fibrosis was very severe and myocyte damage was less evident. Staining for 
type IV collagen was normal, But IR for type I and type Ill collagen was still 
stronger than normal. However, the ratio of type I to type Ill collagen was 
similar to that in normal hearts. Staining for ACE, MMP-I, MMP-2, MMP-9 
and MT-I-MMP were decreased, but still stronger than normal. 
Conclusion: These results show that remodeling of cardiac connective 
tissue in Keshan dieses proceeds through 2 stages: 1) an initial stage of 
MMP activation and lysis of collagens, and 2) a subsequent stage of fibrosis, 
normalization of MMP activity and increased activity of TIMPs. 
1 1138-I 58 / Prognosis of Patients With Cardiac Fabry 
Disease: Comparison With Classical Type 
Ryuichiro Anan, Shoichiro Nakao, Toshihiro Takenaka, Takashi Yoshitama, 
Takeshi Sasaki, Hiroyuki Teraguchi, ChuwaTei. Kagoshima University, 
Kagoshima, Japan 
Background: Fabry disease is an X-linked recessive disorder resulting from 
deficient activity of the lysosomal hydrolase a-galactosidase A. Atypical hem- 
izygotes with residual a-galactosidase A activity have late-onset disease man- 
ifestations limited to the heart (cardiac Fabry disease). Patients with classi- 
cal Fabry disease show poor prognosis, and the mean age of death is 41 
years. However, prognosis of patients with cardiac Fabry disease has not 
been known. 
Methods: Thirteen patients with cardiac Fabry disease (13 males, mean 
age 63 f 9 years) were studied. Diagnosis of cardiac Fabry disease was 
made with following criteria: left ventricular hypertrophy detected by echocar- 
diogram, reduced a-galactosidase A activity, and accumulation of ceramid 
trihexoside in left ventricular myocardial biopsy specimen. Analysis of survival 
was done with Kaplan-Meier product-limit survival curve. Survival of the pa- 
tients with cardiac Fabry disease was compared with that of 21 patients with 
classical Fabry disease. 
Results: The patients with cardiac Fabry disease were followed-up for 
mean period of 3.9 f 1.9 years. There were 5 disease-related deaths. Four 
patients died of congestive heart failure and 1 patient died of ventricular fib- 
rillation The median survival time was 73 years. The 3-year survival after 
diagnosis was 81% and the 5-year survival after diagnosis was 58%. A signif- 
icant difference (P < 0.0001) in life expectancy was observed in patients with 
cardiac versus classical Fabry disease. 
Conclusion: The prognosis of the patients with cardiac Fabry disease was 
significantly better than that of the patients with classical Fabry disease. 
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/ 1138-I 59 1 Morphologic Characterisation of Isolated 
Ventricular Non-Compaction: A Step Towards 
Classification 
Philipp A. Kaufmann, Erwin Oechslin, Rolf Jenni. Division of 
Echocardiography, Cardiology Ztirich, Switzerland 
Background: Isolated ventricular noncompaction (IVNC) is a cardiomyopa- 
thy yet “unclassified” by WHO. As a consequence, the disease is not widely 
known and its diagnose mostly missed, despite the important clinical conse- 
quences (heart failure, arrhythmia with sudden cardiac death and systemic 
embolism). We aimed at determining clear-cut morphologic criteria for IVNC. 
Methods: In seven out of a series of 34 patients with IVNC we have 
established the characteristics of the in vivo echocardiographic pattern. We 
than validated these findings compared to the anatomic examination, the 
cause of which was necropsy in 4 and explantation in 3 patients. 
Results: The following morphologic criteria were found to be diagnostic 
for IVNC: 
(1) Absence of any coexisting cardiac abnormality (by definition) 
(2) Two-layer structure of thickened wall consisting of 
. a compacted (C) thin epicardial band of uniform tissue 
. a much thicker noncompacted (N) endocardial layer of trabecular mesh- 
work with deep endomyocardial spaces 
The ratio of N/C as measured during endsystole was 3.5 * 0.8 
(3) Demonstration of deep perfused intettrabecular recesses by color Doppler 
(4) The predominant localisation of the pathology was mid-lateral (7x), apical 
(6x) and mid-inferior (6x) 
The pathological preparations confirmed the echocardiographic findings. 
Conclusions: Clear-cut diagnositc criteria based on echocardiographic 
findings are established. We suggest, that the WHO classification of car- 
diomyopathies should be reconsidered including the IVNC as a distinct car- 
diomyopathy. 
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1 1139-I 20 1 Use of Routine Functional Testing After 
Percutaneous Transluminal Coronary 
Angioplasty: Results From the ROSETTA 
Registry 
Mark Eisenberg, David Schechter, Jeffrey Lefkovits, Evelyne Goudreau, 
Ubeydullah Deligonul, Koon-Hou Mak, Michael Del Core, Robert Duerr, 
Philippe Garzon, David Brieger, Steven Sedlis. For the ROSETTA 
Investigators; Jewish Genera/ Hospital, Montreal, Canada 
Background: Silent restenosis frequently occurs during the 6 months after 
PTCA. The ACC/AHA Guidelines for Exercise Testing suggest that only se- 
lected groups of pts should undergo routine functional testing (FT) alter PTCA 
for the detection of silent restenosis (eg decreased LVEF, multivessel CAD, 
proximal left anterior descending disease, diabetes mellitus). 
Objectives: 1) To document the patterns of use of post-PTCA FT, and 
2) To determine whether the choice of FT strategy is related to clinical char- 
acteristics of pts or whether physicians use a similar strategy for all of their 
pts. 
Methods: The Routine versus Selective Exercise Treadmill Testing after 
Angioplasty (ROSETTA) Registry is a prospective multicenter study examin- 
ing the use of FT among 811 pts at 13 centers in 5 countries. 
Results: During the 6 month period following a successful PTCA, 51% 
of pts underwent FT (range among centers 12%-81%). Among the pts who 
underwent FT, 42% had a clinical indication, and 58% had FT as a routine 
follow-up. The 1st FT was performed a median of 7 weeks post-PTCA, with 
13% of pts having 2nd tests at a median of 14 weeks, and 4% having ad- 
ditional tests at a median of 20 weeks. Univariate and multivariate analyses 
demonstrated that the chief determinant of the use of routine FT was clinical 
center (p < 0.001). Asidefrom age (p=O.O002) and sex(p=0.03), no baseline 
clinical or procedural characteristics were associated with the routine use of 
post-PTCA FT. 
Conclusions: Physicians do not appear to be adhering to the ACC/AHA 
Guidelines for Exercise Testing regarding the use of post-PTCA FT. None 
of the high risk characteristics identified by the ACC/AHA Guidelines were 
associated with the use of routine post-PTCA FT, and the primary determinant 
of FT was the location of the center at which the pt had their PTCA. 
1 1139-I 21 1 Detection of Myocardial lschemia Using 
Additional Left Posterior and Right Precordial 
Leads During Exercise Electrocardiography 
Vijendra Swamp, Neal Skop, Joel S. Raichlen. Thomas Jefferson IJniversitL: 
Philadelphia, Pennsylvania, USA 
Background: Although stress electrocardiography (ECG) is less expensive 
than imaging stress studies, it is relatively insensitive for detecting myocardial 
ischemia. We examined the value of adding two right sided (RV3, RV4) and 
two left posterior (V8, VS) leads (16 lead ECG) to improve the sensitivity of 
exercise ECG for detecting myocardial ischemia. 
Methods: We prospectively studied 229 patients (141 men and 88 women) 
with a mean age of 56 & 22 who were undergoing nuclear exercise stress 
testing. 49% were hypertensive, 18% diabetic, 48% hypercholesterolemic, 
20% smoked and 45% had a family history of premature coronary artery 
disease (CAD): 32% had known CAD (prior infarction or revascularization). 
Results: Patients exercised 8.8 + 6 minutes achieving an average heart 
rate of 151 bpm with 79.5% achieving their target heart rate. lschemia was 
present in 38 patients (16.6%) as evidenced by at least one reversible petfu- 
sion defect. There was evidence of myocardial ischemia on the standard 12 
lead ECG in 34 patients (14.8%). An additional 12 patients met criteria for is- 
chemia on the 16 lead ECG. The 16 lead ECG increased the sensitivity of the 
12 lead ECG from 41.9% to 65.1% (p < 0.001) with no reduction in specificity 
(91.4% versus 90.3%). The 16 lead ECG improved the sensitivity for detecting 
ischemia in women from 42.8% to 71.4%, in patients with known CAD from 
32.0% to 57.1% and in patients who did not achieve their target heart from 
41.6% to 58.3%. 
Conclusion: The addition of fight precordial and left posterior leads to the 
standard 12 lead ECG significantly improves the sensitivity of the exercise 
ECG for the diagnosis of myocardial ischemia. 
I 1139 122 Cost-Effective Use of the Duke Treadmill Score 
Paul A. Heidenreich, Victor F. Froelicher, Alan M. Garber. Palo Alto VA Palo 
Alto, California and Stanford University Stanford, California, USA 
Background: We wished to determine the cost-effectiveness of using differ- 
ent thresholds of the Duke Treadmill Score (DTS) to decide who should be 
referred for angiography. 
Methods: Our base-case analysis was for a hypothetical cohort of 55 year 
old males with non-specific chest pain (18% probability of coronary artery 
disease per the CASS registry). The sensitivity and specificity of each DTS 
was determined from a database of 1300 patients with coronary angiographic 
data. Using a previously published model we estimated lifetime costs and sur- 
vival for different test results (true positive, true negative, false positive, false 
negative) for different DTS thresholds. We assumed that patients with scores 
less than or equal to the DTS threshold would be referred for angiography. 
The marginal cost-effectiveness was determined by comparing the cost and 
life-years gained for each score with the next highest score. 
Results: Both life-time costs and life-years increased with increasing 
treadmill score thresholds, however costs increased faster resulting in greater 
marginal cost-effectiveness ratios with higher treadmill score thresholds (Fig- 
ure). If $50,000 per year of life gained is considered the threshold for cost- 
effectiveness, then patients with scores of -1 or below should be referred for 
angiography. The optimal threshold score varied with patient age, gender, and 
chest pain characteristics. 
Conclusions: Referring 55 year old males with non-specific chest pain 
and a DTS score of 5-l for angiography provides benefit at a cost similar to 
other accepted health care interventions. 
/ 1139-l 23 I ‘Chronotropic Incompetence and Abnormal Heart 
Rate Recovery are Independently Associated 
With Coronary Artery Disease in Air Force Pilots 
Patrick J. Fitzsimmons, William B. Kruyer, Christopher R. Cole, Michael 
S. Lauer. US Air Force School of Aerospace Medicine, Brooks Air Force 
Base, TX; C/eve/and Clinic Foundation, C/eve/and, OH, USA 
Background: Chronotropic incompetence, or an attenuated heart rate re- 
sponse to exercise, and a decreased heart rate recovery early after exercise 
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have both been shown to be associated with prognosis. Their associations 
with angiographic coronary disease, particularly in relation to each other, have 
1139-i 25 Oral Estrogen Replacement Therapy Reduces 
the Diagnostic Accuracy of Exercise Stress 
Tests in Women _ . 
not been well explored. 
Methods: Consecutive United States Air Force Pilots who underwent 
symptom-limited exercise testing, thallium scintigraphy, and coronary angiog- 
raphy as part of a standard cardiovascular evaluation (N = 967, age = 43 + 
6, all male, 53% smokers, none with diabetes) were studied. Chronotropic 
incompetence was defined as a chronotropic index (CRI) of 50.8 and was 
calculated as (peak heart rate - resting heart rate)/(220 - age - resting heart 
rate): this has been shown to take into account effects of age, resting heart 
rate, and physical fitness. An impaired heart rate recovery (HRR) was defined 
as a fall of heart rate during the first two minutes after exercise of 541 beats 
per minute; this value was calculated by maximizing chi-square values. 
Results: Significant coronary disease (CAD), that is at least a 50% lesion 
of a major vessel, was present in 168 (17%). A low CRI was noted in 65 (7%) 
while a low HRR was present in 254 (26%): at least one abnormality was 
present in 291 (30%). A low CRI was strongly associated with CAD (32% vs. 
16%, odds ratio [OR] 2.45,95% Cl 1.42-4.25, P < 0.001) as was an abnormal 
HRR (26% vs. 14%, OR 2.10, 95% Cl 1.48-2.99, P < 0.001). After adjusting 
for age, resting systolic blood pressure and heart rate, smoking status, thal- 
lium abnormalities, and body mass index, both a low CRI (adjusted OR 2.35, 
95% Cl 1.28-4.32, P = 0.006) and an abnormal HRR (adjusted OR 1.52,95% 
Cl 1.04-2.23, P = 0.03) were independently predictive of CAD. Similarly, the 
presence of at least one heart rate abnormality was strongly associated with 
CAD even afler accounting for possible confounders (adjusted OR 1.70, 95% 
Cl 1.17-2.46, P = 0.005). 
Conclusions: Even after accounting for thallium perfusion abnormalities 
and other possible confounders, both chronotropic incompetence and an ab- 
normally low heart rate recovery early after exercise are strong and inde- 
pendent predictors of angiographic coronary disease among active Air Force 
pilots. 
/ 1139-I 24 1 Increased Prognostic Value of Body Fat Adjusted 
Peak Oxygen Consumption in the Evaluation of 
Obese Patients With Chronic Heart Failure 
A.F. Osman, E. Nunez, C.J. Lavie, M.R. Mehra, R.V. Milani. Ochsner Medical 
Instifufions, New Orleans, Louisiana, USA 
Peak oxygen consumption (PkVOs) is used for the risk stratification patients 
with chronic heart failure and for timing the need for cardiac transplantation. 
Despite the wide variability in body fat content, this parameter is traditionally 
expressed in ml per kilogram of total body weight per minute. 
Methods: We studied 225 consecutive chronic heart failure patients re- 
ferred for cardiopulmonary stress testing. 119 patients were categorized as 
obese (BMI 2 27.8 kg/m2 in men and ?27.3 kg/ma in women). Percentage 
of body fat was measured by the sum of three skinfolds method as described 
by Jackson and Pollock, and lean body mass (LBM) derived by multiplying 
the total body weight by [I - % body fat/l 001. Mean follow-up duration was 
18.9 7t 11.3 months. Baseline clinical, cardiopulmonary follow up duration was 
18.9 * 11.3 months. Baseline clinical, cardiopulmonary parameters as well as 
outcomes were analyzed for differences between both groups (Table). 
Obesen=ll9 Non Obese n = 106 P value 
fw 
Female 
% fat 
AT 
Max VE 
PkVO* 
PkV02 Lean 
(Adjusted to LBM) 
Combined endpoint 
Death 
Transolant 
52 It 117 
23.7% 
29.4% i 7.5 
ii.5 I3.7 
53.3 i 18.4 
14.5 i 4.8 
19.2 + 6.6 
11.71 
6.6% 
5.1% 
55 8 i 12.3 0.003 
15.6% 0.1 
22.2% + 5.6 <0.0001 
13 i 4.1 0.008 
49.8 * 23.3 0.03 
17i6.4 0.0013 
20.9 i 8.3 NS 
18.91t 
11% 
7.9% 
NS 
NS 
NS 
All PkVO;! and AT values are expressed in mVkg/min 
Results: Whereas PkVOa and anaerobic threshold (AT) were significantly 
lower in obese patients, the PkVOa lean (adjusted to lean body mass) showed 
no difference. There was a non-significant trend for better outcome in the 
obese population. 
Conclusions: The use of PkVOa adjusted to lean body mass (PkVOs Lean) 
in obese patients with chrome heart failure describes their functional capacity 
and is a better predictor of clinical outcome. 
Karen S. Rovang, Amy J. Arouni, Syed M. Mohiuddin, Aaron Tejani, Daniel 
E. Hilleman. Creighton University Cardiac Center, Omaha, Nebraska, USA 
Background: Because of its chemical similarity to digoxin, estrogen (EST) 
has been implicated as a possible cause of false positive stress tests. One 
retrospective study reported a 22% false positive rate with oral exogenous 
EST. No prospectiveevaluationofthe effectof ESTon the diagnosticaccuracy 
of stress tests have been reported. 
Methods: 47 healthy, post-menopausal women underwent exercise stress 
testing with and without EST (CONGEST 0.825 mg, po, qday). Women were 
either EST naive, or were off EST for a minimum of 4 weeks prior to base- 
line stress testing. The baseline stress test included stress echocardiography 
which had to be negative for study inclusion. The Bruce protocol was used. 
A positive test was defined as greater than or equal to 1 mm horizontal or 
downsloping STdepression, 80 ms, after the J point. 
Results: Of the 94 stress tests, 85% of maximal predicted HR was achieved 
in 90 tests. 27 (57%) of the women had negative stress tests, both at base- 
line and following EST therapy. IO (21%) had positive stress tests, both at 
baseline and following EST therapy, 10 (21%) had negative baseline stress 
tests which converted to positive following EST therapy. Exercise duration 
and heart rate and blood pressure response to exercise was not significantly 
different between baseline and EST stress test. 
Conclusions: Our prospective study corroborates the findings of previ- 
ously reported retrospective studies indicating that EST is associated with a 
false positive stress test response in post menopausal women. The studies 
indicate that approximately 1 in 5 healthy postmenopausal women will have a 
false positive stress test with oral exogenous EST therapy. 
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872-l Val-HeFT - Valsartan in Heart Failure Trial - 
Population Characteristics 
Jay N. Cohn’, Gianni Tognoni*. On behalfof the Va/-HeFT/nvestigators; 
’ University of Minnesota, Minneapolis, MN, USA; ‘Mario Negri Institute, 
Milan, My 
Congestive heart failure (CHF) remains a high-mortality disease despite treat- 
ment with digoxin, diuretics, beta-blockers, and ACE inhibitors (ACEis). .Mor- 
tality rate at 5 years is still unacceptably high at 50%. The latest addition to 
the CHFarmamentarium are angiotensin II receptor blockers (ARBs), such as 
valsartan, which selectively blocks the AT1 receptor subtype from interacting 
with angiotensin II. Angiotensin II is a potent vasoconstrictor which also acts 
as a growth stimulator in the heart. The possible benefits of using valsartan in 
patients with CHF are being evaluated in a large morbidity and mortality trial, 
Val-HeFT, where valsartan is compared to placebo on top of standard CHF 
medication. Val-HeFT is a multinational trial taking place in 300 centers in 16 
countries. The total number of patients enrolled in Val-HeFT is 5009. Enrol- 
ment started in April 1997 and finished in March 1999. Of the 5009 patients, 
the vast majority (80%) is male. The average age for the entire population is 
62.7 F 11 .I years (mean f standard deviation [SD]). Most of the patients are 
of Caucasian origin (90.3%), with only a few African Americans (6.9%) and 
other ethnic origins making up the remaining 2.8%. Over half of the patients 
are in NYHA class II (61.7%), a third of them are in NYHA Ill (36.2%), and 
only a few are in NYHA IV (1.9%). Regarding the aetiology of CHF, 57.2% of 
patients have an ischaemic origin of their CHF and in the remaining 42.8% it 
is of non-ischaemic origin. The mean left ventricular ejection fraction for the 
Val-HeFT population is 26.7 i 7.2%. Echocardiographic measurement of LV 
dimensions shows a left ventricular internal diastolic dimension, adjusted for 
body surface area, of 3.65 * 0.53 cm/m*. Diabetes was present in 24.4% of 
patients at trial start. Since all patients receive either valsartan or placebo on 
top of their standard medication, identification of major drug classes used as 
background therapy at baseline is of importance. The vast majority of patients 
(92.3%) is on ACEIs; diuretics are used in 84.2% of patients, digoxin in 67.7%, 
beta blockers in 35.5% and other, non-digoxin-like antiarrhythmic drugs in 
3.2%. In summary, the features of the patients included in the Val-HeFT study 
are representative of the larger CHF population present in industrialised coun- 
tries. 
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1 ~-7 872 2 Do Hemodynamics Always Predict Survival in 
Advanced Heart Failure? A Second Look at FIRST 
(the Flolan International Randomized Survival Trial) 
Monica R. Shah, Sandra Stinnett, Steven McNulty, Kirkwood F. Adams, Jr., 
Mihai Gheorghiade, Karl Swedberg, Robert M. Califf, Christopher 
M. O’Connor. Duke Clinical Research Institute, Durham, NC, USA 
Background: Hemodynamically-tailored therapy with ACE-inhibitors and di- 
uretics may improve morbidity and mortality in patients with advanced heart 
failure (HF). We reviewed the FIRSTdatabase to determine whether tailoring 
medical therapy independently improved survival, regardless of the drug used 
to achieve lower filling pressures. 
Methods: In all, 471 patients with NYHA Class IIIB/IV symptoms, ejection 
fraction (EF) i 25%, cardiac index ~2.2 Umin/m2, and pulmonary capillary 
wedgepressure(PCWP) 2 15mm Hgwererandomized toepoprostenol (Epo) 
or standard care. Baseline hemodynamics were recorded on all patients. 
In the Epo group, final hemodynamics were recorded after a 24-hour drug 
titration period. In the control group, baseline measures were used as final 
hemodynamics, as new drugs were not added. Previous analysis showed 
higher 1 -year mortality with Epo. 
Results: Overall, patients with a reduction in PCWP of >9 mm Hg had 
significantly lower l-year mortality than those with a reduction of <9 mm Hg, 
even after adjusting for age, sex, EF, NYHA class, and ischemic etiology 
(hazard ratio, 0.57; 95% Cl, 0.33-0.98; p = 0.04). However, Epo patients with 
a 29-mm Hg reduction in PCWP had l-year mortality similar to that of the 
control group (hazard ratio, 0.84; 95% Cl, 0.50-l .43; p = 0.528). 
Conclusions: A reduction in PCWP of z9 mm Hg may have a positive 
relationship with survival, but the overall effect of tailored therapy appears 
linked to the agent chosen to reduce filling pressures. Decreases in PCWP 
can help guide titration of proven therapies, but the ability of a drug to reduce 
filling pressures does not guarantee that it will reduce mortality. 
II:00 a.m. 
872-3 Left Ventricular Hypertrophy Predicts Death and 
Development of Heart Failure in High Risk Patients 
Withoit Systolic Dysfunction - 
James Mathew, Eva Lonn, David Johnstone, Jeff Probstfield, 
Malcom Arnold, Michael Baird, Kola Danisa, Naiyer Habib, Jackie Bosch, 
Janice Pogue, Salim Yusuf. For the Heart Outcomes Prevention Evaluation 
(HOPE) Investigators; McMaster Unive@M Hamilton, Canada; Galesburg 
Cottage Hospital, Galesburg, Illinois, USA 
Background: The of risk of death and cardiovascular morbidity associated 
with left ventricular hypertrophy (LVH) by electrocardiogram (ECG) in high 
risk patients is not well documented. Whether LVH by ECG predicts the de- 
velopment of congestive heart failure (CHF) in high risk patients without prior 
CHF or left ventricular systolic dysfunction is not known. 
Methods: The HOPE study enrolled 9541 high risk patients (~55 years, 
previous vascular disease or diabetes plus another risk factor) without pre- 
vious CHF or left ventricular systolic dysfunction. Total mortality, predefined 
primary HOPE events (cluster of cardiovascular death, myocardial infarction 
and stroke) and first hospitalization for CHF during a mean follow-up of 3.5 
years were compared in patients with and without LVH on the baseline ECG. 
Cox regression analyses were used to adjust for other possible risk factors. 
Results: 
Outcome LVH present 
N = 791 
LVH absent 
N=8750 
p (log rank) 
Death n (%) 98 (12.4) 696(7.8%) 0.0001 
CHF* n ("'o) 42 (5.3) 217(2.5) 0.0001 
Primary events** n (46) 124(15.7) 1076 (12.3) 0.003 
*First hospitalization for congestive heart failure; **Composite of cardiovascular death, 
myocardial infarction and stroke 
Cox regression analyses conformed the independent association of LVH 
with death (p = 0.0002) and the development of CHF (p = 0.0001). There was 
a trend toward increased risk of primary HOPE events in patients with LVH (p 
= 0.08). 
Conclusion: LVH by ECG is a strong, independent predictor of increased 
risk of death and development of CHF in high risk patients without prior CHF 
or left ventricular systolic dysfunction. 
II:15 a.m. 
I 872 4 The Benefit of Spironolactone in the RALES Trial is Not Primarily Due to a Diuretic Effect 
Robert J. Cody, Bertram Pitt, Alfonso Perez, Richard Bettman. For the 
RALES Investigators; University of Michigan, Ann Arbor, Michigan, USA 
Background: The recent RALES Trial demonstrated a highly significant re- 
duction of the relative risk of mortality in patients with moderate to severe heart 
failure, when spironolactone (Spiro) was added to standard therapy. To deter- 
mine whether benefit was due to a diuretic effect, we prospectively assessed 
the sodium retention score (SRS) in a cohort of 198 patients from the overall 
group of 1663 patients in the trial. 
Methods: The SRS is based upon evidence of fluid retention, with score 
for rales, peripheral edema, hepatomegaly, 53 gallop, jugular venous pulse, 
and change in body weight. The range of values for the SRS is -1 to 11. 
Prospective SRS was obtained for Spiro (n = 99), or placebo (n’ = 99) at 
baseline, and month 1,2,3, and 6 following randomization. 
Results: Survival and hospitalization rates mirrored the overall trial. Ac- 
cording to NYHA functional class, the mean SRS was 4.23 for IV, and 2.36 for 
Ill patients (p < 0.05). Mean SRS for each treatment group: 
Baseline mol mo2 mo3 month6 
Placebo 2.88 2.03 1.75 1.78 1.83 
Soiro 3.07 1.66 1.71 1.56 1.51 
Reduction was comparable in both groups, without a significant treatment 
effect or interaction. For patients with minimal edema (SRS < 3), there was 
no significant difference between placebo and Spiro at baseline, or at any 
time point through 6 months. In those with greater retention (SRS z 3) means 
values were: 
Baseline mol mo2 mo3 month6 
Placebo 5.16 3.15 2.54 2.56 2.29 
Spiro 5.16 2.44 2.45 2.08 2.20 
Reduction was comparable in both groups, without a significant treatment 
effect or interaction. 
Conclusion: Patients in the RALES trial demonstrated mild fluid retention 
at baseline. There was no treatment effect of Spiro on sodium retention (com- 
pared to placebo), regardless of baseline severity. These findings indicated 
that the beneficial effects of Spiro were not primarily related to diuresis, and 
most likely related to other anti-aldosterone effects of Spiro. Overall reduction 
of SRS during follow-up was consistent with comparable clinical management 
in all randomized patients. 
II:30 a.m. 
I 872 5 Clinical Features of Patients with Heart Failure After 
an Acute Coronary Syndrome: Findings From 
GUSTO-lib 
Monica R. Shah, Maria Cecilia Bahit, Christopher B. Granger, 
Donald Beasley, Harvey D. White, Eric J. Topol, Robert M. Califf. Duke 
Clinical Research Institute, Durham, North Carolina, USA 
Background: The development of heart failure (HF) after an acute ST-seg- 
ment elevation myocardial infarction (Ml) is an established risk factor for mor- 
tality. We reviewed theGUSTO-Ilbdatabasetodescribe the clinical featuresof 
patients who develop heart failure after the entire spectrum of acute coronary 
syndromes (ACS). 
Methods: Using thedatabaseof GUSTO-llb(n= 12,142), whichcompared 
hirudin vs. heparin in ACS, we identified patients who developed HF during 
the index hospitalization. HF was defined by either pulmonary edema on chest 
X-ray or at least two of the following: rales > 5 of lung fields, dyspnea, use 
of furosemide, or pulmonary capillary wedge pressure (PCWP) > 18 mm Hg 
and cardiac index < 2.4 Umin/m’. 
Results: In all, 534 patients (4.4%) developed HFafter ACS. Patients who 
developed HF were older and were more likely to have a history of MI, hyper- 
tension, or diabetes. In addition, a higher percentage of women developed HF 
after ACS compared with men - 197 (5.4%) vs. 337 (4.0%); p = 0.001. 
Median aae. vr 
PreviousiCll . 
Hypertension 
Diabetes 
HF (n = 534) 
71 (63.771 
NoHF(n= 11,596) 
65 (55.72) 
p Value 
<O.OOl 
189‘(35.49;.) 305$(26.4%) <O.OOl 
266(49.8%) 5227 (45.1%) 0.033 
157 (29.4%) 2014(17.4%) <O.OOl 
Median systolic BP, mm Hg i30 135 <O.OOi 
Conclusions: Patients who develop HF after ACS are more likely to have 
a history of MI, hypertension, and diabetes and also are more likely to be 
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female. This information can help clinicians predict who will develop HF after 
ischemic events and institute appropriate therapy early in the course of the 
event. 
11:45 a.m. 
El 872 6 Prognostic Significance of Manifestations of Acute Congestive Heart Failure: Results from 
GUSTO Ilb 
Maria Cecilia Bahit, Monica Shah, Christopher Granger, Donald Beasley, 
Eric Bates, Harvey White, Eric Topol, Robert Califf. Duke Clinical Research 
Institute, Durham, NC, USA 
Background: Congestive heart failure (CHF) in the setting of acute coronary 
syndromes (ACS) is associated with increased mortality. The aim of this study 
was to identify the prognostic significance of certain signs and symptoms in 
patients with CHF alter ACS. 
Methods: Using the database of GUSTO Ilb (n = 12142), which compared 
hirudin vs. heparin in patients with ACS, we selected patients who developed 
congestive heart failure during the index hospitalization. CHF was defined by 
signs and symptoms of: 1) pulmonary edema on chest X-ray or 2) at least two 
of the following: rales > 5 up, pulmonary capillary wedge pressure (PCWP) z 
18 mmHg and cardiac index (Cl) < 2.4 Uminlms, dyspnea, use of furosemide. 
We examined the relationship of CHF and its manifestations with 30-day 
mortality using multivariable logistic regression analysis. 
Results: 534 (4.4%) patients developed CHF at a median time of 2 days. 
Patients with CHF had higher 30-day mortality than patients without CHF 
(25.1% vs 3.6%, p < 0.001). In a multivariable model, the significant indepen- 
dent predictors of death, and the percentage of patients with CHF with these 
features, were: 
Hypcxemia 
Hypotension 
Pulmonary Edema 
% of patients 
23% 
12% 
56% 
Odds Ratio 
326 
2.74 
1.48 
Cl 95% P 
2.06-5.15 0.0001 
1.47-5.10 0.0015 
0.96-2.28 0.075 
After accounting for these three predictors in the multi variable model, the 
following did not independently predict 30-day mortality: rales > i up, Ss or 
S4, ejection fraction < 35%, and PCWP > 18 mmHg and Cl < 2.2. 
Conclusion: The signs and symptoms of CHF that are the strongest pre- 
dictors of 30-day mortality after ACS are hypoxemia, hypotension, and pul- 
monary edema on chest X-ray. This information may be helpful for risk strat- 
ification and for refining definitions of CHF following ACS thai best reflect 
prognostic significance. 
ORAL 
LIzI 874 Exercise Testing to Determine Prognosis 
Tuesday, March 14,2000, IO:30 a.m.-Noon 
Anaheim Convention Center, Room 304A 
lo:30 a.m. 
874-l The Long-Term Predictive Value of Peak Oxygen 
Intake in 12,169 Men Referred for Cardiac 
Rehabilitation 
Terence Kavanagh, Donald J. Mertens, Larry F. Hamm, Joseph Beyene, 
Johanna Kennedy, Roy J. Shephard. Toronro Rehabilitation Cenfre and 
University of Toronto, Joronfo, Ontario, Canada 
Background: An understanding of factors contributing to cardiac death is im- 
portant to the risk stratification of patients enrolled in rehabilitation programs. 
Survival analysis was carried out on data from patients referred to a large 
outpatient cardiac rehabilitation program. 
Methods: The sample included 12,169 men, aged 55.0 i- 9.6 years, con- 
secutively referred for rehabilitation between 1968 and 1994 who underwent 
an initial cardiopulmonary exercise test. Using a single-centre observational 
study design, these patients (7,096 myocardial infarction (Ml), 3,077 coro- 
nary artery bypass graft surgery (CABG), 1,996 documented ischemic heart 
disease (IHD)) were followed for a median time of 8.3 years from the time 
of the test. A Cox proportional hazards model tested factors associated with 
time to cardiac death in the entire sample and in each of the three diagnostic 
categories. 
Results: A total of 1,383 cardiac deaths were recorded during follow-up 
(11.4% of the original sample). The most powerful predictor of prognosis in 
all four categories was measured peak oxygen intake (VOs,,,k). For the en- 
tire sample, VOspeak values of 115, 15~22, 222 mL.kg.min’ , resulted in 
risk ratios of 1 .OO, 0.54, 0.32 respectively. Other significant indicators (p < 
0.05) were smoking, angina, ST-segmental depression 20.2 mV, age at re- 
ferral, ventricular ectopy, and use of beta-blockers (protective). Results were 
similar for the MI category, with the exception of angina. In the CABG group, 
smoking, and in the IHD group, smoking, age and ST depression remained 
significant. 
Conclusions: Our data indicate that measured VOzpeak provides valuable 
additional prognostic information in patients referred for cardiac rehabilitation. 
IO:45 a.m. 
874-2 Which Patients With Low-Risk Treadmill Scores 
Need Perfusion Imaging for Risk Stratification? 
lndu G. Poornima, Raymond J. Gibbons, Timothy F. Christian, David 
0. Hodge, Todd D. Miller. Mayo Foundation; Rochester, MN, USA 
Background: The prevalence of severely abnormal perfusion scans in pa- 
tients with low risk Duke treadmill scores is low (<IO%). We sought to define 
a high-risk subgroup in this population using a previously published clinical 
score (CS), in whom perfusion imaging would more likely be abnormal. 
Methods: We studied 1461 patients with low risk treadmill scores who 
had undergone exercise perfusion imaging. Follow-up was 92% complete at 
a mean of 7 + 1 years. The CS is a simple score computed by assigning 1 
point each to the following variables-diabetes, insulin use, male sex, history 
of Ml, typical angina and each decade of age over 40. The perfusion studies 
were categorized by a 14-segment summed stress score (SSS) as normal 
(O-3), moderately abnormal (4-8) or severely abnormal (>8). 
Results: Five-year cardiac morality for the entire population was low at 
2%. The CS and the SSS were both significant (p < 0.0002) independent 
predictors of all 3 endpoints of 1) cardiac death 2) cardiac death/nonfatal Ml 
3) cardiac death/nonfatal Ml/late revascularization. The CS classified 21% of 
patients as high-risk (score 2 5). The prevalence of severely abnormal scans 
was significantly higher in this subgroup (26% vs 9%; p < 0.001). The 5-year 
event-free survival for each of the endpoints based on the clinical score and 
the summed stress scores are shown below: 
sss 
03 
4-8 
>8 
tot.4 
Cardiac Death 
cs c 5 cs>_5 
99% 96% 
99% 100% 
99% 84% 
99% 94% 
Cardiac Death/Ml 
cs < 5 cs>5 
97% 94% 
97% 97% 
96% 78% 
97% 91% 
Cardiac death/Ml/ 
Late Revascularization 
cs < 5 CS>5 
95% 87% 
92% 80% 
78% 66% 
93% 61% 
Conclusions: CS and SSS are independent predictors of cardiac events. 
Patients with CS < 5 had low rates of death and nonfatal MI irrespective of their 
perfusion findings. Patients with CS 3 5 have a higher rate of death/nonfatal 
Ml (9% over 5 years) despite a low-risk treadmill score. Perfusion imaging is 
useful in this group for further risk stratification. 
1l:OO a.m. 
1 874-31 Prognostic Implications of Hysteresis of the 
ST-Segment/Heart Rate Recovery Loop Following 
Maximal Exercise 
Christopher R. Cole, Rami Lehtinen, Jari Viik, Lazaro A. Diaz, JoAnne 
M. Foody, Peter M. Okin, Michael S. Lauer. C/eve/and Clinic Foundation, 
C/eve/and, OH; Cornell Medical Center, New York, NY USA; Ragnar Granit 
Institute, Tampere University of Technology; Tampere, fin/and 
Background: The ST-segment/heart rate (ST/HR) hysteresis loop, a novel 
computerized diagnostic variable, improves the diagnostic accuracy of the 
exercise ECG but its prognostic significance has not been explored. 
Methods: Adults undergoing symptom-limited SPECT thallium exercise 
testing (n = 2480, age 60 f IO, 77% male) were followed 6.2 years. STiHR 
hysteresis was defined as the area within the loop formed by plotting ST de- 
pression against HR during exercise and the first 3 min. of recovery, divided by 
the change in HR during recovery. A cutpoint of 0.001 mV (representative of 
counter-clockwise rotation) was used to define an abnormal response. Com- 
parisons were made to the ST/HR index, a previously validated prognostic 
marker that adjusts the change in ST depression by heart rate change from 
baseline to peak exercise (abnormal z 1.6 pV/beaVmin) and standard ST 
depression. 
Results: There were 205 (8.3%) deaths. An abnormal ST/HR hysteresis 
and ST/HR index were present in 562 (23%) and 513 (21%) respectively. In 
univariate analyses, an abnormal ST/HR hysteresis was predictive of death 
[figure] (Relative Risk [RR] 1.47,95% Cl 1.08 to 2.01 P = 0.01). Standard ST 
analysis was not predictive. Adjusting for age, sex, risk factors, thallium, and 
the ST/HRindex, ST/HR hysteresis remained predictive of outcome (adjusted 
RR for one standard deviation increase 1.26 95% Cl 1.05-l 50: x” = 6, P = 
0.01). The ST/HR index was not predictive in this model. 
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Conclusion: The ST/HR hysteresis was an independent predictor of mor- 
tality in this population even afler adjusting for ST/HR index and thallium 
perfusion defects. 
11:15 a.m. 
( 874-4 1 A Simple Tool as a Strong Predictor of Mortality 
After Acute Myocarciial Infarction in the 
Recanalisation Era: Predischarge Exercise Test 
Caroline Bergmeier, Ralf Zahn, Rudolf Schiele, Andreas Kilkowski, Anselm 
K. Gitt, Ulf Gieseler’ , Helmut Thomass, Jochen Senges. for the 
MITRA-Investigators; ‘Department of Cardiology Herzzentrum 
Ludwigshafen, Speyer; *Bad Diikheim, Germany 
Purpose: Is a predischarge exercise test a predictor of mortality, CABG and 
nonfatal reinfarction in nonselected patients (P) with acute myocardial infarc- 
tion (AMI) in the recanalisation era? 
Methods: The Southwest German “Maximal Individual Therapy in Acute 
Myocardial Infarction” (MITRA) - trial is a prospective multicenter observa- 
tional study of the current treatment of AMI. 4902 consecutive P with AMI 
were discharged from hospital alive from 5/94 to l/97. 
Acute treatment: 58% recanalisation, 94% aspirine, 53% ,&blockers, 51% 
ACE-inhibitors. Mean follow-up time was 18 months. 
Results: 1. A workload 5 75 W in bicycle ergometry could be performed 
in 2626 P (54%). Longterm mortality was 16.9%. 2. In 466 P (10%) signs of 
ischemia (ST-depression 2 1 mm and/or angina) were observed (Longterm 
mortality 8.6%). 3. 1555 P (32%) achieved a workload > 75 W and signs of 
ischemia were absent (Longterm mortality 3.5%). 4. Results of longterm fol- 
low-up in a multivariate analysis (adjusted for age, gender, diabetes, anterior 
wall Ml and recurrent AMI): 
Mortality CABG Reinfarction 
OR (95% Cll OR (95% Cl) OR (95% Cl) 
Exercise O-75 W 3.02 (2.21-4.14) 1.28 (1.03-i .60) 1 .oo (0.73-l .37) 
Positive ischemia 2.01 (1.21-3.33) 2.95 (2.12-4.111 1.34 (0.81-2.211 
OR: Odds Ratio; Cl: confidence interval 
Conclusion: 1. In unselected P after AMI in the recanalisation era about 
half of the P were not able to achieve a workload of more than 75 W in a 
predischarge exercise test, while about 10% showed signs of ischemia. 2. 
Longterm mortality in P with low exercise capacity was two times higher than 
in P with signs of ischemia, and five times higher than in P showing exercise 
capacity > 75 W and no signs of ischemia. 3. Low exercise capacity is a 
strong independent predictor of longterm mortality in the recanalisation era, 
while signs of ischemia predict CABG as well as an elevated mortality, but do 
notpredictnonfatal reinfarction. 
11:30 a.m. 
874-5 Which is the Best Cardiopulmonary Exercise 
Parameter to Identify High Risk Chronic Heart 
Failure Patients? 
Waqar Shamim, Mohammed Yousufuddin, Marcus Flather, Stefan D. Anker, 
Andrew J.S. Coats. Royal Brompton Hospital and National Heart and Lung 
Institute, London, UK 
Background: Peak oxygen consumption (MV02), Left ventricular ejection 
fraction (LVEF) and NYHA class are the most important prognosticators in 
chronic heart failure. The treatment decision including heart transplantation 
is usually based on above variables. Although well established as a strong 
prognosticator, MVOZ still has some limitations. 
Methods: A total of 298 patients aged 58 i 12 yrs; NYHA class 2.3 f 
0.8; resting heart rate 85 f 18; mean BP 96 f 14 LVEF 28 f 13; underwent 
cardiopulmonary exercise test on treadmill (AMIS 2000 Denmark) between 
Jan ‘93 and Dec’96 and followed up until March ‘99. Exercise parameters were 
analysed univariately and multivariately by Cox proportional hazard method 
to identify the better predictor of survival. 
Results: Over a mean follow-up of 36 months, 90 patients died. On uni- 
variate analysis MV02 (p = <0.0002), VENC02 (p = <O.OOOl), anaerobic 
threshold (AT) (p = <O.OOOl), and predicted V02 (p = 0.04) were identified as 
prognosticators. A bivariate analysis model was constructed, which showed 
VENC02 and AT were better prognosticator compared with other combina- 
Variables P-V.&c Hazard Ratio Variables P-value Hazard Ratio 
VE/VCOP <O.OOOl 1.040 (1.02-l ,065) Pred. V02 0.001 1.066 (1.026-1.107) 
AT 0.0002 0.859 (0.7924932) AT <0.0001 0.811 (0.747-0.879) 
VENCOP <O.OOOi 1.054 (1.04&l ,068) Pred. V02 0.04 1.046 (1.001-l ,093) 
Pred. V02 0.04 1.039 (1.00-l ,079) MV02 <O.OOOl 0.856 (0.817-0.696) 
VEA’COP <O.OOOl 1.034 (1.018-i ,052) 
MV02 0.0002 0.907 10.862-0.952) 
tions. Further on multivariate analysis VENCOP was identified as the best 
exercise marker of the mortality. 
Conclusion: This study clearly demonstrates VE/VC02 as the best exer- 
cise marker of prognosis in chronic heart failure. 
11:45 a.m. 
874-6 Chronotropic Incompetence and Abnormal Heart 
Rate Recoverv Predict Mortalitv in Patients 
Undergoing Exercise Testing without Imaging 
Erna 0. Nishime, Chrfstopher R. Cole, Fredric J. Pashkow, Eugene 
H. Blackstone, Michael S. Lauer. C/eve/and Clinic foundation, C/eve/and, 
OH, USA 
Background: Chronotropicincompetence (CRI) and heart rate recovery(HRR) 
have been reported to be independent predictors of mortality in moderate-risk 
patients undergoing exercise thallium testing, but have not been well explored 
in low-risk populations undergoing non-imaging exercise testing. 
Methods: Consecutive adults (n = 9485, age 53 f 11 years, 88% male) un- 
dergoing symptom-limited exercise testing without imaging were followed 3.8 
years. Exclusion criteria included heart failure, valvular disease, pacemaker, 
or uninterpretable electrocardiograms. Abnormal HRR was defined as the 
change in heart rate from peak exercise to 1 minute of recovery (512 beats). 
CRI was defined as the percentage of heart rate reserve utilized (abnormal 5 
0.8). Abnormal ST response was defined by standard criteria. 
Results: There were 157 deaths. Abnormal HRR, CRI and ST response 
were present in 1858 (20%), 1627 (17%) and 1194 (13%) respectively. Both 
abnormal HRR and CRI were present in 659 (7%). In univariate analyses, 
CRI, (Relative Risk [RR] 5.36 95% Cl 3.92-7.32 P < 0.0001) and abnormal 
HRR (RR 4.41; 95% Cl 3.22-6.03; P < 0.0001) were predictive of mortality, 
as was ST response (RR 1.69 95% Cl 1 .I&2.52 P < 0.01). After adjusting 
for age, gender, exercise capacity, angina, baseline RBBB, cardiac risk fac- 
tors, cardioactive medications, prior CAD, peripheral vascular disease, and 
pulmonary disease, HRR (adjusted RR 1.72 95% Cl 1.22-2.41 P = 0.002) 
and CRI (adjusted RR 1.63; 95% Cl 1.13-2.35 P < 0.01) remained‘predic- 
tive. An abnormality in either HRR or CRI predicted mortality (adjusted RR 
1.76 95% Cl 1 .I 7-2.66 P = 0.007). The presence of both HRR and CRI pre- 
dicted markedly increased mortality (adjusted RR 2.82 95% Cl 1.75-4.54 P < 
0.0001) [figure]. After adjusting for heart rate abnormalities, ST response was 
no longer predictive (adjusted RR 1.15, 95% Cl 0.77-l .72, P = 0.47). 
Conclusions: In a low-risk population of patients referred for exercise 
testing, heart rate changes were powerful and independent predictors of mor- 
tality. 
POSTER 
I 1161 Signal Transduction in Growth Regulation 
Tuesday, March 14,2000, Noon-2:00 p.m. 
AnaFeim Convention Center, Hall A 
Presentation Hour: 1:OO p.m.-2:OO p.m. 
1 1161-l 42 1 Stretch Stimulates Phospholipase C Activity and 
Increases Intracellular Calcium Ion Levels in 
Neonatal Cardiomyocytes 
Cindy Ruwhof, Annemieke E.T. van Wamel, Marina L.A.W. Noordzij, 
Arnoud van der Laarse. Dept. of Cardiolog)l Leiden University Medical 
Center, Leiden, The Netherlands 
Background: Stretch plays a key role in development of hemodynamic over- 
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load-induced left ventricular hypertrophy. The signal transduction pathways 
involved in transmission of the stretch signal to the nucleus are largely un- 
known We investigated whether phospholipases C (PLC) and D (PLD) and 
intracellular calcium ([Ca”],) are part of the signal transduction pathways of 
stretch-induced hypertrophy of cardiomyocytes. 
Methods: Cardiomyocytes were isolated from the ventricles of neonatal 
rats and grown on flexible membranes. Cyclic stretch (20%, 1 Hz) was sub- 
jected to the cells by applying intermittently vacuum below the membranes. 
Intracellular caicium was measured fluorimetrically using Fura2-AM. PLC ac- 
tivity was determined by formation of inositol-triphosphate (IPs) after loading 
with 3H-inositol 30 h before start of the experiments, PLD activity was mea- 
sured by formation of choline after loading with 3H-choline 30 h before start of 
the experiments. 
Results: After 5, 15, and 30 min of stretch, the formation of IPs had in- 
creased with 48%, 80%, and 98% over control, respectively (p 5 0.05). The 
PLD activity was unchanged. The [Caa+], increased upon 5 min of stretch by 
72% over control (p 5 0.05). In the presence of diltiazem (L-type Ca”+ antago- 
nist) and gadolinium chloride (stretch activated channel inhibitor), the [Ca”+]r 
elevation upon stretch was attenuated to increases of 47% and 42% over 
control, respectively (p 5 0.05). Furthermore, there was a positive correlation 
between [Ca’+]r elevation and amplitude of stretch (r = 0.98, p 5 0.01). 
Conclusion: Phospholipase C and intracellular calcium are involved in 
stretch-induced signal transduction, whereas phospholipase D is not involved. 
These results support our contention that the sensor is most likely a sarcolem- 
mal comoonent. 
Analysis of Repair of UV-Induced DNA Damage 
in Transcriptionally Active and inactive Genes in 
Rat Cardiac Fibroblasts and Terminally 
Differentiated Myocytes 
Caroline G.C. van der Wees, Maaike P.G. Vreeswijk, Marion Persoon, Leon 
H.F. Mullenders, Arnoud van der Laarse. Leiden University Medical Centre, 
Leiden, The Netherlands 
Background: Nucleotide excission repair (NER) is a major repair pathway 
responsible for the removal of a variety of structurally unrelated DNA lesions. 
Within NER two subpathways can be distinguished: transcription-coupled re- 
pair (TCR), responsible for the removal of lesions from the transcribed strand 
of expressed genes and global genome repair (GGR), responsible for repair 
of the entire genome. The repair capacity of terminally differentiated cells is 
largely unknown. To determine whether terminally differentiated cardiac my 
ocytes are able to repair DNA damage by NER, we studied induction and 
repair of UV-induced cyclobutane pyrimidine dimers (CPD) in transcriptionally 
active and inactive genes. 
Methods: Myocytes and fibroblasts were isolated from ventricles of neona- 
tale rats. To determine the level of RNA synthesis 14C-thymidine prelabelled 
cells were incubated in the presence of sH-uridine after UV irradiation, The 
ratio of 3H to 14C was taken as a measure for RNA synthesis. Removal of CPD 
was analyzed in the transcriptionally active @and hprt genes and the tran- 
scriptionally inactive cmos gene after UV irradiation of 10 J/m2 using the CPD 
specific enzyme T4 endonuclease V and quantitative Southern blot analysis. 
Results: UV immediately inhibits RNA synthesis in a dose dependent 
manner, reducing RNA synthesis to 40% in fibroblasts and to 30% in myocytes 
after a dose of IO J/m2 compared to unirradiated cells. A recovery to 80% in 
fibroblasts and to 60% in myocytes was found 24 h later. The frequency of 
&‘-induced CPD in the different genes was similar between myocytes and 
fibroblasts. After 24 h a removal of CPD of 75% from the transcribed strand 
of the active genes and 10% of the nontranscribed strand of the active genes 
and both strands of the inactive gene was found in fibroblasts. CPD removal 
in myocytes was 60% in the transcribed and 10% in the nontranscribed strand 
of the active genes. 
Discussion: Both fibroblasts and myocytes recover from UV-inhibited 
RNA synthesis and efficiently remove CPD from the transcribed strand of 
active genes, which means that terminally differentiated myocytes and car- 
diac fibroblasts are able to repair UV-induced DNA damage by TCR. 
LIIIII 1161-I 44 Chronic Angiotensin Converting Enzyme Inhibition Restores the Responsiveness of 
Cardiac Mitogen-Activated protein Kinase in 
Rats With Heart Failure 
Wataru Hayashida, Yasuki Kihara, Koichi Inagaki, Yoshitaka Iwanaga, 
Asuka Yasaka, Shigetake Sasayama. Kyoto University Graduate School of 
Medicine, Kyoto, Japan 
Background: Cardiac mitogen-activated protein kinase (MAPK) pathways 
are involved in the adaptive hypertrophy. However, their significance remains 
unclear in the diseased hearts. Using the Dahl salt-sensitive rats with hyper- 
tension as a model of congestive heart failure (CHF) transition, we studied the 
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alterations in myocardial MAPK activation during the CHF transition. We also 
tested whether the altered MAPK activation is affected by chronic angiotensin 
converting enzyme inhibition. 
Methods: The Dahl rats fed high-salt diet were treated with temocapril (20 
mg/kg/day, n = 7) or vehicle (n = 6) from the compensated hypertrophy stage 
(11 -week old) to the CHF stage (17-week old). As a control, the normotensive 
Dahl rats fed low-salt diet (n = 5) were employed. The heart was isolated 
from each animal, and was coronary-per-fused with angiotensin II (Ang, I @M) 
on the Langendorff preparation. The Anginduced activation of extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and ~38 MAPK 
in the LV myocardium was studied by the immunoprecipitation-kinase assay. 
Results: (1) The Ang-induced ERK activation was comparable in the con- 
trol and CHF rats. (2) In contrast, the maximal activation of JNK and p38 
was remarkably decreased (47 f 1 O%* and 62 It 9%* of the control, respec- 
tively) in the CHF rats. (3) Compared with vehicle, the temocapril therapy de- 
creased echocardiographic LV diameter (-8%“*) and improved LV shortening 
(+I1 %‘“). Finally, (4) temocapril significantly restored the responsiveness of 
the Ang-induced JNK and ~38 activation to 79 f 19%** and 91 i 15%** of the 
control, respectively. 
Conclusion: The Anginduced activation of multiple MAPKs is differen- 
tially regulated in the CHF hearts. The altered activation of JNWp38, but not 
of ERK, may be involved in cellular events underlying the CHF transition. 
The data also suggest that chronic angiotensin converting enzyme inhibition 
not only ameliorates cardiac remodeling, but potentially restores the normal 
responsiveness of hypertrophy-related signaling such as JNWp38 pathways. 
* = p < 0.01 vs. the control, and ** = p < 0.05 vs. vehicle. 
1161-I 45 Coordinated Regulation of Cell Cycle Withdrawal 
During Cardiogenesis 
Donald Chen, Richard Wu, Karen Haseroth, Xiaoqin Qu, Feiran Lou, Hal 
A. Skopicki. Co//ege offhysicians and Surgeons at Columbia UnivefsifL: 
New York, New York, USA 
Cardiomyocytes exit the cell cycle by the immediate neonatal period. There- 
after, the majority of cells reside “frozen” in the Gl/S phase, and are notewor- 
thy for their complete resistance to cell cycle reactivation. Based on recent 
studies that have noted marked tissue-specific expression and organ-spe- 
cific defects in homologous recombinants null for members of the cell-cycle 
regulatory paradigm, we hypothesized that cardiac specific handling of GliS 
proteins may render the Gi/S arrest phenotype seen in the adult heart. Mul- 
tilabel indirect immunofluorescence detected the progressive disappearance 
of proliferating nuclear cell antigen (PCNA) that paralleled a reduction in BrdU 
incorporation into cardiomyocytes during mouse cardiogenesis. By day 12.5, 
nearly 18% of cardiomyocytes were unlabeled with PCNA, cdk2 or BrdU. This 
reached nearly 40% at day 15.5 and less than 1% at day neonatal day 3. 
Cyclin D family member expression was both temporally and spatially reg- 
ulated. Cyclin Di protein was present in the nucleus of proliferating cells 
from embryonic day 9.5 p.c. Expression progressively decreased as a per- 
centage of all cardiomyocytes throughout the fetal period. By day 17.5 p.c., 
expression was largely limited to the endocardium and endothelial lining of 
vessels. lmmunoblot analysis indicated an apparent increase in Cyclin Dl 
at day 15.5 p.c., followed by a reduction through the neonatal period. Cyclin 
02 expression, associated with either growth promotion or arrest depending 
on cell type, appeared within the nucleus of cardiomyocytes by day 11.5 p.c. 
Coexpression and colocalization with cdk4 and cdk6 was present. However, 
by day 15.5, cyclin D2 was exclusively cytoplasmic. This was confirmed by 
subcellular fractionation and immunoblot analysis. Cyclin D3, first detected 
at embryonic day 12.5 pc. within the nucleus, remained present throughout 
cardiogenesis. Cyclin dependent kinases 4 and 6 were both detected as early 
as day 9.5 pc. with no change in relative expression levels throughout the 
neonatal period. 
Conclusions: These data demonstrated cell cycle arrest in subsets of 
cardiomyocytes beginning during the mid-embryonic period of cardiac de- 
velopment and progressively increases throughout cardiogenesis. Moreover, 
tissue-specific expression of cell cycle regulatory proteins, unlike hematopoi- 
etic and endoderm derived organ systems, is present and may contribute to 
cell cycle withdrawal via protein down-regulation and compartmentalization. 
I 
1161 146 Transcription Factor Control of Myogenic 
Differentiation in a Myogenic Model Cell Line 
Mercy Davidson, Jennifer Cho, Xiaoqin Qu, Donald Chen, Hal A. Skopicki. 
College of Physicians and Surgeons at Columbia University, New York, New 
York, USA 
The regulatory control of mesodermal differentiation into myocyte lineages 
(smooth, skeletal and cardiac) is apparently controlled at the highest levels of 
differentiation by the presence and absence of cellular determination factors. 
Using a membrane fusion protocol, we have isolated an immortalized cell 
216A ABSTRACTS - Cardiac Function and Heart Failure JACC February 2000 
line derived entirely from adult human cardiomyocytes. Cells do not sponta- 
neously contract in culture, but are capable of terminally differentiating when 
placed in low serum conditions, similar to H9c2 cells. To further understand 
the regulatory role of transcription factors in determining their cellular pheno- 
type, we analyzed mRNA expression patterns for presence and absense of 
known regulators or markers of both skeletal and cardiac muscle lineages. 
Reverse transcription followed by PCR with specific human primers indicated 
the presence of GATAVI and ANP transcripts, but not GATA IV. Nkx2.5 mRNA 
was detected only in differentiated ceils, consistent with the expression of car- 
diac-specific lineage markers. Transient transfection overexpression of TGFB 
family members in proliferating cells resulted in the temporally restricted ex- 
pression of Nk2.5, indicating competence for cardiomyocyte determination. 
Interestingly, Myf5, but not MyoD or myogenin, was detected at both the pro- 
tein and mRNA level in proliferating and differentiating cells. No downstream 
markers of the skeletal muscle lineage were expressed, indicating a block in 
the skeletal muscle paradigm. 
Conclusion: These data suggest the presence of competent periods for 
cardiomyocyte determination and the ability of cardiomyocyte-derived muscle 
cell lines to inhibit skeletal muscle determination despite Myf5 expression. 
1 Ii 61-I 47 1 Spl-Dependent Expression of the Cardiac 
Troponin T (cTNT) Gene in Avian Embryonic 
Myocytes can be Compensated for by the MEF-2 
Site of the cTNT ‘Cardiac Element’ 
Anthony Azakie, Doff B. McElhinney, S.B. Larkin, Ian K. Farrance, Charles 
P. Ordahl. University of California, San Francisco, CA, USA 
Background: Sarcomeric proteins are coordinately expressed during my- 
ocardial differentiation, implying common mechanisms of cardiac-specific 
gene regulation, cTNT is expressed throughout development in avian cardiac 
myocytes (CM) and until day 19 of embryogenesis in skeletal muscle (SM). 
A minimal promoter (-129 cTNT) is sufficient for high levels of expression 
in embryonic SM. High levels of expression in CM, however, require an ad- 
ditional promoter element between -268 and -201, which has been termed 
the ‘cardiac element’ (CE). In addition to binding sites for other transacting 
factors, the cTNT promotor contains a GC box at -55 to -50 that appears to 
be a binding site for the zinc-finger transcription factor Spl. In this study, we 
examined the contribution of Spl and its GC box binding site to regulation of 
the cTNT gene. 
Methods and Results: Western blot analysis of nuclear extracts from 
CM and SM of day 12 and 19 chick embryos revealed equivalent levels of 
Spl. DNA binding assays of the GC box showed 2 sequence-specific protein 
species bound in both CM and SM extracts, 1 ofwhich comigrated with purified 
Spl protein.Transienttransfectionsof PrimaryembryonicCM with theminimal 
promoter containing a mutated Spl site resulted in a 5-6 fold reduction of 
reporter gene expression relative to wild-type promoter. When the region of 
CE containing the A/T-rich (MEF-2) site was placed upstream of the mutated 
minimal promoter, cTNT expression was restored to levels greater than those 
seen with CE upstream of wild-type minimal promoter. 
Conclusion: These results suggest that the Spl binding site is important 
for operation of the minimal promoter in embryonic CM, but can be compen- 
sated for by upstream placement of the A/l-rich site from the cTNT CE. 
I 1161 148 Novel Induction of Heat Shock Proteins by Magnetic Field Stress in Myocytes in vitro and in 
vivo 
Masatomo Nakao, Richard Wu, Martin Blank, Arthur Pilla, Reba Goodman, 
Hal A. Skopicki. Osaka Medical College, Osaka, Japan; The College of 
Physicians & Surgeons at Columbia University: New York, New York, USA 
Heat-shock protein (Hsp) induction has been previously demonstrated to.pro- 
tect myocardial cells from anoxic, ischemic and growth-factor deprivation in- 
jury. Prior attempts to induce Hsp expression in cells have been limited by the 
cellular toxicity of drugs used or the modest levels of Hsp induction obtained. 
We have recently demonstrated that low frequency magnetic field stress can 
potently induce Hsp70 protein levels in vitro and promote cell survival in viva. 
Moreover, we have isolated a magnetic-field responsive enhancer element 
in the Hsp70 promoter. Therefore, we hypothesized that control of Hsp70 
induction, both in vitro and in vivo, could be achieved by modulation of an 
external magnetic field. Proliferating H9c2 cells exposed to a 8 mG 60 Hz 
frequency field manifested induction in Hsp70 reporter gene expression at 14 
orders of magnitude lower energy than heat stress. This was significant when 
compared to 2-3 fold increases in control Hsp70 proteins levels from cells 
exposed to hyperthermia at 43°C (p < 0.01). Mutation of the enhancer ele- 
ment NCTCTN completely abolished the electromagnetic (EM) field induction 
of Hsp70. In viva, B57BU6 mice (n = 40) were exposed to 60 Hz magnetic 
fields (sinusoidal or quasirectangular EM stresses) at varying field strengths 
and the induction of Hsp70 at the protein level by immunoblot was assessed 
at 30 minutes, 1, 2 and 5 hours. A biphasic response was noted with a nearly 
40% relative increase in Hsp70 protein levels at 30 minutes followed by a 
second 60% increase at two hours. In vivo augmentation increased linearly 
with increasing field strength into the toxic range. 
Conclusion: Magnetic field induction of Hsp70 offers the potential of a 
non-invasive, highly effective means of inducing myocardial Hsp cytoprotec- 
tion in vivo. 
) 1161-I 49 1 Early Apoptosis in the Non-lschemic Area After 
Myocardial Infarction 
Kerstin Schwarz, Gregor Simonis, Nicole Herzog, Ruth H. Strasser. Dept. of 
Cardiology University of Heidelberg Medical Centec Heidelberg, Germany 
Background: In the non-ischemic area after a myocardial infarction, struc- 
tural changes of the myocardium occur. This remodeling of the infarcted heart 
is associated with adverse clinical outcome. If increased apoptosis may con- 
tribute to the remodeling in this normally perfused area of the heart and if these 
processes are triggered at an early time point after the myocardial infarction 
has not been shown so far. To address this question, regional myocardial 
ischemia in a closed chest model of rat hearts was used. 
Methods: LAD ligation was performed in male Wistar rats (150 9). Sham- 
operated animals served as controls. After 7 days and 4 weeks, left ventric- 
ular enddiastolic pressure (LVEDP) was determined to confirm heart failure. 
In biopsies from the nonischemic, left ventricular posterior wall, the levels 
of activated caspase 3 and of the bcl-2 and bax protein were determined by 
Westernblot analysis and compared to the sham-operated controls. 
Results:. LAD ligation for 7 days resulted in moderate heart failure, as 
indicated by an increase in LVEDP to 13 mmHg (Controls, 6 mmHg). Overt 
signs of severe heart failure such as pleural effusion were absent. Activated 
caspase 3 as detected by proteolytic cleavage of the enzyme’s precursor 
protein was increased by 59 & 22%. The bcl-2/bax ratio was shifted to lower 
values, demonstrating an increased rate of apoptosis in the remote area as 
early as 7 days after the ischemic insult. These markers of apoptosis were 
similarly increased 4 weeks after myocardial infarction. 
Conclusion: Already after 7 days of chronic myocardial infarction, in- 
creased levels of apoptotic marker proteins can be observed in the nonis- 
chemic, remodeling myocardium. The increase of apoptotic markers in close 
association with mild signs of heart failure indicate that apoptosis is rapidly 
initiated in the area remote from the infarction. The trigger for this apoptosis at 
a distance is unknown but might be an important therapeutic target to prevent 
remodeling after myocardial infarction. 
1161-I 50 Sodium and Calcium ion Effects on Bioenergetic 
Processes in Diabetic Heart Mitochondria 
Andriy M. Babsky, Nicolai M. Doliba, Nataliya M. Doliba, Andrey Savchenko, 
Suzanne Wehrli, Juan Crestanello, Mary D. Osbakken. University of 
Pennsylvania, Philadelphia, Pennsylvania; Children’s Hospital, Philadelphia, 
Pennsylvania; MCP Hahnemann, Philadelphia, Pennsylvania; Covance, 
Princeton, New Jersey; USA 
Background: We and others found that baseline intracellular Na+ is approx- 
imately two times higher in diabetic (DM) cardiomyocytes than in Control 
(CON). We also find that Na+ (0.1-10 mM) can depress State 3 respiration 
in isolated heart mitochondria (Mito) and that DM Mito are more sensitive to 
Nat than CON Mito. We hypothesize that Na+ induced changes are realized 
through activation of the Na+/Ca*+ exchanger in the mitochondrial membrane, 
which leads to decrease of intramitochondrial Ca”+. If this is the case, addi- 
tion of Ca2+ prior to Na+ should prevent the Na+ induced changes on State 3 
respiration. 
Methods: To further evaluate this hypothesis Mito were isolated from 
hearts of CON and streptozotocin-induced (4 weeks) DM rats. Mito respi- 
ration and ADP phosphorylation were studied using routine polarographic 
techniques. Ca2+ (in free concentrations 0.035 PM and 0.114 @M) was added 
into the polarographic cuvette before addition of 3 mM Na+. Two min after Na+ 
addition, Mito respiration was activated by ADP. 
Results: In DM, Na+ decreased State 3 to lower levels than in CON. Gas+ 
(0.035 PM) reversed the Na+ depressant effect on State 3 in CON (p < 0.05), 
but not in DM. The higher concentration of Ca*+ (0.114 PM) increased State 3 
above baseline in both CON and DM. Similar Na+ and Ca*+ induced changes 
were found for the rate of ADP phosphorylation, but not for State 4 respiration 
and ADP/O ratio. 
Conclusion: These data support our hypothesis that increased intracellu- 
lar Na+ in DM cardiomyocytes can led to depletion of Mito Ca”+ which in turn 
can influence of ATP synthesis. 
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1162-l 51 Low Incidence of Ventricular Arrhythmias in 
Patients on Low Dose Parenteral lnotropes at 
Home Awaiting Cardiac Transplant Using an 
External Wearable Defibrillator 
Simon Maybaum, Marie Ellena Cordisco, Donna Mancini. Columbia 
Universitl: New York, New York, USA 
Background: Previous reports have suggested that home inotropic therapy 
in patients with end stage CHF is associated with an increased mortality, pre- 
sumably due to an increase in arrhythmia. Due to the change in UNOS guide- 
lines since l/20/99, hemodynamically stable cardiac transplant candidates 
have been discharged on low dose parenteral inotropic therapy (dobutamine 
~7.5 w/kg/min, milrinone ~0.5 pikgimin). We assessed the frequency of com- 
plex ventricular arrhythmias in patients on and off inotropes at home awaiting 
cardiac transplant. 
Methods: 18 patients listed for transplant were discharged home with a 
LIFECOR external defribiltator (11 patients on inotropes, 7 without). 3 pa- 
tients were treated with amiodarone and 8 with a beta-blocker. The LIFECOR 
defibrillator is a vest like garment that uses 4 sensing chest electrodes. The 
investigator programs the minimum heart rate for arrhythmia detection and de- 
fibrillation energy level for each patient. This device provides continuous EKG 
monitoring and can discharge 2 shocks at 200 or300 joules. Arrhythmia detec- 
tion rate was programmed above 140 bpm (range 140-I 70; mean 162 i 10 
bpm). 2 lead EKG strips generated by device alarms or patient symptoms were 
reviewed. An event was defined as 3 or more consecutive ventricular beats. 
Results: A total of 10183 monitored hours (mean wear time per patient 
566 + 955 hours) were reviewed. There were only 3 (asymptomatic) events 
and no therapy was delivered. 2 of the 3 events were in the inotrope group. 
One patient off inotrope was hospitalized with a wide complex tachycardia 
that was determined to be rapid atrial fibrillation with aberrancy. There was 1 
sudden death in a patient on inotrope who was not wearing his defibrillator at 
the time. tn 634 hours of previous monitoring, he had had no events. 
Conclusions: Although we continue to recommend continuous monitor- 
ing for patients on parenteral inotropic therapy at home or in hospital, there 
appears to be a low incidence of complex ventricular arrhythmias in patienfs 
with end stage CHF on low dose parenteral inotropic therapy. 
/ 1162-f 52 1 Angiotensin II-Type-1 (ATl) Receptor Blockade 
With 80 mg of Valsartan is Incomplete in Patients 
With Congestive Heart Failure (CHF) 
Ulrich P. Jorde’ , Vana Suryadevara, Thierry H. Le Jemtel. ‘Columbia 
University; Albert Einstein College of Medicine, New York, New York: USA 
Background: ATI-receptor blockers (ARB) may provide an alternative or 
additional means to angiotensin converting enzyme inhibitors (ACEI) to sup- 
press the renin-angiotensin system in CHF. We have previously reporteded 
variable vascular reactivity (VR) to angiotensin II (All) in pts with CHF, i.e. the 
peak response (PR) in systolic blood pressure (SBP) to 5 rig/kg (All) ranged 
from O-27 mmHg. It is unknown whether this variability in VR is relevant in the 
response to standard dose ARB. 
Methods: 32 pts with CHF (NYHA ll/lll(3/31), LVEF < 45% (32 f 9), serum 
creatinine < 2.5 mgidl) who had received full dose (40 mg daily of a long acting 
or 150 mg of a shortacting) ACEI for at least 3 months were studied. Ascending 
(2.5, 5, 10, 20, 40, 60, 80, 100 rig/kg) doses of exogenous All (Clinalfa Ag, 
Switzerland) were injecfed prior and 90 min after oral administration of 80 
mg of valsartan to determine the dose required to elicit a rise in peak SBP of 
20 mmHg (PD20). Blood pressure and heart rate were recorded continously 
using beat per beat, non-invasive monitoring (Colin Pilot, San Antonio, Texas). 
Results: The PD 20 before and after valsattan is shown in the figure. 
Mean PD20 changed from 10.5 (lt4.9) to >76.4 (125.4 mmHg). The PR to All 
was fully inhibited (i.e. PD20 t 75 n/kg) in 24134 pts. When pts were grouped 
according to the initial PD20 (O-5, 610, >lO), the PR was fully inhibited in 
2/11, 10/11, and II/11 pts, respectively. PD20 before and after ARB were 
correlated significantly (R 0.55, P 0.001). 
Conclusion: 80 mg of valsartan acutely is not sufficient to fully inhibit the 
PR to All, i.e. block all AT-I receptors, in about 4 of patients with CHF on full 
dose ACEI therapy. The dose of ARB required for full blockade is variable in 
these pts and may be defined by the pressor response to All. 
1162-l 53 ACE Inhibition and All Blockade Following 
Experimental Myocardial Infarction: Effects on 
Ventricular Hypertrophy, Remodeling and 
Function 
Arun J.C. Prahash’ , Sudhir Gupta, lnder S. Anand. ‘Department ofMedicine; 
Division of Cardiology VAMC and University of Minnesota, Minneapolis, USA 
Background: ACE-inhibition (ACEi) has been proven to improve ventricular 
remodeling and survival following a myocardial infarction (Ml). We compared 
the effects of ACEi (Enalapril 1 mg/kg), Angiotensin II receptor blockade (Allb, 
Candesattan 10 mg/kg) and their combination on ventricular hypertrophy and 
remodeling in a rat model 6 weeks post-Ml. 
Methods: Sprague-Dawley rats were randomly assigned to different treat- 
ment groups (ACEi, Allb, ACEi + Allb) or water (Control) within 24 hours of 
MI and treated for 6 weeks. Ventricular remodeling was assessed by echocar- 
diography at 5 weeks post-MI in all hearts. At 6 weeks, hemodynamics was 
studied in separate groups by carotid catheterization (Group 1: Mean arterial 
and LV end-diastolic pressure) and isolated heart perfusion (Group 2: Iso- 
volumic LV developed pressure and dP/dt). Ventricular septal thickness was 
quantified in fixed tissue sections to measure compensatory hypertrophy. 
Control ACEi Allb ACEi+ 
(N, Groups 1,2) 
infarct Size. % LV 
(683 
28-c2 
W4 
28 i 6 
(654 
28 12 
Allb (6,6) 
21 &4 
Septal thickness, mm 2.12 f 0.01 1.8 i 0.06 1.7fo.i* 1.6* o.i* 
Heart WtITibia, g/cm 0.51 * 0.02 0.48 i 0.02 0.41 -i- 0.02* 0.40 i 0.02* 
LV dimension, mm 7.2 i 0.04 7.0 i 0.05* 6.3 + 0.05*+ 6.6 * 0.03*+* 
MAP, mm Hg 96 z!z 8 84 i 8 58 i 6* 49 + 6”* 
LVEDP, mm Hg 1511.7 6 i 1.6” 3 i 0.9* 2 f 0.4* 
LVDP, mm Hg 56 + 9 91 *5* 75 * 5 94 iz 4* 
LVdP/dt, mm Hg/sec 1423 xt 220 1983*106 1755+ 101 2188zt 102* 
P < 0.05 * Vs Control, + Vs ACEi and, * Vs Allb 
Allb either alone or in combination with ACEi significantly reduced com- 
pensatory LV hypertrophy following Ml while ACEi alone did not. Both ACEi 
and Allb reduced LV chamber remodeling with the combination providing 
added benefit to either of the treatments alone. While all treatments reduced 
invivo LVEDP, Allb treated rats had significantly lower MAP. ACEi and Allb 
combination also improved LV systolic function in isolated hearts. 
Conclusion: Post-Ml Allb favorably alters LV chamber remodeling and 
cardiac hypertrophy and provides additional benefit when combined with 
ACEi. 
1 1162-l 54] @ Blocker Use in Heart Failure: Which Patient 
Characteristics Determine Physician Use of p 
Blockers in Community Practice? 
Edward F. Philbin, Thomas A. Rocco, Jr., Paul L. Jenkins. Henry Ford 
Hospital, Detroit, MI; Unify Health System, Rochester, NL: USA 
Background: Because b adrenergic blockers @B) reduce mortality and pre- 
vent disease progression in patients with heart failure (HF), they have an 
emerging role in its treatment. The purpose of this study was to describe 
those patient-specific characteristics that determine physicians’ selection of 
candidates for prescription of flB in community practice. 
Methods: From a registry of 2,906 unselected consecutive patients with 
confirmed HF admitted to IO acute care community hospitals during 1995 
and 1997, we identified 2,351 hospital survivors who had complete chart 
abstraction and prospective follow-up for 6 months after hospital discharge. 
Results: Mean age (75 & 11 years), sex (55% women) and mean left ven- 
tricular (LV) ejection fraction (EF) (36 i 15%) were similar to other community 
hospital-based cohorts. @B were prescribed to 405 of 2,351 patients (17%) 
at hospital discharge, BB use increased from 1995 to 1997 (14% vs. 20%, P 
< 0.0001). Bivariate analyses demonstrated numerous differences between 
patients treated with BB and those not. The IO significant determinants of BB 
use derived from logistic regression using stepwise selection are shown in 
the Table (OR = adjusted odds ratio, Cl = confidence intervals). Notably, indi- 
cators of HF severity (duration of HF, NYHA functional class, serum sodium, 
radiographic cardiomegaly, atrial fibrillation and ventricular arrhythmia) were 
not significant predictors. Also, age, sex, race and socioeconomic status were 
not significant 
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Predictor OR (95% Cl1 Predictor OR (95% Cl) 
~  I  
Acute ischemia 1.98(1.16-3.39) IV diuretic drip 0.63 (0.42-0.94) 
Hvcertension 
Lv’EF z 40% 
1.83 (1.33-2.53) 
1.56 il.l&2.06j 
2 oral diuretics 0.30 (0.14-0.65) 
Digitalis use 0.70 (0.5%0.92j 
1997 (vs. 1995) 2.18(1.61-2.96) Nitrate use 1.33 (1.02-1.75) 
Cardiologist 2.06 (1.49-2.84) Aspirin use 1.47 (1.12-1.93) 
Conclusions: In patients with HFtreated in thecommunity setting, gB use 
increased from 1995 to 1997, with cardiologists being more likely to prescribe 
these drugs than other physicians. lschemic heart disease, hypertension and 
diastolic HF appear to be the major determinants of gB use, while classic 
indicators of HF severity are not. Thus, vigorous educational programs may 
be in order to improve clinical practice. 
1 1162-l 55 1 Baseline Predictors of Tolerability of 
Beta-Blockade in Patients With Chronic Heart 
Failure: The Carvedilol Open-Label Assessment 
(COLA) Study 
Henry Krum, Daniel Ninio, Peter MacDonald. For the COLA Investigators; 
Monash University, Prahran, Victoria, Australia 
BackgrounU: Beta-blockers have been found to be highly efficacious and 
well-tolerated in clinical trials of patients (pts) with chronic heart failure (CHF). 
However, it, is uncertain whether these agents are as well-tolerated in ev- 
eryday clinical practice, outside of the trial setting. To address this question 
we performed a retrospective analysis of tolerability in 700 consecutive pts 
prescribed the alpha/beta-blocker, carvedilol, specifically for CHF. 
Methods: Tolerability was assessed in both hospital specialist (503 pts) 
and private (192 pts) practice.Tolerabilitywasdefined ascurrentlyon catvedilol 
or on this therapy at time of death or transplantation. In order to meet criteria 
for tolerability, carvedilol had to be prescribed at a stable dose for 13 months. 
Results: Within the cohort, 78 pts had stopped catvedilol, 539 pts were 
currently receiving the drug, 43 pts had died and 35 pts had been transplanted. 
Overall, 89% of pts tolerated carvedilol (88% hospital specialists, 92% private 
practitioner). Baseline predictors of tolerability were assessed by proportional 
hazards analysis. Factors that indicated worse tolerability by uni-variate anal- 
ysis were increased age (relative risk [RR] 1.02, 95% confidence interval [Cl] 
1.0-l .3), low diastolic blood pressure (RR 1.03,95% Cl 1.01-l .06) and raised 
plasma urea (RR 1.03, 95% Cl 1.02-I .05). NYHA Class was also a marker 
of tolerability (% not tolerated: 4% Class I; 10% Class II; 13% Class Ill & 18% 
class IV). However, no single baseline parameter was an independent marker 
of inability to tolerate carvedilol by multi-variate analysis. We also sought to 
assess tolerability according to traditional precautions or contraindications to 
beta-blockade. Tolerability for these sub-groups were: COPD/asthma 86% 
(76 pts), diabetes 86% (117 pts), peripheral vascular disease 85% (51 pts), 
concomitant amiodarone therapy 84% (192 pts) & head rate ~70 bpm 82% 
(91 pts). 
Conclusion: Beta-blocker therapy was well tolerated in everyday clinical 
practice, including non-hospital-based private practice. There was no single 
multi-variate predictor of poor tolerability, although there was a clear associ- 
ation with NYHA class as well as age, diastolic blood pressure & serum urea 
on univariate analysis. Carvedilol was tolerated well.among selected patients 
with traditional precautions for prescribing of beta-blockade in CHF. 
1162-l 56 Carvedilol Dose-Response in Heart Failure: 
Experience in Clinical Practice 
Lou Vadlamani, Donald Wayne, D.P. Suresh, Vijay Sanghvi, Lynne Wagoner, 
Mark Meyer, Sumant Lamba, William T. Abraham. Univefsifyof Cincinnati 
College of Medicine and Greater Cincinnati Cardiovascular Consultants, 
Cincinnati, Ohio, USA 
Background: Several randomized controlled trials have demonstrated the 
clinical benefits of beta-blockade in patients with systolic heart failure (HF). 
Howeverwithonlyone exception, the Multicenter Oral Catvedilol Heart Failure 
Assessment (MOCHA), these studies have mandated a forced-titration to a 
target beta-blocker dose. Thus, little is known about the dose-related effects 
of beta-blockade in HF. 
Methods: We reviewed 194 cases of chronic carvedilol use in clinical prac- 
ticefrom 2sites a university-based heartfailureclinicand acommunity-based 
cardiology practice. The characteristics of the HF patients were: age, 55.0 f 
I .l years (range 21-82); gender, 113 men and 81 women; race, 106 white and 
88 African American; etiology, 104 ischemic (ISC) and 90 nonischemic (IDC); 
and baseline LVEF 31 IIZ 6%. Carvedilol dose was determined by patient tol- 
erance and did not differ by site of practice. Doses ranged from 6.25 mg/day 
to 100 mg/day. LVEF was re-evaluated 4-8 months following maintenance 
therapy. 
Results: For the entire group, LVEF significantly increased by 6.03 f 
0.41% (p < 0.001). The increase in LVEF was greater in IDC compared to ISC 
(9.10 f 0.56 vs. 3.37 f 0.47%, p < O.OOl), confirming previous observations. 
There was no effect of race nor gender on the LVEF response. However, a 
significant dose-response relationship was observed. For the most commonly 
prescribed doses, 12.5 mg/day (n = 22) 25 mg/day (n = 52) and 50 mg/day 
(n = 87), the change in LVEF was 2.22 f 0.99%, 5.75 f 0.77%, and 8.03 f 
0.58%, respectively (p < 0.001). 
Conclusion: These observations support a dose-response relationship 
for beta-blockade in HF. 
/ 1162 157 Ranolazine Improves Left Ventricular 
Performance in Dogs With Chronic Heart Failure 
Hani N. Sabbah, Takayuki Mishima, Brandon J. Biesiadecki’ , 
George Suzuki, Pervaiz Chaudhry, Omar Nass, Brent Blackburns, 
Bee-Lian Huang* , William C. Stanley’ Henry Ford Heart and Vascular 
Institute, Detroit, Michigan; ‘Case Western Reserve Universig Cleveland, 
Ohio; “CV Therapeutics, Inc., Pa/o Alto, California, USA 
Background: Abnormalities of energy metabolism are often cited as key ele- 
ments in the progressive worsening of LV dysfunction that characterizes the 
heart failure (HF) state. We tested the hypothesis that switching the substrate 
use of the heart away from fatty acids toward glucose will ameliorate the 
hemodynamic abnormalities associated with HF. 
Methods: LV dysfunction and failure (LV ejection fraction 27 i 2%) was 
produced in 7 dogs by intracoronary microembolizations. Hemodynamic mea- 
surements were made before (PRE) and after (POST) intravenous adminis- 
tration of ranolazine, a partial fatty acid oxidation (pFOX) inhibitor devoid of 
any positive inotropic effects. Ranolazine was given as a bolus (0.5 mg/kg) 
followed by a continuous infusion for 40 min (1 .O mg/kg/hr). 
Results: Ranolazine significantly improved LV function, tended to reduce 
preload and had no undesirable effects on heart rate or systemic pressure: 
Pre Post P-value 
Heart Rate (beats/min) 
Mean Aottic Pressure (mmHg) 
LV End-Diastolic Pressure (mmHg) 
Peak LV +dP/dt (mmHg/sec) 
Peak LV -dPidt (mmHg/sec) 
LV stroke Volume (ml/stroke) 
LV End-Systolic Volume (ml) 
LV Eiection Fraction (%) 
69zt5 
92 * 9 
1351 
1673f157 
1581zk144 
2ozt2 
55f3 
27zk2 
6615 0.175 
102zt6 0.153 
11f2 0.038 
1920*133 0.038 
1854*110 0.044 
27z!zl 0.001 
49*3 0.001 
3552 0.001 
Conclusion: Shifting substrate use away from fatty acids oxidation with 
RAN acutely improves LV performance in dogs with HF. Additional studies are 
needed to determine whether the observed benefits can be maintained with 
chronic therapy. 
I 1162 158 Effect of Carnosine on Left Ventricular Systolic and Diastolic Performance Before and After 
Congestive Heart Failure 
Hideo Tachibana, Tomohiko Ukai, Katsuya Onishi, Heng-Jie Cheng, 
Zhu-Shan Zhang, Che-Ping Cheng. Wake Forest Universify Schoolof 
Medicine, Winston-Salem, NC, USA 
Background: Carnosine (CAR) (B-alanyl-I -histidine) is an endogenousdipep- 
tide with high concentrations in the heart. Its levels have been reported to 
decrease in several pathologic states associated with myocardial depression 
and cellular [cas’], deregulation. However, its direct cardiac effect is unclear. 
Its functional significance in heart failure (CHF) is unknown, 
Methods: We assessed the cardiac and vascular responses to CAR in 
8 chronically instrumented, conscious dogs before and after pacing-induced 
CHF. 
Results: Before CHF, CAR (0.2-0.33 mmol/kg/min, iv) caused rapid, sus- 
tained (up to 30 min) reductions in left ventricular (LV) end-systolic pressure 
(Pss 88 vs 95 mmHg), the total systemic resistance (TSR, 0.070 vs 0.076 
mmHg/ml/min) (p <r 0.05), but without significant changes in heart rate (HR) 
and the time constant of relaxation (r, 31.1 vs 32.3 ms). LV contractile per- 
formance, measured by the slopes of LV pressure (P) volume (V) relations 
(Rs), was also unaffected. After CHF, CAR produced similar reductions in 
Pss (84 vs 90 mmHg) and TSR (0.084 vs 0.090 mmHg/ml/min). However, t 
(48.3 vs 51.9 ms) and minimum LV P (15.2 vs 18.7 mmHg) were significantly 
decreased. Stroke volume (9.6 vs 8.9 ml) was increased due to a decreased 
end-systolic V (Vss, 40.6 vs 41.5 ml). The slopes of P-V Rs (EEs, 4.9 vs 3.7 
mmHg/ml; dE/dt,,,, 50.7 vs 36.6 mmHglsec/ml; MSW, 48.7 vs 43.5 mmHg) 
(p < 0.05) were increased with CAR, indicating enhanced LV contractility. 
Similar observations were obtained at constant HR with right atrial pacing or 
autonomic blockade. 
Conclusion: In conscious animals, both before and after CHF, CAR is 
equally effective in producing arterial vasodilation. However, only in CHF does 
CAR augment both LV contractility and the rate of relaxation. 
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/ 1162 159 Anabolic Steroids Improve Myocardial Performance in Dilated Hearts in Failure 
Haruo Tomoda, Naoto Aoki. To!& University Hospital and Yamafo Seiwa 
Hospital, Kanagawa, Japan 
Background: In advanced cardiac diseases, morphological and functional 
restoration of the deteriorated myocardium may be an important therapeu- 
tic intervention. This study was undertaken to investigate whether anabolic 
steroids, which are reported to increase cardiac muscle as well as skeletal 
muscle in normal subjects, could improve myocardial performance in dilated 
hearts in failure. 
Methods: Twenty patients with left ventricular (LV) diameter of more than 
60 mm were studied (dilated cardiomyopathy IO, aortic regurgitation 5 and mi- 
tral regurgitation 5). All of them were placed on oral administration of anabolic 
steroid, oxymetholone (n = 12) or metenolone (n = 8) (5 or IO mg daily; average 
6.7 i 0.7 mgiday), for 3 months, Conventional cardiac medications were not 
changed throughout the study period. LV myocardial performence was eval- 
uated by Doppler echocardiographic methods, and the following parameters 
were derived: LV end-diastolic diameter (Dd), LV end-systolic diameter (Ds), 
LV mass, LV ejection fraction (EF), LV end-systolic wall stress, isovolumic 
relaxation time (IRT), and the ratio of early to late mitral flow velocities (A/E). 
Plasma atrial and brain natriuretic peptides (ANP and BNP) were measured 
by immunoradiometric assay. 
Results: Dd decreased from 68 rt 2 mm to 64 i 2 mm (p < O.OOi), Ds 
decreased from 53 & 3 mm to 47 i 3 mm (p < O.OOl), LV mass decreased 
from 373 & 32 gm to 339 + 29 gm (p c 0.005), EF increased from 42 i 5% 
to 50 f 5% (from 28 f 2% to 38 * 4% in dilated cardiomyopathy, p < 0.002), 
and LV stress decreased from 160 ZIZ 17 x 1 O3 dynes/cm” to 134 f 17 x 1 O3 
dynes/cm* (p < 0.001) after 3 months of drug administration. IRT and A/E did 
not show significant change. Plasma ANP decreased from 50 & 5 pgiml to 22 
f 3 pg/ml (p x O.OOl), and BNP decreased from 105 + 12 pg/ml to 55 & 13 
pgiml (p < 0.001). Patients’ activity based on NYHA classification improved 
from 2.4 5 0.2 to 1.9 i 0.2 (p < 0.05). There was no significant difference in the 
effects by oxymetholone and metenolone. There were transient side effects of 
digestive organs in 3 cases by oxymetholone, but there was no apparent side 
effect by metenolone. 
Conclusion: Anabolic steroids were shown to improve LV myocardial per- 
formance in dilated hearts in failure, most probably by directly improving my 
ocardial contractile ability. 
POSTER 
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Tuesday, March 14,2000, Noon-2:00 p.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: 1:OO p.m.-2:OO p.m. 
1163-l 20 Death Rates From Heart Disease in Los Angeles 
County (1987-1997): Reductions in White and 
African Americans but Increases in Hispanics 
and Asian/Pacific Islanders 
Robert A. Kloner, Hong Chen. Heart Institute, Good Samaritan Hospital 8 
University of Southern California, Los Angeles, CA, USA 
Background: Death rates from heart disease have declined in the United 
States since the 1950’s. The purpose of our study was to determine whether 
this benefit occurred in all subgroups of the population by age, gender, and 
race over the last decade in Los Angeles County. 
Methods: 234,095 death records for Heart Disease in Los Angeles County 
were obtained from Los Angeles County Department of Health between 1987 
and 1997. 
Results: Crude death rates for heart disease fell for patients over the age 
of 65 between 1987 and 1997 from 299 per 100,000 population per year to 
171 (p = 0.0001) and for patients under 65 (68.5 to 34.9, p = NS). Age adjusted 
death rates of heart disease (per 100,000 population) fell between 1987 and 
1997 by 23% (from 180 in 1987 to 139 in 1997; p = 0.0001). These rates fell 
for men (from 225 to 187; p = O.OOOl), women (142 to 101; p = O.OOOl), whites 
(194 to 133; p = O.OOOl), and African Americans (301 to 222; p = 0.0006), 
but actually increasedfor Hispanics (112 to 123; p = 0.003) and Asian/Pacific 
islanders (78 to 105; p = 0.001). Among these were increases for-Chinese, 
Korean, Filipino, Mexican and Central American populations. 
Conclusions: While there has been a steady decline in death from heart 
disease in Los Angeles County in men, women, and elderly there does appear 
to be differences in response by race. African Americans and white patients 
experienced substantial reductions over the ten-year period, while Hispanic 
and Asian/Pacific Islanders experienced a significant increase. The mecha- 
nism is unknown but may include differences in various socioeconomic, di- 
etary, and cardiac risk factors. If these factors can be identified then perhaps 
they can be modified to reverse the trend toward an increase in death rates in 
Hispanics and in Asian Pacific Islanders in Los Angeles County, California. 
\1163-121 1 Long Term Survival Following CABG and PTCA 
in the Elderly: A Study of 4,993 Patients in 
Northern New England 
F. Lee Lucas, Paul D. McGrath, David J. Malenka, Hebe Quinton, Mirle 
A. Kellett Jr., Thomas J. Ryan Jr., Robert Clough, Theodore Silver, 
Peter VerLee, David E. Wennberg, Gerald T. O’Connor. For fhe Northern 
New England Cardiovascular Disease Study Group, Lebanon, NH, USA 
Background: The elderly represent a rapidly growing population offered by- 
pass (CABG) and angioplasty (PTCA). We sought to determine long term 
survival following revascularization in Northern New England. 
Methods: We studied 4,993 patients age 2 75 undergoing CABGiPTCA 
during 1992-96. Records were linked with the National Death Index to deter- 
mine long-term survival. Proportional hazards regression was used to adjust 
for case-mix. 
Results: Total follow-up time was 9740 person-years (mean 1.9 person 
years). Overall, the estimated adjusted probability of survival was 90.1% at 
one year and 78.4% at 4 years. CABG patients had a 25% reduced hazard of 
mortality versus PCI patients (RH 0.75, 95% Cl 0.64-0.89). 
I, CABG 
0 1 2 3 4 5 
Years 
Conclusion: The majority of elderly patients survive 4 or more years af- 
ter CABG or PTCA. CABG may confer a survival advantage compared with 
PTCA. 
/ 1163-l 22 1 Explaining the Relationship Between Age, 
Cardiogenic Shock and Outcomes: 
Echocardiographic Observations From the 
SHOCK Trial 
James L. Januzzi, Ravin Davidoff, Lisa A. Mendes, Christopher 
R. Thompson, Lynn A. Sleeper, Richard Steingart, Ken Gin, Vladimir Dzavik, 
Mark Goldberger, Judith S. Hochman, Michael H. Picard. Forfhe SHOCK 
Investigators; Massachusetts General Hospital, Boston, Massachusetts, 
USA 
Background: The SHOCK (Should We Emergently Revascularize Occluded 
Coronaries for Cardiogenic Shock) trial was an international, multicenter ran- 
domized study, which compared the effects of early revascularization (ERV) 
strategy vs. initial medical stabilization (IMS) in patients with cardiogenic 
shock. Compared to younger patients, no survival benefit from ERV was seen 
in patients ~75 years of age. 
Methods: In order to better understand this finding, we systematically 
reviewed echocardiographic findings as a function of age among the two 
treatment groups at randomization, including measures of global LV function 
(left ventricular ejection fraction-LVEF, LV area change-LVAC), regional LV 
function (hypercontractility of distal myocardial segments-HC), and valvular 
disease (degreeof mitral regurgitation-MR, incomplete mitral leafletclosure-- 
IMLC). 
Results: Of the 302 patients randomized in the SHOCK Trial, 169 had 
interpretable echocardiograms, of which 127 had quantitiative data available. 
Among the patients aged z 75 years in the ERV group, 2/4 (50%) had an EF 
< 0.25, compared to lo/54 (19%) of the younger ERV patients. Among the 
patients aged 2 75 years in the IMS group, only 2/15 (13%) had an EF c: 
0.25, compared to 16/44 (36%) of the younger IMS patients (p = 0.009). When 
age was examined as a continuous variable, a significant inverse association 
between age and LVEF remained (p = 0.05). When compared with younger 
ERV patients, aged patients had more remote-zone HC (75% vs. 29%, p = 
0.05), and a trend towards lower LVAC (p = 0.10). There were no significant 
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differences in MR grade or IMLC detected between young or old patients 
irrespective of treatment strategy. 
Conclusions: These data suggest that elderly patients in the ERV group 
had a significant excess of low ejection fractions and remote-zone HC at 
randomization. This excess of high-risk findings among aged patients in the 
ERV may partially explain the apparent lack of benefit from an ERV strategy 
for patients z 75 years of age in the SHOCK trial. 
1 1163-I 23 ] Serial Echocardiographic and Clinical Follow up 
in Medicare-Aged Patients Undergoing 
Percutaneous Balloon Mitral Commissurotomy 
Richard A. Krasuski, John J. Warner, Andrew Wang, Katherine Kisslo, J. 
Kevin Harrison, Thomas M. Bashore. Duke University Medical Center, 
Durham, NC, USA 
Background: Percutaneous Balloon Mitral Commissurotomy (PBMC) can be 
performed safely in patients (pts.) of Medicare age. The long-term echocar- 
diographic and clinical results in this age group remain unclear. 
Methods: Serial 2-D and Doppler echocardiographic measures along with 
clinical findings were assessed in 57 elderly pts (ages 65-85, mean = 71) com- 
pared to 265 younger pts (ages 12-64, mean = 47) undergoing lnoue PBMC. 
Results: Baseline, 24 hour, 6 month and 3 year data were analyzed. 
Baseline echocardiographic scores were significantly higher in the Elderly 
(9.8 vs. 8.5; p = 0.001). In elderly pts. the post-procedural mitral gradient by 
echocardiography was similar (5.9 vs. 6.1 mmHg; p = NS), the planimetered 
MVA was smaller (1.7 vs. 2.0 ems; p = 0.008) and there was no difference 
in mitral regurgitation (MR) compared with the younger group. At 8 months 
the gradient was 5.6 vs. 5.4 mmHg (p = NS), the planimetered MVA was 
1.6 vs. 1.8 cm* (p = 0.003) and the MR grade was 1.5 vs. 1.3 (p = NS). By 
3 years the gradient was 6.5 vs. 5.4 mmHg (p = NS) and MVA 1.4 vs. 1.8 
(p = 0.002). MR grade was 1.8 compared with 1.3 in the younger pts (p = 
NS). The decremental change in the MVA from baseline was similar in both 
groups. From a symptom standpoint, there was no evidence of worsening in 
the elderly population over the same follow-up period. Three year event-free 
survival (death, repeat PBMC or mitral valve replacement) was similar in both 
groups (81% in the younger pts and 80% in the elderly group). 
Conclusions: Compared to a younger aged group the initial result of per- 
cutaneous balloon mitral commissurotomy in the Medicare aged population 
is less effective. Over time, serial echocardiographic data reveal a similar de- 
cline in the MVA in both groups. Symptoms remain improved, though, and 
long term outcome appears identical between the two groups. 
L-I.--l 1163 124 Predictive Value of the Annual 
Electrocardiogram (ECG) 
Mahesh Amin, Bruce J. Flareau, James L. Fozard, Daphene S. Gage, 
Jennifer R. Copeland, Bernadette 0. Stevenson, William E. Hale, Kevin 
J. Ferrick. Morton Plant Mease Health Care and Montefiore Medical Center, 
Bronx, New York, USA 
Background: ECGs are often performed routinely during annual physical 
examinations without clear benefit in risk stratification. The predictive value of 
performing these ECGs is unknown, 
Methods: In the Florida Geriatric Research Program (FGRP), longitudinal 
medical information is collected annually from men and women volunteers 65 
years and older. Over 1700 volunteers per year have participated for the past 
25 years. The data include health history obtained using self reported answers 
to a questionnaire in addition to a yearly ECG, screening blood work and blood 
pressure measurement. Mortality data is gathered through death certificates 
and verified by the primary care physician’s medical records. ECGs from 1992 
to 1999 were interpreted by a board certified cardiologist blinded to clinical 
status. ECGs for the 5 years preceding cardiovascular events or permanent 
pacemaker implantation were reviewed for 28 pre-determined abnormalities. 
Logistical regression analyses were used to assess statistical significance. 
Results: The age distribution of the population reviewed was 40% be- 
tween the age of 65-74, 44% between 7584 and 16% over the age of 85 
years. The population was 66% female. Of the 3153 charts reviewed, hyper- 
tension was found in 43% of the patients, 24% had established heat-l disease. 
EGG conduction abnormalities were noted in 29% (left anterior hemiblock 
12%, first degree atrioventricular (AV) block 7%, right bundle branch block 
6.6%, left bundle branch block3.1%, second degree AV block0.5%, leftposte- 
rior hemiblock0.2%), leftventricular hypertrophyin 12%and atrialfibrillation in 
5%. Between 1992 and 1999,322 myocardial infarctions, 558 new complaints 
of angina, 268 cerebrovascular accidents and 58 permanent pacemaker im- 
plantation occurred. No single abnormality identified on the ECG within 5 
years preceding a cardiac event predicted future events. 
Conclusion: The routine annual ECG is not predictive of an adverse car- 
diac event in an elderly patient without signs or symptoms of unstable cardiac 
disease. 
) 1163-I 25 1 Chronic Heart Failure in the Elderly: The Value of 
Cardiopulmonary Exercise Testing in Risk 
Stratification 
L. Ceri Davies, Darrel P. Francis, Massimo Piepoli, Adam C. Scott, 
Piotr Ponikowski, Andrew J.S. Coats. National Heart & Lung Institute, Royal 
Brompton Hospita/, Dovehouse St. London, SW3 6L): UK 
Background: Chronic heat-l failure (CHF) is common in the elderly and is 
associated with a poor prognosis. Cardiopulmonary exercise testing is widely 
used in the assessment of younger patients with CHF, but its usefulness in 
older patients is unknown. We set out to assess prognostic markers in a cohort 
of CHF patients over the age of 70 with 2-year follow-up. 
Methods: Between Januay 1992 and May 1997, 50 patients with CHF 
over the age of 70 (mean age 75.9 years [SD 4.5; range 70.2-86.11; 8 fe- 
male) were evaluated at the Royal Brompton Hospital. They underwent car- 
diopulmonary exercise testing (peak oxygen consumption (peak VOs): mean 
15.2 ml/kg/min [SD 4.51; VEIVCOs slope: mean 38.7 [SD 11.81) assessment 
of functional status (New York Heart Association [NYHA] class: 3 class I, 
25 class II, 20 class Ill, 2 class IV), radionucleide measurement of left-ven- 
tricular ejection fraction (mean 32.8% [SD 14.3]), measurement of serum 
sodium (mean 139 mmol/l [SD 2.81) and echocardiography (end-diastolic di- 
mension: mean 6.1 cm [SD 1 .I]; end-systolic dimension: mean 4.7 cm [SD 
1.51). 
Results: At the end of the follow-up period in May 1999,26 patients (52%) 
had died (median time to death 23.9 months, interquartile range 9.2-31.8 
months). The median follow-up duration for the survivors was 47.7 months (in- 
terquartile range 31.5-53.5 months). On univariate analysis, VENCOs slope 
(p < O.OOOl), NYHA class (p x O.OOl), peak VOs (p < 0.01) ESD (p < 0.05) 
and serum sodium concentration (p < 0.05) had significant predictive power. 
A multivariate model using these five variables identified only VENCOs (p < 
O.Ol), NYHA class (p < 0.05) and peak VOs (p < 0.05) as conveying signifi- 
cant independent prognostic information. 
Conclusions: Elderly patients with CHF have a high mortality (52% at 2 
years). Cardiopulmonary exercise testing provides important information for 
risk stratification within this group and has a role in their assessment. 
1163-l 26 Is Treadmill Exercise Testing Useful in the 
Elderly? A Population-Based Study in Olmsted 
County, MN 
Tauqir Y. Goraya, Steven J. Jacobsen, Susan A. Weston, Todd D. Miller, 
Patricia A. Pellikka, Bernard J. Gersh, Veronique L. Roger. Mayo C/inic, 
Rochester, USA 
Background: The prognostic value of TMET has been derived primarily in 
referral populations of middle-aged patients (median age < 55 years) at ter- 
tiay-care centers. The generalizibility to community dwelling elderly persons 
is uncertain. 
Methods: A population-based study of persons living in Olmsted County, 
MN who underwent TMET (1987-I 990) was undertaken to test the hypothesis 
that TMET has equal prognostic value among elderly (~65 years, n = 514) and 
younger (~65 years, n = 2593) persons and to examine its incremental value 
over clinical data. 
Results: Elderly persons were more likely to have a history of Ml, dia- 
betes, hypertension, hyperlipidemia and comorbidity (all P < 0.05). Younger 
patients achieved a higher workload (10.7 vs 6.0 METS, P < 0.001) and had 
fewer positive exercise ECG responses (9.1% vs 27.9%, P < 0.001). At 6 
years, overall survival (63% vs 92%, P < 0.05) and event-free (cardiac death, 
nonfatal MI and heart failure) survival (66% vs 95%, P < 0.05) were worse for 
elderly. The univariate associations between TMET variables and outcome 
are shown below: 
TMET All-Cause mortality Cardiac events 
variable Young Elderly Young Elderly 
Workload 0.74.f 0.75t 0.75t 0.77t 
(0.69, 0.79) (0.70,0.81) ‘“.‘,1;;i80’ (0.71, 0.82) 
Angina 1.48 1.12 1.55* 
(0.65,3.40) (0.69, 1.81) 
Positive 1.73 1.05 
(1.8y;95) (1 .OO, 2.41) 
1.41 
EKG (0.92, 3.26) (0.69, 1.60) (1.69, 4.65) (0.95,2.10) 
Risk Ratio (95% confidence interval): +P < 0.0001; *P < 0.05 
After adjustment for clinical variables, workload was the only additional 
TMET variable predictive of death and cardiac events (all P < 0.0001) and 
the strength of association (16% reduction in mortality for 1 MET increase 
in exercise capacity) was similar in both age groups. Each MET increase in 
exercise capacity also resulted in 10% and 16% reduction in cardiac events 
for younger and older patients respectively. 
Conclusion: In this population-based study of elderly residents, TMET 
provides incremental prognostic information to clinical data: of all TMET vari- 
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ables, workload exhibits the strongest association with outcome and its pro- 
tective effect is of the same magnitude as in the younger persons. 
ORAL 
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Anaheim Convention Center, Room 304A 
2:00 p.m. 
El 882 1 Cellular Rejection and Rate of Progression of 
Transplant Vasculopathy: A 3 Year Serial 
Intravascular Ultrasound Study 
Javier Jimenez, Samir R. Kapadia, Mohamad H. Yamani, Luba Platt, Randall 
E. Starling, James B. Young, Steven E. Nissen, E. Murat Tuzcu. The 
Cleve/snd C/ink Foundation, C/eve/and, O/i, USA 
Background: Although intravascular ultrasound is established as the optimal 
method for early detection of transplant vasculopathy, the risk factors deter- 
mining the rate of progression remain uncertain, 
Methods: We evaluated 47 patients undergoing heart transplantation from 
1993 to 1995. Intravascular ultrasound was performed at baseline (within 2 
months) and annually for three years to determine maximum intimal thickness 
and area stenosis in each coronary segment. Vasculopathy was defined as a 
lesion with intimal thickness > 0.5 mm not present at baseline. Biopsies were 
scored by assigning a numerical weight to each ISHLT grade during the first 
year. 
Results: New lesions were identified in 30 patients. Average biopsy score 
was >I.0 in 35 patients with a significant linear correlation between the rate 
of intimal thickening and biopsy score (r = 0.47, p = 0.004). However, lesions 
were detected in 7 of 12 (58%) patients with biopsy score < 1 .O. Comparing 
biopsy scores > 1 .O vs. ~1 .O, the rote of progression of intimal thickening was 
similar (97 * 96 vs. 97 c 110 @meters/year, p = 0.88). 
Conclusions: The rate of progression of vasculopathy correlates with 
biopsy score. However, lower biopsy scores do not preclude progressive 
vasculopathy. These findings suggest that injury from cellular rejection con- 
tributes to vasculopathy but does not explain disease severity in all patients. 
2:15 p.m. 
882-2 Expression of Suppressors of Cytokine Signalling 
(SOCS) in Experimental Cardiac Transplant 
Rejection 
Pauline Diamond, Ann McGinty, Qinsheng Jiao’, Barbara Murphy’, 
Catherine Godson, Declan Sugrue, Hugh McCann, Hugh R. Brady. Cenfre 
for Molecuiar Inflammation and Vascular Research, Department of Medicine 
and Therapeutics, University College Dublin, UK; ‘Division of Transplant 
Nephrology, Mount Sinai Medical Center, 1 Gustave Levy Place, New York, 
USA 
Background: The suppressors of cytokine signalling proteins function as 
negative regulators of cytokine-activated Jak/STAT signal transduction. The 
present study assessed the profile of SOCS in a rat heterotopic model of acute 
cardiac transplant rejection. 
Methods: Animals were sacrificed at days 1, 3, 5 and 7 post-transplan- 
tation and the native and donor heart retrieved. Expression of SOCS and 
leukocyte trafficking determinants was assessed by RT-PCR. 
Results: Constitutive expression of SOCS-2 and qtokine inducible SH2 
sequence (CIS)-I was detected in all tissues: CIS-1 mRNA levels were ele- 
vated over control in mismatched tissue at day 3. SOCS-I mRNA was de- 
tected in allogeneic transplant tissue only at day 5. SOCS-3 expression was 
also restricted to mismatched tissue, but was apparent throughout the time 
course. mRNA for the cytokines tumour necrosis factor (TNF)-n, interleukin 
(IL)-I@, IL-2 and interferon (IFN)-y was elevated specifically in allogeneic 
transplants. Although mRNA for vascular cell adhesion molecule (VCAM)-1 
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was expressed constitutively, mRNA levels for this adhesion molecule and 
intercellular adhesion molecule (ICAM)-l were elevated in rejecting organs 
as compared to control. Expression of regulated upon activation normal Tcell 
expressed and secreted @ANTES) and macrophage inflammatory protein 
(MIP)-la was constitutive, with mRNA levels for these chemokines being el- 
evated over control levels in allogeneic allografts, mRNA for growth related 
oncogene (GRO) and monocyte chemoattractant protein (MCP)-I was de- 
tected in mismatched transplants only. The chemokine receptors CCR-I and 
CXCR-2 were detected in all specimens but upregulated in allogeneic organs. 
CCR-2 was detected in rejecting hearts only. 
Conclusions: These results provide evidence that SOCS-I , -3 and CIS-1, 
and the cytokines which induce their upregulation, may be critical determi- 
nants in the process of acute cardiac rejection. 
2:30 13.m. 
I 882 3 Can Combined Indices of Diastolic and Systolic 
Myocardial Performance Reliably Predict Cardiac 
Al-lograft Rejection’? 
Krishnamoorthy Vivekananthan, Thomachan Kalapura, Myung H. Park, 
Robert Scott, Richard V. Milani, Mandeep R. Mehra. Ochsner Heart and 
Vascular Institute, New Orleans, Louisiana, USA 
Background: Systolic and diastolic myocardial performance characteristics 
are altered during allograft rejection. Non-invasive diagnostic markers of allo- 
graft rejection have thus far not been found to be clinically useful. 
Hypothesis: We examined the clinical utility of the Tei index (TI), a com- 
bined index of systolic and diastolic performance (derived as a composite ratio 
of isovolumetric contraction time (ICT) and isovolumetric relaxation time (IRT) 
to the ejection time (ET), in predicting and following cardiac allograft rejection. 
Method: Twenty heart transplant recipients with moderate cellular rejec- 
tion (ISHLT Grade ? 3A) underwent echocardiographic assessment to derive 
the TI at baseline (rejection free), during treatment for rejection, and following 
recovery from rejection (Group I). A parallel group of 20 non-rejectors (ISHLT 
Grade 4 IA) were also similarly examined to serve as controls (Group II). 
Result: In Group I patients, there was a mean increase of TI by 97.6% (p 
< 0.0001) during the rejection episode as compared to baseline. Following 
treatment, TI dropped to its baseline value. In the control group there was 
no significant change in Ti over time. The change in TI in patients with ‘IllA 
cellular rejection was independent of the ejection fraction (EF) at baseline and 
change in EF during the rejection episodes. 
TI TI TI p-V&E 
Baseline Reiection Recovetv 
Group I (n = 20) 0.42 + 0.18 0.83 + 0.33 0.39+16 <0.0001 
Group II (n = 20) 0.42 iO.12 0.42 * 12 0.42 + 0.1 NS 
p-!/&E NS 0.016 NS 
1.6 1 
0 ’ @ah m Pm 
(G,911) @rmj W.4 
Inferences: 1) TI, a sensitive marker of early diastolic and systolic perfor- 
mance, accurately predicts the onset of and recovery from cardiac allograft 
rejection. 2) Furthermore, employing the Tei Index can provide a clinically 
useful non-invasive indicator to assess the impact of therapy for amelioration 
of allograft rejection. 
2:45 p.m. 
/ 882 4 Increased Incidence of Atrial Flutter Associated With the Rejection of Heart Transplantation 
Guanggen Cui, Jon Kobashigawa, Luyi Sen. UCLA Medical Centerand 
UCLA School of Medicine, Los Angeles, CA, USA 
Atrial fibrillation (Af) and flutter (AF) are common dysrhythmias following heart 
transplantation (HXT), however, their etiology and clinical significance have 
not been defined. To determine the precise incidence of persistent Af and 
AF, and their association with the rejection of HXT, 892 consecutive patients 
undergoing orthotopic HXT at UCL.A Medical Center between February 1984 
to December 1998 were included in the study. Total of 83 patients had AF 
with total of 92 episodes, 11 of them converted to Af. Seventy-eight patients 
had Af with total of 90 episodes, 7 of them converted to AF. The incidence of 
AF (9.3%) was same as Af (8.7%). Significant inter-atria1 conduction defect 
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manifested by increased of the terminal force of the P wave in Lead Vl (ptf-Vi 
> 0.04 s) and/or 1st degree AV Block was observed in 86% patients before 
AF and 82% patients before Af were occurred. AF occurred during 15 days 
after transplantation was not associated with rejection. However, AF initiated 
after 3 months of HXT was associated with severe rejection (grade IllA and 
1118, p < 0.01). In 40 AF occurred 3 month after HXT, 18 were associated with 
IIIA and IIIB rejection, 10 IA-IB, 5 humoral rejection, 7 with rejection grade 
0, these 7 patients with other 13 have been shown transplant coronary artery 
disease (TCAD). Atrial rate was 250-375 beats/min. Eighty-three episodes 
were type I AF, and 9 were type II. Ninety-one AF episodes were converted to 
sinus rhythm during 1 hour to 9 days by either Class I antiarrhythmic agents, 
atrium overdrive pacing, or electric conversion combined with triple immuno- 
suppressive regimens. There was no difference in the prevalence of AF or 
Af between biatrial and bicaval anastomoses, and preoperative diagnosis of 
ischemic and idiopathic dilated cardiomyopathy. These results suggest that 
the increase in the incidence of,AF after orthotopic HXT is the consequence 
of the cellular and humoral rejection of HXT and TCAD, and which, could be 
predicted by the abnormality of PtfVl. 
3:00 p.m. 
I 882 5 A Randomized Trial of Tacrolimus vs Neoral Cyclosporine in Heart Transplant Recipients 
Jon A. Kobashigawa, Jaime D. Moriguchi, Jennifer M. Chuang, 
Lianne Wener, Lawrence Yeatman, Thomas Ro, Danielle Devereaux, 
Nobuyuki Kawata, Hillel Laks. University of California af Los Angeles, Los 
Angeles, California, USA 
Background: Controversy continues as to the benefits of tacrolimus vs. Neo- 
ral cyclosporine as primary immunosuppression in heart transplant recipients. 
Previous randomized multicenter trials (US, n = 88; and European trials, n = 
82) have studied tacrolimus vs. Sandimmune cyclosporine, revealing simi- 
lar outcomes. However, a new microemulsion formulation of cyclosporine, 
Neoral, has shown benefit over Sandimmune cyclosporine in the reduction 
of rejection subgroups in a randomized trial on heart transplant recipients. 
Therefore, we conducted the first randomized trial of tacrolimus vs. Neoral cy- 
closporine in heart transplant patients. All follow-up was completely standard- 
ized due to the study being performed in a single center. Between November 
1996 and September 1998, 67 heart transplant patients were randomized to 
tacrolimus (33 patients) or Neoral cyclosporine (34 patients), both in combina- 
tion with cotticosteroids and azathioprine. Tacrolimus and Neoral were both 
initiated orally post-transplant with levels targeted to prespecified ranges. The 
demographics of both groups were without significant differences in percent 
female, donor and recipient age, pretransplant diagnosis, cold ischemic time, 
percent Status I, and race. First year survival, freedom from ISHLT grade 3A 
rejection, freedom from any treated rejection, OKT3 treated rejection were 
similar in both groups. Angiography and intravascular ultrasound were per- 
formed at baseline and at one year. Side effect profile was similar in both 
groups. 
N Survival Freedom Freedom from Avg. serum creatinine % Patients 
from 3A any treated at txlone year post-tx on BP meds. 
rej. rej (w$W 
Tacrolimus 33 85% 70% 70% 1.311.2 65% 
NC?OEl 34 85% 79% 76% 1511.5 76% 
Conclusion: Tacrolimus and Neoral cyclosporine appear to be compara- 
ble as primary immunosuppression in heart transplant recipients. Transplant 
coronary artery disease and intravascular ultrasound to be discussed. 
3:15 p‘.m. 
El 882 6 Mycophenolate Mofetil Improves Early Steroid Withdrawal in Orthotopic Heart Transplant 
Recipients 
Shashank S. Desai, David DeNofrio, Andrew Kao, Theodore A. Frank, 
Michael A. Acker, Evan Loh. University of Pennsylvania, Philadelphia, PA, 
USA 
Background: Mycophenolate mofetil (MMF), a more specific inhibitor of lym- 
phocyte function than azathioprine (AZA), has been shown to decrease re- 
jection following solid organ transplantation. We examined whether the imple- 
mentation of MMF in place of AZA increased the ability to achieve successful 
steroid withdrawal in onhotopic heart transplant (OHT) recipients without ad- 
versely affecting outcome. 
Methods: We prospectively followed 105 consecutive heart transplant re- 
cipients at the Hospital of the University of Pennsylvania. The first 57 patients 
received AZA along with cyclosporine (CSA) and corticosteroid immunosup- 
pression. The next 48 patients received MMF along with CSA and cotticos- 
teroid immunosuppression. Both patient groups were placed on a standard 
corticosteroid weaning protocol. Clinical variables between the AZAand MMF 
groups were compared. Four patients who died less than one month were 
excluded from the analysis due to lack of exposure to the cotticosteroid taper 
protocol. 
Results: Patient characteristics included: age of 53 f 10 years; 79% 
males; 75% Caucasians; and 56% were diagnosed with an ischemic car- 
diomyopathy. Baseline demographics were not significantly different between 
the AZA and MMF groups. In the MMF versus the AZA group, significant 
differences were observed in the percentage of OHT recipients free of cor- 
ticosteroids at 12 (54% vs. 32%; p = 0.028) and 18 months (68% vs. 43%; 
p = 6.015). There was a trend to a shorter mean time to steroid free (57 f 
2.5 weeks vs. 63 & 2.5 weeks; p = 0.09 Kaplan-Meier Log Rank) in the MMF 
recipients when compared to the AZA group at 18 months. No differences 
in survival, rejection episodes, time to first rejection, or total infections were 
observed between the two groups within the first year. 
Conclusion: MMF allowed more OHT recipients to become steroid free 
without an adverse effect on mortality, infection, or rejection episodes com- 
pared to an AZA based immunosuppressive regimen. This benefit of MMF 
should be considered when determining the optimal immunosuppressive ther- 
apy following OHT. 
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/- 1183 142 Prrmary Platelet Nitric Oxide Resistance and Oxidative Stress in Patients With Chronic Heart 
Failure 
R.A. Anderson, G.R. Ellis, D.J. Blackman, Y.Y. Chirkov’, P.E. James, 
S.K. Jackson, M.J. Lewis, J.D. Horowitz’, M.P. Frenneaux. Wales Heart 
Research Institute, University of Wales Colege of Medicine, Cardiff, Wales, 
UK; ‘Cardiology Queen Nizabeth Hospital, Adelaide, Australia 
Platelet activation has been described in chronic heart failure (CHF) but the 
mechanism is unknown. Primary platelet NO resistance has been recently 
been described in ischaemic heart disease (IHD). Increased oxidative stress 
may contribute to impaired endothelial function in CHF and IHD, it may also 
reduce platelet responsiveness to nitric oxide (NO). We therefore studied 
platelet responsiveness to NO using sodium nitroprusside (SNP) and nitro- 
glycerine (NTG) and oxidative stress in patients with CHF and investigated 
the effect of the underlying aetiology, on these parameters. 
Methods: 35 subjects with chronic heart failure [21 due to dilated car- 
diomyopathy (DCM), 14 ischaemic cardiomyopathy (ICM)] were studied and 
compared with 13 healthy controls. We assessed the inhibitory effects of SNP 
and NTG on ADP-induced platelet aggregation (impedance aggregometry). 
NO resistance was defined as less than 20% inhibition of platelet aggrega- 
tion by SNP (1O-5 M) and/or NTG (1O-4 M). Oxidative stress was assessed 
by lipid-derived free radicals, ex vivo by electron paramagnetic resonance 
spectroscopy and by markers of lipid peroxidation (TBARS). 
Results: (Mean f SD) Platelet responsiveness to SNP and NTG on 
ADP-induced aggregation was 70 f 31% and 53 f 31% respectively in 
healthy controls compared to 58.4 & 34% and 40 f 31% in DCM and 59.5 * 
34% and 36 f 32% in ICM. 33% of ICM and 35% of DCM patients exhibited 
primary platelet NO resistance compared to 14% of controls (C). Patients with 
heart failure had greater levels of lipid derived free radicals, (3561 f 2479 
(DCM) and 3389 f 1923 (ICM) vs 855 f 392 (C) and TBARS [4.9 * 2 (DCM), 
6.5 f 4 (ICM) vs 3 i 1.4 (C)] both p < 0.05, but there was no significant 
correlation with platelet NO resistance. 
Conclusions: Platelet NO resistance does occur in a third of CHF pa- 
tients, the presence of enhanced oxidative stress is not directly related to this 
phenomenon. This highlights a subset of CHF patients who would particularly 
benefit from antithrombotic therapy. 
L--d 1183 143 The Skeletal Muscle Intrinsic Mitochondrial 
Oxidative Capacity is Preserved in Severe Heart 
Failure 
Bertrand Mettauer, Joffrey Zoll, Herve Sanchez, Eliane Lampert, 
Florence Ribera, Vladimir Veksler’ , Xavier Bigard, Eric Epailly, 
Jean Lonsdorfer, Renee Ventura-Clapier’ CHRUStrasbourg, ‘INSERM U 
446, and CRSSA Grenoble, France 
Background: For a given work, the skeletal muscle (SM) metabolism of 
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chronic heari failure (CHF) patients is less oxidative than in controls (C), 
leading to a decreased max 02 uptake (mV0,). Whether this results from a 
decreased substrates delivery orfrom an impaired mitochondria (MT) intrinsic 
oxidative capacity remains unclear. Although the MI density and enzyme con- 
tent may be diminished in CHF, the MI respiratory features have never been 
directly assessed in CHF. 
Methods: We obtained SM vastus lateralis biopsies in 12 CHF patients at 
the time of transplantation, in 8 sedentary C (SED) and in 9 physically active C 
(PA). All the CHF and C had their mVOn (mllminikg) measured. After saponin 
permeabilization and with saturated levels of 02 and substrates, we measured 
the SM tissue 02 uptake (~mollminig dry weight) in an oxygraphic chamber 
without phosphate acceptor (VO), and with increasing levels of the acceptor 
ADP that allowed to measure the Ml max tissue O2 uptake (Vmax), the Km for 
ADP (FM) and the acceptor control ratio (ACR = VmaxA/O). 
Results: As the saponin permeabilization keeps the whole Ml population 
within the cell achitecture, the Vmax defines the subject’s MI oxidative capac- 
ity, the Km (CHF:148 rt 36, SED:III f 51, PA:557 i 117*) represents the 
MI affinity for ADP and the ACR (CHF:3.1 f 0.3, SED:2.9 * 0.6, PA:65 i 
1 .I “) defines the phosphorylation-VO, coupling efficiency. The VO, Vmax and 
mVOp are shown on figures. Values: means & SEM, *p .Z 0.05 vs CHF 
Conclusion: In CHF patients, the intrinsic SM Ml oxidative capacity, Ml 
affinity for ADP and coupling efficiency just reveal untraining, beeing all similar 
to the one of SED. This opens the question whether an impaired substrate 
delivery would represent the main determinant of the abnormal Ml exercise 
metabolism in CHF. 
/ 1183-I 44 / Alveolar-Capillary Diffusion Impairment and 
Lung Water (LW) Content in Severe Heart Failure 
0-W 
Giancarlo Marenzi, Piergiuseppe Agostoni, Marco Guazzi, Marco Grazi, 
Maurizio Bussotti, Maurizio Guazzi. lnsfitute ofCardio/ogl: University of 
Milan, Centro Cardiologico ‘Wbr~zino”, IRCCS, Milan, /t&y 
Background: The relationship between LW content increase and alveolar- 
capillary diffusion for carbon monoxide (DLco) reduction in severe HF has not 
been completely defined. 
Methods: LW, lung volumes and DLco were evaluated in 15 normal sub- 
jects and in 28 patients with severe HF (NYHA Ill-IV), in the latter before and 
4 days after fluid removal by extracorporeal ultrafiltration (UF, 3973 f 2205 
ml; weight reduction = 5.8 f 3.7 kg). In particular, we measured vital capacity 
(VC), alveolar volume (Va), LW (single breath expiratory decay of CH4, C2H2 
and CO), DLco and its two components: diffusing membrane resistance (Dm) 
and capillary volume content (Vc). We named LW the lung tissue (mainly 
water) which is reachable by inspired gases. 
Results: 
Controls Before UF After UF 
vc CL) 4.7 z!c 1 2.1 IO.7" 2.5 GcO.7"# 
va CL) 6.3 * 1.3 4.1 i 1.6* 4.6 i 1.4-8 
LW (ml) 42Oi-13 640 i 1801 550 * 170** 
Dlco (ml/min/mmHg) 2945 17&4* 17i5" 
Dm (ml/min/mmHg) 47% 11 231-7- 2518* 
vc (ml) 102-1-20 loo*38 87139 
DLcoNa 4.5il 4.3 i 1 3.8 -t l# 
LwNa 67+11 156114 121 rt18*# 
DmNa 7.1*3 6.0 i 2" 6.8 zk 2# 
Data are mea” zt SD. * = p < 0.01 VS. Controls: # = p < 0.01 vs. Before UF. 
Conclusions: In severe HF: 1) LW increase is associated with reduction 
in lung volumes (VC, Va), DLco and Dm; 2) DLco and Dm are normals when 
related to Va indicating that impairment of alveolar-capillary diffusion capacity 
in HF is mainly due to lung surface reduction; 3) after UF, LW decrease is 
associated with lung volumes increase and normalization of DmiVa, the for- 
mer suggesting reduction of total LW content, the latter reduction of LW in the 
alveolar-capillary membrane. 
/ 1183 145 Effect of Cardiac Sympathetic Nervous Tone on Mode of Death in Chronic Heart Failure 
Hans Peter Brunner-La Rocca, Murray D. Esler, Garry L. Jennings, David 
M. Kaye. Baker Medical Research Institute, Alfred Hospita/, Melbourne, 
Australia 
Background: The relation of aspects of cardiac sympathetic nervous function 
(norepinephrine (NE) spillover, NE synthesis, NE stores) to progression of 
heart failure (HF) in comparison to sudden death is not well defined. 
Methods: We studied 116 patients with moderate to severe HF (EF 19 f 
7%) and a mean follow-up of 17.7 f 18.7 months. Cardiac sympathetic ner- 
vous function was measured using coronary sinus blood sampling and iso- 
tope dilution methodology. Cardiac sympathetic activity was estimated from 
cardiac NE spillover, NE synthesis from the overflow of the NE precursor dihy- 
droxyphenylalanine (DOPA), and NE stores from the overflow of the tritiated 
NE metabolite [3H]dihydroxyphenylglycol. 
Results: Increased cardiac NE spillover and DOPA overflow rate were 
strong predictors of nonsudden death (both p < O.OOl), whereas cardiac sym- 
pathetic activity was less predictive of sudden death (p c 0.05). Small cardiac 
NE storeswere related to death from worsening CHF, indicating progression of 
disease to be associated with defective sympathetic innervation. In contrast, 
large stores were related to sudden death. 
Conclusions: Chronically high cardiac sympathetic activity is a major con- 
tributor to progression of disease, despite cardiacsympathetic innervation be- 
ing defective in these patients. In contrast, high cardiac sympathetic activity 
is a risk factor for sudden death primarily in combination with intact cardiac 
sympathetic innervation. 
/ 1183 146 High Circulating Levels of Terminal Complement are Associated With Adverse Outcomes in Heart 
Failure 
David J. Clark, Michael W. Cleman, Scott A. Rollins, Leonard Bell, Steven 
E. Pfau, Tarik M. Ramahi, Habib Sarnady, John F. Setaro. Yale University, 
New Haven, CT; Alexion Pharmaceuticals, New Haven, CT; Yale University, 
USA 
Background: Terminal complement activation has been linked to myocardial 
injury and ventricular dysfunction. We previously demonstrated a significant 
elevation in the levels of serum C5b-9 (sC5b-9), the terminal complement 
complex, in patients with congestive heart failure (CHF). The purpose of this 
study was to determine the relationship between the levels sC5b-9 and clinical 
outcome. 
Methods: We determined 6 month clinical follow up data in a group of 36 
patients with NYHA Class II-IV CHF whose original evaluation included ven- 
tricular function studies and serum assays for C5b-9 levels. Combined clinical 
events included death, urgent (Status 1) cardiac transplant, or admission to 
hospital with worsening heart failure. These patients were stratified into 2 
equal groups by using the median sC5b-9 level (highest 50% vslowest 50%). 
Results: At entry, the mean left ventricular ejection fraction was 20%. 
The SC569 levels in these 36 CHF patients (138 f 28 ngfml)(mean f sem) 
were significantly (p < 0.001) elevated compared to healthy controls (20 f IO 
rig/ml). The study population had a 36%(13/36) combined event rate overall 
at 6 months. Patients in the group with the highest 50% SC569 levels suffered 
a significantly higher incidence of clinical events (log-rank test, p = 0.02). 
Conclusions: We found that among patients CHF, serum with increased 
levels of C5b-9 were significantly associated with adverse outcomes at 6 
months. 
/ 1183-I 47 1 Interaction Between Age and Gender on TNF 
Levels in Patients With Moderate to Severe Heart 
Failure 
Biykem Bozkurt, Dorellyn Lee-Jackson, Adrienne Chee, Anita Deswai, 
Douglas L. Mann. Baylor Coiege of Medicine, Houston, JX, USA 
Previous studies have shown that patients with heart failure (HF) have in- 
creased levels of TNF in their circulation. However, the influence of age and 
gender on TNF levels in HF patients has not been studied. Therefore, we 
examined baseline TNF levels in 1187 patients with NYHA class Ill-IV HF, 
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enrolled in the Vesnarinone Trial (VEST). There was a significant linear re- 
lationship between age and TNF levels for males (p < O.OOl), whereas for 
females the relationship was dichotomous: TNF levels were modestly ele- 
vated in women ri 50 yrs (-3.8 pgiml), whereas strikingly elevated in women 
b- 50 yrs (-7.0 pg/ml). 
Conclusion: TNF levels f as a function of increasing age in males with 
advance HF, whereas TNF levels t significantly in women with HF > 50 yrs 
of age. The finding that TNF levels t in women of postmenopausal age with 
HF is consistent with the fact the estrogen protects against the toxic effects of 
TNF and estrogen therapy may be beneficial in HF. 
/J Systemically Measured Cytokines are 
Independently Predictive for Increased Mortality 
in Patients With Chronic Heart Failure 
Mathias Rauchhaus, Wolfram Doehner, Veronica Koloczek, Josef Niebauer, 
Darrel P. Francis, Anrew J.S. Coats, Stefan D. Anker. Cardiac Medicine, 
NHLI London, UK 
Background: Extensive work has been focused on the potentially causal role 
of inflammatory cytokines to the progression of chronic heart failure (CHF). 
Only little is known on their prognostic value. 
Methods: Concentrations of tumor necrosis factor-a (TNFol), soluble TNF 
receptors (sTNFR1 + 2) and interleukin-6 (IL-6) were studied in 120 CHF 
patients (ischemic/non-ischemic: 74/46, NYHA Illlllll/lV: 7/36/59/i 8, age 62 
f 1 ys, LVEF 30 f 2%, peak VOn 17 f 1 ml/kg/min, mean + SE) (min. 
follow-up 6 months [ms], focus: all-cause mortality). 
Results: Of the patients, 44 (37%) died after 0.13-75.1 ms (mean 11.9). 
In univariate Cox proportional hazard analysis, sTNFR1 + 2, IL-6, total (n 
= 91) and bioactive (n = 95) TNFor predicted mortality as well as did age 
(p < O.OOOl), peak VOa (p = O.OOOl), creatinine (p = 0.0002), NYHA class 
(p = 0.002) and body wasting (p = 0.005). In multivariate analysis, sTNFR1 
emerged as the strongest independently predicting cytokine (all p < 0.01). 
In stepwise regression, only sTNFR1 (p < O.OOOl), age (p = 0.02) and LVEF 
(p = 0.04) remained significant predictors independenly of each other. In re- 
ceiver operator (ROC) curves, the best mortality predicting concentrations of 
sTNFR1 were 1460 pg/mL (6 ms: sens 79%, spec 64%) 1486 pg/mL (12/24 
ms: sens 71/75%, spec 73/85%, respectively), and 1015 pg/mL (36 ms, sens 
89%, spec 80%). The area under the curve for death prediction was consis- 
tently larger for sTNFR1 than for peak VOs at respective time points between 
636 ms. 
Conclusions: Soluble TNFRI concentrations predict increased long-term 
mortality in CHF patients independently and more sensitive and specific than 
other established CHF prognosticators. 
1 1183-l 49 1 The Prognostic Role of Relative Lymphocyte 
Concentration in Patients With Heart Failure and 
Low Ejection Fraction 
Jalal K. Ghali, Susan Anderson, David DeMets, Jay N. Cohn. Cardiac 
Centers of Louisiana at Willis-Knighton Heart Institute, Shreveport, 
Louisiana; University of Minnesota, Minneapolis, Minnesota, USA 
Baseline relative lymphocyte concentration (RLC) has been proposed as a 
predictor of prognosis in patients with heart failure and low ejection fraction. In 
Vesnarinone Trial (VEST), 3566 class Ill and IV heart failure patients, predom- 
inantly male (76%) mean age 62, mean LVEF 21%, on conventional therapy 
were randomized to vesnarinone or placebo. lschemia was the etiology in 
60%. A total of 770 patients (22%) had RLC < 16% and 2796 (78%) had 
RLC 2 16%, A proportional hazard stepwise regression analysis was per- 
formed to examine the correlation of the following baseline covariates: RLC, 
All Cause Mortality 
RR Cl 
Combined Morbidity and Mortality 
RR Cl 
NYHA 1.9 1.04-2.3 NYHA 2.04 1.7-2.3 
RLC 1.05 1.04-I .06 CTR 1.04 1.03-l .05 
LVEF 1.04 1.03-l .06 RLC 1.04 1.03-l .05 
CTR 1.03 1.02-l .04 LVEF 1.07 1.03-l .05 
fw 1 .Ol 1.01-l .02 Female 0.08 0.7-0.9 
Etioloav 1.2 1.04-l .4 
cardiothoracic Ratio (CTR), etiology, NYHA, age, gender and LVEF to end 
points. 
Conclusion: 1) Baseline RLC is a predictor of mortality as well as com- 
bined morbidity and mortality in heart failure patients with low ejection fraction, 
2) This finding may have relevance in designing clinical trials, listing for cardiac 
transplantation and potentially in management. 
Is Endotoxin a Trigger in Congestive Heart 
Failure (CHF) Patients With Acute Cardiogenic 
Pulmonary Edema (ACPE)? 
Shaker A. Mousa’ , Bong Hee Sung, Porur Somasundram, Robert Blum, 
Michael F. Wilson. ‘DuPont Pharmaceuticals Co., Wilmington, De/aware; 
Millard Fillmore Hospital, State Unix of New Yorkat Buffalo, Buffalo, NL: USA 
Background: Recurrent hospital admission for ACPE is a major problem for 
treatment and management of patients with CHF. Interactions between leuko- 
cytes, endothelium, and platelets may play an important role in the symptoms 
and deterioration in CHF patients. The present study was undertaken to de- 
termine the circulating biochemical changes between endotoxin challenge in 
normal healthy subjects and CHF patients with ACPE. 
Methods: Circulating plasma tissue factor, plasma soluble endothelial cell 
adhesion molecule marker (s-VCAM) and sP-selectin in addition to TNF-or, 
and TNF-or receptor 1 (RI) levels in 36 patients hospitalized with class Ill and 
IV CHF were monitored. These parameters were compared to plasma levels 
after acute endotoxin challenge in normal healthy subjects. The mean age of 
the CHF group was 76 f 12 years and mean LV ejection fraction was 31 i 
7%. Eighteen healthy volunteers were used as control. TNF-or and TNF-ol RI, 
sP-selectin, tissue factor and sVCAM-I levels were analyzed with Quantikine 
immunoassay kits. 
Results: Table summarizes assay results (mean f SEM). P < O.OOi= 
control versus acute CHF or endotoxin. 
Biochemical Markers 
s-VCAM @g/ml) 
Control 
502 (60) 
En&toxin Acute-CHF 
1,040 (140)‘* 1,420 (425)* 
Tissue Factor (pg/ml) 
sP-selectin (rig/ml) 
TNF-a! (pgiml) 
112 (26) 170 (50)” 195 (25)* 
38.6 (5.6) 89 (12)‘* 84 (6.1)* 
1.6 (0.3) 770 (172)” 5.0 (0.7)* 
6.4 (4.2)3” 
TNF-or Ri (pg/ml) 912 (80) 3,300 (470)2’ 2,077 (190)* 
’ Peak levels at 24 hours, 2peak levels at 2-4 hours, 31evels at 24 hours. 
Conclusions: A comparable biochemical change in different cellular mark- 
ers was demonstrated between acute endotoxin challenge in normal healthy 
subjects and CHF patients. Thus, interactions between leukocytes, endothe- 
lium, and platelets may play an important role in symptoms and progression 
of CHF. This study raises the possibility that endotoxin-like substances might 
be the triggers for cellular and functional insults in CHF patients with ACPE. 
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1 1184-l 51 1 Regional Sympathetic Denervation and 
Myocardial Perfusion Disturbance are Related 
Phenomena Preceding Wall Motion 
Abnormalities in Chagas’ Cardiomyopathy 
Marcus V. Sirnoes, Antonio 0. Pintya, Guilherme B. Marin, Alvaro 
V. Sarabanda, Cleide M. Antloga, Benedito C. Maciel, Jose A. Marin-Neto. 
Cardiology Division, Medical School of RibeMa Preto, USF: Brazil 
Background: Autonomic derangement and myocardial perfusion abnormali- 
ties with normal coronary arteries have been described in Chagas’ cardiomy- 
opathy. This study aimed at investigating the relationship of these abnormali- 
ties with the myocardial damage in chrome Chagas’ heart disease (CHD). 
Methods: We prospectively investigated 18 normal volunteers (38 f 3 y., 
9 M), and pts with CHD presenting progressive degrees of myocardial dys- 
function: Stage I (normal global and segmental LV function), 12 pts (43 f 4 
y., 7 M); Stage II (abnormal segmental with normal global LV function), 13 pts 
(48 & 3 y., 9 M); Stage Ill (abnormal global and segmental LVfunction), 12 pts 
(59 i 3 y., IO M). All underwent ‘s31-MIBG and 20’Thallium stress-redistribu- 
tion SPECT imaging. Quantitative segmental uptake assessment compared 
to controls was performed by polar map analysis. Global and segmental LV 
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function was evaluated by tomographic radionuclide angiocardiography. One 
way ANOVA was employed for mean comparisons, and topographic associa- 
tion was tested by Chi-Square test. 
Results: The area of reduced MIBG uptake and global abnormal perfusion 
area (including reversible, fixed and paradoxical defects) for each group are 
shown (mean + SEM): 
stage I stage II stage Ill 
‘231-MIBG 3.7 i 2.1 6.3 zt 2.3# 19.3 + 3.3# 
20’ Thallium 5.6j: 1.4 10.3 * 2.7 19.8 -I 6.0& 
‘p < 0.001 for differences from stage I. ‘p < 0.01 for difference from stage I 
Positive topographic correlation was found between reversible defects 
(RD) and reduced MlBG uptake, as 31 of 56 segments (55%) presenting RD 
showed abnormal MIBG uptake that was seen in only 104 of 573 segments 
(18%) without RD (Chi-square =39.719, p < 0.0001). 
Conclusions: Regional abnormalities of cardiac sympathetic function oc- 
cur early in the course of Chagas’ cardiomyopathy and are topographically 
related to myocardial perfusion disturbances. These abnormalities tend to ag- 
gravate as more severe myocardial damage occurs. Such findings strongly 
suggest a pathogenetic role for these disturbances in CHD. 
1 1184-l 521 inducible Nitric Oxide Synthase Contributes to 
Development of Murine Chagasic 
Cardiomyopathy 
Madhuiika Chandra, Stefka B. Petkova, Herbert 6. Tanowitz, Vitaliy Shtutin, 
Louis M. Weiss, Murray Wittner, Jamshid Shirani. Albert Einstein College of 
Medicine, Bronx, New York, USA 
Background: Chagas’ disease, caused by T: cruzi, is associated with my- 
ocarditis, and expression of myocardial cytokines and inducible nitric oxide 
synthase (NOS2). To assess functional significance of NOS2 in this murine 
model, we infected NCS2 knockout (KO) and wild-type (WT) mice with Tu- 
lahuen strain of 7: cruri. 
Methods: Transthoracic echocardiography (ATL HDI 5000 cv; 1015 MHz) 
was performed in 9 infected KQ (KOI), 9 control KO (KOC), 9 infected WT 
(WTI) and 9 control WT (WTC) at 10 days post-infection (PI). Repeat studies 
were performed in 5 surviving KQI, 6 surviving WTI, 9 KOC and 9 WTC 19 
days PI. 
Results: No differences were found at day IO in left ventricular (LV) wall 
thickness in diastole (WTd, mm), end diastolic diameter (EDD, mm), end 
systolic diameter (ESD, mm), LV fractional shortening (FS%), or qualitative 
assessment of right ventricular (RV) dilation (graded from 0 [absent] to 3 + 
[severe]) between KOC and KOI. However ESD (1.2 f 0.6 v 0.8 & 0.2) and 
RV (0.6 + 0.7 v 0.0 f 0.0) were larger in WTI v WTC. At day 19, HR was 
lower in KOI v KOC, without differences in EDD, ESD, WTd, RV or FS% 
(Table). WTI had larger EDD, ESD, and RVand lower HR and FS% than WTC 
(Table). Proinflammatory cytokines (TNF-a, IFNy, IL-lb, IL-f?) and IL-10 were 
induced in the myocardium of infected mice. All infected mice died by day 25. 
At necropsy, heart weight was higher in WTI v KC1 (129.2 & 15.6 gm v 108.9 
f 7.2 gm, p = 0.02). Marked inflammation, necrosis and parasite pseudocysts 
were seen in the myocardium of all infected mice. 
Day n HH EDD ESD WTd FS % RV 
19. @Pm) (mm) (mm) (mm) (grade) 
WTC 9 557rt74 2.1 i 0.2 0.9 i 0.2 0.7 + 0.1 57Lk-7 010 
WTI 6 413f65” 3.3 4 0.7* 1.9 i 0.7* 0.7I!zO.l 45*11* 1.6 i 0.5t 
KOC 9 512zt92 2.3 i 0.3 0.8 i 0.2 0.8 + 0.1 62 i 5 ozko 
KOI 5 272i52* 2.4 zk 0.4 1.1 io.2 0.9 + 0.1 5619 0.7 5 0.6 
‘p < 0.05 “s WTC, +p = 0.0005 “s WC, fp = 0.0005 “s KOC 
Conclusion: NOS2 appears to play a role in development of LV and RV di- 
lation and reduction in FS% associated with fulminant myocarditis secondary 
to murine infection with Tulahuen strain of T: Cruzi. 
L-i 1184 153 Apoptosis and Inducible Nitric Oxide Synthase 
in Acute Chagasic Myocarditis 
Julian C. Escobar, Zilton A. Andrade, Sujuan Qian, Sonia G. Andrade, 
William K. Nelson, Moses Sadigursky, Zu-Xi Yu, Victor J. Ferrans. National 
lnsfitutes of Health. Bethesda, Maryland, USA; Fudacao Oswaldo Cruz, 
Bahia, Brazi/ 
Background: Recent studies have identified increased activity of inducible 
nitric oxide synthase (INOS) as an important factor contributing to the oc- 
currence of apoptosis in the heart in various conditions. The present study 
was designed to determine whether similar changes occur in acute chagasic 
myocarditis. 
Methods: Dogs (n = 6) were sacrificed 14 days after i.p. inoculation with the 
21-SF strain of Trypanosoma cruzi (400,000 organisms/kg bw). Uninfected 
dogs were used as controls. Sections of formalin-fixed, paraffin-embedded 
myocardium were immunostained with a polyclonal antibody against iNOS 
and a secondary antibody conjugated with fluorescein isothiocyanate. The 
sections were then processed for the detection of apoptosis by the nick end 
labeling method (rhodamine-conjugated antibody), counterstained with DAPI 
to demonstrate the DNA in tissue cells and T. cruzi, and examined by confocai 
microscopy to evaluate the topographic relationships between the two staining 
reactions. 
Results: Apoptosis was most commonly detected in macrophages and 
lymphocytes, but was also observed in endothelial cells and interstitial den- 
dritic cells in areas of inflammation, as well as in infected and noninfected 
myocytes. The parasites within some of the infected myocytes gave a posi- 
tive reaction for apoptosis. Reactivity for iNOS was strong in myocytes and 
macrophages. In myocytes, the extent of apoptosis in intracellular T. cruzi 
correlated with the intensity of staining for INOS. 
Conclusion: This study shows that iNOS activity is greatly increased in 
areas of inflammation in acute chagasic myocarditis, and suggests that this 
enzyme plays a role (by generating nitric oxide) in inducing apoptosis in T. 
cruzi and host cells. Cytokines, and T. cruzi antigens probably stimulate the 
production of iNOS in these areas. It is likely that this apoptosis contributes to 
the cessation of the acute phase of Chagasic myocarditis. 
1 1184-l 541 Effects of HIV Glycoprotein 120 on Cell 
Contractions and L-Type Ca2+ Channel Current 
in Rabbit Ventricular Myocytes 
Fuhua Chen, Kevin Shannon, Shulan Ding, Paul Krogstad, Monica Silva, 
Glenn T. Wetzel, Thomas S. Klitzner. UCLA School of Medicine, Los Angeles, 
California, USA 
Background: The most common and life-threatening cardiovascular com- 
plication of HIV infection is the development of heart failure associated with 
severe global left ventricular dysfunction, or cardiomyopathy. However, the 
pathogenesis of HIV-related cardiomyopathy has not yet been characterized. 
We recently examined the effects of an HIV surface envelop protein, glycopro- 
tein 120 (gp 120) on cell contractions and L-type Gas+ current and in rabbit 
ventricular myocytes. 
Methods: Single adult New Zealand ventricular cells were isolated using 
an enzyme dissociation method. Cell contractions were induced by electric 
field stimulation (20-30 volts, a 3.5 msec duration, every 3 set). Intracellu- 
lar- Caa+-store induced contraction (caffeine-triggered cell contraction) was 
induced by a one-second of exposure to IO mM caffeine to extracellular so- 
lution to activate the sarcoplasmic reticulum (SR) Ca2+ release. Whole cell 
L-type Ca*+ channel currents were measured using standard voltage-clamp 
techniques. 
Results: We found that perfusion with solution containing 0.1 yg/mL of gp 
120 significantly inhibited field stimulated contraction (from 5.8 i: 0.5 to 3.9 & 
0.5 pm, mean & SEM, n = 12, p < 0.01) in isolate rabbit ventricular myocytes 
(37°C). On the other hand, gp 120 did not significantly decrease the SR Gas+ 
store, or the caffeine-triggered contraction (from 7.4 * 0.6 to 6.9 i 0.7 pm, n = 
12, p = NS). Further, we found that 0.1 &mL of gp 120 significantly inhibited 
L-type Ca*+ current in rabbit ventricular myocytes (from 6.9 --t 0.8 to 4.3 i 0.6 
pA/pF, n = 8, p < 0.01) as compared with perfusion with buffer alone (from 6.5 
i 0.4 to 6.1 i 0.3 pA/pF, n = 6, p = NS). Subsequent perfusion with control 
solution prevented further decrease in the Ca2+ current. 
Conclusion: These results show that HIV gp 120 inhibits contractility in 
single cardiac cells, and that this inhibition appears to result from an inhibition 
of trans-sarcolemmal Ca*+ current. 
1 1184-I 55 1 Onset of Cardiac Symptoms After Mediastinal 
Irradiation an Ominous Sign Due to Frequently 
Combined Disease of Coronary Arteries, 
Heart Valves, Pericardium and Conduction 
System 
Christine H. Attenhofer Jost, Juraj Turina, Paul R. Vogt, Franz W. Amann, 
Gabor Stitsch, Rolf Jenni. Division of Cardiology, University HospitalZurich, 
Switzerland 
Background: Significant cardiac complications after radiation therapy (RT) of 
the mediastinum are rare but can considerably influence long-term morbidity 
in these patients (pts). There are only few data on etiology and prognosis of 
cardiac symptoms in this pt population. 
Methods: Since 1990 we evaluated 22 pts in our cardiology division for 
symptomatic heart disease after mediastinal RT. All pts’had a clincal exam, 
complete 2D - and Doppler echocardiography, and a 12 lead ECG. Data were 
collected on cardiac catheterizations, cardiac surgery or pacemaker insertion. 
Results: Age at begin of RT was 37 i 15 years (yrs), age at last follow-up 
56 f 15 yrs. The RT was administered at different RT centers because of 
lymphoma (IO pts), breast cancer (9 pts) or other tumors (3 pts). A cardiac 
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murmur was present in 18 pts (82%), dyspnea on exertion in 18 pts (82%) 
and angina in 11 pts (50%). A history of heart failure was found in 8 pts (36%). 
Moderate or severe valvular heart disease was frequent: 6 pts (27%) had 
aortic stenosis, 5 pts (23%) aottic regurgitation, 4 pts (18%) tricuspid regurgi- 
tation, 5 pts (23%) mitral regurgitation. One pt (5%) had mild mitral stenosis. 
Significant valvular disease was present in 17 pts (77%), significant coronary 
artery disease (CAD) in IO pts (45%), disease of the conduction system in 10 
pts (45%) and pericardial disease in 6 pts (27%). A combination of at least 2 
pathologies was found in 15 pts (68%). Heart surgery was necessary in 8 pts 
(36%) including coronary ariey revascularization, valve replacement, and/or 
pericardectomy. Postoperative course was often prolonged and 2 pts died 
due to heart failure with severely abnormal diastolic function (25% mortality). 
Pacemaker insertion was necessary in 2 patients (9%). Overall, six pts (27%) 
died 14-24yrs after RT; causes of death were: heart failure after heart surgery 
(2 pts), peripheral arterial emboli with kidney failure (1 pt), heart failure (1 pt), 
sudden cardiac death (1 pt), and prosthetic valve endocarditis (1 pt). 
Conclusions: In the long-term follow-up after mediastinal RT, onset of 
cardiac symptoms is often due to a combination of different pathologies of 
valves, coronary arteries, conduction system or the pericardium. It frequently 
leads to major cardiac complications including heart surgery and may be the 
cause of death. 
I 1184 156 Prevalence of Effusive Constrictive Pericarditis 
Among Patients Diagnosed With Constrictive 
Pericarditis 
John H. Haley, Lieng H. Ling, Marion E. Barnes, James B. Seward, Jae 
K. Oh. Mayo C/i& Rochester, MN, USA 
Background: Pericardial effusion (PE) may be present in patients (pts) with 
constrictive pericarditis (CP) some even requiring pericardiocentesis. Yet, we 
are unaware of any data regarding the frequency with which PE occurs among 
the different etiologies of CP and how frequently pericardiocentesis is per- 
formed in pts with CP. 
Methods: We reviewed the CP database at the Mayo Clinic to determine 
the frequency with which pericardial effusion (PE) occurs in pts with CP. The 
database is comprised of all pts diagnosed with CP at the Mayo Clinic from 
1985 to 1998. There are 212 pts in the database, 210 of whom have had an 
echocardiogram. 
Results: Fifty-one pts (24%) were found to have a PE (78.4% males with 
a mean age of 53.7). Table 1 demonstrates the frequency with which PE was 
noted in association with vaying etiologies of CP. Pts with an idiopathic cause 
of CP weresignificantly less likely (p < 0.05) and pts with a history of irradiation 
as the cause of CP were significantly more likely (p < 0.05) to have PE. No 
other etiologies were statistically more or less significantly associated with 
PE. 
Table 1 
Etiology Number cases WI % cases wi Pericardio- 
cases effusion effusion centesis 
Idiopathic 58 8 14% 1 
PCS 46 12 25% 3 
Viral pericarditis 34 10 29% 3 
irradiation 25 13 52% 6 
CVD 15 3 20% 1 
Infection IO 4 40% 3 
malignancy 3 0 0% 0 
uremia 2 0 0% 0 
unspecified 1 1 100% 0 
PCS = previous cardiac surgery: CVD = collagen vascular disease 
Of the pts with a PE, 17 (33.3%) underwent pericardiocentesis. These pts 
had similar symptoms, signs, and long-term survival compared to pts without 
PE. 
Conclusions: Effusive constrictive pericarditis is not uncommon, occur- 
ring in 24% of pts with CP. Underlying constriction should be considered in pts 
presenting with PE and evidence of increased right atrial pressure. 
[ 1184-l 57 1 Increases of Cardiac Troponin I Compared to 
Creatin Kinase in Acute Pericarditis 
Roland R. Brandt, Karsten Filzmaier, Uwe Janssens, Peter Hanrath. 
University Hospital, Aachen, Germany 
Background: The diagnostic role of cardiac Troponin I (Trl) is well established 
in ischemic myocardial injury. The purpose of this study was to compare 
the serum levels of Trl and creatine kinase MB enzyme (CK-MB) in acute 
pericarditis. 
Methods: We prospectively studied IO consecutive patients (9 men, 1 
woman, age 42 f 15 years) admitted through the Emergency Department. 
The diagnosis of acute pericarditis was based on the presence of 2 out of 
3 criteria: typical chest pain, pericardial friction rob, and characteristic ECG 
changes. Significant coronay artery disease was excluded by coronary an- 
giography or exercise stress testing. Trl (normal value < 0.4 @ml, fluoro- 
metric enzyme immunoassay) and CK-MB (normal value < 6.0 U/L) were 
measured within 24 hours of symptom onset. 
Results: Abnormal values of Trl were noted in 7 out of IO patients, in 
whom the average levels were 18.7 f 18.4 (range 4.6 to 48.7 ng/mL). Six of 
seven patients with increases in Trl also had elevated CK-MB levels (21.7 f 
12.3 U/L). 
Conclusions: Troponin I as a serum marker for myocardial injury is el- 
evated in the majority of patients with acute pericarditis probably due to in- 
flammatoy myocardial involvement and, thus, cannot be used to differentiate 
acute pericarditis from ischemic myocardial injuy. An increase in Troponin I is 
slightly more frequent than creatine kinase MB enzyme elevations reflecting 
the more sensitive nature of Troponin I. 
/ 1184-l 58 1 Post-Operative Cardiac Tamponade in the 
Modern Surgical Era: Analysis of 4561 
Consecutive Patients After Open Heart Surgery 
Jeffrey T. Kuvin, Nibal A. Harati, Natesa G. Pandian, Robert M. Bojar, Kamal 
R. Khabbaz. Tufts-New England Medical Center, Boston, MA, USA 
Background: Pericardial effusions resulting in cardiac tamponade (CT) are 
uncommon after open heart surgey (OHS) but have been associated with in- 
creased morbidity. Characteristics and outcomes of this population are poorly 
defined. 
Methods: This retrospective analysis of 4561 consecutive patients follow- 
ing OHS (9/l 993-4/l 999) examined patients who developed post-operative 
CT. 
Results: 49 patients (1 .I %) were found to have moderate sized or larger 
pericardial effusions; 78% of these patients had CT. Analysis of those with 
CT revealed a mean age of 59 years. Surgical procedures included coro- 
nay artery bypass grafting (CABG) alone in 24%, valve surgery f CABG in 
73%, and other in 3%. The incidence of CT following CABG alone was 0.2%, 
whereas it was 0.6% after valve f CABG. Antifibrinolytic therapy was admin- 
istered during surgery in 95% of cases. Aspirin was given to 84% of patients 
within 3 days of surgery; heparin and/or warfarin to 84% Prior to diagnosis of 
CT, the maximum INR and PTT detected were 2.5 f 0.3 and 51 i 4 seconds, 
respectively. Mean time to diagnosis of CT was IO f 1 days after OHS. 49% 
of pericardial effusions were posterior and 46% were circumferential; only 
one-third of the effusions were considered large by echocardiography. 35% 
of patients underwent pericardiocentesis and 43% surgical drainage. There 
were no in-hospital cardiovascular deaths. 
Conclusion: CT after OHS is more common following valve surgery and 
with early postoperative anticoagulation, even when well-controlled. Changes 
in anticoagulation protocols may reduce the incidence of CT after OHS. When 
diagnosed and treated promptly, post-operative CT should not increase mor- 
tality. 
1184-l 59 Are Sporadic Cardiac Myxomas a DNA 
Repair-Deficient Heart Disease? 
John Parissis’,*, George Sourvinos ’ , Flora Sotsiou3, Spilios Karas2, 
Dimitrios Spandidos’ ‘Medical School of Crete, Heraklion; *Amalia Fleming 
Hospital, Athens; 3Evangelismos Hospital, Athens, Greece 
Background: Microsatellite instability (MIN) is an early event in DNA repair- 
deficient diseases and have been recently described as a possible patho- 
genetic mechanism of several human tumors, reflecting an elevated mutation 
rate in the genome of neoplastic cells. The implication of MIN in pathogenesis 
of sporadic cardiac myxomas has not been previously investigated. 
Methods: To investigate the incidence of MIN in these rare tumors, II 
surgically excised sporadic cardiac myxomas (left atrial: IO, left ventricular:l) 
were studied using 30 highly polymorphic microsatellite markers (Research 
Genetics, Inc, USA) located on a wide range of chromosomal arms. Extracted 
DNA from myxoma tissue specimens and respective normal myocardial tis- 
sue was subjected to polymerase chain reaction (PCR). PCR products were 
electrophoresed in a 10% polyacylamide gel and silver stained. MIN was 
scored by comparing the electrophoretic pattern of the microsatellite markers 
amplified from paired DNA preparations (tumor/normal tissue). The analysis 
in the MIN positive cases was repeated at least twice and the results were 
highly reproducible. 
Results: Seven cardiac tumors (64%) exhibited MIN in at least one marker. 
Five of them were classified as tumors with high MIN (unstable for >2 genetic 
loci), while the other two as tumors with low MIN (unstable for 52 genetic loci). 
One tumor exhibited evidence of MIN in 6 markers (extensive genome desta- 
bilization), while the most frequently affected marker was D17s855 (27%), 
located on chromosome 17q (wihin BRCAI). Markers with high incidence of 
MIN were D17s250 (proximal to BRCAI), D17s579 and D7s520. MIN was 
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more frequently detectable in chromosome 17 than the other studied chromo- 
somes. No association was found between the presence of MIN and the age, 
the tumor location or the tumor size. 
Conclusions: A considerable incidence of MIN was detected in sporadic 
cardiac myxomas indicating the presence of a decreased fidelity in DNA repli- 
cation and repair in tumor tissue, This observation suggests that sporadic 
cardiac myxomas may be a DNA repair-deficient heart disease. 
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1185-l 20 The Interrelationship Between Myocardial Fibrin, 
Serum Soluble Intercellular Adhesion 
Molecule-l, Cardiac Troponin I and Subsequent 
Transplant Coronary Artery Disease 
Carlos A. Labarrere, David R. Nelson. Mefhodisf Research Institute, Clarian 
Health Partners, Indianapolis, IN; Department of Biostafisfics and 
Epidemiology, C/eve/and Clinic Foundation, C/eve/and, OH, USA 
Background: The presence of fibrin within the microvasculature and car- 
diomyocytes, elevated serum levels of soluble intercellular adhesion mole- 
cule-l (ICAM-I) and serum cardiac troponin I are all independent risk factors 
for subsequent outcome in heart transplant recipients. We studied the inter- 
relationship between all these factors and the combined risk for subsequent 
transplant coronary artery disease. 
Methods: Serum soluble ICAM-I and cardiac troponin I were studied in 
serial samples obtained during the first three months after transplantation 
(5.3 -+ O.i/Patient) from 128 cardiac allograft recipients using the sandwich 
enzyme-linked immunosorbent assay technique. The limit of detection for 
serum cardiac troponin I was 0.5 ngiml. Matching endomyocardial biopsy 
specimens were studied immunohistochemically for myocardial fibrin, Serial 
coronary angiograms (3.5 + 0,2/Patient) were studied to evaluate coronary 
artery disease. 
Results: The presence of myocardial fibrin within the first three months fol- 
lowing transplantation was significantly associated with serum soluble ICAM-I 
levels (p = 0.004) and with serum cardiac troponin I concentrations (p < 
0.001). Allograft recipients with myocardial fibrin, elevated serum soluble 
ICAM-I and elevated serum cardiac troponin I had respectively 6.9 (95 per- 
cent confidence intervals: 3.6-13.0, p < O.OOl), 2.7 (95 percent confidence in- 
tervals: 1.3-5.6, p = 0.009) and 1.8 (95 percent confidence intervals 1 .I-3.0, p 
= 0.02) times greater risk to develop coronary artery disease during follow-up. 
Conclusions: The presence of myocardial fibrin is associated with el- 
evated serum soluble ICAM-I, elevated serum cardiac troponin I and sub- 
sequent coronary artery disease suggesting an activated and procoagulant 
microvasculature associates with a worse outcome. 
1 1185-l 21 1 Catecholamine Sensitivity Changes With Time 
After Cardiac Transplantation 
Nicola D. Holt, Kim Hetherington, John H. Dark, Janet M. McComb. Freeman 
Hospital, Newcasfle upon Tyne, UK 
Background: The denervated transplanted human heart shows presynaptic 
B receptor supersensitivity and upregulation which may affect heart rate (HR) 
responses. The mechanism of the observed improvement of HR response to 
exercise with time after orthotopic cardiac transplantation is not fully known, 
but changes in catecholamine sensitivity may contribute. 
Methods: We studied serial changes in catecholamine sensitivity follow- 
ing transplantation in 19 adult recipients at 3, 6, 12, 24 and 52 weeks post 
transplant. Intravenous adrenaline (ADR) and noradrenaline (NOR) (6 incre- 
mental doses from 0.01 to 0.16 wg/kg) were given and HR response to each 
dose measured in beats/min at each time interval. 
Results: Mean HR response with ADR dose of 0.16 @g/kg and with NOR 
dose 0.12 kg/kg (dose limited by diastolic hypertension) were compared:- 
lime(wks) 3 5 12 24 52 
AD!? 32.8 rt 8.5 40.5 * 9.2 47.6 i 11.7 45.3 + 9.6 47.3i 12.5 
NOR 17.9 * 6.5 19.5 13.6 24.1 zk 4.4 25.816.2 22.3 zt 7.9 
HR response to both ADR and NOR changed significantly during the first 
year post transplantation (p 4 0.01, ANOVA). HR response to ADR was sig- 
nificantly less at 3 weeks compared with 6 weeks and later (p < 0.005, paired t 
test, Bonferroni correction); there was no significant change in HR thereafter. 
HR response to NOR changed significantly from 3 to 24 weeks and 6 to 12 
and 24 weeks (p < 0.005, paired t test, Bonferroni correction) but did not sig- 
nificantly change at any other times. Sensitivity to either catecholamine did 
not significantly change after 12 weeks. 
Conclusion: These changes in catecholamine sensitivity may have im- 
portant implications for HR response after cardiac transplantation. 
[ 1185-I 22 1 Urine Fibrinopeptide A as a Risk Factor for 
Cardiac Events Following Heart Transplantation 
Ali F. Sonel, Jacqueline O’Donnell, Joseph P. McConnell, Kathy Crecelius, 
Carlos A. Labarrere, Nils Bang, Laura Hiles, Aly Darroca, Vincent J. Pompili. 
Clarian Health Partners, Inc., Indianapolis, IN, USA 
Background: Depletion of arteriolar tissue plasminogen activator and a pro- 
coagulant microvasculature are associated with development of transplant 
coronary artery disease. We demonstrated the usefulness of fibrinopeptide A 
(FPA) in detecting transplant coronary artery disease but the value of FPA in 
risk stratifying patients’ cardiac events following heart transplantation is not 
known. 
Methods: Urine FPA levels were determined prospectively during outpa- 
tient visits of heart transplant recipients. A FPA level ‘_ 3.2 ng/mg creatinine 
was considered abnormal. Cardiac events studied were mortality, non-fatal 
myocardial infarction, development of NYHA class Ill or IV heart failure, re- 
transplantation and revascularization. 
Results: A total of 73 patients were enrolled in the study and FPA levels 
in urine were determined at the time of enrollment. Patients had a mean age 
of 53 i 11 years, 79% were males, and they had 6 & 3 years follow up post 
cardiac transplantation at the time of enrollment. Patients were followed for 
a mean of 9 i 2 months after enrollment and evaluated for cardiac events. 
During follow up 14 patients (19%) developed a total of 18 events (2 deaths, 2 
non-fatal myocardial infarction, 4 revascularizations and IO congestive heart 
failure). Four of 59 (7%) of event-free patients had abnormal FPA compared 
to 8 of 14 (57%) of patients with events (p < 0.0001). The mean FPA level 
in event-free patients was 1.3 i 0.1 ngimg creatinine campared to 8.9 f 4.1 
ng/mg creatinine in patients with events (p = 0.0002). 
Conclusions: Following cardiac transplantation, patients with elevated 
FPA are more likely to develop cardiac events compared to those with normal 
FPA levels. FPA may be a useful non-invasive marker to stratify patients at 
risk following cardiac transplantation and elevated FPA could be associated 
with the generation of fibrin within a prothrombogenic microvasculature. 
1185-l 23 Non-Invasive Detection of Transplant 
Vasculonathv Usina Indium-111 Taaaed 2D3 
Antibody in a Swine Model -- 
Javier Jimenez, Dillip Sawatt, Tammy Donahay, Lorraine Schofield, Ban An 
Khaw, Lynne L. Johnson. Rhode /s/andHospita/, Providence Rhode Island, 
USA 
Background: Accelerated transplant vasculopathy (ATV) is one of the major 
causes of morbidity and mortality in cardiac transplantation. The goal of this 
study is to investigate an indium-111 tagged monoclonal antibody (Z2D3) 
which targets proliferating smooth muscle cells (SMC) for the detection of 
ATV. 
Methods: A coronary artery segment from a farm pig was transplanted into 
the carotid position of 10 Yucatan minipigs. Between 1 and 12 wk after surgery 
animals were injected with In-l 11 Z2D3 and thymidine analogue BrDU. Twelve 
hr later the animals were imaged with SPECT and planar imaging in-vivo, 
sacrificed, and the vessels imaged ex-vivo. Stains for BrDU, H&E, Movat’s 
pentachrome, and actin were performed. 
Results: Scans were positive in 5/l 0 (50%) of the animals in-vivo and in 
6110 ex-vivo. Three of the 10 grafts were patent and all three of these were 
scan + in addition to 2 of the occluded grafts. SMC proliferation was demon- 
strated in all scan + patent and occluded grafts and additional inflammatory 
ceil infiltrates were demonstrated in occluded vessels. Percentage of actively 
proliferating SMC by BrDU-actin staining was 5.7% in scan + occluded grafts 
and 4.9% in scan + patent grafts. 
Conclusions: Vascular rejection in this model has a large inflammatory 
component involving both proliferating SMC and inflammatory cell infiltrates. 
In-111 Z2D3 shows promise for identifying ATV in this model. 
1 1185-l 24 / Influence of Electrical Stimulation on Subtotally 
Mobilrzed Latissimus Dorsi Muscle 
Valeri Chekanov, Michelle Maternowski, Victor Nikolaychik. Heart Care 
Associates, Sinai Samaritan Medical Center, Milwaukee, WI, USA 
Background: In a preliminary investigation, we showed that different regi- 
228A ABSTRACTS - Cardiac Function and Heart Failure JACC February 2000 
mens of electrical stimulation (ES) applied for 2 weeks to newly mobilized 
latissimus dorsi muscle (LDM) may either cause further damage to already 
ischemic muscle, or be beneficial by promoting recapiilarization and angio- 
genesis. We hypothesized that a cautious electrical stimulation protocol would 
help the muscle recover from ischemia, increase the angiogenic potential, and 
be beneficial for indirect myocardial revascularization after cardiomyoplasty. 
Methods: In this investigation we submitted totally mobilized LDM to ES 
for 2 months after a 2 week delay. A standard Medtronic protocol was used, 
however the number of contractions per minute (CPM) were changed: 60 
CPM - series I; 30 CPM - series II; 15 CPM - series III. We also added 
autologous biological glue (ABG) with aprotinin to the ES at 15 CPM (series 
IV). Light microscopy, immunostaining, and transmission electron microscopy 
were used to analyze samples. 
Results: Series I(60 CPM) Dramatic changes in muscle morphology were 
seen: most muscle fibers were swollen and shrunken, some were necrotic and 
calcified. Capillaries occupied 2.15 f 0.7% of area (3.99 f 0.24% in control). 
The majority of endothelial cells (EC) were damaged, cuboidal in shape with 
disrupted plasma membranes. 
Series /I (30 CPn/l) There was a high proportion of swollen degenerative 
cells, basophilic degeneration, and shrunken wavy fibers. Capillaries occu- 
pied 3.02 f 0.39% of area. EC showed morphological degeneration with 
cytoplasmic projections into the capillary lumen, 
Series I// (15 CPM) Occasional fiber degeneration without shrunken wavy 
fibers were seen. Capillaries occupied 5.01 f 0.56% of area. EC appeared 
normal without the degeneration of intracellular components. 
Series IV(f5 CPM+ABG + aprotinin) The muscle appeared normal with- 
out evidence of degeneration. Capillaries occupied 6.01 f 0.6% of area. EC 
were normal and tightly adjoined. 
Conclusion: Conventional ES at 30 CPM depresses angiogenic poten- 
tial. ES at 60 CPM is dangerous for the already ischemic muscle. ES at 
15 CPM prevents muscle damage and accelerates angiogenesis, especially 
when combined with an application of ABG + aprotinin. 
L-L 1185 125 Effects of Adenovirus Versus Liposome-Mediated Ex Viva Therapeutic Gene 
Transfer on the Function of Cardiac Allografts 
Luyi Sen, Guanggen Cui, Haimin Luo, Hill Laks. UCLA Medical Center, UCLA 
School of Medicine, Los Angeles, CA,, USA 
Virus and nonvirus-mediated immunosuppressive cytokine gene therapy has 
been shown to be preventive for cardiac allograft rejection in various animal 
models. However, the adverse effects of gene therapy on cardiac function 
have not been elucidated, since all of the heart transplant models reported 
previously are not in a complete working state. Recently, we have devel- 
oped a functional cervical heterotopic heart transplant model in rabbit. Using 
this model, we have been able to compare the efficiency, efficacy and ad- 
verse effects of optimized adenovirus (Adv) and liposome (Lip)-mediated ex 
viva IL-10 gene transfer in the donor hearts. In functional heart transplant 
model, both Adv and Lip-mediated IL-IO gene transfer efficiency was signifi- 
cantly increased (1.5 and 1.8 fold) compared with that in nonfunctional model. 
Adv-IL-IO gene transfer efficiency remained 3.8 folds higher than Lip-IL-10 
gene transfer. In Lip group, IL-IO overexperssion in donor hearts reached 
peak at post-operation-day (POD) 6 and maintained at plateau for 2 weeks, 
then slowly reduced, but it was transient in Adv group. The longevity of ‘al- 
lograft was increased from 8 f 2 days in Control group to 30 + 6 days in 
Lip-IL-10 treated group and 1.5 f 3 days in Adv-IL-IO group. In comparison 
with that in Lip and Control groups, both allografts and isografts left ventricular 
systolic pressure was significantly reduced (22 & 6%) by ex viva Adv vector 
with and without IL-10 gene transfer, and end-diastolic pressure was signifi- 
cantly increased (25 & 7%) at 2 hours and 3 days after transplantation (p < 
0.01). Ventricular tachycardia occurred in 1 l/30 cases in Adv group, but none 
in Lip group (n = 38, p < 0.01). These results demonstrated that Lip-mediated 
ex vivo intracoronary IL-10 gene transfer has higher preventive efficacy and 
less adverse effects in cardiac allograft rejection, although the efficiency is 
lower than Adv-mediated gene transfer. This heterotopic bi-venticular func- 
tional heart transplant model will be an useful in therapeutic study. 
) 1185-l 26 ) Cardiomyoblast-Mediated Ex Viva Gene Transfer 
into the Infarcted Myocardium 
Sharon Aboulafia-Etzion, Jonathan Leor, Israel M. Barbash, Orit Manor, 
Yosef Granot, Alexander Battler. Cardiac Research Center, Faculfy of Health 
Sciences, Ben Gurion Universik Beer Sheva, lsrael 
Background: Gene transfer to the heart for investigation and therapy of dis- 
eases is a rapidly expanding field with a potential clinical application, However, 
introduction of therapeutic genes into the infarcted myocardium is seriously 
limited because of the intense inflammatory response. We examined the pos- 
sibility that cardiomyocytes could be genetically marked or modified before 
being grafted to the infarcted heart under conditions applicable to the clini- 
cal setting. In addition, we tested the hypothesis that this approach may be 
superior to direct injection of adenoviral vector. 
Methods: Rats were subjected to extensive myocardial infarction by per- 
manent LAD coronary artery occlusion. We delivered a replication-defective 
recdmbinant adenovirus carrying the fl-galactosidase reporter gene (4 x IO” 
OD/ml) to cultured rat fetal cardiac myocytes. Almost all fetal cardiomyocytes 
in the primary culture expressed ,+galactosidase 24 hours after recombinant 
adenovirus transfection. These cells (1 x 106) were transplanted into the in- 
farcted rat hearts 7 days after induced myocardial infarction (n = 5). Another 
group of infarcted rats (n = 5) was subjected to direct injection of adenovirus 
carrying the same reporter gene. 
Results: Expression of the p-galactosidase gene in the grafted cells was 
demonstrated by staining with X-gal, resulting in a blue color. Transgene ex- 
pression was recognized 7 days after transplantation and was significantly 
greater than expression achieved by direct injection of adenovirus into my- 
ocardial infarction, 
Conclusions; Our results demonstrate that ex vivo gene transfer to the 
infarcted myocardium is feasible and significantly more efficient than direct 
adenoviral vector mediated gene delivery. Our results suggest that the ex 
vivo approach may partially eliminate one of the major hurdles facing the 
application of gene therapy to myocardial infarction. 
ORAL 
1890) Cardiogenic Shock: New Insights and 
Approaches 
Tuesday, March 14, 2000,4:00 p.m.-500 p.m. 
Anaheim Convention Center, Room 304A 
4:00 p.m. 
890-l ~c~~eE$o-Doppler Findings in Shock Complicating 
Chi-Ming Chow, Ravin Davidoff, Lisa A. Mendes, Christopher R. Thompson, 
Lynn A. Sleeper, Richard Steingart, Ken Gin, Vladimir Dzavik, Judith 
S. Hochman, Michael H. Picard. For the SHOCK Tra/; Massachusetts 
General Hospital, Boston, MA, USA 
Background: Restrictive LV filling as assessed by Doppler is associated with 
adverse outcomes or poor survival in subsets of cardiomyopathies. To assess 
the prevalence and prognostic significance of Doppler patterns in patients 
with cardiogenic shock (CS) complicating acute myocardial infarction (AMI), 
we examined the Doppler patterns in patients enrolled in the SHOCK Trial, a 
multicenter, randomized trial of emergency early revascularization (ERV) vs. 
a strategy of initial medical stabilization (IMS). 
Methods: Transmitral Doppler patterns were examined on baseline echocar. 
diograms upon entry to the study. The parameters examined include peak E 
and A velocities, deceleration time (DT), time velocity integrals (n/l) of E and 
A waves, and E/A ratio. 
Results: A total of 63 baseline echocardiograms were examined (34 ERV, 
29 IMS). A wide spectrum of Doppler patterns were observed without differ- 
ence between the two treatment groups. Mean f SD values for all 63 patients: 
Peak E (m/s) 0.79 + 0.32 
TVI E (m) 0.08 f 0.04 
DT Imsec) 129zk 68 
Peak A (m/s) 0.57 
TVI A (m) 
* 0.29 
0.070 i 0.11 
Restrictive patterns were common with 47% of patients presenting with 
E/A ratio > 1.2 and 25% of patients > 2.3. DT -Z 115 msec was noted in 54% 
of patients. There is a trend for higher peak E velocity (PI .O m/s) to be asso- 
ciated with 30-day survival in the IMS group; OR = 8.25 (p = 0.06). Changes 
in Doppler parameters over time including comparison of the effects of the 
treatment strategies on LV filling in addition to hemodynamic correlations will 
be presented. 
Conclusions: Although diastolic Doppler filling patterns are diverse, the 
restrictive filling pattern is common early among patients presenting with CS 
complicating an AMI. This is suggestive of a high prevalence of elevated LA 
pressure and poor LV compliance early in this condition. 
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El 890 2 Short Term Results of Left Ventricular Assist and 
Comprehensive Medical Management as Bridge to 
Recovery Therapy for Advanced,Heart Failure 
Marc A. Silver, Mark S. Slaughter, Pat S. Pappas, Antone J. Tatooles, 
Szabolcs Szabo. Heart Failure lnsfifufe and Lef? Ventricular Assist Program, 
Christ Hospital and Medical Center, Oak Lawn, Illinois, USA 
Background: Both medical and surgical therapies have been shown to atten- 
uate heart failure (HF) symptoms and improve survival in pts. with advanced 
HF. Infrequently, and usually only as bridges to heart transplantation, are med- 
ical therapies applied in the setting of left ventricular rest. We report short term 
results of this multidisciplinary approach in unselected pts. with advanced HF. 
Methods: Five men, aged 44 to 68 years, with NYHA functional class 
4 HF, moderate to severe mitral regurgitation and contraindications to heart 
transplantation underwent mitral valve repair and required LV assist with a 
Thoratec paracorporeal device. LVAD support was an average of 55 days 
(range 30 to 118 days). All patients had maximal HF medications uptitrated 
and also received exercise training regimens. Improvement in exercise tol- 
erance (peak VO2), as well as echocardiographic (% fractional shortening), 
physical, biochemical and neurohormonal markers (plasma norepinephrine, 
tumor necrosis factor a) indicated the probability of LV recovery and device 
weaning proceeded over 7-14 days, At device explantation all patients also 
received partial left ventriclulectomy. 
Results: All patients were discharged at 3-5 days post-explant. All pts. 
are functional class 1 at 11 to 119 (mean 86) days following explantation. 
Pm-oo Durina Su~oan Post-LVAD 
FC 4 1 
% FS 13 20 19 
pvo2 16.9 18.2 23.2 
PNE 806 305 461 
TNFa 26 25 21 
Conclusions: The combination of optimal medical therapy plus mitral 
valve repair and left ventricular assist applied to patients with advanced HF 
can provide successful bridge to recovery in unselected patients with desir- 
able short term results. This approach may provide an additional option for 
many pts. with advanced HF. 
4:30 km. 
890-3 Improved Survival Following Acute Myocardial 
Infarction Comolicated bv Cardioaenic Shock With 
LVAD/Transplant Suppori: A Stud; Comparing 
Aggressive Intervention With Conservative 
Treatment 
Wakkas Tayarra, Randall C. Starling, James B. Young, Osama Wazni, Fouad 
J. Jubran, Nicholas Smedira, Patrick MC Carthy. ClevelandClinic Foundation, 
C/eve/and, Ohio, USA 
Background: While the prognosis for patients (pts) with myocardial infarction 
(Ml) has steadily improved, it remains poor for those developing cardiogenic 
shock (CS). With advancements in mechanical circulatory support and revas- 
cularization, pts with CS may have an improved likelihood of survival. 
Methods: We analyzed 138 consecutive cases at the Cleveland Clinic 
from 1992-I 998 who met the institutional criteria for CS following Ml to deter- 
mine the effect of treatment modality on outcome. All pts received intensive 
medical therapy (IMT) and IABP support. While 95 pts were treated with ag- 
gressive interventions (percutaneous intervention (PCI}, CABG, heart trans- 
plantation or left ventricular assist device (LVAD)), 43 remained on IMT alone 
(conservative group). 
Results: The two groups were comparable for baseline characteristics. 
The effect of revascularization, transplantation or LVAD, as well as conserva- 
tive treatments including thrombolytic therapy and inotropic support, on the 
in-hospital survival were evaluated (Table). 
N Mortality p-value 
Overall 138 62% (86/I 38) 
Conservative 43 81% (35/43) 
Aggressive 95 54% (51/95) 0.0006 
PCI or CABG 82 60% (49/82) 0.0064 
TransplanffLVAD 17 29% (5/17) 0.023 
p-values represent comparison with conservative group 
Conclusions: These data suggest that an aggressive interventional strat- 
egy, particularly cardiac transplantation, improves survival in pts with CS. 
While overall mortality was 62%, it was highest in the conservative group 
(81%) and lowest among the most aggressively treated ptswith transplant/LVAD 
(29%). 
4:45 p.m. 
I 890 4 L-NMMA (A Nitric Oxide Synthase Inhibitor) is 
Effective in the Treatment of Cardiogenic Shock 
Gad Cotter, Edo Kaluski, Alex Blatt, Olga Milovanov, Yaron Moshkovitz, Ronit 
Zaidenstein Ah Salah, Daniela Alon, Michael Metzger, Zvi Vered, 
Ahuva Golik. Assaf-Harofeh Medical Center, Zerifin, lsrael 
Objective: To assess the safety and efficacy of L-NMMA (a nitric oxide syn- 
thase inhibitor) in the treatment of cardiogenic shock. 
Methods: Eleven consecutive patients with refractory cardiogenic shock 
were enrolled in this study. All patients underwent coronary catheterization 
and primary PTCR when feasible upon admission and coronary catheter- 
ization. Patients were enrolled if having refractory cardiogenic shock after 
>24 hours from admission despite treatment with mechanical ventilation, 
intra-aortic balloon pump (IABP) and high doses of cathecolamines, and if 
deemed beyond treatment by two expert cardiologists. L-NMMA (Clin-Alpha, 
Cal-Biochem) was administered as an intravenous bolus of 1 mg/kg and con- 
tinuous drip of 1 mglkgihr for 5 hours, Treatment with fluids, cathecholamines, 
mechanical ventilation, and IABP was kept constant throughout the study. 
Results: Within 5-10 minutes of L-NMMA administration, mean arterial 
blood pressure increased from 75 + 9 to 106 f 19 mmHg (+41%). During 
L-NMMA administration urine output increased from 68 i 30 cc/hr to 158 f 
67 cc/hr (+132%). Cardiac index decreased within 1 hour (during the steep 
increase in blood pressure and afterload) from 2.0 * 0.6 to 1.7 i 0.5 l/minims 
(-15%) however it gradually increased to 1 .Q f 0.5 I/minims after 5 hours 
of treatment. The heart rate as well as the wedge pressure remained stable. 
Twenty-four hours following L-NMMA discontinuation MAP (101 i- IO mmHg 
(+35%)) and urine output (186 & 78 cc/hour (~174%)) remained increased, 
however wedge pressure and cardiac index returned to pre-treatment level. 
No adverse events, new ischemia, nor arrhythmias were detected. Ten out 
of 11 patients could- be weaned off mechanical ventilation and IABP. Eight 
patients were discharged from the coronary ICU and seven are alive at 1 
month follow-up. 
Conclusion: L-NMMA administration has favorable clinical and hemody-. 
namic effects on patients in cardiogsenic shock. 
ORAL 
/ 901 Adjunctive Nondrug Therapies for Heart 
Failure 
Wednesday, March 1.5, 2000, 8:30 a.m.-IO:00 a.m. 
Anaheim Convention Center, Room 304A 
8:30 a.m. 
901-l First Clinical Experience Demonstrating 
Improvement of Hemodynamic Parameters in Heart 
Failure Patients Through the Application of 
Non-Excitatory Electrical Signals 
Carlo Papone, Gabriele Vicedomini, Maria L. Loricchio, Carlo Meloni, 
Andriano Salvati, Yoav Kimchy, Walid Hadad, Ricardo Aviv, Yuval Mika, 
Nissim Darvish, ltzhak Kronzon, Shlomo Ben-Haim. San Raphael Hospital, 
Mano, Ifafy; impulse Dynamics, Tiraf ffaCarme/; Technion, Haifa, Israel; 
New-York University, New-York, USA 
Background: Heart failure (HF) patients have traditionally been treated with 
a variety of drugs with therapeutic merits and undesirable systemic side ef- 
fects, Lately. new strategies such as biventricular pacing are being tested for 
HF treatment in the hope to reduce unwanted side effects. We tested the 
possibility of improving global left ventricular (LV) performance by applying 
non-excitatory electrical Cardiac Contractility Modulation (CCM) signals to 
heart failure patients. 
Method: In an acute study within an EP lab setting, 21 HF patients (15 
male, 9 with ischemic and 12 with idiopathic cardiomyopathy, mean ejection 
fraction 28 f 1.3%) were treated by CCM signals during DDD pacing or normal 
sinus rhythm (NSR). The signals were generated by an external experimental 
device and delivered by a catheter that was placed transvenously, via the 
coronary sinus in the great or the lesser cardiac veins. The signals were 
synchronized to the electrical activity of the LV and were delivered during 
the absolute refractory period. Application was done in periods of up to 30 
minutes. 
Results: Marked improvement in LV systolic parameters was observed 
during CCM application. The pulse pressure increased by 18.1 f 3.6%, LV 
end systolic pressure increased by 10 i 0.95% and LV dp/dt increased by 
13.6 f 1.2%. CCM has been shown to be compatible with all standard pacing 
modes as well as during normal sinus rhythm (NSR). The CCM inotropic effect 
was not proarrhythmic and did not have any significant side effects. 
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Conclusions: A novel method for the treatment of HF has been demon- 
strated showing significant improvement of hemodynamic parameters during 
the application of CCM signals. Further studies are planed to optimize the 
CCM signal parameters in different clinical settings and for different patholog- 
ical conditions. 
III 
8:45 a.m. 
901 2 Left Ventricular Pre-Excitation Improves 
Mechanoenergetics of Patients With Dilated 
Cardiomyopathy and Ventricular Conduction Delay 
Gregory. S. Nelson, Ronald D. Berger, Barry J. Fetics, Maurice Talbot, David 
A. Kass. The Johns Hopkins Hospital, Baltimore, Maryland, USA 
Background: Left ventricular or bi-ventricular pre-excitation of the left heart by 
VDD pacing improves systolic function in patients with dilated cardiomyopathy 
(DCM) and discoordinate wall motion associated with left bundle branch block 
(LBBB). This is achieved at an unaltered heart rate largely due to improved 
ejection efficiency by more coordinated contraction. We hypothesized that in 
contrast to positive inotropes such as dobutamine that concomitantly elevate 
myocardial oxygen demand (MVOs), VDD pacing achieves systolic benefits 
with minimal energetic cost. 
Methods: Eight DCM patients with LBBB (LV ejection fraction: 20.9 f 
8.3%; QRS duration: 176.0 f 9.8 ms; mean I- SD) underwent catheteriza- 
tion with a dual-sensor micromanometer catheter to measure proximal aortic 
and LV pressures, an intravascular Doppler wire to assess mean coronary 
flow (a,,,), and arterial-coronary sinus oxygen difference (AAVOs) sampling. 
Mean Q,,, x AAVOs was used to index relative changes in MVOs. Data were 
compared between normal sinus rhythm, VDD pacing in a lateral coronary, 
vein, and dobutamine, the latter titrated to match dP/dt,,, change with pac- 
ing. 
Results: VDD pacing enhanced dP/dt,, 42.9 f 15.3% (n = 8, P < 0.001) 
and pulse-pressure 19.8 f 11 .O% (n = 7, P < 0.005). In 718 patients, MVOz 
decreased -10.8 i 8.5% (P c 0.02), AAVO, -4.5 + 4.0% (P < 0.02) and 
mean Q c0r -6.3 f 10.7% (NS). In the one patient whose MVOs increased, 
dP/dt,, rose 77% and pulse-pressure 39%, a contractile response which 
was nearly twice the mean. By experimental design, dobutamine increased 
dP/dt,,, similar to pacing (37 f 15% n: = 7. P x 0.001). However, unlike pac- 
ing, dobutamine increased MVOs 39.6 f 41 .I% (P < 0.005 versus pacing). 
Conclusion: VDD pacing may be an attractive alternative to conventional 
DCM therapy in thispatient group because it enhances systolic function while 
at the same time generally decreasing the energy requirements of the failing 
heart. 
9:00 a.m. 
901-3 Long-Term Benefit of Cardiac Resynchronization in 
Heart Fpilure Patients: The 12 Month Results of the 
InSync Trial 
Daniel Gras, Serge Cazeau, Philippe Mabo, Cliff Bucknall, Anthony 
S.L. Tang, Henk Oude Luttikhuis, Anders Kirstein-Pedersen. Forthe /nSync 
Investigators; Clinique Bizet, Paris; University of Rennes Hospital, Rennes, 
France; St. Thomas Hospital, London, UK; University of Ottawa Heart 
Institute, Ottawa, Ontario, Canada; St. Sophia Ziekenhuis, Zwolle, The 
Netherlands; Skejby Sygehus, Aarhus, Denmark 
Background: The InSync trial is a prospective, multicenter, non-randomized 
study designed to assess cardiac resynchronization (CR) using atrial-syn- 
chronous biventricular pacing in patients with advanced hear-i failure (NYHA 
class Iii/IV), dilated cardiomyopathy (EF 5 35%, LVEDD z 60 mm) and QRS 
duration ‘_I 50 msec. 
Methods: 103 pts, who were optimized on standard medical therapy, are 
included in this study. NYHA class, 6 minute hall walk distance, and quality of 
life using Minnesota Living with Heart Failure are assessed at baseline, 1,3,6 
and 12 months post-implantation. The last patient was enrolled in November 
1998. 
Results: Results atfollow-up (FU) for 1 (Ml), 6 (M6), and 12 (M12) months 
are presented for data paired to baseline (Base) in the table below: 
NYHA Functional Quality of Life 6 Minute Hall Walk 
Glass S&e Distance (meters) 
N BSSS FU N Base FU N ElFIS2 FU 
Ml 88 3.3+0.5 2.4i0.8" 76 52zk18 32i19* 62 304A108 355zklOP 
M6 72 3.3zkO.5 2.1ztOo.S* 68 53i20 32+23* 54 304zk109 359zk103' 
Ml2 34 3.3-i:O.5 2.O?cO.7* 33 53zk22 29*19* 24 342kll9 395zk81** 
9:15 a.m. 
I_) 901 4 Responders and Nonresponders to Cardiac Resynchronization Therapy: Results From the 
InSync Trial 
Daniel Gras, Philippe Mabo, Cliff Bucknall, Anthony S.L. Tang, Henk 
Oude Luttikhuis, Anders Kirstein-Pedersen, Eric M. Dvorak, Michael 
R.S. Hill. For the /nSync Investigators; Clinique Bizet, Paris, France; 
Medtronic, Inc., Minneapolis, MN, USA 
The InSync clinical study is a prospective, multi-center, longitudinal trial evalu- 
ating cardiac resynchronization therapy in patients (pts.) with advanced heart 
failure (NYHA Class III/IV), dilated cardiomyopathy (EF 5 35%, LVEDD ? 60 
mm) and ventricular conduction abnormalities (QRS > 150 ms). 
Methods: 102 pts. implanted with the InSync system, including a transve- 
nous left ventricular lead via the coronary veins, were included in this analy- 
sis. Clinical endpoints were compared between baseline and last follow-up for 
groups defined as responders and nonresponders based on improvements in 
NYHA class (?I), quality of life (~30), and 6 min walkdistance (ml00 m). 
Results: Comparing outcomes for responders (N = 72 pts.) defined as pts. 
with improvement in NYHA class, the results were improvement in quality of 
life [23 f 24 vs 0 & 24, p < 0.051, shortening of QRS duration [31 f 31 ms vs 
-11 f21 ms, p< 0.051, improvement inLVEF%[5.2*9.7%vs-0.8rt9.1%, 
p = 0.0541 and decrease in LVEDD [2.5 f 6.5 mm vs -1.5 f 3.7 mm, p = 
0.0671. Comparing outcomes for responders (N = 80 pts.) defined as pts. with 
improvements in one of three endpoints, the result was significant shortening 
of QRS duration [29 & 32 ms vs -14 i 18 ms, p < 0.05]. Comparing outcomes 
for responders (N = 35 pts.) defined as pts. with improvements in two of three 
endpoints, the results were significant shortening of QRS duration [35 f 27 
ms vs 17 & 36 ms, p < 0.051 and improvement in LVEF% [8.4 f 11.6% vs 2.3 
+ 7.5%, p c 0.051. 
Conclusions: Responders to cardiac resynchronization therapy had con- 
sistent shortening of QRS duration, Dependent on the definition of respon- 
der, improvements were also observed in quality of life, LVEF% and LVEDD. 
These results suggest that cardiac resynchronization provides functional im- 
provement in heart failure patients. Randomized control studies will provide 
further information regarding the efficacy of cardiac resynchronization therapy 
and appropriate patient selection for this therapy. 
9:30 a.m. 
901-5 Improvement in Left Ventricular Performance by 
Enhanced External Counterpulsation in Patients 
With Heart Failure 
John Gorcsan Ill, Lawrence Crawford, Ozlem Soran, Hao Wang, 
Donald Severyn, Paul-Andre de Lame, Virginia Schneider, Arthur 
M. Feldman. University of Pittsburgh, Pittsburgh, PA, USA 
Background: Enhanced external counterpulsation (EECP) is a novel nonin- 
vasive therapy consisting of gated diastolic sequential leg compression pro- 
ducing similar hemodynamic effects as an intra-aortic balloon pump. Although 
preliminary data suggest that EECP has favorable effects on exercise capac- 
ity in patients with heart failure (HF), its effects on LV function has not been 
characterized. 
Methods: To test the hypothesis that EECP may have beneficial effects 
on LV performance in HF, 8 patients with NYHA Class II or Ill HF and ejection 
fraction (EF) < 40% were studied. Preload-adjust maximal power (PAMP) 
was assessed as a relatively load independent measure of LV performance 
before and after EECP treatment consisting of 35 x I-hr sessions over 7 
weeks. Medical therapy was unaltered during this time. Pressure volume 
relations were simultaneously estimated using echocardiographic automated 
border detection as a surrogate for LV volume and photoplythesmography as 
a surrogate for LV ejection pressure to calculate PAMP noninvasively. 
Results: Significant increases in PAMP were observed after EECP ther- 
apy from 4.2 f 1.6 to 5.4 f 2.0* mWlcm4, *p < 0.05 vs. baseline. EF also 
increased from 25 f 10 to 29 f 8* % and hear-i rate decreased from 73 f 5 to 
65 * 5* mini, *p < 0.01 vs. baseline. 
Conclusions: EECP therapy was associated with improvements in PAMP 
and EF along with decreases in hear-i rate in these HF patients. EECP appears 
to be beneficial to LV function in HF patients and may be a useful adjunct to 
medical therapy. 
*p < 0.0001 **p = 0.01 
Conclusions: The InSync trial data suggest that CR may provide long- 
term clinical improvement, in selected patients with advanced heart failure. 
JACC February 2000 
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901-6 lmproved Left Ventricular Function and Reduced 
Peripheral Resistance After Long-Term Exercise 
Training in Patients With Chronic Heart Failure: The 
Leipzig Heart Failure Training Trial 
Rainer Hambrecht, Stephan Gielen, Axel Linke, Eduard Fiehn, Jiangtao Yu, 
Claudia Walther, Nina Schoene, Gerhard Schuler. University of Leipzig - 
Heart Centel; Leipzig, Germany 
Background: Exercise training has been shown to augment functional work 
capacity in particular by peripheral adaptations in patients (pts.) with stable 
chronic heart failure (CHF), whereas effects on central hemodynamics remain 
contradictory. The Leipzig Heart Failure Training Trial is a large prospective 
monocenter study to evaluate the effects of long-term exercise training in pts. 
with CHF on left ventricular function and hemodynamic response to exercise. 
Methods: 73 pts. with CHF due to dilated cardiomyopathy (n = 61) or 
ischemic heart disease (n = 12) were prospectively randomized to either a 
training group (T) (n = 36; left ventricular ejection fraction by ventriculography 
[LV-EF,,rh] 27 i 1%) or to a physically inactive control group (6) (n = 37; 
LV-EF,,m 27 f 2%). At the study begin and after 6 months pts. underwent 
symptom-limited ergospirometry with measurement of central hemodynamics 
by thermodilution and echocardiography with determination of the LV volumes 
and sphericity indices (longitudinal/transverse LV-diameter). 
Results: After 6 months, a reduction in systemic vascular resistance 
(SVR) at peak exercise by 20% was observed in T (from 770 i 71 to 613 
j: 41 dynessec.cm-5; p < 0.01 vs. C) with a concomitant increase in LV 
stroke volume by 15% (from 95 i 9 to 109 * 8 mL; p < 0.05 vs. C). There 
was a small but significant reduction in left ventricular end-diastolic diameter 
(LVEDD) by 6% (from 69 f 2 to 65 rt 2 mm; p < 0.001 vs. C) and an increase 
in LV-EF,,h, by 17% (30 ;t 2 to 35 f 2; p < 0.01 vs. baseline). Changes in 
SVR at rest were correlated with changes in SV (r = -0.76; p < 0.001) and 
changes in LVEDD (r = 0.45; p < 0.001). In T LV endsystolic sphericity index 
increased from 1.40 & 0.05 to 1.50 + 0.05 (p < 0.05 vs. C). 
Conclusion: In pts. with CHF long-term exercise training is associated 
with a considerable afterload reduction. This beneficial training effect results 
in a small, but significant reduction in cardiomegaly, improvement of left ven- 
tricular geometry and cardiac function. 
MODERATED POSTER SESSION 
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101 O-l 67 FAdrenergic Blockade in Developing Heart 
Failure: Effects on Myocardial Inflammatory 
Cytokines, Nitric Oxide, and Remodeling 
Sumanth D. Prabhu, Bysani Chandrasekar, David Ft. Murray, Gregory 
L. Freeman. UTHealth Science Centerand South Texas Veterans Health 
Care System - Audie Murphy Division, San Antonio, Texas, USA 
Background: Whether /?-adrenergic blockade modulates expression of in- 
flammatory cytokines and nitric oxide (NO) in failing myocardium is not known. 
We examined the effects of chronic metoprolol administration on chamber re- 
modeling, myocardial TNF-a, IL-lb, and IL-6 expression, and NO during the 
development of left ventricular (LV) dysfunction induced by left coronary artery 
ligation in the rat. 
Methods and Results: Twelve weeks after ligation in untreated rats, 
echocardiography and LV weight revealed significant LV dilatation, systolic 
dysfunction, and hypertrophy compared to sham (p < 0.001). Papillary mus- 
cle studies revealed isoproterenol hyporesponsiveness unaltered by NO syn- 
thase (NOS) inhibition. Myocardial inducible NOS (INOS) mRNA in nonin- 
farcted regions and circulating NO metabolites were undetectable. Myocardial 
TNF-ol, IL-ID, and IL-6 mRNA and protein were markedly elevated compared 
to sham (p < O.OOi), with two-fold higher expression (p < 0.025) of IL-6 com- 
pared to TNF-cu or IL-Ifi. Metoprolol administration starting 48 hours after 
ligation resulted in: 1) less LV dilatation, hypertrophy, and systolic dysfunc- 
,tion (p < 0.02) 2) preservation of the isoproterenol response (p < 0.025) via 
NO-independent mechanisms, and 3) reduced myocardial gene expression 
and protein production of TNF-ol and IL-ID (2.9 fold reduction, p < 0.025), but 
not IL-6, which remained markedly elevated. The degree of mRNA expres- 
sion of TNF-a and IL-la, but not IL-6, correlated well with the degree of LV 
hypertrophy, regardless of metoprolol. 
Conclusions: During heart failure development, adrenergic activation 
contributes to increased myocardial expression of TNF-u and IL-lj, but not 
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IL-6 and one mechanism whereby fi-adrenergic blockade improves myocar- 
dial function and remodeling may be related to attenuation of TNF-o and IL-ID 
expression, independent of iNOS and NO. 
9:12 a.m. 
/ 1010 168 Omega-3 Fatty Acids Improve Blood Pressure Control in Hypertensive Heart Transplant 
Recipients 
T. Holm, A.K. Andreassen, P. Aukrust, 0. Geiran, J. Kjekshus, S. Simonsen, 
L. Gullestad. Departments of Cardiology and Surgery, and Research Institute 
for Internal Medicine, Rikshospitalet, University of Oslo, Norway 
Hypertension is common in cyclosporine treated heart transplant recipients 
(HTx) and optimal control may be difficult to achieve. Omega-3 fatty acids 
may reduce blood pressure in cyclosporin treated HTx. The aim of the present 
study was to investigate if omega-3 fatty acids reduce blood pressure (BP) in 
already hypertensive long time survivors of heart transplantation. 
Methods: In a double blind fashion, 46 clinically stable hypertensive HTx 
(44 males, age 58 & I, mean * SEM), 6 (range l-l 2) years after transplan- 
tation, were randomized to receive either 4 g of omega-3 fatty acids daily 
or placebo for one year. Compliance was ascertained by determination of 
serum phospholipid acids. Ciclosporine, prednisolon and azathioprin were 
used for immunosuppression, and 37 patients received other antihyperten- 
sive medication. Ambulatory 24 hour BP monitoring was performed first prior 
to randomization and at the end of the study. Hypertension was defined as 
mean 24 hour BP above either systolic 139 mmHg or diastolic 87 mmHg. 
Results: The two groups had comparable demographic characteristics, 
and blood levels of ciclosporine did not at any point differ between groups. 
None had any signs of allograft rejection during the study period. After 12 
months, systolic BP increased 8 * 3 mmHg (P < 0.05) in the placebo group, 
while no increase (0 i 2 mmHg) was recorded in the treatment group. No 
significant change in diastolic BP were found in either two groups. Plasma 
creatinine increased from 121 f 6 to 132 i 5 mmol/l (P = 0.01) and glomerular 
filtration rate (GFR) decreased 74 & 5 to 68 f 4 mlimin (p < 0.05) in the 
placebo group while no significant change in these parameters were seen in 
the omega-3 group. 
Conclusion: Daily administration of omega-3 fatty acids may improve 
BP control in already hypertensive HTx. Preservation of kidney function may 
contribute to the antihypertensive effect of omega-3 fatty acids. 
9:24 a.m. 
101 O-l 69 The Effect of Estrogen Replacement on 
Thrombus Formation in Elderly Women 
Mary Ann McLaughlin, Kelly J. Baek, Juan J. Badimon, Stella Palencia, 
Rama Vidhun, Cheryl Aber, James H. Chesebro, Valentin Fuster. Mount 
Sinai School of Medicine, New York, New York, USA 
Background: Alterations of the coagulation and fibrinolytic pathways are im- 
portant in the pathogenesis of atherosclerotic heart disease. In women, after 
menopause, there are changes in hemostatic factors towards hypercoag- 
ulability. Estrogen has been shown to have both favorable fibrinolytic and 
unfavorable hypercoagulable effects. We sought to determine the net effect 
of estrogen replacement therapy (ERT) on blood thrombogenicity in elderly 
postmenopausal women with cardiovascular disease. 
Methods: We prospectively studied 25 post-menopausal women, over 
the age of 65 years, who had evidence of cardiovascular disease. Patients 
were randomized to estradiol 1 mg. daily vs. placebo and were evaluated 
at baseline and after three months of therapy. Blood thrombogenicity was 
measured as thrombus formation in the Badimon ex-vivo perfusion chamber. 
Non-anticoagulated blood was perfused for 5 minutes directly from patients 
into the perfusion chamber at high shear rate conditions (1690/set) mimick- 
ing mildly stenosed coronary arteries. Porcine tunica media served as the 
thrombogenic substrate. Thrombus formation (THR) was measured as area 
covered by thrombus, analyzed by computer-assisted planimetry performed 
by 2 blinded observers. 
Results: Estrogen replacement therapy resulted in a 20% reduction in 
thrombus generation (p 5 0.02) compared to controls. This reduction in throm- 
bus formation provides evidence that estrogen therapy, in the absence of 
progesterone therapy, favors decreased thrombosis rather than coagulation 
during the first three months of therapy. 
Conclusions: This study is the first to date to show a reduction in throm- 
bus formation in women treated with ERT. A reduction in thrombogenicity may 
result in a reduction in cardiac morbidity and mortality in post-menopausal 
women treated with ERT. Further studies of the thrombogenicity of the combi- 
nation therapy of estrogen and progesterone therapy are warranted. 
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EIII 1010 170 Change in Diastolic Left Ventricular Function After One Year of Antihypertensive Treatment: 
The LIFE Study 
I iOlO-172 1 Angiotensin-Converting Enzyme Inhibitor Use in 
Diastolic Heart Failure is Associated with a 
Reduced Risk of Death 
Kristian Wachtell, Jonathan N. Bella, Jens Rokkedal, 
Vasilios Papademetriou, Bjorn Dahlbf, Tapio Aalto, Eva Gerdts, Richard 
B. Devereux. Glostrup University Hospita/, Glostrup, Denmark; The New York 
Hospital-Cornell Medical Center, New York, USA 
Edward F. Philbin, Thomas A. Rocco, Jr., Norman W. Lindenmuth, Paul 
L. Jenkins. Henry Ford Hospital, Detroit, Ml; Unity Health System, Rochester, 
N‘L: USA 
Background: We have previously reported that patients with left ventricular 
(LV) hypertrophy (LVH) have impaired diastolic function and that this was as- 
sociated with LVH. It remains unclear what impact antihypertensive treatment 
and LV mass reduction have on the prevalence of LV diastolic function. 
Background: The role for angiotensin-converting enzyme inhibitor (ACEI) 
use in patients with heartfailure (HF) and abnormal left ventricular (LV) systolic 
function is established. The utility of ACEI among HF patients with preserved 
function is unknown. This study examined the association between ACEI use 
and clinical outcomes among a group with HF and normal LV systolic function. 
Methods: Doppler echocardiograms were recorded at baseline in unmedi- 
cated patients with stage I-III hypertension and LVH determined by ECG (Cor- 
nell voltage duration ~2,440 mm x msec or Sokolow Lyon: SVI + RV5/RV6 < 
38 mm) after 14 days of placebo treatment; follow-up echocardiograms were 
done after 1 year of blinded treatment with either losartan or atenolol, and in 
some cases supplemented with thiazide and calcium antagonist in order to 
reach target blood pressures (BP) of 140/90 mmHg. 
Methods: From a registry of 2,906 consecutive patients with confirmed 
HF admitted to IO hospitals, we identified 1,694 with measurement of LV 
function. Of these, 721 were hospital survivors, had a LV ejection fraction (EF) 
> 40% or normal contractility and were followed prospectively for 6 months 
after discharge. 
Results: In 711 patients needed diastolic measurements, systolic BP 
(SBP) was reduced from on average 174 f 21 to 150 f 20 mmHg, dias- 
tolic BP (DBP) from 95 f II to 84 f 10 mmHg. LV mass was reduced from 
234 f 56 to 207 & 50 g (all p < 0.001). Decrease in isovolumetric relaxation 
time was related to reduction in LV mass (r = 0.165) and relative wall thickness 
(RWT) (r = 0.154, both p < O.OOl), but was not related to the decrease in 
either SBP or DBP (NS). Decrease in RWT, SBP and DBP did correlate to 
increased E/A-ratio, whereas LV mass changes did not (NS). Normal LVfilling 
increased from 15 to 26%, abnormal relaxation decreased from 67 to 57%, 
pneudonormalization from IO to 5% and restrictive filling pattern remained at 
4%. However, most patients retained some of abnormal mitral flow pattern, 
Ten percent had normal mitral valve flow pattern at baseline but developed 
abnormal mitral flow pattern and only 20% changed from abnormal to normal 
mitral flow pattern after one year of antihypertensive treatment, 
Results: Median age was 75 years; 66% were women, Mean EF was 
51 f 9%. ACEI were prescribed to 382 of 721 (53%) (ACEI+) at hospital 
discharge; 339 (47%) were discharged without ACEI (ACEI-). Compared 
with ACEI-, ACEI+ had lower EF (49 f 8% vs. 52 & 9%, P = 0.0002) and 
lower serum creatinine (1.4 i: 1.2 vs. 1.8 + 1.8, P = 0.001). ACEI+ were 
more likely to receive digoxin, diuretics and warfarin, but less likely to receive 
calcium blockers (all P < 0.05). Mean hospital length of stay (7.2 vs. 7.6 days), 
hospital charges ($7,777 vs. $8,096) and NYHA functional class 1 month after 
discharge (2.2 vs. 2.3) were similar for ACEI+ and ACEI- (all P > 0.05). 
Crude death and hospital readmission rates are shown in the Table. Logistic 
regression was used to account for baseline differences between the groups; 
adjusted odds ratios (OR) and confidence intervals (Cl) are also shown in 
the Table. As shown, mortality was lower among ACEI+; hospital readmission 
rates also favored ACEI+ but the differences were not statistically significant. 
Conclusion: Twelve percent LV mass reduction through antihypertensive 
therapy normalizes LV filling parameters in 20% of patients, while 10% de- 
velop LV filling abnormalities and 69% remain unchanged. One year of treat- 
ment might not be long enough time to normalize LV diastolic filling in majority 
of patients. 
Outcome ACEI+ ACEI- P Adj. OR 95% Cl P 
6-month mortality 11.3% 16.8% 0.03 0.46 0.27-0.78 0.004 
HF rehospitalization 22.3% 24.5% 0.48 0.81 0.56-l .18 0.27 
Any rehospitalization 43.2% 47.5% 0.25 0.82 0.59-I .I2 0.21 
Death or readmission 45.8% 51.0% 0.16 0.81 0.59-l .l 1 0.19 
9:48 a.m. 
101 O-l 71 Evaluation of Global Left and Right Ventricular 
Function during Supine Physical Exercise by 
Ultra-Fast Magnetic Resonance Imaging 
Conclusions: In patients with HF treated in the community setting, ACEI 
use among the sizeable subset with preserved LV systolic function is associ- 
ated with reduced mortality and a trend for fewer hospital admissions. Large, 
prospective, randomized, controlled trials are now required to confirm these 
interesting but preliminary and hypothesis-generating results. 
Arno A.W. Roest’.a, Patrik Kunz*, Hildo J. Lamb’, Willem A. Helbing*, Ernst 
E. van der Wall’.‘, Albert de Roos’~‘. ‘Interuniversity Cardiology institute of 
The Netherlands, Utrecht; 2Leiden University Medical Center, The 
Netherlands 
IO:12 a.m. 
101 O-l 73 Omapatrilat Improves Volume Homeostasis in 
Chronic Heart Failure 
Background: Cardiac response to physical exercise may be impaired in pa- 
tients with heart disease and can be abnormal in the absence of clear symp- 
toms at rest. Magnetic resonance imaging (MRI) is an excellent tool to evalu- 
ate ventricular function, especially of the right ventricle. However, assessment 
of ventricular response to physical exercise by MRI is difficult due to increased 
motion artifacts during exercise. Aim of this study was to evaluate left (LV) and 
right (RV) ventricular response to supine physical exercise with the application 
of an ultra-fast MRI sequence. 
Dougal R. McClean, Hamid Ikram, Ian G. Crozier, Michelle Reynolds, A. 
Mark Richards, M. Gary Nicholls. Christchurch Hospital, Christchurch, New 
Zealand 
Background: Omapatrilat is a new compound that simultaneously inhibits 
angiotensin converting enzyme (ACE) and neutral endopeptidase. We exam- 
ined file effects of chronic vasopeptidase inhibition (VPI) on volume home- 
ostasis in patients, with symptomatic heart failure. 
Methods: Ventricular function at rest and during exercise was studied in 
15 healthy volunteers using an ultra-fast turbo field echo planar imaging MRI 
sequence. Individual exercise levels were based on the workload at 60% of 
the prior measured maximal oxygen uptake. Exercise was performed on a MR 
compatible ergometer. Ten slices in the short-axis direction covered both left 
and right ventricle and were obtained using 5 breath-holds, Each breath-hold 
was performed during an 8-heartbeat suspension of exercise and in this period 
2 short-axis slices were acquired. 
Methods: Nineteen patients with NYHAclass ll+lll and LVEF 5 40% were 
randomised to one of five omapatrilat doses for 12 weeks. Diuretics were not 
increased over 12 weeks, Blood volume using indocyanine green dye method. 
venous blood for ANP and left ventricular volumes using echocardiography 
were measured at baseline and after 12 weeks. 24-hour urine volume and 
sodium excretion was measured on day one and day 83. Data is presented as 
low dose (2.5,5, IO mg) or high dose (20,40 mg). (mean f SEM) 
Results: 
Results: Ejection fraction (EF) of the LV and the RV increased in all voi- 
unteers in response to exercise (LV: +I2 ZIZ 5%; RV: cl0 f 4%). Furthermore, 
increase in stroke volume (SV) from rest to stress of the LV (+I5 i- 9 ml) and 
the RV (+I4 & 7 ml) was observed in all subjects. For the LV, increase in EF 
and SV was the result of a combined decrease in end-systolic volume (ESV) 
(-20 f 11 ml) and end-diastolic volume (EDV) (-6 f IO ml). Whereas for the 
RV, increase in EF and SV was the result of a decrease in ESV (-19 f IO ml). 
Changes at 12 weeks Low dose In = 101 Hiah dose fn = 9) 
Blood Volume (ml) 
Urine Volume (ml) 
Urine Sodium (mmol) 
End Diastolic Volume (EDV)(ml) 
End Systolic Volume (ESV)(ml) 
Ejection Fraction (%) 
Plasma ANP fumol/L) 
-44*249 -749 zt 164* 
181218 398i113 
2117 41 *12* 
11 *lo -15 * 6* 
0.5 * 5 -33i5** 
2.5 12.1 7.1 * 1.2 
-3.9 + 6.8 38.9+ 14.8* 
Conclusion: This study shows that it is feasible to evaluate cardiac re- 
sponse to supine physical exercise in healthy subjects with an ultra-fast 
MRI sequence. In agreement with literature, SV and EF of both ventricles 
increased in response to exercise mainly due to a decrease in ESV. 
Change in Blood Volume was correlated with change in ESV (r = 0.64; p < O.Ol), and 
change in urine volume (r = -0.64: p < 0.01). * = p < 0.05 and *’ = p c 0.01 vs. low dose 
group. 
Conclusions: High dose chronic omapatrilat therapy produces beneficial 
changes in patients with chronic heart failure by reductions in left ventricular 
and circulatory blood volumes coupled with potentiation of natriuretic peptides 
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and natriuresis at 12 weeks. Further studies are needed to compare these 
changes with selective ACE inhibition alone. 
IO:24 a.m. 
101 O-l 74 Better Systolic Function, But No Better Survival, 
for Women With Advanced Heart Failure: 
Findings From the Duke Databank for 
Cardiovascular Disease 
Monica Ft. Shah, Linda Shaw, Christopher M. O’Connor, Robert M. Califf. 
Duke Clinical Research Institute, Durham, NC, USA 
Background: Women with heart failure (HF) may have a higher rate of pre- 
served systolic function than men with HF. How this relates to differences in 
survival is unknown. We prospectively studied 1344 patients to identify the 
distribution by sex of heart failure with preserved systolic function vs. systolic 
dysfunction, and the effects of systolic function and gender on survival over 2 
years. 
Methods: We identified 663 women and 681 men with Class IV HF symp- 
toms from the Duke Cardiovascular Databank. Those with an ejection fraction 
(EF) z 40% on ventriculography were considered to have preserved systolic 
function. 
Results: Women with advanced HF were more often hypertensive (68.5% 
vs. 63.1%; p = 0.039) were more likely to have preserved systolic function 
(64.9% vs. 40.8%; p = O.OOi), and had a higher EF (median 50% vs. 35%; p = 
0.001). Women were less likely to have ischemic cardiomyopathy (54.7% vs. 
73.3%; p = 0.001). A Cox model showed no significant difference in mortality 
overall between women and men at 2 years, even after adjusting for age, 
preserved systolic function, and etiology of HF. 
Adjusted 
Mortality 
6 months 
1 year 
2 years 
Preserved Systolic Function 
WlXTR?l- Men p Value 
0.14 0.12 
0.20 0.17 - 
0.30 0.26 0.30 
Systolic Dysfunction 
Women Metl p Value 
0.17 0.16 
0.24 0.23 
0.36 0.40 0.58 
Conclusions: Women with Class IV heart failure symptoms are more 
likely than men to have preserved systolic function. Despite this, and despite 
having a lower rate of ischemic cardiomyopathy and higher ejection fractions, 
women with advanced heart failure die at a rate similar to that of men with this 
disease. 
IO:36 a.m. 
101 O-l 75 Passive Ventricular Constraint in Advanced 
Heart Failure Prevents a Further Decline in 
Cardiovascular Function 
John M. Power, Jai Raman, Melissa Byrne, Cliff Alferness. University of 
Melbourne (A&RMC Campus), Heidelberg, Australia 
Background: Passive ventricular constraint in early experimental heart fail- 
ure has been shown to the halt the progressive deterioration in cardiac func- 
tion associated with dilated cardiomyopathy. We examined the efficacy of this 
treatment in advanced heart failure. 
Methods: A Transonic 20A cardiac output (CO) flowprobe was implanted 
on the pulmonary artery of 12 adult merino sheep. The animals were paced at 
180-l 90 bpm for 21 days and then for 42 days at 200-210 bpm to induce ad- 
vanced heat-l failure. In 6 animals an Acorn cardiac support device (Acorn Car- 
diovascular Inc, St Paul MN) was implanted, via a partial sternotomy, around 
both ventricles. Pacing then was recommenced for a further 28 days in ani- 
mals. Cardiovascular parameters were determined using echocardiography 
and a submaximal treadmill exercise protocol at baseline, in advanced failure 
and at termination of pacing. 
Results: Cardiovascular function was significantly depressed in all ani- 
mals in advanced failure in comparison with baseline and continued to decline 
in non-implanted animals over the additional 4 weeks of pacing. However in 
the implanted animals deterioration was arrested or significantly improved in 
comparison with implant. 
Group Baseline Early HF Late HF Final 
LV Ejection Fraction 
No Implant 49% 32% 25%’ 19%” 
Acorn Implant 53% a%* 22%* 34%X 
LV + dP/dt (ma) 
No Implant 1636 1148 992* 887 
Acorn’lmplant 1573 1310 112s* 1443* 
“p < 0.05 
Conclusion: In this animal model of advanced heart failure passive ven- 
tricular constraint was able to reverse the deterioration in cardiovascular func- 
tion observed in control animals. 
lo:48 a.m. 
IIIII 1010 176 Altered Left Ventricular lnotropic Reserve and Mechanoenergetics Early in the Development of 
Heart Failure 
Sumanth D. Prabhu, Gregory L. Freeman. UTHealth Science Centerand 
South Texas Veterans Health Care System - Audie Murphy Division, San 
Antonio, Texas, USA 
Background: Whether alterations in left ventricular (LV) inotropic reserve and 
mechanoenergetics manifest early in the evolution of heart failure, or whether 
they are late adaptations to more fundamental abnormalities is unclear. 
Methods: six anesthetized, autonomically blocked dogs instrumented with 
LV micromanometers, piezoelectric crystals, and coronary sinus catheters 
were studied before and after 24 hours of rapid ventricular pacing (RVP). The 
endsystolic pressure-volume (P as-VES) relation was determined at several 
different afterloads produced by graded infusions of phenylephrine. At each 
afterload, myocardial oxygen consumption (VOs) and LV pressure-volume 
area (PVA) were determined to construct the VOa-PVA relation. 
Results: RVP resulted in reduced preload with proportionate reductions 
in SW and dP/dtMAx, but no significant reduction in baseline LV contractility. 
In response to increased afterload, the baseline Pas-Vas relation shifted to 
the left with maintained end-systolic elastance (Eas). In contrast, after RVP, in 
response to comparable increases in afterload, the Pas -Vas relation displayed 
reduced Eas (P < 0.05) and significantly less leftward shift as compared 
to control (p < 0.05). As compared to the control VOa-PVA relation, RVP 
significantly increased the VOs axis intercept (1.25 f 0.08 vs. 0.90 i 0.10 
J/bt/lOO g LV, p < 0.05) with maintenance of the slope. 
Conclusions: Short-term RVP results in attenuation of afterload-induced 
enhancement of LV performance and increases energy consumption for non- 
mechanical processes with maintenance of contractile efficiency. This sug- 
gests that early in the development of tachycardia heart failure, there is 
blunting of length-dependent activation and increased 0s requirements for 
excitation-contraction coupling, basal metabolism, or both. 
POSTER 
lIYIIl 1206 Potential New Therapeutic Approaches in 
Heart Failure 
Wednesday, March 15,2000,9:00 a.m.-11:OO a.m. 
Anaheim Convention Centsr, Hall A 
Presentation Hour: 1O:OO a.m.-II :00 a.m. 
1206-l 42 Activation of Protein Kinase C in the lschemic 
and in the Non-lschemic Area After LAD Ligation 
is Blocked by Pretreatment With Ramiprilate 
Gregor Simonis, Kerstin Schwarz, Lflrike Oehl, Ruth H. Strasser. 
Department of Cardiology: University of Heidelberg Medical Center, 
Heidelberg, Germany 
Background: Acute myocardial infarction leads to increased expression and 
activation of the protein kinase C (PKC) isoforms PKC-S and PKC-E in the 
ischemic myocardium. In the area remote from the infarction, only PKC-E is 
upregulated after 45 min of regional ischemia. PKC may contribute to the 
process of remodeling in the infarcted heart. Angiotensin converting enzyme 
(ACE)-inhibition has been shown clinically to prevent remodeling in the area 
remote from the infarction. To address the question if therapeutic ACE inhibi- 
tion may also prevent the expressional upregulation of PKC, an experimental 
model of myocardial infarction was used. 
Methods: Male wistar rats (200 g) were pretreated with Ramiprilate (IO 
pg/kg daily i.p.) for 7 days. Controls were injected with saline. After 7 days, 
regional myocardial infarction was induced by ligation of the LAD (45 min) 
in an open chest model. Sham-operated animals served as controls (co). In 
biopsies from the ischemic and from the remote myocardium the major PKC 
isoforms expressed in rat heart, PKC-a, PKC-8 and PKC-E, were determined 
by Westernblot analysis. 
Results: Treatment with Ramiprilate increased the expression of PKC-E 
significantly to 140% of the saline controls both in the cytosolic and in the par- 
ticulate fraction (p < 0.05). Expression of PKC-S and PKC-ol was unchanged. 
In the ischemic area of the heart, the induction of cytosolic PKC-S and PKC-E 
seen in the saline group (to 161 * 25 and to 145 f 13% of co, p < 0.01) 
was blocked by pretreatment with Ramiprilate. In the area remote from the 
infarction, the selective cytosolic upregulation of PKC-E (149 i 16% of co, n 
= 14, p < 0.01) could be completely prevented by Ramiprilate. Expression in 
the particulate fraction did not change in any group. 
Conclusion: The selective regulation of PKC-E in the non-ischemic, re- 
mote area after myocardial infarction can be blocked by ACE inhibition. These 
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data suggest that ACE inhibition may prevent remodeling of the infarcted heart 
in part by a modulation of the expression of protein kinase C. 
I 1206 143 Enhanced Angiotensin II Type 2 Receptor mRNA and Protein Expression During Cardioprotection 
Induced by Receptor Blockade During 
Ischemia-Reperfusion in Isolated Working Rat 
Hearts 
Bodh I. Jugdutt, Yi Xu, Alexander S. Clanachan. UniversityofAlberta, 
Edmonton, Alberta, Canada 
Background: We hypothesized that improved recovery of mechanical func- 
tion after ischemia-reperfusion (IR) induced by acute angiotensin II (Angll) 
type 2 receptor (ATaR) blockade is an ATaR mediated effect that is associated 
with AT$t upregulation. 
Methods: We assessed changes in ATs R and Angll type 1 receptor (AT, R) 
expression (immunoblots) in isolated working rat hearts subjected to 30 min 
global ischemia and 30 min reperfusion. Groups of adult hearts (n = 6) were 
exposed to no drug/no IR (control), IR and IR plus the ATsR antagonist PD 
123,319 (PD, 0.3 mmol/l). 
Results: Compared to controls, IR reduced recovery of LV work and down- 
regulated ATaR mRNA and protein, and AT, R mRNA (not protein). In contrast, 
PD improved recovery of LV work after IR (0.85 vs 0.58 joules, P < 0.001) and 
upregulated ATaR mRNA and protein but did not change ATlR mRNA or 
protein. 
Conclusion: The results suggest that PD-induced cardioprotection in 
acute IR is ATaR-mediated. 
1206-I 44 Systemic and Myocardial Expression of Brain 
Natriuretic Peptide After Adenoviral-Mediated 
Gene Transfer Using a New Catheter-Based 
Approach 
Birgit Kantor, Robert S. Schwartz, Cheri S. Mueske, Laurel S. Kleppe, 
Denise Heublein, Maria Palasis, John C. Burnett, Robert D. Simari. Mayo 
Clinic and Foundation, Rochester, Minnesota, USA 
Background: Brain natriuretic peptide (BNP) is a potent natriuretic, diuretic, 
and vasoactive hormone produced and released by cardiomyocytes. In heart 
failure, plasma BNP levels increase and may be protective in early stages 
of the disease. We investigated whether intramyocardial injection of an aden- 
ovirus expressing human BNP (hBNP) in dogs would result in local myocardial 
expression and secretion of mature BNP into the systemic circulation. 
Methods: In 5 normal dogs, an adenoviral vector (ADV-hBNP) encoding 
hBNP cDNA was injected into the left ventricular myocardium from the en- 
docardial side using a new percutaneous catheter-based technique (Boston 
Scientific). Each heart was injected at 5 different sites with ADV-BNP (1.4 x 
IO9 pfuisite). Two dogs injected with an adenoviral vector encoding Lac Z 
served as controls. Three animals were euthanized 3 days after infection and 
2 dogs at 14 days, Central venous and coronary sinus human and canine 
BNP levels were measured using specific radioimmunoassays. RT-PCR and 
immunohistochemistry of treated and control myocardium were performed. 
Results: lmmunostaining for hBNP was present in myocytes and non 
myocytes of treated dogs and absent in controls. hBNP mRNA expression 
was verified by RT-PCR. Venous canine BNP did not change from baseline 
(16.8 f 2.3 pg/ml). Baseline hBNP was 0.6 f 0.8 pg/ml. Time course studies 
showed a peak at day two (57.2 f 12.8 pgiml; approx. 3 times normal canine 
values) with total duration of expression for 12 days. Coronary sinus hBNP at 
72 hrs was 208.0 f 106.1 pg/ml indicating high local hBNP levels. 
Conclusions: Catheter-based, adenoviral-mediated gene transfer of hu- 
man BNP in dogs results in local and systemic BNP expression up to 12 
days after infection, These results suggest a new approach for local myocar- 
dial and systemic gene-based therapies for cardiovascular diseases with the 
advantage of high regional protein concentrations. 
I1206-145 / Possible Molecular Mechanisms Responsible for 
the Beneficial Effects of Physical Training on 
Cardiac Function During Development of Heart 
Failure 
Jie Wang, Geng-hua Yi, Bolin Cai, Andrew R. Marks, Lu Lu, David 
E. Gutstein. Columbia University: New York, New York; Mt. Sinai Medical 
Center, New York, New York, USA 
Background: We Previously reported that daily physical training (PT) pre- 
served cardiac function during development of heart failure (HF). The cardiac 
sarcoplasmic reticulum calcium ATPase (SERCA2a), Na+/Cas+ exchanger 
(Exchanger) and ryanodine receptor (RYR2) are proteins involved in regulat- 
ing myocyte Gas+ homeostasis and maintaining normal cardiac function. The 
goal of this study is to test whether PT alters those proteins during develop- 
ment of HF. 
Methods: Left ventricular (LV) samples were obtained for mRNA level 
(northern analysis, band intensities normalized to GAPDH) and protein level 
(Western Analysis, band intensities normalized to tubulin) from 3 groups of 
dogs: 5 normal dogs: 5 dogs with cardiac pacing-induced HF (210 bimin for 
3 wks, 240 b/min for the 4rh wk) and 5 dogs with the same cardiac pacing 
regimen plus daily PT (5.5 f 2.2 km/hr, 2 hours/day). 
Results: Results (Table) reveal that in HF state, SERCA2a was signifi- 
cantly decreased, Exchanger was significantly increased while RYR2 was un- 
changed in both mRNA and protein levels. However, all three Ca*+-handling 
molecules in both mRNA and protein levels were relatively preserved in the 
pacing plus PT group. 
SERCA2a 
mRNA Protein 
Exchanger 
mRNA Protein 
RYR2 
mRNA Protein 
Normal 1.17i0.11 4.0010.62 0.28-1-0.01 0.2110.03 1.0010.23 0.82~kO.84 
CHF 0.78ztO.11” 1.40*0.21* 1.0010.09* 0.36zkO.O8* 0.60f0.21 0.53ztO.51 
CHF&PT 1.07f0.15 2.70+0.21 0.60*0.01 0.2atO.08 1.20+0.35 0.36*0.21 
Results are expressed as mean * SD; *p < 0.05 vs. Normal. 
Conclusion: Thus, PT may ameliorate cardiac function during develop- 
ment of HF in part via normalization of expression of Gas+-handling proteins, 
1206-l 46 Effect of Vasopeptidase Inhibition With 
Omapatrilat in a Canine Model of 
Tachycardia-Induced Heart Failure 
Henry H. Holzgrefe, Susan R. Arthur, James R. Powell. Bristol-Myers Squibb 
Pharmaceutical Research Institute, Princeton, New Jersey, USA 
Background: Omapatrilat (OMA), a clinically advanced member of a novel 
class of cardiovascular compounds, the vasopeptidase inhibitors (VPls), si- 
multaneously inhibits neutral endopeptidase and angiotensin converting en- 
zyme. 
Methods: The effect of chronic oral therapy with OMA (10 mgikg bid) and 
an ACE inhibitor (fosinopril [FOS] 30 mg/kg bid) alone, or in combination with 
a diuretic (furosemide, 20 mg/kg bid) were compared in a canine model of 
pacing-induced cardiomyopathy. Pacemaker and stimulating electrode were 
surgically implanted to produce rapid right ventricular pacing @VP) at 210 
bpm. Following surgical recovery, dogs were randomly assigned to one of 
6 treatment protocols (see table). Systemic hemodynamic parameters were 
measured after 28 days of drug and RVP. Data (mean f standard error) were 
compared by one-way ANOVA or Students t-test as appropriate. 
Results: Following RVP, mean arterial pressure, heart rate, left ventricular 
end diastolic pressure, and peak systolic wall stress were similar in FOS, FOS 
+ furosemide, and OMA groups. OMA produced the greatest reductions in 
peak diastolic wall stress and left ventricular end diastolic volume (LVEDV) 
(normalized to % control) (see table). 
Group 
Sham (n = 6) 
Vehicle (n = 13) 
Furosemide (n = 6) 
Fosinopril (n = 6) 
FOS + Futosemide (n = 6) 
Omaoatrilat fn = 6) 
wall stress 
Wm2) 
16.5 i 2.0 
68.0 + 4.8 
58.6i11.5 
41.3 * 5.38 
51.7 i 4.@ 
31.2+1.7= 
LVEDV 
W 
104.0 f 5.9 
177.2 i 9.5 
146.1 i 6.3 
150.5 i- 6.dab 
158.8 zk Q/tab 
128.6 f 5.8a 
ap < 0.05 vs Vehicle; “p < 0.05 vs OMA 
Conclusion: OMA reduced ventricular dilation, resulting in a reduction 
of diastolic wall stress in a canine model of pacing-induced cardiomyopathy. 
Beneficial effects were significantly greater than those produced by either an 
ACE inhibitor or combination ACE inhibitor plus diuretic. OMA may offer a 
novel therapeutic approach in the treatment and protection of patients with 
evolving heart failure compared with conventional therapy. 
JACC February 2000 ABSTRACTS - Cardiac Function and Heart Failure 235A 
I 1206 147 Gene Expression of C-Type Natriuretic Peptide is induced bv Heart Failure and Markedlv 
Suppressedby Aging in the Mouse Lung 
Marco Testa, Giovanni Spetti, Ermenegildo De Ruvo, Annarita Russo, Vito 
M. Fazio, Raffaele Fanelli, Thierry H. LeJemtel, Karen L. Vikstrom. Cafholic 
University Rome; CSS-IRCCS, San Giovanni Rofondo, Italy; AECOM, Bronx, 
NY; SUNY HSC, Syracuse, NL: USA 
Backgrounds: The molecular adaptations induced by heart failure (HF) in 
the lung and the influence of aging on these processes remain poorly defined. 
C-type natriuretic peptide (CNP) is produced by endothelial cells and causes 
vasorelaxation through the activation of natriuretic peptide receptor B (NPRB) 
on smooth muscle cells. CNP also inhibits angiotensin II dependent endothelin 
1 gene expression (GE) and it may thus play a role in modulating pulmonary 
hemodynamics, especially when vasoconstricting neurohumoral systems are 
activated. We have used a previously described transgenic (TG) mouse model 
of HF (resulting from cardiac-specific expression of a mutant myosin heavy 
chain) to assess whether CNP and NPRB GE in the lung is altered early during 
the development of HF, and how this process is modulated by aging. 
Methods: Lungs were obtained from 8 and 12 months old (m.o.) male TG 
mice (8 and 6 animals respectively) and from age and sex matched non-TG 
littermate controls (CT). At these ages TG mice exhibit severe, progressive left 
ventricular dilatation and systolic dysfunction, but not yet significant lung and 
liver congestion. GE was assessed by semiquantitative RT-PCR and p-actin 
mRNA levels were used to normalize CNP and NPRB mRNA levels. 
Results: GNP GE was increased in the lungs of 8 m.o. TG mice, when 
compared to age matched CT mice (1.5 fold, p < 0.05), but this increase was 
no longer significant in the 12 m.o. mice. Moreover, CNP GE was significantly 
lower in the older mice (either TG or CT) when compared to 8 m.o. mice (3 
fold, p < 0.05). NPRB GE was similar in TG and CT mice and it was >2 fold 
lower in the older mice. 
Conclusion: CNP GE is induced by HF and suppressed by aging in the 
mouse lung. NPRB GE, while not altered by HF, is also suppressed by aging. 
Enhanced CNP expression appears to be a transient pulmonary adaptation 
to heart failure that is suppressed by aging. 
L-l--A 1206 148 Antioxidant Vitamins Attenuate Cardiac Dysfunction in Tachycardia-Induced 
Cardiomyopathy 
Junya Shite, Janice Gerloff, Amy Mohan, Chang-seng Liang. University of 
Rochester Medical Center, Rochester, New York, USA 
Background: increasing evidence suggests that oxidative stress plays an im- 
portant role in heart failure. We have recently shown that antioxidant vitamins 
A, C and E (Vit) attenuate norepinephrine-induced fi-receptor downregula- 
tion and improve cardiac i?-adrenergic responsiveness. We speculate Vit may 
exert beneficial effect in heart failure when oxidative stress is increased. 
Methods: Rabbits with rapid ventricular pacing (360 bpm) were randomly 
assigned to receive Vit subcutaneous pellets (A: 20 mg, C: 200 mg, E: 200 mg) 
or placebo for 8weeks, and compared to control rabbits without pacing (n = 9 in 
each). We measured: 1) serial LV end-diastolic dimension (Dd) and fractional 
shortening (FS) by echocardiography; 2) LV dP/dt response to isoproterenol 
(AdP/dt, mmHg/sec); and 3) total cardiac oxidative stress by measuring the 
ratio of myocardial reduced to oxidized glutathione (GSH/GSSG). 
Results: Rapid pacing produced progressive increase of Dd and decline 
of FS. Vit attenuated the changes of Dd and FS in pacing (Figures). At the 
end of 8 weeks, pacing resulted in a reduced AdP/dt (Control 2662 f 72, 
Pacing 1693 + 98*) and an increase in GSSG as reflected by a decrease 
in GSH/GSSG (Control 156 * 22, Pacing 24 + 6”). Vit improved AdP/dt in 
pacing animals to 2304 f 168t and GSHiGSSG to 71 f 15*t. 
(values are means + SE, “p < 0.05 vs Control, +p < 0.05 vs Pacing) 
14$ 154 
0 ’ 2 b & 8’WW 1 4 6 s’b=k) 
Conclusion: Myocardial oxidativestress wasincreasedin pacing-induced 
heart failure. Antioxidant Vit reduced the total oxidative stress and attenuated 
the systolic dysfunction, LV remodeling and B-adrenoceptor subsensitivity. 
The result suggests antioxidant therapy may be beneficial in the treatment of 
heart failure. 
1 1206-l 49 ) Effects of Candesartan and Enalapril on 
Contractility, Intracellular Ca2* Handling and 
Myofibrillar Ca2+ Responsiveness in Failing 
Myocardium oif Postinfarction Rats 
Jiang-Yong Min, James P. Morgan, Achim Meissner, Rudiger Simon. 
BIDMC/Harvard Medical School, Boston, USA; University of Kiel, Germany 
Pharmacological modification of the renin-angiotensin system is an estab- 
lished tool for the treatment of heart failure. However, the cellular mechanism 
of this beneficial effect remains obscure. The present study investigated the 
effects of chronic candesattan and enalapril treatment on contractile function 
and intracellular Ca*+ homeostasis in failing myocardium from postinfarction 
rats. 
Methods and Results: Myocardial infarction was induced by perma- 
nent ligation of the left coronary atiery. The animals were treated orally with 
placebo or candesartan (10 mg/kg/d) or enalapril (10 mg/kg/d) or a combi- 
nation of both drugs. Isometric force, tetanic force and the free intracellular 
Ca2+concentration ([Ca*+]i) were determined in isolated papillary muscles 
(PM) after 6 weeks of chronic treatment. In comparison to the placebo group, 
PM from the drug-treated groups exhibited a marked improvement of isomet- 
ric force and a minor increase of systolic [Ca’+]i both at control conditions as 
well as during isoproterenol stimulation. Moreover, the myofibrillar Ca2+ re- 
sponsiveness as estimated by the force generation of tetanized preparations 
was significantly increased in PM from the drug-treated groups. 
Conclusion: In failing myocardium from postinfarction rats, combined 
therapy with candesartan and enalapril proved to be the most effective regi- 
men to improve contractile force, systolic CaZ+ handling and myofibrillar Ca2+ 
responsiveness.. 
I 1206 150 Increased Aldosterone Synthase and Type I 
Mineralocorticoid Receptor Expression in 
Experimental Chronic Heart Failure 
Johann Bauersachs’ , Markus Kellner2, Martin Wehling”, 
Daniela Fraccarollo’ , Georg Ertl’ , Michael Christ”. ‘Medizinische 
Univers&?fsklinik, Wiirzburg; “Institut fiir Klinische Pharmakologie, Klinikum 
Mannheim, Universit& Heidelberg, Germany 
Background: The systemic renin-angiotensin-aldosterone system is stim- 
ulatedfollowing myocardial infarction (MI). While the local, cardiac renin-angiotensin 
system is involved in left ventricular (LV) remodeling after MI, the role of the 
recently discovered cardiac steroid system is unclear. We evaluated quantita- 
tive changes of the local steroid system in experimental heart failure after MI. 
Methods: Three months after coronary ligation or sham-operation (Sham), 
hemodynamic studies were pet-formed in male Wistar rats. Competitive RT- 
PCRs of right and left ventricular (RV, and LV) tissue samples were done. 
Results: LV enddiastolic pressure (LVEDP) was significantly increased by 
Ml (Sham: 2.8 f 0.8 mmHg, n = 7; Large [Ml area 38.8 f 4.4%]: 5.3 i 0.2 
mmHg, n = 7; Extensive [MI area 53.0 + 2.0%]: 19.0 f 6.4 mmHg, n = 7, p < 
0.05 vs Sham). LV mRNA-expression of aldosterone synthase (CYP 1182), 
the key enzyme of aldosterone synthesis, was significantly increased about 
2.5 fold, while LV expression of ll/+hydroxylase (CYP 1181) was decreased 
by -14%. In addition, LV type I mineralocorticoid receptor (MR) expression 
was increased up to 3.2 & 0.4 attomol/wg RNA in extensive Ml vs Sham-oper- 
ated rats (1.2 rt 0.3 attomol/wg RNA: p < 0.05). Increase of MR-expression 
was significantly correlated to Ml-induced increase of LVEDP (p < 0.05). In 
cells stable transfected with the human MR, isoproterenol-induced increase 
of intracellular CAMP was 7 fold increased vs wild-type cells pointing to a 
MR-mediated modulation of cellular catecholamine signaling. LV-expression 
of the glucocotticoid receptor (GR) was unchanged. 
Conclusion: Receptors and enzymes of the steroid system are locally ex- 
pressed and modulated in chronic heart failure after experimental Ml probably 
due to severe myocardial dysfunction. The clinical relevance of these find- 
ings is supported by the beneficial effects of MR-blockade in congestive heart 
failure in addition to ACE-inhibition (RALES-study). 
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ELI 1207 151 Predicting the Absence of Coronary Disease in 
Patients With Svstolic Heart Failure of Unclear 
Etiology - 
Russell F. Kelly, James T. Thomas, Ahmed S. Hashim, Khaled Albasha, 
Smitha J. Thomas, Joseph E. Parrillo, James E. Calvin. 
Rush-Presbyterian-St. Luke’s Medical Center and Cook County Hospital, 
Chicago, IL, USA 
Background: It is controversial whether all patients with systolic heart failure 
(CHF) of unclear etiology should undergo coronary angiography in order to 
identify patients with coronary disease (CAD) who might benefit from revas- 
cularization. 
Methods: The prevalence of CAD (>50% stenosis in a major vessel) was 
studied in all patients with a primary diagnosis of CHF of unclear etiology 
who underwent angiography at an inner-city public hospital over 5 years. 
Patients with ejection fraction 2 SO%, known CAD, prior myocardial infarction, 
or another etiology for CHF (eg, valve disease) were excluded. 
Results: Of 124 patients (58% male, age 55 f 11 yr, ejection fraction 32 
f IO%), 27% had CAD, including 15% with “severe CAD” (left main, 3-ves- 
sel, or 2-vessel involving the proximal left anterior descending). Multivariate 
predictors of the absence of severe CAD in these patients included absence 
of diabetes (OR 0.25; 95% Cl 0.08-0.82; p = 0.02) and 12 other risk factors 
(OR 0.26; 95% Cl 0.08-0.84; p = 0.02); age and absence of Q waves or left 
bundle branch block (Q/LBBB) on electrocardiogram were borderline signif- 
icant (both p = 0.06). Use of a retrospectively defined algorithm (performing 
anglo only in patients with diabetes, ~2 other risk factors, or Q/LBBB) would 
have identified 94% of patients with CAD, including 100% with severe CAD, 
and avoided angiography in 44% of patients without CAD. 
Conclusions: Severe CAD is not uncommon in patients with systolic CHF 
of unclear etiology, suggesting that a strategy of routine angiography may be 
appropriate. However, if confirmed by further studies, application of a simple 
algorithm using clinical parameters that are easily determined may eliminate 
the need for angiography in many patients without significant CAD. 
L--d 1207 152 Volume Overload and Co-Morbid Conditions of 
Hospitalized Heart Failure Patients 
Keith Aaronson, Pamela Russman, David Bruckman, Todd Koelling, David 
B. Dyke, Robert J. Cody. University of Ajichigan, Ann Arbor, Michigan, USA 
Background: Heart failure is a common discharge diagnosis, particularly 
within the elderly population. We evaluated a cohort of patients admitted over 
a two year period, to identify characteristics contributing to this phenomenon. 
Methods: Patients admitted to the University of Michigan Medical Cen- 
ter during 1996 and 1997 were evaluated. Charts were abstracted and data 
entered for all features relevant to clinical characterization, using standard 
coding and practice guideline parameters. Only one index admission was en- 
tered into the analysis for each patient. Data were scanned and analyzed for 
demographic features and associated features. 
Results: 312 admissions were identified in the specified time period; with 
an age of 64.5 + 15 years, and males were 60.1%. 11.5% of all patients were 
received in transfer from another institution, and 45.3% of the total cohort had 
also been admitted within the previous 30 days. At least 74% were admitted to 
a Cardiology service. NYHAclass was I (3%), II (35%), Ill (45%), and IV (17%). 
In 292 patients (93.6%), the reason for admission was dyspneaifluid overload. 
88.1% of these received diuretics within the first 12 hours of admission. The 
association of dyspnea and initial diuretic use was of borderline significance 
(p = 0.073, Fisher exact test, 2-tailed). 75% were weighed within the first 12 
hours. Other reasons for admission (nonexclusive) were chest pain (19%) 
syncopeiarrhythmia (II%), and renal dysfunction (5%), with other reasons 
less than 2%. Co-morbidities at the time of admission included prior myocar- 
dial infarction (39%), chronic lung disease/pneumonia (35%), atrial fibrillation 
(33%) moderate renal impairment (16%) diabetes with end organ damage 
(14%) and peripheral vascular disease (14%). 
Conclusion: In a large referral center, the primary reason for admission 
was dyspnea and fluid overload, requiring diuretic therapy within the first 12 
hours of admission. Almost half of these patients had a prior admission within 
30 days. Co-morbid conditions such as pulmonary disease and atrial fibrilla- 
tion contribute to morbidity at the time of admission. Treatment strategies and 
patient classification must consider the multi-factorial nature of decompensa- 
tion at the time of admission in this population, particularly in the elderly. 
1 1207-l 53 ) Correlates of Mortality/Morbidity in Patients With 
Heart Failure -A Risk Score Analysis 
Bertram Pitt, Robert Segal, Jennifer D. Rodenhouse, George H. Klinger, 
Zhongxin Zhang, Balasamy Thiyagarajan. University of Michigan, Ann Arbor, 
Michigan; Merck Research Laboratories, West Point, Pennsylvania, USA 
Background: Identification of heart failure (HF) patients at high risk for hospi- 
talizations and death may allow for intervention that could improve outcomes 
and reduce costs. Utilizing data from the 48 week losartan vs captopril ELITE 
HF study (722 ACE inhibitor nai’ve patients, age ) 65 years, NHYA Class 
II-IV, EF 5 40%), we identified significant risk factors associated with all- 
cause death and/or hospitalization and created a risk score based on a linear 
combination of risk factors, 
Methods: Univariate analysis (Cox proportional hazards model) was used 
to identify significant factors associated with death and/or hospitalization. Mul- 
tivariable regression (Cox model) was then performed including all variables 
that were found significant in univariate analysis. The coefficients from the 
multivariable regression were combined to create a single risk score (R), 
which was then standardized on a scale of 0 to IO. 
Results: The following risk factors significantly correlated with risk for 
death and/or hospitalization: NYHA Class (p = O.OOOl), ischemic heart dis- 
ease (0.0031), diabetes mellitus (0.0055), atrial fibrillation (0.0083), S-uric 
acid (p = 0.0436) and relative lymphocyte concentration (p = 0.0462). In ad- 
dition, the risk ratio (i.e. relative hazard rate, RHR) of losartan/captopril de- 
creased with an increase in riskscore, (0.82 2 RHR 2 0.59, when 0.17 5 R 5 
10.0). 
Conclusions: The independent risk factors for morbidity and mortality 
identified in this study are consistent with those previously reported; a mor- 
bidity/mortality risk score can be used to identify potential high risk patients. 
Furthermore, in this study, the relative hazard rate shows that losartan has a 
greater effect in high-risk patients vs. captopril. 
1207-l 54 Outcomes Improve and Hospitalizations Fall for 
Health Maintenance Organization Patients in 
Heart Failure TreatmenrProgram 
Catherine Chelimsky-Fallick, John S. Golden, Donna J. Mateski, E. 
Kirk Huang, Cecelia A. Gramsky, Colleen M. Healey, Sharon R. Josephson, 
Mary C. Langford, Susan J. Morikawa, Carol A. Offutt, Patricia A.G. Powers, 
Shonda Spells-Hampton, Suzanne J. Wingate. Cardiology Kaiser 
Permanente Mid-At/antic States, Rockvile, Mary/and, USA 
Background: Academic heart failure (HF) management programs have been 
successful at restoring euvolemia, decreasing hospitalizations, and decreas- 
ing mortality in decompensated HF patients (pts). However, pts in these pro- 
grams are often cardiac transplantation candidates and, as such, lack the 
comorbidities of a general patient population. We sought to evaluate the suc- 
cess of a program where comorbidities such as diabetes mellitus, chronic 
renal insufficiency, and active smoking were not exclusion criteria, and where 
social support was not an entry requirement. 
Methods: We studied 183 consecutive pts with systolic dysfunction en- 
rolled in our HF treatment program (HFTP) prior to February 15, 1999. Entry 
criteria included an ejection fraction < 35%, class Ill or IV New York Heart 
Association (NYHA) symptoms, and a creatinine < 3.5 mg/dl. Mean age was 
61 * 13 years. 40% had diabetes mellitus. 45% of pts had an ischemic eti- 
ology. Diuretics and angiotensin converting enzyme inhibitors (ACEI) were 
titrated to optimal dosing to achieve clinical compensation (ClinComp), de- 
fined as achieving a stable weight for at least 2 weeks with best functional 
class possible. Beta blockers were then uptitrated in the usual fashion. 
Results: Total hospital days were decreased from 641 for the 6 months 
prior to entry into the HFTP to 292 days (p < 0.05) for the 6 months after 
entry. Actuarial survival at 12 month was 91%. Mean follow up was 13.3 Jr 5.3 
months. 
Initial 
Most Recent 
NYHA class 
3.3 + 0.4 
2.4 f 0.7, p < 0.001 
ACEI (mg) 
2Ozt16 
29 * 15, p < 0.01 
ClinComp (%) 
29 
77, p < 0.001 
Conclusion: In adiverse HMO population with a high proportion of pts with 
comorbidities, especially diabetes meltitus, a HF management program can 
achieve significant improvement in NYHA class and clinical compensation 
with good survival rates and substantial cost savings from a greater than 50% 
decrease in hospital days. 
JACC February 2000 
1 1207-I 55 / Promoting Best Physician Practices: The 
Canadian CHF Clinics Network 
J. Malcolm 0. Arnold, Jonathan Hewlett, Rita Nigam, Wlodzimierz Czarnecki, 
Andrew Ignaszewiski, Marie-Helene LeBlanc, Peter Liu, John D. Parker, 
A.R.J. Rajakumar, Stuart Smith, Koon Teo, Israel Belenkie. University of 
Western Ontario, London, Ontario, Canada 
Introduction: Heart failure presents an increasing clinical burden to both 
patients and physicians. Changes in clinical practice frequently lag behind 
advances in treatment described in large clinical trials. The Canadian CHF 
Clinics Network has been established in 11 initial centres across Canada to 
improve the current management of chronic heart failure (CHF). to implement 
new proven therapies in a timely manner, and to collaborate in innovative re- 
search approaches tooptimise patient management. By consensus, a manual 
of CHF management for physicians, nurses, and patients, a national comput- 
erized database, and a strategy of education to enhance CHF treatment in the 
community have been developed 
Results: Selected mean characteristics of the 573 patients entered into 
the database over the first 6 months are: age 60 years; male 73%: ischemic 
27%; NYHA Class I7.9%, II 29.1%, Ill 35.6%. IV 12.4%; LVEF 22%, LVEF 
> 45% 4.7%; Minnesota HF score 44; history of hypertension 25%; dyslipi- 
daemia 27%: diabetes 23%; current smoker 7%; renal dysfunction 10%; atrial 
fibrillation 18%. Treatment profiles for drug use were: ACE-I 83%; AT1 blocker 
8%; beta blockers 49%; furosemide 88%; digoxin 60%; long acting nitrates 
29%; antiplatelet 37%; warfarin 37%; amlodipine 13%; amiodarone 15%; hy- 
polipidemics 35%; hypoglycaemics 22%. The Frequency of change in man- 
agement as the result of physician-patient interaction resulted in: medication 
change 34%. blood work 53%; ECG 43%; education regarding medication 
36%, CHF 32%. fluid/salt/weight 33%, exercise 27%, 43% of patients were 
on both an ACE-I and a beta blocker, 7% were on spironolactone. The mean 
daily doses of drugs were: captopril 90 mg, enalapril 22 mg, lisinopril30 mg, 
carvedilol28 mg, metoprolol75 mg, spironolactone 41 mg. furosemide 97 mg. 
Conclusion: These data demonstrate that specialised CHF clinics have 
high utilization of proven therapies in combination with emphasis on patient 
education and can promote best physician practices in a broad range of com- 
munities across a country. 
j Program 
1207 156 The Cost Benefit of Implementing a Heart Failure 
David J. Whellan, Stuart D. Russell, Michael A. Blazing, Michael S. Cuffe, 
Ruth Ann Greenfield, Robert Taber, Wendy A. Gattis, Laura Gaulden, 
Bradi Granger, Christopher M. O’Connor. Duke University Medical Center, 
Durham, North Carolina, USA 
Background: Systematic approaches for the management of congestive 
heart failure (CHF) have been identified as a means of improving quality 
of care, but little is known their impact on cost. We hypothesized that a heart 
failure program would result in improved quality of care at reduced cost. 
Methods: Patients with either ejection fraction < 20%, recent hospitaliza- 
tion for CHF, or New York Heart Association (NYHA) class Ill and IV CHF were 
enrolled in the Duke Heart Failure Program between 70198 and 4/15/99 (n 
= 117). Data on age, ejection fraction, etiology, referring physician, angioten- 
sin inhibitor (ACEi) and beta-blocker (BB) use, % target ACEi and BB dose, 
hospitalizations, and clinic visits were collected from clinic notes and admin- 
istrative databases” Analyses were performed using Wilcoxon rank sum test 
to compare continuous variables and chi-square test to compare categorical 
variables. 
Results: The mean age was 62 -4 14 years; 38% were female; 47% lived 
greater than 30 miles from the medical center; 50% were NYHA class Ill 
and IV; and the median ejection fraction was 23%. The median time in the 
program was 4.9 months. Although ACEi use did not increase significantly, 
ACE dose did (74% vs 97% of target dose, p = 0.02). BB use and dose 
significantly increased (52% vs 76% on BB; 24% vs 40% of target dose; p < 
0.001 for both). Hospitalization rate and ALOS significantly decreased (1.86 
hosp/pt year vs 1.21 hosp/pt year, p = 0.01; 7.67 vs 6.07 days, p = 0.01). 
Total clinic visits and cardiology clinic visits, including heart failure clinic visits, 
significantly increased (7.8 vs 12.9 visits/pt year, p < 0.001 for total; 1.5 vs 7.7, 
p < 0.001 for cardiology). Outpatient costs increased 27% and inpatient costs 
decreased 38% (p = NS for both). Cost per discharge decreased 32% (p = 
0.02). Total cost decreased 37% (p = 0.06). There was a significant difference 
in post-enrollment cost by NYHA class (p = 0.001) and geographical location 
(p = 0.003), with NYHA class IV patients and patients living closer to Duke 
costing more. 
Conclusion: By shifting care to the outpatient setting, total cost of care 
decreased. Implementing a heart failure program improved medication usage 
and decreased hospitalizations. Certain patient characteristics may influence 
cost from a healthcare delivery system’s perspective. 
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CIII . 1207 157 Impact of a Managed Care Heart Failure Support Service on Quality of Life and Resource 
Utilization 
Edward P. Syron, Ellen F. Murray, Debra L. Long, Laura A. Antell. Blue Cross 
of Northeastern Pennsylvania, Wilkes-Barre. Pennsylvania; SmithKline 
Beecham, Philadelphia, Pennsylvania, USA 
Background: The heart failure (HF) research literature has indicated the 
benefit of outpatient support services in breaking the cycle of repeat hospi- 
talizations for HF. This investigation builds upon that previous observational 
research by measuring in a randomized controlled study design, the effective- 
ness of a voluntary service that supports both HF patients and the health care 
providers who care for them. 
Methods: Claims data analysis identified high risk HF candidates for ran- 
domization into an intervention or usual care control group. The intervention 
consisted of a nurse-driven telephonic patient education and support service 
that focused on adherence to HF medications, diet, symptom monitoring and 
coping skills. Providers received monthly progress updates, fax alerts and ed- 
ucational mailings based on The Agency for Health Care Policy and Research 
Clinical Practice Guidelines. Patient quality of life and physical functioning 
were assessed with the Minnesota Living With Heart Failure Questionnaire 
(MLWHF) and the New York Heart Association Classification (NYHA) respec- 
tively. Patient reported behaviors and resource utilization were assessed dur- 
ing each telephone contact. Health care costs were retrieved from claims 
submitted to the health plan. 
Results: Median age of patients using the service was 75 (range 35-99.) 
In this group, the MLWHF scores improved after 2 months of service use 
(41.5 versus 39; p < 0.001). NYHA classification showed a trend toward fewer 
patients classified as NYHA class III and IV after 3 months of service use (p 
= 0.26). The number of patients who reported utilization of outpatient office 
visits, hospitalization and emergency room visits decreased after 4, 8 and 12 
weeks of service use compared to the 4 week period prior to service use. The 
percentage of patients who reported weighing daily increased from 17% to 
85% after 4-8 weeks (p = 0.02). Health care costs for the intervention group 
decreased 41% during 6 months of service use compared to a 3.2% increase 
observed in the control group. 
Group Net Payment Net Payment Average Cost Average Cost Per % 
-Pm -post Per Month-Pm Month-Post Change 
Control 53,038,684 $1,567,902 $253,224 $261,317 +3.2% 
(n = 205) ($1,275 pmpm) 
Intervention $1,194,523 $352,161 
($1 $;;;r4pm) 
($1,048pmpm) (ss$:88~~;nl, 
-41% 
(n = 95) 
Pre: 5/l/97-4/30/98; Post: 8198-1199. 
Conclusion: A managed care support service can enhance quality of life 
and reduce hospitalizations in HF patients. These reductions are associated 
with significant cost savings. 
1207-l 58 The Diagnostic Evaluation of Newly Discovered 
Heart Failure: Opportunities for Improvement 
From the R.E.A.C.H. Study 
Peter A. McCullough, Edward F. Philbin, Barbara Czerska, John A. Spertus, 
W. Douglas Weaver. Henry FordHeart and Vascular Institute, Detroit, 
Michigan; The Mid America Heart Institute, Kansas City: Missouri, USA 
Background: The 1994 Agency for Health Care Policy and Research con- 
sensus guidelines for the diagnostic evaluation of congestive heart failure 
(CHF) recommend a baseline evaluation of ventricular systolic function and 
a laboratory and clinical search for reversible causes of CHF. There are no 
population-based studies to evaluate current practice patterns and their out- 
comes. 
Methods: The REACH study is a prospective cohort study of 26,442 CHF 
patients within the Henry Ford Health System (HFHS) in Detroit, Michigan. 
Claims data from all diagnostic procedures were available from 1995-1998 in 
3353 patients with CHF diagnosed within one year, who were members of the 
HFHS health maintenance organization. These individuals are homogeneous 
with respect to access to care and cardiac procedures. 
Results: Rates for diagnostic tests were as follows: chest x-ray 88%, 
EGG 88%, echocardiogram 71%, radionucleotide ventriculogram 2%, cardiac 
catheterization 25%, stress testing 30%, biochemistry profile 90%, complete 
blood count 88%, urinalysis 74%, and thyroid stimulating hormone 46%. The 
mortality rates were 5% and 6% in the groups with some form of ischemia 
evaluation (stress test or cath) versus not, p = 0.15. Likewise there were no 
differences in mortality (6% vs 5%) in those with and without measures of 
ventricular function (echo or MUGA), p = 0.56. 
Conclusion: Unlike consensus guidelines for treatment, guidelines with 
respect to the diagnostic evaluation of newly diagnosed CHF are unlikely to 
impact short term mortality given the targeted use of tests by clinicians based 
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upon individual presentation. Areas for improvement include the evaluation of 
cardiac ischemia and thyroid disorders as potential reversible causes of CHF. 
1 1207-l 59 ] Quality of Life Measures Predict Mortality and 
Hospitalization in Patients With Advanced Heart 
Failure. Insights From the EPICAL Study 
Franpois Alla, Serge Briancon, Yves Juilliere, Paul-Michel Mertes, 
Jean-Pierre Villemot, Francis Guillemin, Faiez Zannad. The EflCAL 
lnvestiga tors; Epidemiology and Cardiology Clinical lnvestiga t/on Center, 
INSERM-CHU, University Henri Poincar6, Nancy, France 
Background: Survival and quality of life (QOL) are poor in patients with con- 
gestive heart failure (CHF). However, the relationship between survival and 
QOL measures is poorly investigated. The aim of this study was to evaluate 
the value of QOL measurement as a prognostic factor for survival and for 
rehospitalization in a prospective cohort of patients with advanced CHF. 
Methods: A measure of QOL was performed with a generic questionnaire: 
the Duke Health Profile (DHP) and a disease specific one: the Minnesota Liv- 
ing With Heart Failure Questionnaire (MLHF) in asample of 108 patients regis- 
tered in the EPICAL program (JACCI 999,33). This program identified patients 
with severe CHF defined by a hospitalization for a NYHA grade III/IV dyspnea, 
edema or hypotension, and LVEF < 30%. Questionnaires were previously 
translated and transculturallyvalidated in French. Scores ranged from 0 (poor- 
est QOL) to 100 (best QOL). QOL measures were performed one month after 
hospital discharge. General, physical, mental and social dimensions, adjusted 
for other prognostic variables were tested in a multivariate Cox model. 
Results: QOL was poor (DHP global score: 54 [50-571; MLHF global 
score: 64 [59-681). One year survival was 76% and one year hospital-free- 
survival 38%. With both questionnaires and on univariate analysis, general 
and physical dimensions were significantly associated with survival while 
general, physical and social dimensions were significantly associated with 
hospital-free-survival. Only in the MLHF questionnaire, this relation remained 
signifiant for hospital-free-survival after adjustment for other pronostic factors 
(serum sodium, history of renal failure, number of prior hospitalization and 
duration of the causal disease): RR associated with 10 points decrements in 
the score of global, physical and social dimensions in the MLHF questionnaire 
were respectively 1 .I7 [l.Ol-1.361, 1 .I6 [I .03-i ,301 and 1.13 [I .02-l .24]. 
Conclusion: QOL assessment is a predictor of mortality and is an in- 
dependent predictor of hospital-free-survival in patients with advanced CHF. 
QOL assessment with disease specific questionnaire may provide additional 
information for routine clinical management and therapeutic decision as well 
as for risk stratification in clinical trials, 
POSTER 
112081 Heart Transplant: Grafl Function 
Wednesday, March 15,2000,9:00 a.m.-11 :00 a.m. 
Anaheim Convention Center, Hall A 
Presentation Hour: 10:00 a.m.-l I:00 a.m. 
11208-120 / Absence of L-Arginine Effect on the Coronary 
Hypersensitivity to Serotonin in Cardiac 
Transplant Recipients 
Vincent Crasset, Philippe Unger, Jean-Luc Vachiery, Jean-Louis LeClerc, 
Guy Berkenboom. Cardiology Department, Erasme Hospital, Free University 
of Brussels, Brussels, Belgium 
Background: Coronary hypersensitivity to serotonin (5HT) promotes platelet 
aggregation and therefore, the progression of the atherosclerotic process. 
This abnormality occurs in the early stages of coronary atherosclerosis when 
the responses to bradykinin (Bk) are still preserved. 
Methods: To determine whether such changes also occur early after car- 
diac transplantation, intracoronary injections of Bk and 5HT were performed 
in 7 control patients (CTRL), in 19 patients with dyslipidemia (CA) and 15 
cardiac TX recipients (1 year after operation, TX). Coronary angiography was 
normal in the 3 groups. In the segments where 5HT effects were the most pro- 
nounced, the diameter changes (expressed as % of baseline) were measured 
by quantitative angiography. 
Bk Bk Bk 5HT ISDN 
60 ng 200 PQ -__. 200 ng 600 ng 364 
CTRL (n = 7) 108zk2 117+2 122*2 107&3 125f5 
CA (n = 19) 106+2 11354 116+2 81 k 2* 127&Z 
Tx(n=i5) 10311 11312 115*2 85 f 3* 121 * 3 
*P < 0.05 vs CTRL; ISDN = isosorbide dinitrate 
Results (see table): After selective infusion of L-arginine (40 mg/min for 
12 min) the 5HT-induced constriction was significantly attenuated in CAgroup 
(from 82 i 3 to 95 f 4%, n = 8) but not in TX group (from 83 f 3 to 77 j, 6, n = 
9). 
Conclusions: In the early stages of the graft vasculopathy, the response 
to Bk is preserved; nevertheless, the absence of L-arginine effect on the re- 
sponses to 5HT suggests that other mechanisms than reduced EDNO avail- 
ability are involved in the abnormal response to this amine. Immune process 
promoting the release of EDCFs such as endothelin and/or, superoxide anion 
might play a role. 
/ 1208-l 21 1 Coronary Flow and Diameter Increase and 
Immediate Epicardial Endothelial Dysfunction 
Improvement by Quinaprilat lntracoronarily in 
Heart Transplant Recipients 
Wolfgang von Scheidt, Sinan Pehlivanli, Bruno M. Meiser, Michael Weis. 
Klinikum GroBhadern, University of Munich, Munich, Germany 
Background: Chronic treatment with the ACE-inhibitor quinapril has been 
shown to improve atherosclerosis-associated epicardial coronary endothelial 
dysfunction in humans. However, acute effects of quinaprilat (Q) intracoronar- 
ily (ic) concerning flow, diameter and improvement of endothelial dysfunction 
are unknown. 
Methods: We investigated epicardial (QCA) and microvascular (icDoppler) 
vasodilation in response to Q (1.5 mgi3 min and 5 mg/5 min ic) in 22 heart 
transplant recipients (HTR), a population prone to endothelial dysfunction and 
morphological coronary alterations, 31 & 36 months after transplantation. En- 
dothelial function was evaluated as acetylcholine response (ACh 150 mcgi5 
min ic) before and after Q ic. 
Results: Q increased proximal (6 * 9%, p < 0.05) and distal (14 i 19%, 
p < 0.01) epicardial coronary diameter and increased blood flow (coronary 
flow reserve, CFR, 2.2 i 0.5, p -< 0.01). CFR to Q correlated inversely to 
LNMMA-tested basal NO-mediated blood flow (r = -0.58, p c: 0.01) and was 
independent of epicardial intimal thickening (IVUS) or endothelial dysfunction. 
Epicardial endothelial dysfunction (i.e. >I 0% diameter decrease in response 
to ACh) was in part reversible after Q (26% decrease of diameter constriction, 
p i 0.05), whereas microvascular endothelial dysfunction (i.e. CFR to ACh < 
2.5) remained unchanged. 
Conclusion: Q ic dilates epicardial vessels and the microcirculation in 
HTR, independent of functional and morphological alterations. Epicardial en- 
dothelial dysfunction improves acutely after Q. These beneficial effects of Q 
on coronary vasomotion and endothelial function probably may lead to a lower 
incidence of functional and morphological manifestations of cardiac allograft 
vasculopathy during longterm treatment with this drug. 
I 1208 122 Bicaval Anastomosis Yields Better Cardiac Transplant Atrial Function 
Jing Ping Sun, Micheal K. Banbury, Lori L. Price, Mario J. Garcia, Brian 
P. Griffin, William J. Stewart, James B. Young, Patrick M. McCarthy, James 
D. Thomas. The C/eve/and Clinic Foundation, C/eve/and, OH, USA 
Background: In an effort to improve physiologic and clinical outcomes and 
maintain normal anatomy, bicaval rather than the traditional biatrial anasto- 
mosis has been utilized in cardiac transplantation. 
Aim: The purpose of this study was to identify any benefit resulting from 
bicaval cardiac transplantation. 
Methods: All adult primary heart transplant recipients (bicaval in 126 pts 
and biatrial in 115 pts) without prior left ventricular assist device between i/95 
and 12/98 were included. Complete echo study 5 1 year post operation was 
done on 59 bicaval, and 53 biatrial pts. 
Results: There were no significant differences between cardiac transplan- 
tation by the two techniques, for age and sex of recipient and donor, transfu- 
sion, primary diagnosis, post operative length of stay, pericardial effusion, 
aortic, mitral, tricuspid and pulmonary valvular regurgitation. The 2 year sur- 
vival are similar (85 vs 87%, p = 0.28). Cardiac transplantation using bicaval 
method requires significantly fewer permanent pacemakers (4 vs 16.5%, p 
< 0.01). Bicaval pts also had better left and right atrial function, measured 
by mitral (M) and tricuspid (T) peak velocity (PV in cm/set) and velocity time 
integrals (VTI in cm): 
Parameter MPV MVTI TPV TVTI RA EF (%) 
Bi-caval 52* 17 4.7s 1.9 46116 4.5 * 1.7 19+9 
Bi-atrial 41 fl6 3.5 zt 3 38f12 3.8 * 1.7 15*9 
0 <O.Ol <O.Ol co.01 0.03 0.05 
Conclusion: Although technically were demanding, the bicaval technique 
for transplantation caused fewer bradycardic complications, and significantly 
improves atrial transport function. 
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I. 1208 123 Serial Assessment of Coronary Flow Reserve in Pediatric Cardiac Transplant Recipients 
Shinichi Nunoda, Chieko Fujii, Norihiro Hotta, Makoto Shinagawa, 
Yutaka Kubo, Kuniaki Ohtsuka, Shin-ichiro Ohkawa. Department of 
Medicine, Tokyo Women’s Medical University Daini Hospital, Tokyo, Japan 
Background: lntracoronary ultrasound (ICUS) provides an information of epi- 
cardial allograftvascuiopathy (AV) in transplant (TX) recipients (Rs). However, 
it is difficult and risky to do it frequently in pediatric TX Rs, and the assessment 
of AV by tCUS is limited in only epicardial coronary artery. The purpose of this 
study was to measure coronary flow reserve (CFR) serially in pediatric TX Rs 
and to assess the AV which appears also in intramyocardial coronary vessels. 
Methods: The subjects consisted of 6 pediatric Rs (5 months to 11 years 
(ys) old at TX) who had been cared for at least 3 ys postTx. The longest fol- 
low-up period among 6 pediatrfc Rs was 9 ys. After injection of isosorbide dini- 
trate, phasic coronary artery velocity was analyzed in the proximal segment of 
the angiographically normal left anterior descending coronary artery using a 
0.014.in, 15MHz Doppler guide wire (DGVV). CFR was obtained from the ra- 
tio of adenosine-induced (0.15 mg/kg/min intravenously) hyperemicibaseline 
time-averaged peak velocity. We also studied clinical risk factors which may 
contribute to AV. 
Results: 2 of 6 Rs showed significant decrease of CFR during the fol- 
low-up periods. 1 of these 2 Rs showed the decrease of CFR from 2.9 at 6 ys 
postTx to 1.4, which was obtained a few months before his sudden death at 7 
ys postTx. His coronary angiogram before his death showed the progression 
of irregularity, however, only at the distal portions. The another patient showed 
decrease of deceleration time from 150 to 100 msec in his echocardiogram in 
proportion to the decrease of CFR from 3.8 to 2.8, although his other non-inva- 
sive parameters and coronary angiogram remained normal. The remaining 4 
Rs showed no significant decrease of CFR (A CFR 0.1 - 0.3) during the fol- 
low-up periods. Among possible risk factors, suboptimal immunosuppression 
and neither use of diltiazem nor pravastatin contributed to the progression of 
AV. 
Conclusion: Serial assessment of AV including intramyocardial small ves- 
sels can be safely done by using DGW in pediatric Rs and it is possible to mod- 
ulate postTx care before the manifestation of diastolic or systolic dysfunction. 
1 1208-I 24 1 !mpact of Remodeling on Coronary Lumen Loss 
m Transplant Vasculopathy: A Serial 
Intravascular Ultrasound Study 
Khaled M. Ziada, Samir R. Kapadia, Marlene Goormastic, Fatih S. Ertas, 
Timothy D. Crowe, Gustav0 Rincon, Steven E. Nissen, E. Murat Tuzcu. The 
Cleveland Clinic Foundation, Cleveland, OH, USA 
Background: In atheroscerotic disease, arterial remodeling or change in ex- 
ternal elastic membrane (EEM) size affects the degree of luminal stenosis. 
However, the impact of remodeling on lumen size in early cardiac allograft 
vasculopathy remains undefined. 
Methods: Intravascular ultrasound was performed in 127 patients at ~8 
weeks and 1 year after transplantation. Lumen area (LA), external elastic 
membrane (EEM) area, intimal area (IA = EEM area-LA) and intimal thickness 
(ITmax) were measured. Vasculopathy lesions were sites that contained no 
disease at baseline and ITmax > 0.5 mm at 1 year. 
Results: Vasculopathy lesions were identified in 144 (13%) of 876 coro- 
nary sites matched between baseline and 1 year follow-up. LA decreased 
from 15.9 i 5.7 to 13.2 f 5.4 mm* and IA increased from 1.9 i 1.4 to 5.5 
f 2.0 mm2 (p < 0.0001 for both). EEM area increased from 17.7 i 6.1 to 
18.8 5 6.0 (p < 0.0005), although there was EEM area loss at 55 (38%) sites. 
By simple and step-wise linear regression, both IA and EEM area changes 
influenced LA change, but the change in EEM area alone explained 70% of 
the change in LA (figures). 
-5 0 5 10 0 lb 
Conclusions: Despite very rapid intimai proliferation, arterial remodeling 
is the major determinant of the degree of lumen loss in allograft vasculopathy 
in the first year after transplantation. 
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( 1208-125 1 Heart Transplant Recipients With Normal 
Coronary Angiograms: Is Intravascular 
Ultrasound Really Necessary? 
Volker Klauss, Klaus Pethig’ , Helen Kalies, Elke Pichlmayer, 
Bernd Heublein’, Johannes Rieber, Christoph H. Spes, Bruno Reichart, 
Uwe Siebert, Axe1 Haverich’, Harald Mudra, K. Theisen. Dpt of Cardiology 
Klinikum Innenstadt, University of Munich; ’ Hannover Medical School, 
Germany 
Background: Previous studies have shown that abnormal findings by in- 
travascular ultrasound (IVUS) may predict cardiac events in patients (pts) 
after heart transplantation (HTx). However, a substantial part of pts included 
in these studies had already an abnormal coronary angiogram, which by itself 
is a strong prognostic parameter for adverse events. We therefore sought to 
evaluate the role of IVUS in pts with a normal coronary angiography using a 
multivariable cox analysis. 
Methods: At 2 transplant centers, 172 pts (mean recipient age 46 & 12 
years; mean donor age, 32 & 12 years) with angiographically normal coronary 
arteries were studied with IVUS 2.7 f 2.8 years after HTx. IVUS-parameters 
(maximal intimal thickness, mean and maximal intimal index) as well as clin- 
ical characteristics and risk factors for cardiac allograft vasculopathy (CAV) 
were related to cardiac events (cardiac death, myocardial infarction, revascu- 
larization procedures and retransplantation due to CAV). Only variables with 
a p-value 5 0.2 in the bivariate screening were included in the multivariable 
cox analysis. 
Results: During a follow-up periode of 2.8 i 1.3 years (range, 0.04 to 
6.0), 14 cardiac events occurred (cardiac death, n = 2; revascularization, n = 
II, retransplantation for CAV, n = I). By multivariable analysis, only maximal 
intimal index > 30% by IVUS (risk ratio [RR] 11.2; 95% Cl, 3.0-65.1) and body 
mass index (BMI) > 25 kg/m2 (RR 10.5; 95% Cl, 2.8-62.1) (all p < 0.002) 
were independent predictors of cardiac events. 
Conclusion: This multivariable analysis demonstrates that among all non- 
invasive parameters, BMI had a prognostic impact. Despite a normal coronary 
angiogram, IVUS was highly predictive for subsequent cardiac events. Thus, 
a normal coronary angiogram in heart transplant recipients is not a reliable 
criterion for risk stratification. It is therefore necessary to perform IVUS in this 
group of pts. 
11208-l 26 ) A Combined Doppler Echocardiographic and 
Histopathological Evaluation of Myocardial 
Fibrosis in the Cardiac Allograft 
Malcolm I. Burgess’, Tarek M. Aziz’, Nizar Yonan”, Philip Hasletona, Simon 
G. Ray’ ‘Northwest Regional Cardiac Centre; “Cardiac Transplantation 
Unit; Wythenshawe Hospital, Manchester UK 
Aim: Myocardial fibrosis is a common finding in the cardiac allograft recipient 
but its impact on myocardial function and clinical status has not been fully 
defined. Since the Tei index reflects both systolic and diastolic myocardial 
performance we have examined its relationship to histological appearances 
at endomyocardial biopsy. 
Methods: We prospectively evaluated the degree of fibrosis in 356 en- 
domyocardial biopsies performed in 65 heart transplant recipients (mean age 
41, 18% female) at a mean of 23 months post-transplantation. Fibrosis score 
in biopsies was based on H&E staining. Biopsies with rejection 1 grade 2 were 
excluded. The Tei index was measured in all recipients at the time of biopsy 
and was calculated by dividing the sum of the left ventricular isovolumic con- 
traction and relaxation times by the left ventricular ejection time. 
Results: There was a significant correlation between the Tei index and 
fibrosis score (r = 0.42 p = 0.002). Patients with fibrosis score > 5 were more 
likely to have had previous rejection episodes than those with fibrosis score of 
~5 (p = 0.001). The Tei index and pulmonary capillary wedge pressure were 
higher in recipients with a fibrosis score of >5 (0.71 f 0.26 and 21 + 3.5 
respectively) compared to those with fibrosis score 4 5 (0.49 f 0.11 and 15 
& 2.1 respectively; p = 0.003 and 0.03). The mean NYHA status was 2.1 + 
0.6 for recipients with fibrosis score > 5 compared to 1.3 & 0.3 for those with 
fibrosis score of ~5 (p = 0.04) The incidence of single, two and three vessel 
coronary artery disease did not correlate with either fibrosis score or the Tei 
index. 
Conclusion: Frequent cellular rejection is associated with fibrosis in the 
cardiac allograft. Subsequent global myocardial dysfunction is reflected in 
poor functional capacity. The Tei index is a clinically useful measure of my- 
ocardial dysfunction after cardiac transplantation, 
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ORAL 
Newer Agents for Heart Failure 
Wednesday, March 15,2000, lo:30 a.m.-Noon 
Anaheim Convention Center, Room 304A 
IO:30 a.m. 
909-i Beneficial Effects of Vasopeptidase Inhibition on 
Mortality and Morbidity in Heart Failure: Evidence 
From the Omapatrilat Heart Failure Program 
John B. Kostis, Jean L. Rouleau, Marc A. Pfeffer, Michel F. Rousseau, 
Hamid Ikram, Michel Komajda, Chunlin Qian, Alan J. Block, James 
J. Hanyok, David P. Synhorst, Hubert Pouleur. For the Omapatrilat Heart 
Failure lnvestigatqr..; UMDNJ-Robert Wood Johnson Medical School, New 
Brunswick, NJ, USA 
Background: The vasopeptidase inhibitor, omapatrilat (OMA), inhibits ACE 
(Ki = 6.0 nM) and neutral endopeptidase (EC 3.4.24.11; Ki = 8.9 nM), which 
degrades vasoactive peptides including bradykinin, the natriuretic peptides 
and adrenomedullin. 
Methods: To assess its long-term safety in heart failure (HF), a total of 
1242 patients (NYHA II, 63%; III, 35%; IV, 1%; EF, 28%) were randomized in 
two double-blind lisinopril (LIS) controlled trials: a52 week trial (OMA, n =340, 
dose 20 mg; LIS, n = 329, dose 20 mg) and a 24 week trial (OMA, n = 289, 
dose 40 mg; LIS, n = 284, dose 20 mg). 
Results: In each trial, OMA improved the combined endpoint of death or 
hospitaljzation for worsening HF (RR: 0.78, 95% Cl: 0.56, 1.11 with 20 mg; 
RR: 0.53, 95% Cl: 0.27, 1.02 with 40 mg). In the pooled analysis, there was 
a statistically significant reduction with OMA (RR: 0.72, 95% Cl: 0.53, 0.97; 
figure). 
Both drugs were well tolerated. The overall incidence of cardiovascular 
serious adverse events (AE), AE of renal dysfunction, and marked elevations 
in creatinine were lower with OMA than with LIS. Hypotension was more 
common with OMA (11.0% vs. 6.5%) but syncope occurred more often with 
LIS (5.1% vs. 1.4%). There was one case of angioedema with LIS and none 
with OMA. 
Conclusions: In these studies, vasopeptidase inhibition with OMA ap- 
peared superior to ACE-I in preventing death and worsening HF. A definitive 
trial of 4420 patients, OVERTURE, is ongoing to compare enalapril with a 40 
mg dose of OMA. 
IO:45 a.m. 
909-Z Subcutaneous BNP Administration in Symptomatic 
Human Heart Failure: A Novel Therapeutic Strategy 
for Congestive Heart Failure 
Horng H. Chen, Lynda J. Nordstrom, Margaret M. Redfield, John C. Burnett, 
Jr.. Mayo Clinic, Rochester, MN, USA 
Background: Brain natriuretic peptide (BNP) is a cardiac hormone with va- 
sodilating, natriuretic, renin-angiotensin-aldosterone (RAAS) inhibiting and 
lusitropic properties. We have previously demonstrated that acute subcuta- 
neous (SQ) administration of BNP in experimental mild heart failure (HF) 
result in elevation of plasma BNP and its second messenger cGMP with na- 
triuresis and reduction in cardiac filling pressures in the absence of activation 
of the RAAS. Furthermore, chronic SQ BNP in experimental HF resulted in 
increases in cardiac output (CO) and decreases in pulmonary capillary wedge 
pressure and systemic vascular resistance. 
Methods: The objective of the current study was to assess the safety 
and efficacy of multiple doses of SQ BNP (Scios, CA) in human subjects 
with NYHA class 11-111 HF. We defined the safety, cardiorenal and humoral 
responses to SQ BNP administered q 12 hours with a total of 5 doses over 72 
hours in a dose-titration design (n = 8). Echocardiography, renal function and 
humoral profile were performed both 1 hour before and after the I*’ and 5rh 
dose. The mean dose of BNP was 12 Mg/kg q 12 hrs. 
Results: (* p < 0.05 vs Baseline) With the Is’ dose, CO increased (4.8 
i 0.4 to 6.4 i 0.5 I/min*) and systolic blood pressure decreased (125 f 
5 to 104 & 3 mmHg*) without a change in heart rate. Plasma BNP (167 f 
115 to 830 i 470 pg/ml*), cGMP (4 f 2 to 14 f 4 pmol/ml*) and urinary 
cGMP excretion (3900 f 930 to 10800 i 5000 pmol/min*) increased with 
increased natriuresis* and diuresis*. Despite natriuresis, plasma renin activity 
decreased* while plasma aldosterone remained unchanged. These favorable 
responses were maintained with multiple dosing and similar responses were 
observed with the 5rh dose. All subjects tolerated the 5 doses of SQ BNP well 
without major adverse events. 
Conclusion: We conclude that SQ BNP represents a novel, safe and effi- 
cacioustherapeuticstrategy in human HFtodeliverchronically, BNP, acardiac 
hormone which possesses unique beneficial cardiorenal and neurohumoral 
properties. 
11:OO a.m. 
CII 909 3 Effect of lmmunomodulating Therapy With Intravenous lmmunglobulin in Chronic Heart Failure 
Lays Gullestad, Halvdan Aass, Jan Fjeld, Halvdan Ihlen, Svein Simonsen, 
John Kjekshus, Sigurd Nitter Hauge, Thor Ueland, Stig S. Freland, 
Pal Aukrust. Rikshospitalef, Oslo, Norway 
Background: Immunologic and inflammatory responses appear to play a 
pathogenic role in the development of CHF. We and others have previously 
demonstrated downregulatory effects of intravenous immunglobulin (IVIG) on 
various inflammatory and immunologic parameters with relevance for CHF. 
We therefore examined the effect of long-term treatment with IVIG on func- 
tional capacity and cardiac performance in patients with CHF. 
Methods: 41 patients (mean age 60 + 9 years) with chronic symptomatic 
CHF and left ventricular ejection fraction (LV-EF < 40%), 23 with coronary 
artery disease (CAD) and 16 with idiopathic dilated cardiomyopathy (IDCM), 
already optimally treated (93% ACE-inhibitors, 76% B-blocker) were random- 
ized between IVIG (0.4 mg/kg i.v. as a daily infusion for 5 days and thereafter 
as one infusion each month) or placebo in a double-blind trial lasting for 6 
months. Efficiency parameters were examined at baseline and end of study. 
Results: (I) LV-EF increased from 26 + 2 to 31 & 3% during IVIG (p < 
0.01) while remaining unchanged in the placebo group (28 f 2 to 29 & 2%, 
ns). (3. The beneficial effect on LV-EF in the IVIG group was most marked 
in those with CAD and in those with LV-EF > 15% at baseline. (iir) IVIG also 
increased the peak VOs (p = 0.06) and significantly decreased pulmonary 
capillary wedge pressure (p < 0.03) while no such effects were seen in the 
placebo group. (iv) Both in the placebo group (p < 0.05) and particularly in 
the IVIG group (p < 0.008), there was a significant improvement in clinical 
performance as evaluated by NYHA classification. (v) In the IVIG group there 
was a -35% reduction in plasma pro-ANF levels (p c 0.003) while no change 
was seen in the placebo group. 
Conclusions: In patients with moderate to severe CHF on optimal cardio- 
vascular treatment regimens, immunomodulating therapy with IVIG resulted 
in increased functional capacity, cardiac performance and hemodynamic vari- 
ables. Our findings underscore a potential for immunomudulating therapy in 
such patients, and larger studies examining the effect of IVIG or other im- 
munomudulating agents in CHF patients including the effect on mortality, are 
warranted. 
11:15 a.m. 
909-4 Safety and Efficacy of ENBRELD (Etanercept) in the 
Treatment of Chronic Heart Failure 
Biykem Bozkurt, Guillermo Torre-Amione, Ozlem Z. Soran, Arthur 
M. Feldman, James Whitmore, Marshelle Warren, Douglas L. Mann. Baylor 
College of Medicine, Houston, TX; University of Pittsburgh, Pittsburgh, PA; 
lmmunex Corporation, Seattle, WA; Baylor College of Medicine, Houston, 
TX, USA 
Background: Previous studies in heart failure patients have shown that in- 
hibition of TNF by etanercept in patients with heart failure improves clinical 
endpoints during 3 months of continuous treatment. This follow-up study in- 
vestigates the safety of etanercept with treatment up to 6 additional months, 
and describes continuing efficacy and lack of a rebound effect in patients who 
were withdrawn from etanercept therapy. 
Methods: Forty-seven patients with NYHA class Ill-IV heart failure were 
studied for 3 months in a randomized, double-blind, placebo-controlled trial. 
Four patients discontinued from the double-blind portion of this trial. Following 
completion of the 3-month blinded trial, 12 of the patients started on a 6 month, 
open-label extension arm of the trial. The remaining 31 patients (placebo = 
IO; etanercept = 21) were discontinued from study drug and followed for an 
additional 3 months to evaluate loss of effedt over time. These patients were 
then offered open-label treatment in a separate protocol. 
Results: For patients who were continued on the open-label extension 
arm of the trial, there was (1) no increase in the frequency of adverse events, 
(2) evidence of a sustained improvement in NYHA class. For patients who 
were discontinued from study drug, there was (1) no increase in serious ad- 
verse events following drug discontinuation, suggesting that there was no 
rebound effect and (2) the incremental increase in LVEF following 3 months 
of treatment with 12 mg/m* (p = 0.02) returned to baseline 3 months after 
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discontinuation of etanercept. The reduction in LV end systolic volume at 3 
months of treatment with 12 mg/m’ persisted at 1 month after discontinua- 
tion of etanercept (p = 0.04). Ten of the etanercept-treated patients with an 
improvement in NYHA class from baseline, discontinued etanercept after 3 
months of treatment. Five (50%) of these patients experienced a return to 
baseline 30 days after discontinuation of etanercept, consistent with loss of 
TNF antagonism. 
Conclusions: Sustained treatment with etanercept for 9 months appears 
to be safe and well tolerated in patients with advanced heart failure. Discon- 
tinuation of etanercept is associated with a return to baseline in clinical status 
consistent with a drug effect. No acute rebound was seen. Some leftventricu- 
lar structural changes persisted off drug for 1 to 3 months, suggesting that the 
beneficial effects of etanercept on LV remodeling may be sustained. 
11:30 a.m. 
/ 909-5 1 Acute Hemodynamic and Neurohumoral Effects of 
Selective ETA Receptor Blockade in Patients With 
Congestive Heart Failure 
Georg Noll, Veselin Mitrovic’, Lukas E. Spieker, Richard Pacher2, 
Mathias Schulze3, Christoph Schalcher, Wolfgang Kiowski, Thomas 
F. Ltischer. On behalf of the ET 003 investigators; Cardiology: University 
Hospital, Ziirich, Switzerland; ‘Kerckhoff Clinic, Bad Nauheim; 3Herz- und 
Kreislaufzentrum, Cardiology, Dresden, Germany: 2Allgemeines 
Krankenhaus, Wien, Austria 
Background: Nonselective ETA/~ receptor antagonists improve hemodynam- 
its in patients with CHF. Since ETa receptors mediate the release of nitric 
oxide and the clearance of ET-I, selective ETA antagonists are of special in- 
terest. The aim of this study was to investigate the hemodynamic effects of 
the selective ETA receptor antagonist LU135252 in patients with congestive 
heart failure (CHF). 
Methods: The hemodynamic effects of a single oral dose of the selective 
ETA receptor antagonist LU135252 (1, IO, 30, 100, or 300 mg) were investi- 
gated in a multicenter study involving 95 patients with CHF (NYHA 11-111) with 
an ejection fraction 135%. 
Results: Baseline ET-l positively correlated with pulmonary vascular re- 
sistance, pulmonary capillary wedge pressure (PCWP), mean pulmonary 
artery pressure (MPAP, r = 0.37-0.50, P < 0.0004), but were inversely re- 
lated to cardiac index (Cl; r = -0.36, P = 0.0004). Two hours after LU135252, 
plasma ET-I did not significantly increase after 1 mg, but did so by 23% (P 
= 0.003), 29% (P = 0.0018), 56% (P < O.OOOl), and 101% (P < 0.0001) 
after IO, 30, 100, and 300 mg, respectively, while plasma catecholamines re- 
mained constant. LU135252 dose-dependently increased Cl and decreased 
mean arterial pressure, right atrial pressure, MPAP, PCWP, and systemic and 
pulmonary vascular resistance (P < 0.035-c 0.0001). Heart rate remained 
constant or decreased slightly. 
Conclusion: In patients with CHF, a single oral dose of the selective ETA 
receptor antagonist LU135252 improves hemodynamics in adose-dependent 
manner without activation of other neurohumoral systems and is well tolerated 
over a wide dose range. 
Ii:45 a.m. 
909-6 Improved Hemodynamics With the ETA Selective 
Receptor Antagonist BMS-193884 in Patients With 
Heart Failure 
William Smith, Bruce Iteld, Thierry LeJemtel, lgnatius Thomas, 
David Deitchman, Susan P. Williams, Daniel Reyner, Mel Blumenthal. New 
Orleans Center Clinical Research, New Orleans, L-A; Bristol-Myers Squibb, 
Princeton, NJ, USA 
Background: Endothelin (ET) antagonists may contribute to the manage- 
ment of heart failure (HF) patients (pts). We evaluated the acute hemody- 
namic effects of BMS-193884 (BMS), an orally administered ETA receptor 
antagonist. 
Methods: 116 pts with NYHA Class II-IV HF, LVEF i35%, pulmonary 
capillary wedge pressure (PCWP) ~16 mmHg, and cardiac index (Cl) ~2.7 
Umin/m’ were randomized to double blind treatment with BMS (5 to 200 mg; 
n = 75) or placebo (PBO; n = 41). Hemodynamics, which were similar at 
baseline among treatment groups (overall PCWP = 23.3 mmHg and Cl = 2.1 
UminIm”), were monitored for 24 hours. Pts were then treated for 4 weeks as 
outpatients. 
Results: BMS was well tolerated, with adverse events evenly divided be- 
tween pts receiving BMS and placebo. No clinically significant increases in 
LFTs were noted. The table shows major hemodynamic indices for the treat- 
ment groups as adjusted mean changes from baseline 4 hours after dosing. 
The decrease in PCWP and mean arterial blood pressure (MAP) were ac- 
companied by significant increases in Cl, reaching a plateau of 0.57 Umin/m’ 
at 50 and 100 mg. There was a trend for more pts receiving BMS (28%) to 
improve by 1 NYHA Class than in the placebo group (8%). 
Effect of 6MS-193884 vs Pi30 (change from baseline) 
PCWP Cl MAP HR SVR 
PBO -1.6 0 0 1 4 
BMS i0mg -2.7 0 -3 -1 -145 I-41 
BMS 25 mg -2.2 0.2v -2 4 -200 l-131 
EMS 50 mg -6.1 0.57* -7” 1 -433* [-231 
BMSI 00 mg -7.7= 0.58’ -1o* 6 -399’ [-261 
* p < 0.05 vs PBO; PCWP (mm Hg); Cl (Umin/m2); MAP (mm Hg); HR = heart rate 
(b/min); SVR = systemic vascular resistance (dynes sec.cme5); [ ] = adjusted % change 
from baseline 
Conclusion: The ETA selective antagonist BMS-193884 produces a fa- 
vorable hemodynamic response and is well tolerated in pts with HF. 
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